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Chapter 1 
Introduction
 
1.1 General considerations
An	important	issue	in	medicine	is	that	the	efficacy,	the	safety	and	the	costs	of	medical	
treatment modalities are appropriately in concordance. Patient safety should be the 
dermatologist’s number one priority, especially in the treatment of non-life threatening 
diseases such as acne, vitiligo and psoriasis. In dermatology, intra-patient studies 
(right-left	studies)	provide	an	ideal	means	to	evaluate	the	efficacy	of	topical	treatment	
modalities.	Double-blind,	 crossover	 studies	 have	 proven	 their	 benefit	 in	 systemic	
treatment. In addition to the observations by physicians, the patient’s quality of life 
studies	 became	 indispensable	 to	 determine	 the	 overall	 efficacy	 of	 the	 treatment.	
Assessing the costs of medical treatment is more complex. The costs of treatments 
are not only determined by the price of drugs, medical apparatus and duration of 
treatments, but also by the reduction of patient’s working hours, travel costs, and, 
last but not least, the costs of treating side effects of medication. Physicians and 
patients are both increasingly aware of the risks of medical interventions. 
Primum non nocere	 (nonmaleficence)	 is	 a	 Latin phrase, imputed to Hippocrates, 
means “First, not to harm”. It reminds the physician and other health care providers 
that	they	must	consider	the	possible	harm	that	any	medical	intervention	may	inflict	and	
that human acts with good intentions may have unwanted consequences. A closely 
related phrase is “Sometimes the cure is worse than the illness.” The situation in 
which a subject has a complication of treatment that is more severe than the disease 
for which the treatment was been given must be avoided. The dictum primum non 
nocere is not necessarily the guiding principle in cancer therapy. The goal of cancer 
treatment	 is	 first	 to	 eradicate	 the	 cancer.	 Primum	 non	 nocere	 would	 therefore,	
theoretically, give way to primum succurrere	 -	 “first,	 hasten	 to	help”.	This	 implies	
that successful treatment of skin cancer requires the detection and the diagnosis 
at an early stage, so that it can be cured with minimal surgical complications. Many 
patients all over the world suffer from psoriasis, acne, vitiligo, actinic keratosis 
and non-melanoma skin cancer (NMSC). Although seldom life threatening, these 
disorders of the skin are important considering the burden imposed on the quality of 
life of the sufferer, the costs of the treatment, the loss of productive time caused by 
treatments and the side effects of the treatments.
There is currently no cure for psoriasis, although a wide range of therapies are 
available,	 varying	 considerably	 in	 terms	 of	 efficacy	 and	 toxic	 effects.1 The level 
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of compliance to treatments in patients with psoriasis is low, with reported non-
compliance in 40% of the patients.2,3	 	Factors	such	as	efficacy2,4 and the duration 
of	the	treatment	can	influence	the	decision	of	whether	to	continue	with	treatment.3 
Factors	 such	 as	 adverse	 effects,	 time	 to	 improvement	 and	 relapse	 influence	 the	
choice of treatment by patients with psoriasis. Most patients would be willing to try 
out different aspects of the treatment to achieve an improvement in their psoriasis 
with a minimum of adverse effects. In other words, patients may indicate that they 
would wait longer for a treatment to work if the chances of severe adverse effect 
such as skin cancer and liver damage were considerably reduced. Patients consider 
the long-term risks of skin cancer and liver damage to be the most important adverse 
effects and are prioritized above short-term risks of drug-induced hypertension or 
skin irritation.5 
Vitiligo poses no threat to a patient’s life, although the de-pigmented areas are 
susceptible to actinic damage. On the one hand, meticulous sun protection is 
imperative to prevent unfavorable consequences of sun damage such as phototoxic 
dermatitis and skin cancer. On the other hand, phototherapeutic approaches are 
most effective in the treatment of vitiligo.6 Long-term treatments with UVB and PUVA 
induce accelerated photo-aging, cutaneous and systemic immunosuppression7 and 
an increased risk of skin carcinoma.8,9 The therapeutic use of immunosuppressive 
drugs is based on the hypothesis that vitiligo is an autoimmune disorder and their 
effectiveness supports it. Corticosteroids may be applied topically10 or administered 
systemically.11-13 Cyclophosphamide14,	 5-fluouracil15 and levamisole16 have been 
used to treat vitiligo by modifying the immune response with varying therapeutic 
efficacy.	Severe	side	effects,	which	may	occur	with	systemic	 immunosuppressive	
regimens,	 require	 careful	 analysis	 of	 the	 benefit–risk	 ratio.	Potential	 serious	 side	
effects caused by long-term systemic steroids and immunosuppressive agents may 
not justify their use because vitiligo is a pigment disorder.6 Recently, non-steroidal 
topical immunosuppressive therapy with calcineurin inhibitors (tacrolimus and 
pimecrolimus), has been introduced.17-19	Their	anticipated	improvement	in	the	risk–
benefit	 ratio	as	compared	with	 the	 ratio	of	 steroids	and	other	 immunomodulators	
has not yet been established.20 Acne vulgaris is a multi-causal disorder of the 
pilo-sebaceous glands. Four major factors are responsible for the development 
of acne lesions. These include abnormal desquamation of the follicular epithelium 
causing the obstruction of the pilo-sebaceous canal, the stimulation of sebaceous 
secretion by androgens at puberty, the presence and the growth of bacteria and the 
subsequent	attraction	of	lymphocytes	and	leukocytes	resulting	in	an	inflammation.	
The	 inflammatory	 component	 of	 acne	 lesions	 is	 usually	 associated	 with	 the	
proliferation of Propionibacterium (P.) acnes in the follicular unit. Standard treatment 
today	consists	of	peeling	the	skin	and	reducing	P.	acnes	and	inflammation	by	using	
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topical benzoylperoxide gel, azelaic acid cream, tretinoin cream, adapalene gel and 
topical antibiotics. Systemic antibiotics and anti-androgens (in female patients) are 
used	when	this	approach	is	not	effective.	However,	the	efficacy	of	antibiotic	treatment	
is progressively reduced by the increasing resistance of the bacteria to the used 
antibiotics.	Side	effects	may	also	limit	their	use.	When	other	treatments	fail,	the	final	
remedy is oral isotretinoin, which is very effective, even in recalcitrant acne, but its 
use is even more limited by moderate to serious side effects. Photodynamic therapy 
(PDT) may be an alternative treatment for acne, but the lowest possible light dose 
should be used in order to minimize the side effects.21
There is a discrepancy between therapists on their goals of treatment. On the one 
hand, therapists may aim for a rapid and a sustained control of the disease process, 
irrespective of the adverse events. On the other hand, therapists may aim at an 
improvement in the quality of life with minimal side effects irrespective of the duration 
of improvement or a lack of complete control of the disease. Complete clearance 
of skin lesions is often not a realistic goal.22 Generally, most patients will be willing 
to try out different aspects of the treatment to achieve an improvement in their skin 
disease with minimal adverse effects. Consultation with patients and evaluation of 
their goals are an important part of the therapeutic process. Potent treatments may 
provide more complete and prolonged clearance of widespread disease, but also 
have a higher risk of serious side effects, which must be considered when choosing 
a treatment strategy.23 
The investigations described in this thesis were pursued in order to optimize the 
efficacy	and	the	safety	profiles	of	different	therapeutic	modalities	for	treating	psoriasis,	
vitiligo, acne and non-melanoma skin cancer (NMSC).
1.2 Aims of the investigations described in this thesis were two-fold: 
I.	 To	optimize	the	risk-benefit	ratio	in	the	treatment	of	plaque	type	psoriasis	by	
using Pulsed Dye Laser (PDL) therapy. 
a.	 An	evaluation	of	the	efficacy	and	the	safety	of	PDL	therapy.
b. A comparison of the results of PDL therapy with those of Ultra-
Violet B (UVB) treatment, which is the standard photo-therapy for 
psoriasis. 
c. An assessment of the putative synergism of the combined PDL- and 
UVB therapy.
d. An investigation into the histopathological changes in psoriatic 
lesions at various time intervals after PDL therapy.
11
II. To evaluate the effect of enhanced penetration of drugs into the skin using 
liposomes as carriers for water- and fat soluble drugs.
a.	 An	 assessment	 of	 the	 efficacy	 and	 the	 side	 effects	 of	 Khellin	
encapsulated in liposomes in the treatment of vitiligo. 
b.	 An	assessment	of	the	efficacy	and	the	side	effects	of	5-aminolevulinic	
acid 0.5% (5-ALA) encapsulated in liposomes in the treatment of 
acne. 
c.				 An	 evaluation	 of	 the	 quality	 of	 fluorescence	 detection	 of	 non-
melanoma skin cancer at an early stage using 5-aminolevulinic acid 
0.5% encapsulated in liposomes in combination with a specialized 
computerized detection and visualization system.
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Chapter 2    
Basic principles
2.1    Sunlight and photobiology
Without sunlight there would have been no organic life on our planet 
Photobiology is the study of the effects of non-ionizing radiation on living systems and 
reflects	all	types	of	interaction	of	light	with	micro-organisms,	plants,	animals	and	human	
beings.1 Sunlight provides the majority of the energy on earth. All living organisms require 
solar energy (electromagnetic radiation) in an assimilated and utilizable chemical form 
for the metabolic activities associated with growth and development.2 Photosynthesis 
is the photochemical reaction whereby plants use chlorophyll to convert carbon dioxide 
and water into oxygen and energy-rich carbohydrates. These stored carbohydrates are 
ingested by herbivorous animals. Carnivorous animals in turn acquire photo-synthetically 
produced energy indirectly by feeding on plant-eating animals that have stored the ingested 
chemical energy in their tissues (food chain).2  Although in The Holy Bible Genesis I is 
stated that God said “Let there be light and there was light, and God saw that it was good”, 
sunlight in fact has a range of positive, but also negative biologic effects. (Table 1).3 Two 
major positive physical properties of the sun are its light and its warmth. Light (visible 
radiation) provides the capacity to see, solar heat (infrared radiation) is responsible for the 
planet earth being inhabitable. Warmth is of great comfort to human beings and accounts 
for the positive values, such as “warm feelings”. Worship of the sun as a religious symbol 
of strength, authority and majesty can be traced back to the beginnings of human history 
(Table 2). Photo-medicine involves diagnostic and therapeutic photo-biology.1  
Electromagnetic radiation
Electromagnetic	(EM)	radiation	is	defined	by	the	wavelength	(λ)	and	the	frequency	(v).	
Wavelength is the distance between two corresponding points on each successive 
wave (Figure 1). Frequency is the number of waves that passes a point per second. The 
product	of	the	wavelength	and	frequency	λ	x	v	was	shown	by	Einstein	to	be	constant	
and equal to the speed of light in a vacuum = 3 x 108 meters/second = 300,000 km per 
sec.	Electromagnetic	radiation	is	classified	as	a	sequence	of	increasing	wavelengths	into	
cosmic rays, gamma rays, X-rays, ultraviolet light, visible light, infrared light, microwaves 
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and radio waves (Figure 2). Ultraviolet (UV) C of wavelengths between 200-280 nanometer 
(nm) does not reach the earth because it is absorbed by the ozone layer (thickness 3 mm) 
in the stratosphere.2 
The UV radiation spectrum lies between the wavelengths of 100 nm and 400 nm 
according to the international agreement. The Commission Internationale de 
l’Eclairage	(CIE)	adopted	the	following	general	definitions4:
Ultraviolet C (UVC)   = 200-280 nm
Ultraviolet B (UVB)    = 280-315 nm
Ultraviolet A (UVA)    = 315-400 nm, subdivided into UVA2 315-340 nm 
     and UVA1 340-400 nm. 
Alternative	definitions	in	use	for	UV	radiation	are4: 
Ultraviolet C (UVC)   = 150-280 nm/100-290 nm
Ultraviolet B (UVB)   = 280-320 nm/290-320 nm
Ultraviolet A (UVA)  = 320-400 nm/320-410 nm 
Longer wavelengths are divided into:
Visible light = 400-800 nm   
Infrared light (heat)  = 800-17000 nm 
Microwaves and radio waves >17000 nm.   
Wavelengths of shorter than about 200 nm propagate only in a vacuum and are not 
relevant in phototherapy. Very short wavelengths such as cosmic rays, gamma rays 
and X-rays penetrate deeply into the human tissues where they may cause extensive 
damage. This radiation is called ionizing radiation because it ionizes molecules due 
to its high energy. This ionizing radiation is useful in the treatment of malignant 
diseases when destruction is the goal of the therapy.2 Optical penetration into the 
skin	is	defined	by	the	combination	of	absorption	and	scattering.	Both	are	higher	at	
shorter wavelengths resulting in a gradual increase in the depth of penetration into 
the skin at longer wavelengths over a broad spectrum (290 nm to 1300 nm). Laser 
light	with	wavelengths	above	1300		nm	only	penetrate	superficially	because	of	the	
high	absorption	coefficient	of	tissue	water	(Figure	3).		
The concept that EM radiation consists of individual discrete packets of energy = quantum 
=	photon	was	first	proposed	by	Max	Planck	(1901:	the	quantum	theory).	The	EM	waves	
are described by the following three physical properties: the frequency v, the wavelength 
λ and the photon energy E. Frequencies range from about a million billion Hertz (gamma 
rays) down to a few Hertz (radio waves). Wavelength is inversely proportional to the 
wave frequency so that gamma rays have very short wavelengths that are fractions of the 
size of atoms, whereas radio wavelengths are higher than 17000 nm. Photon energy is 
directly proportional to the wave frequency so that gamma rays have the highest energy 
and radio waves have very low energy. Planck related the energy of an individual packet 
to the frequency of the radiation by means of a constant, named the Planck’s constant (h 
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= 6.63x10 -34 Joule-second. 2	The	energy	(E)	of	a	photon	=	hv,	v	=	1/λ	=>	E	=	h/	λ.		This	
means, that the energy of a photon is inversely proportional to the wavelength (Figure 1). 
In other words, the shorter the wavelength, the higher is the energy of the photon. The 
longer the wavelength the lower is the energy. The wavelength of the light waves (and 
other EM waves) is decreased when present in a medium (matter).
2.2           Light and skin
2.2.1 Ultraviolet light B (UVB: 280 nm to 320 nm)
Irradiation of the skin with UVB has become one of the most common therapies for 
several skin diseases such as psoriasis, eczema and vitiligo. This therapy can be 
given	as	broad-band	(BBUVB,	280–320	nm)	or	narrow-band	(NBUVB,	310-315	nm).	
In	normal	skin,	UVB	increases	the	synthesis	of	transforming	growth	factor	(TGF)-α	
by keratinocytes, accelerates keratinocyte proliferation and increases the overall 
epidermal thickness.5 Several cytokines thought to initiate or enhance psoriatic 
pathology are also increased after UVB irradiation of skin or cultured keratinocytes: 
Interferon	 (IFN)-γ6,	 tumor	necrosis	 factor	 (TNF)-α	 7, interleukin (IL)-18 , IL-69  and 
IL-8.10		Furthermore,	UVB	increases	leukocyte	infiltration11 and activates neutrophil 
effector functions.12  Therefore, it may be anticipated that the therapy of psoriatic 
skin	with	UVB	would	worsen	hyperplasia	and	inflammation	in	the	lesions.	However,	
an entirely opposite effect was observed. The effects of UVB on normal skin are 
paradoxical in relation to its therapeutic effects. The effects on psoriatic skin include 
reduced epidermal thickness, a lowered keratinocyte proliferation, a decreased 
presence	of	reactive	IL-6	in	the	lesions	and	the	elimination	of	IFN-γ-induced	proteins	
(HLA-DR and ICAM-1) from the psoriatic keratinocytes.13,14  The explanation for this 
paradox was believed to be because of the consistent and the profound depletion 
of T lymphocytes from the psoriatic epidermis upon UVB therapy indicating that a 
systemic effect was a negligible factor.14 Studies also showed that dermal lymphocytes 
were less affected by UVB therapy14 because only 5-10% of the incidental radiation 
in the UVB spectrum penetrated the epidermis up to the basal layer. The remaining 
energy was scattered at the epidermal surface or was absorbed by keratinocyte 
proteins or other molecules.15	Keratinocytes	appeared	 to	be	 relatively	 resistant	 to	
the cytotoxic effects of UVB. It was cytotoxic for keratinocytes at levels that were at 
least 10-fold higher than those for lymphocytes. The deletion of activated lymphocyte 
clones from psoriatic epidermis produced a sustained therapeutic improvement. 14 
Thus, it was thought that UVB phototherapy was effective in chronic plaque psoriasis 
through local effects. Therapy with UVB also reduced contact hypersensitivity (CHS) 
to a number of antigens, 16,17 by targeting the epidermal compartment, inhibiting the 
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proliferation of keratinocytes and the migration of Langerhans cells (LC), abrogating 
antigen presentation and inducing apoptosis of activated skin-homing T cells.14,18,19  
Sensitization occurs when an antigen (Ag) is presented by dendritic cells to CD4+ 
T lymphocytes carrying the appropriate T cell receptor (TCR) in association with 
the major histocompatibility complex (MHC) class II molecules. In addition, the 
interaction of co-stimulatory molecules such as B7 with CD28 is required. This 
suppression in the immune response is called local immunosuppression20 because 
the sensitization and the UV exposure affect the same skin area. The systemic 
effect of UVB therapy on psoriasis was considered to be little and unlikely to be 
of clinical importance. This led to the conclusion that the systemic effect of UVB 
was	 too	 small	 to	 be	 a	 reason	 to	 alter	 the	 interpretation	 of	 the	 findings	 of	within-
subject comparative phototherapy studies.21 Later on, it became apparent that the 
immunosuppression by UVB was more complex than that assumed earlier. UVB 
also exerted immunosuppressive effects that were independent of the direct cell 
cytotoxicity and depletion of the Langerhans cells at the site of exposure. 22 Higher 
UV doses also affect immune reactions induced at a distant, non-UV-exposed site. 
Accordingly, CHS could not be induced in mice which were exposed to high doses 
of UV radiation even if the contact allergen was applied at a non- irradiated site.23 
This type of suppression is called systemic immunosuppression, which is mediated 
via mechanisms other than the local immunosuppression. The question of how UV 
radiation can interfere with the induction of an immune response at a distant non-
UV-exposed skin area remained unanswered for quite a long time. Today, it is clear 
that UV radiation stimulates keratinocytes to release soluble immunosuppressive 
mediators including IL-10, which enter the circulation and thereby can suppress the 
immune system in a systemic manner.24 Studies in various UV-mediated tolerance 
models (local, systemic, high dose, low dose) showed different regulatory T cells 
(also called suppressor T cells) with unique phenotypes that were involved in these 
systems. Currently, best characterized are the regulatory T cells involved in the 
low dose suppression of CHS. UV-induced regulator cells transferring suppression 
belong to the CD4+CD25+ subtype,25  they express CTLA-4,24 bind the lectin dectin-2 
26 and in contrast to the classical CD4+CD25+ T cells release high amounts of IL-10 
upon	antigen-specific	activation.24 Therefore, several mechanisms are involved in 
UV-induced immunosuppression20:
- UV radiation suppresses the expression of MHC class II and co-stimulatory 
molecules (e.g. B7), which are expressed on antigen-presenting cells and 
which are crucial for the interaction with T cells. UV radiation also down-
regulates the expression of CD80 and CD86 on human Langerhans cells 
and on blood-derived dendritic cells.27,28 
- UV radiation stimulates keratinocytes to release soluble immunosuppressive 
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mediators	such	as	IL-10	and	TNF-α,	which	are	responsible	for	the	systemic	
immunosuppression.25 
- UV radiation converts trans-urocanic acid (UCA) into cis-UCA, which 
also exerts immunosuppressive effects.20 UVB induces reactive oxygen species 
which may contribute to impair the function of antigen- presenting cells after UV 
radiation.29  
There is a certain proportion of human population whose immune response will 
be compromised by UV radiation. This indicates that there are UV-susceptible 
and UV-resistant individuals. The immune system does not only protect from 
infectious agents, but also from malignant cell transformation. At an early stage, 
transformed cells may be recognized as ‘‘foreign’’ and attacked by the immune 
system (tumor immunology). This may particularly apply in both non-melanoma 
skin cancer and malignant melanoma. There is striking evidence for a strong 
correlation between the risk of developing skin cancer and immunosuppression. 
Chronically immunosuppressed individuals such as organ transplant recipients run 
a	 significantly	 higher	 risk	 of	 developing	 skin	 cancer.	This	 risk	 certainly	 increases	
with the cumulative UV load.30 Currently available devices are designed to deliver 
wavelengths of between 310-315 nm (NBUVB) for treating certain dermatologic 
skin	disorders.	 	Erythemogenic	doses	below	300	nm	produce	significant	clearing;	
however, these wavelengths also produce the highest erythema and burning. 
The wavelengths within the action spectrum, which produce the best therapeutic 
response at sub-erythemogenic doses of UV light therapy in psoriasis are between 
310 and 315 nm.31 The effects of UV light may result in two main categories of 
observable	changes.	The	first	 category	consists	of	acute	changes,	which	 include	
membrane damage, induction of cytoplasmic transcription factors, DNA damage and 
isomerization of urocanic acid. The second category consists of sub-acute changes, 
which	include	alteration	of	antigen-presenting	cell	populations	and	the	modification	
of intracellular and intercellular signaling mechanisms. This overall effect creates 
a change in the environmental cytokine patterns in the epidermis and the dermis, 
which is more favorable for the development of a T helper (Th)-2 cell-like response 
as a result of UV effects on the skin.32 
It	 is	 standard	 in	 NBUVB	 therapy	 to	 first	 obtain	 a	 minimal	 erythema	 dose	 for	
effectiveness while limiting   the side effects of repetitive erythemogenic doses. The 
usual starting dose for NBUVB therapy ranges from 50% to 70% of the minimal 
erythema dose (MED). The MED is determined by a simple procedure that takes a 
total of 15 to 20 minutes. Delivery of the doses for the MED can be done at the time 
of	the	initial	visit	and	the	first	full	body	or	partial	body	dose	of	NBUVB	therapy	may	be	
started	2	days	later.	The	protocols	may	range	from	therapy	of	three	to	five	times	per	
week once the MED and the initial dose have been determined. Comparison trials 
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to determine the most effective methods for the delivery of NBUVB reported no real 
statistical	difference,	although	there	was	a	slight	 improvement	with	therapy	of	five	
times per week.33 The more aggressive use of NBUVB therapy, using 70% to 90% of 
the MED was not statistically superior to a 50% of the MED.34 Other important factors 
in the most effective use of NBUVB therapy included lubrication of the skin with a 
non-UVB	absorbing	lubricant	such	as	mineral	oil,	which	decreased	the	reflectance	
from the scales of the psoriatic plaques. Caution should be exercised not to use 
agents containing salicylic acid, which would absorb UVB. 
Therapy with NBUVB is advanced by increasing the dose of each successive 
intervention by at least 10% of the MED up to 20% or even 25% of the MED and uses 
the clinical parameters such as the pinkness of the patient’s skin or any complaint 
of burning to evaluate the degree of progress on a daily basis. Typically, 15 to 20 
therapy sessions may be necessary to achieve an improvement of more than 50% 
in psoriasis. Some patients show no clearance with NBUVB because of the severity 
of their psoriasis or their intolerance to UV light therapy. Combination therapy, other 
modalities of UV light therapy or systemic treatments may be considered in such 
resistant cases.31  A 308 nm excimer laser is a XeCl excimer laser, which emits a 
wavelength of 308 nm and has many physical properties of lasers: a monochromatic 
and coherent beam of light, selective treatment of the target, high penetration and 
the	ability	to	deliver	high	fluence.	It	can	directly	irradiate	lesional	skin,	thus	sparing	
the surrounding normal skin from unnecessary radiation. Clinical data indicated that 
treatment of psoriasis vulgaris with a 308 nm excimer laser was effective after about 
15 treatments.35 Most treatments were scheduled twice a week. The initial dose 
is one to two folds of the MED and the subsequent doses are then increased by 
20–30%	on	every	other	two	to	three	treatments.	Others	used	very	high	multiples	of	
the MED, such as 4 and 6 times the MED and claimed initial long-term remissions 
in some patients.36 
Adverse effects of UVB therapy may be acute or chronic.37 
Acute adverse effects of UVB: 
- Erythema and burning. NBUVB had a reduced incidence of burning episodes 
for therapeutically equivalent UV regimens as compared with BBUVB.
- Blisters occurred within the psoriatic lesions halfway through NBUVB therapy 
were reported, but usually resolved spontaneously in spite of continued 
treatment.38 
- Pruritus was mainly associated with dryness of the skin. The use of regular 
emollients was recommended during the treatment and for about 4 weeks 
thereafter.
Chronic adverse effects of UVB:
- Photo-ageing is the result of cumulative DNA damage, whereby UVB 
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causes epidermal changes. Clinically it presents as wrinkling, dryness and 
coarseness of the skin, freckling, telangiectasia, yellowish and mottled 
pigmentation, loss of strength and comedones.
Histologically, there is elastosis in the upper dermis together with degenerated 
and slightly reduced collagen.
- Carcinogenesis. In a systemic review of the literature between 1980 and 1996 
an increased risk of about 2% per year was estimated for non-melanoma 
skin cancers because of UVB therapy.39 
2.2.2 Laser 
2.2.2.1  History
The	word	LASER	is	an	acronym	for	Light	Amplification	by	the	Stimulated	Emission	of	
Radiation. That radiation is in the form of photons of light, which are the end product of light 
amplification	that	is	produced	in	turn	by	stimulated	emission.	The	concept	of	stimulated	
light emission was initially introduced by Einstein in 1917. Einstein proposed that a photon 
of electromagnetic energy could stimulate the emission of another identical photon from 
atoms or molecules that are in an excited state.40	The	first	laser	was	developed	by	Maiman	
in 1959 using a ruby crystal to produce red light with a wavelength of 694 nm.41 In 1963, 
Goldman pioneered the use of lasers for cutaneous pathologies by promoting ruby laser 
treatment for a variety of cutaneous diseases.42-45 The development of the Carbon dioxide 
(CO2) and the Argon lasers soon followed and served as the focus of cutaneous laser 
research during the next 2 decades42,46. The CO2 laser emitting infrared light at 10,600 nm 
was used for tissue vaporization and destruction of various epidermal and dermal lesions. 
Unfortunately, the continuous-wave (CW) CO2 laser also had a high rate of hypertrophic 
scar formation and pigment alterations because of prolonged tissue exposure to laser 
energy resulting in excessive thermal injury to the skin.42,47 The Argon laser produced 
blue-green light (wavelengths 488 and 514 nm) that was primarily used to treat benign 
vascular birthmarks. Although most port-wine stains and hemangiomas were effectively 
lightened, there was an unacceptably high rate of hypertrophic scar formation.42,48,49 
Cutaneous laser surgery was revolutionized in the 1980s with the introduction of the 
theory of selective photothermolysis by Anderson and Parrish (Table 3).50
2.2.2.2  Stimulated emission, population inversion and light amplification 51 
Every atom and molecule has a natural tendency to exist in its natural or resting state. 
The orbiting electrons of the atom or the molecule occupy a given natural position in this 
resting state. A photon of energy must be absorbed by the atom or the molecule for an 
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electron to move to a higher orbital level. Once an electron has moved to a higher orbital 
level, its natural tendency will be to return to its normal or resting state. In doing so, a 
given packet of energy will be released as a photon that will be characteristic for that 
atom or molecule. Such an emission of energy is called spontaneous emission. When 
many atoms or molecules undergo spontaneous decay, the emissions are out of phase 
with each other. However, if an electron in an excited state is stimulated by a photon of 
enough energy then that photon will cause orbital decay of the electron returning it to its 
resting state and result in the emission of a second photon identical to the incident photon. 
The net result is that two photons of the same wavelength (color) traveling in the same 
direction and in phase both spatially and temporally are released from the atom. This 
process	is	termed	stimulated	emission	and	is	the	first	necessary	element	in	the	production	
of laser light. The majority of the particles are in the resting state in a normal population 
of atoms or molecules. Pumping enough energy into the system will raise the majority of 
atoms or molecules to their excited state. Such a change, called a population inversion, is 
necessary for the production of laser light. Once a population inversion has occurred and 
so long as the energy continues to be pumped into the system, the stimulated emission of 
in-phase photons will result on their impact on other excited-state electrons resulting once 
again in additional in-phase photons that, in turn will do the same i.e. produce more in-
phase photons. When this chain-reaction “mass production” of in-phase photons occurs 
within	the	unique	structure	of	the	laser	optical	resonator,	the	process	is	magnified	further	
resulting	in	light	amplification	(Figure	4).
2.2.2.3 Laser Design 51-52 
The design of every laser is basically the same. A laser uses a power source, a lasing 
medium, and a chamber to stimulate the emission of photons (Figure 4).  The chamber 
(also	called	the	optical	cavity,	laser	cavity,	or	resonator)	has	a	fully	reflecting	mirror	at	one	
end	and	a	partially	reflecting	mirror	at	the	opposite	end.	The	partially	reflecting	mirror	has	
an opening with a shutter. The chamber contains a medium, which can be solid (ruby- 
and Nd:YAG-lasers), liquid (dye lasers), or gas or a mixture of gases (Argon- and CO2 
lasers). The medium is called an active medium when energized into its excited state 
by a power source. The active medium can be achieved through a variety of different 
sources including electricity, radio-frequency enhancement, light, chemical reaction and 
mechanical power. The external power source excites the atoms in the lasing medium. As 
unstable	atoms	release	their	photons,	they	travel	through	the	laser	chamber,	are	reflected	
by the mirrors at both the ends of the chamber and collide with other excited atoms in 
the lasing medium. This triggers a cascade of reaction resulting in numerous photons. 
Photons of the same wavelength, energy and phase are released at the same moment 
by	opening	the	shutter.	The	laser	light	continues	to	be	amplified	as	long	as	the	population	
inversion to an excited state continues. Laser light has several unique properties that 
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distinguish it from other light sources. These key properties (monochromaticity, coherence, 
collimation and high power) are the basis for the therapeutic applications of laser energy. 
On the one hand, non-laser light sources such as intense pulsed light devices emit light 
of	many	different	wavelengths	modulated	by	a	cutoff	filter.	On	the	other	hand,	laser	light	
is monochromatic, i.e.  all of the light emitted by a laser is of a single, discrete wavelength 
determined by the laser medium. The monochromatic nature of laser light is a critical 
property for the application of laser technology in clinical practice because cutaneous 
chromophores	selectively	absorb	light	of	different	wavelengths.	The	specific	wavelength	
of laser light also affects the distance it can penetrate into the tissue. The depth of the 
penetration of laser light generally increases with the increasing wavelength within the 
spectrum	of	visible	 light.	The	depth	of	 the	 target	chromophore	as	well	as	 the	specific	
wavelength absorbed by that chromophore must be taken into account when one chooses 
a laser for clinical use. Another unique property of laser light is that the light is coherent, 
i.e. the waves of light are in phase with each other in both time and space. The coherent 
nature of laser light is due to the process of stimulated emission. The light emitted from 
a laser is in the same direction and in the same phase. Collimation refers to the parallel 
nature of the waves emitted by a laser.42		A	laser	creates	a	collimated	beam	by	reflecting	
the light in a chamber between two mirrors that allows the exit of parallel waves only. The 
tendency toward divergence is low because the waves of light are parallel to each other. 
The	amplification	process	within	the	laser	cavity	produces	a	high	power	density.		Energy	
and power both quantify the amount of light emitted from a laser. The unit of energy is 
the joule (Joule = name of English physicist, 1818-1889, 1 joule = 0.239 calorie, 1 calorie 
= amount of heat required to warm 1 gram of water to 1 degree) and represents work. 
Fluence refers to the energy density of a laser beam measured in joules per square 
centimeter. Irradiance, the power density of a laser beam, is the power of the laser beam 
divided	by	the	area	of	the	laser	beam	(spot	size	=	π	x	r2) and is expressed as watts per 
square centimeter (W/cm²). Peak power is inversely proportional to   the pulse width or W 
=	J/sec:	1	joule	in	1	second	=	1	Watt,	1	joule	in	1msec	=	1000	Watts,	1	joule	in	1	μsec	=	
1,000,000 Watts. Fluence and irradiance are directly proportional to each other: Fluence 
(J/ cm²)  = irradiance x exposure time =  W/cm² x sec. The effect of laser light on human 
skin	can	be	affected	by	power,	time	and	spot	size.	If	the	power	or	time	is	doubled,	fluence	
increases	by	a	factor	of	2.	If	the	spot	size	is	doubled	the	fluence	decreases	by	a	factor	
of	4.	Decreasing	the	spot	size	by	a	factor	of	2,	results	in	an	increases	the	fluence	by	a	
factor of 4.
2.2.2.4 Laser-tissue interactions
Light	may	interact	with	tissues	in	four	key	ways:	transmission,	reflection,	scattering	and	
absorption. Transmission refers to the passage of light through a tissue without having any 
effect	on	that	tissue	or	on	the	properties	of	the	light.	Reflection	refers	to	the	repelling	of	the	
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light from the surface of the tissue without an entry into the tissue. Approximately 4% to 
7%	of	the	light	is	reflected	from	the	surface	of	the	skin.50	The	amount	of	the	light	reflected	
increases	with	the	increasing	angle	of	incidence	with	the	least	reflection	occurring	when	
the laser beam is directed perpendicularly to the tissue. Scattering of the light occurs after 
it has entered the tissue. Scattering is due to the heterogeneous structure of tissues, with 
variations in the particle size and the index of refraction between different parts of the 
tissue determining the amount of scatter. Scattering spreads out the beam of light within 
the tissue resulting in the irradiation of a larger area than anticipated. Scattering also 
limits the depth of penetration because it can occur forwards as well as backwards. Most 
scattered light is because of the interaction with dermal collagen in the skin. Generally, the 
amount of scattering of laser light is inversely proportional to the wavelength of the laser. 
Longer wavelengths thus penetrate the tissue more deeply. An exception to this rule is 
the laser light beyond the mid-infrared region in the electromagnetic spectrum.53 Laser 
light	with	wavelengths	of	more	than	1300	nm	only	penetrates	superficially	because	of	the	
high	absorption	coefficient	of	the	tissue	water.	Laser	light	absorption	by	specific	tissue	
targets is the fundamental goal of clinical lasers. According to the Grothus-Draper law, 
light must be absorbed by the tissue to produce any effect in that tissue. The absorption 
of the photons of laser light is responsible for its effects on the tissue. The components 
of the tissue that absorb the photons preferentially depend on the wavelength. These 
light-absorbing tissue components are known as chromophores. Frequently targeted 
chromophores in the skin include melanin, hemoglobin, water and exogenous tattoo 
inks (Figure 3). Absorption of energy by a chromophore results in the conversion of 
that energy into thermal energy.  A very short pulse of intense laser light will cause an 
explosive expansion in the tissue called a photomechanical (or photo acoustic) reaction. 
A longer pulse of less intense laser light causes rapid heating and denaturation in the 
tissue called photo-thermal effect. Lower intensities applied for longer times may result in 
photochemical tissue reactions. The theory of selective photothermolysis refers to laser 
energy	absorption	by	a	target	chromophore	without	any	significant	thermal	damage	to	the	
surrounding tissue. The laser must produce a beam of light with a wavelength preferentially 
absorbed by the chromophore in the lesion to achieve selective photothermolysis. Equally 
important is the pulse duration of the laser beam that must be shorter than the thermal 
relaxation time of the chromophore to prevent the spread of thermal energy beyond the 
targeted	chromophore.	The	thermal	relaxation	time	(TRT)	is	defined	as	the	time	required	
by the chromophore to cool down to half of its peak temperature after laser irradiation. 
The TRT is proportional to the square of the size (d = diameter) of the chromophore 
and inversely proportional to the thermal diffusivity of the tissue (k = 1.3 x 10-3 cm2/sec). 
Therefore, smaller objects cool down faster than larger ones. For example, 0.5- to 1.0-
μm	melanosomes	have	a	TRT	of	 approximately	 1	μsec,	whereas	100-μm	capillaries	
have a thermal relaxation time of approximately 10 msec. If the pulse width is larger than 
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the	 thermal	 relaxation	 time,	non-specific	 thermal	damage	occurs	because	of	 the	heat	
diffusion	into	the	surrounding	tissue.	Finally,	the	energy	(fluence)	delivered	to	the	target	
must be high enough to destroy the chromophore within the pulse duration. Based on the 
theory	of	selective	photothermolysis,	the	wavelength,	the	pulse	duration	and	the	fluence	
of	a	laser	can	be	tailored	to	provide	selective	damage	to	the	lesions	without	non-specific	
thermal damage to the surrounding tissues.
Most	cutaneous	lasers	produce	a	beam	with	a	Gaussian	profile	in	which	the	intensity	
peaks at the center of the beam and attenuates at the periphery. Clinically, this results 
in the necessity of treating tissue with some overlap of the laser beam to deliver energy 
to the tissue in a more uniform manner. Other modes of operation for lasers result in a 
doughnut-shaped or target-shaped distribution of energy delivery with the intensity of the 
laser	light	at	the	edge	of	the	beam	being	higher	than	at	the	center	or	fluctuating	across	the	
diameter of the beam.54 	These	modes	tend	to	approach	a	more	constant	intensity	profile,	
thus overlapping needs to be kept to a minimum to prevent overheating of the tissue at 
the periphery of the laser beam. The spot size of a laser is equivalent to the laser beam 
cross	section.	The	spot	size	directly	affects	the	fluence	and	the	irradiance	of	a	laser	beam	
as mentioned above. The spot size is also clinically important because of the scattering 
of the laser light in the skin. A small spot size allows more scattering both sideways and 
backwards than a larger spot size. This results in a more rapid reduction of the energy 
fluence	 in	 the	 tissue	 than	with	a	 larger	spot	size.	A	 large	spot	size	of	7-	 to	10-mm	is	
needed for the maximum penetration of laser light into mid-dermal or deeper targets. 
Increasing the depth of the penetration levels off with spot sizes of 10- to 12-mm.  
Lasers may differ in the manner in which their light is emitted or delivered. Some lasers, 
notably those with gaseous active media are capable of the continuous discharge of 
light also called continuous wave (CW). The power output of such lasers does not vary 
with time and is usually relatively low when compared with other forms of delivery. Such 
continuous waves can be broken up by an optical or a mechanical shutter that simply 
breaks	up	the	delivery	profile	of	the	CW	beam,	but	does	not	alter	the	power	output	of	
the beam per se. Such delivery, although confusing, is called pulsed delivery (of the CW 
beam). Lasers not capable of CW delivery (notably, solid lasers) are able to build up a 
“head” of power before releasing their “shock wave” or pulse of relatively high power. 
The pulses delivered by such lasers are usually quite short and are followed by a lag 
phase before another pulse can be generated.  The duration and the power of the pulse, 
as well as the duration of the lag phase differ for the various pulsed lasers. When the 
chromophore such as oxy-hemoglobin in the blood vessels (target) is located deeper in 
the skin, then unintended overlying targets such as epidermal melanin may be damaged. 
The selectivity of the laser for its intended target can also be improved by surface cooling. 
Cooling is also used to reduce the pain during laser therapy.
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2.2.2.5 Pulsed Dye Laser (PDL) 42
The basis of the laser therapy of vascular lesions is the destruction of abnormal vessels by 
the absorption of laser energy without damaging the surrounding tissues. The principles 
of	selective	photothermolysis	are	defined	as	the	targeting	of	an	exact	dose	of	 intense	
photo-thermal	energy	at	a	specific	wavelength	to	a	specific	structure,	a chromophore, 
to achieve a selective destruction of the target. The PDL conforms to the principles of 
selective photothermolysis. These are: 1) The pulse duration is less than the TRT of the 
target. The pulse duration of 0.45 milliseconds (ms) is shorter than the TRT (1 millisecond) 
of small- to medium- sized blood vessels; 2) The wavelengths 585 nm and 595 nm reach 
and are preferentially absorbed by oxy-hemoglobin in the desired target tissues (blood 
vessels	in	the	superficial	dermis)	(Figure	5);	3)	The	proper	fluence	reaches	a	damaging	
temperature in the target tissue without damaging the surrounding tissue structures. The 
PDL	therapy	is	performed	with	fluences	ranging	from	3	to	10	J/cm2 and a spot size of 2- 
to 10-mm with no more than 10% pulse overlap to minimize the risk of extensive thermal 
injury. It is well documented that hemoglobin peaks at 420 nm, 540 nm and 577 nm. The 
longer wavelengths penetrate the tissue deeper than the shorter wavelengths (Figure 6). 
Initially, the wavelength chosen for pulsed dye lasers was 577 nm. However, wavelengths 
from	585	to	595	nm	provide	a	deeper	penetration	with	an	insignificant	difference	in	the	
absorption by hemoglobin. As the laser light passes through the epidermis to the target 
vessels, it is absorbed by the hemoglobin and converted into heat within the abnormal 
vessel walls. Normal sized vessels are also heated, but because they are much smaller, 
they conduct heat away very rapidly and do not reach the temperature that is high enough 
to cause coagulation. The heating of the vessel walls causes coagulation or destruction of 
the	vessel.	The	Cynosure	laser	system	is	different	from	other	flash	lamp	pulsed	dye	lasers	
because	of	the	different	beam	profiles	characteristic	of	the	individual	manufacturer.		The	
Cynosure	beam	profile	resembles	a	“top	hat”	with	sharper	edges.		Other	systems	have	a	
beam	profile	that	is	not	as	clearly	defined	and	with	fuzzy	edges.	The	homogeneous	beam	
profile	of	the	Cynosure	laser	eliminates	the	need	to	overlap	the	delivered	pulses.
Adverse effects of PDL treatment:
- Purpura always occurs, may become darker 24-48 hours after treatment and 
lasts approximately 10 days.
- Hypo-pigmentation is represented by a decreased amount of pigment in 
the treated area as compared with the untreated, surrounding tissue. It is 
more commonly seen in dark skinned patients, but may also occur after sun 
exposure prior to laser treatment.
- Hyper-pigmentation is represented by an increased amount of pigment in the 
treated area as compared with the untreated, surrounding tissue. It may be 
caused by extravasation of erythrocytes through the laser-damaged vessels, 
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but it is usually caused by the activation of melanocytes in de epidermis. 
Pigmentation changes are usually transient and last for an average of 6 
months.
- Small minute spots of depression may occur post-laser therapy, if laser 
fluences	were	 too	high	or	 if	 there	was	a	significant	amount	of	overlapping	
during the therapy.  In	most	cases,	punctate	depressions	will	fill	in	naturally	
during the healing phase.
- Textural surface changes have occasionally been noted in patients who have 
failed to comply with the post-therapy skin care instructions. Surface changes 
usually involve small areas of excoriation. Hypertrophic scarring has never 
been reported.
- Blisters	and	crusts	may	be	an	indication	of	sun	exposure	or	a	too	high	fluence	
for the skin type. The blistered area should be treated with antibiotic ointment 
twice daily.  
Air cooling devices or cryospray systems are highly recommended to be used in 
conjunction with PDL therapy to minimize pain during the procedure and to prevent 
the activation of melanocytes or any damage to the melanocytes in the epidermis. 
2.2.3  Light absorption 2
The	 absorption	 of	 light	 is	 a	 specific	 and	 a	 unique	 event	 because	 each	 type	 of	
molecule	 is	 capable	 of	 absorbing	 radiation	 only	 in	 specific	wavelength	 ranges.	A	
molecule that has absorbed light enters an “excited” state, which exists for only a 
fraction of a second. Following photon absorption, molecules leave the ground state 
and are raised to a higher energy level known as the singlet excited state *S1. If an 
excited *S1 molecule does not undergo chemical change to form a photoproduct, 
it	may	emit	 the	energy	as	 light	 in	a	process	referred	 to	as	fluorescence	or	 it	may	
shed its excess energy as heat (decay). An excited *S1 molecule may also form a 
longer-lived triplet state *T1 by inter-system crossing. An *T1excited molecule may 
shed its excess energy as light. This process is called phosphorescence or heat 
(decay) (Figure 6). Heat can be used medically in laser surgery and diathermy. The 
quantum theory makes clear how light absorption works. The entire energy of a 
photon is absorbed by a molecule or it is not absorbed at all and the absorption of 
one photon involves only one molecule. The energy of the photon is taken up by 
the molecule and the photon ceases to exist as a result of absorption. Molecules 
exist	only	in	states	of	specific	energy.	The	energy	possessed	by	a	molecule	cannot	
be	varied	continuously,	but	only	in	specific	jumps	depending	on	the	specific	orbital	
distributions of the electrons in the molecule, which conform to the laws of quantum 
mechanics.	Each	of	 the	allowed	electronic	states	or	 levels	has	a	specific	energy.	
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The energy difference (ΔE) between the ground state and the excited state is the 
energy required to raise the molecule from the ground state to that excited level. 
The energy of a photon of wavelength λ is h/ λ.	The	 light	of	specific	wavelengths	
only which correspond to the energy differences between the ground state and the 
excited states of a given molecule will be absorbed by that molecule. The energy 
level of the excited state is inversely proportional to the absorbed wavelength as 
ΔE = h/ λ.  Each absorption process corresponds to a certain ΔE. The minimum 
amount of energy (hv1) necessary to raise a molecule to an electronically excited 
state is the amount required for the lowest excited state corresponding to the longest 
wavelength of light absorbed by the molecule. More energy (hv2) and consequently 
a shorter wavelength of light are required to excite a molecule to a higher excited 
state. More wavelengths may be absorbed by a molecule according to the number 
of the orbital distributions of the electrons in the molecule. These wavelengths are 
read in a spectrometer as the absorption spectrum of a molecule. Actually, such 
simple line spectra are obtained only for atoms. When atoms are covalently joined 
together into molecules, new motions such as rotation and vibration occur. These 
add additional energy to the electronic states resulting in many more absorptions. 
The absorption spectrum of a molecule is made up of numerous lines representing 
the absorption probability at each wavelength. The lines are spaced so closely 
together that they cannot be distinguished and only the contour of their heights is 
recorded. The wavelengths that have the highest probability of absorption are called 
the absorption maxima of the absorption spectrum. The absorption maxima may be 
used as identifying characteristics of a compound. The absorption spectrum of a 
chemical compound is related to the molecular structure of that compound and the 
color of a compound is determined by the wavelengths that are absorbed (Figure 
7).
2.2.4 Topical photodynamic therapy (PDT)
Heme-containing enzymes are essential for energy metabolism. Protoporphyrin (Pp) IX 
is the immediate precursor of heme in its biosynthetic pathway and thus every nucleated 
cell in the body must have at least a minimum capacity to synthesize PpIX. PpIX does not 
enter	the	cells	from	the	extra-cellular	fluid	via	the	plasma	membrane,	but	is	synthesized	
within the mitochondria of the cells. 5-Aminolaevulinic acid (ALA) is a naturally occurring 
delta amino acid that is converted into PpIX. The synthesis of heme is regulated by 
a feedback mechanism in which free heme inhibits the synthesis of 5-ALA catalyzed 
by 5-ALA synthetase. This process is regulated so closely that photo-sensitizing 
concentrations of PpIX never accumulate under normal conditions. However, an excess 
of exogenous 5-ALA bypasses this negative feedback control mechanism resulting in 
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a transient intracellular accumulation of PpIX.55 Photo-sensitization can be achieved 
either by administering exogenous photo-sensitizing molecules (porphyrins, chorins, and 
phthalocyanines) or by taking advantage of the endogenous pathways via the topical 
application of precursors such as 5-aminolaevulinic acid (5-ALA) or its derivatives.56 
The molecule 5-ALA itself is not a photo-sensitizer. 57 Topically applied, 5-ALA and 
its ester derivatives use the intrinsic cellular heme biosynthetic pathway to produce 
photo-active porphyrins via a series of enzymatic reactions between the mitochondria 
and the cytosol. Following activation of PpIX  with light of the appropriate wavelength, 
reactive oxygen species (ROS), particularly singlet oxygen are generated by transfer 
of the energy to the molecular oxygen present in the tissue. These ROS modify either 
continuous cellular functions, damage other components of the target cell including the 
mitochondria, the endoplasmic reticulum and the plasma membrane 58,59 or induce cell 
death by necrosis or apoptosis60,61 depending on their amount and their location within 
the target tissue. Supplementing this direct assault are the indirect pathways of cellular 
destruction	such	as	the	recruitment	of	inflammatory	cells,	increased	immune	response	
and vascular compromise.62 Singlet oxygen can also destroy the photo-sensitizing agent 
itself and prevent further action, a process referred to as photo-bleaching. Following 
PDT, after photo-bleaching, the synthesis of PpIX continues and reappearance of PpIX is 
subsequently observed. 
The accumulation of PpIX following administration of 5-ALA is more pronounced in 
rapidly proliferating cells such as pre-malignant and malignant cells as compared with 
the surrounding normal tissue.63-65  This phenomenon is due to the decreased activity 
of ferrochelatase in the neoplastic cells. The latter enzyme catalyses the insertion 
of	iron	into	PpIX	finally	forming	non-photodynamically	active	heme.	Along	with	the	
deficiencies	in	the	metabolic	pathway	of	heme,	other	factors	including	the	increased	
5-ALA uptake, the limited availability of iron, the cell cycle, the proliferation activity, 
the mitochondrial density, the increased temperature and the lower pH values were 
suggested to alter the biosynthesis of heme in the neoplastic cells.64,66 The increased 
permeability of many cutaneous neoplasms because of a damaged skin barrier will 
further enhance the activity when 5-ALA is applied topically. 67 Two products for 
topical	PDT	of	actinic	keratoses	(AK)	have	received	marketing	authorization.	In	the	
USA, the 5-ALA hydrochloride 20% (Levulan®	Kerastick®, DUSA Pharmaceuticals 
Inc.,	Wilmington,	MA,	USA)	has	been	approved	for	the	photodynamic	therapy	of	AK	
in combination with blue light (417 nm) for 1000 sec (16 min and 40 sec) at 10 J/cm2, 
after	14–18	hours	incubation	with	light	protection.68,69 Shorter incubation times (1-3 
hours) in combination with blue light (405 nm) were reported in different studies.70,71 
In Europe the methyl ester of 5-ALA methyl 5-aminolaevulinate (MAL) 16% in a 
cream formulation (Metvix® , Galderma, Photocure ASA Oslo, Norway), has been 
approved	for	the	therapy	of	AK	and	basal	cell	carcinoma	(BCC)	in	combination	with	
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red	 light.	MAL	showed	a	more	selective	accumulation	 in	AK	and	BCC	and	being	
more lipophilic than 5-ALA led to higher porphyrin synthesis than 5-ALA.64,65  MAL is 
applied after removal of crusts for 3 hours under occlusion. Both ALA and MAL led 
to the production of PpIX, which showed a large peak in absorption spectra at 409 
nm (Soret-band) with much smaller peaks at 506 nm, 532 nm, 580 nm and 635 nm 
(Q-bands) (Figure 8). While blue light such as that emitted by the Blu-U® (DUSA 
Pharmaceuticals, Wilmington, MA) or Omnilux Blue™ (Photo Therapeutics Inc., 
Carlsbad, CA) takes advantage of the highest absorption spike at 417 nm, it is limited 
by the depth of penetration to about 1.5- to 2-mm. Red light (>600 nm) requires higher 
energy levels to achieve the same effect (because of the lower PpIX light absorption 
at longer wavelengths), but has the advantage of being able to penetrate deeper.68 
The effectiveness of PDT depends on (1) the photo-sensitizer used, its ability to 
selectively penetrate the diseased tissue and the duration of application; (2) the 
activating light source, its ability to penetrate into the desired target and the duration 
of exposure; and (3) the type of target cells and their oxygenation status. To be 
effective, the damage resulting from PDT must surpass cellular repair mechanisms, 
a feature referred to as the minimum photodynamic dose.
The goal of PDT is the selective destruction of targeted abnormal cells while preserving 
the normal structures. The initial step to PDT is the photo-sensitization of the abnormal 
cells.72 The key cellular principle is the preferential accumulation of photo-sensitizers in 
tumor cells causing a cascade effect of radical oxygen species once illuminated. Many 
photo-sensitizers are lipophilic and accumulate in membrane structures damaging both 
the plasma membrane as well as the mitochondrial structures.73 The net result is cell 
death by apoptosis and necrosis. It is important to note that although PDT results in 
singlet oxygen species, these reactive radicals are short lived with a radius of action of 
only	0.01	μm	and	therefore,	have	very	low	mutagenic	potential	for	DNA	damage.74  At the 
tissue level, PDT was found to have an effect on both the tumor and its vascular supply. It 
is	postulated	that	water-soluble	sensitizers	have	a	higher	affinity	for	the	vascular	system,	
whereas the lipophilic molecules have a direct effect on the tumor itself.55 
Conventional	light	sources	are	divided	into	four	sub-categories	(the	first	three	covering	
the entire visible spectrum):68 
- Incandescent lamps are essentially conventional light bulbs
- High-pressure arc lamps
- Low-pressure arc lamps
 - Light emitting diodes (LED) are small semiconductors with a narrow 
wavelength	band	of	20–50	nm
Lasers	by	definition	are	monochromatic	light	sources.	Diode	lasers	(632	nm	and	670	nm)	
and pulsed dye lasers (585 nm and 595 nm) have been used in PDT. Given that lasers 
emit coherent light, they can be focused with high precision even on very small target 
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areas with sharp boundaries.75 
It was reported in a comparative trial that light of shorter wavelengths is less effective 
in the treatment of Bowen’s disease at a theoretically equivalent dose. 76 Therefore, 
only the use of red light was recommended for PDT of skin tumors.81 Non-melanoma 
skin cancer of up to a thickness of 2- to 3-mm can be treated with red light; thicker 
lesions require multiple treatments or tissue preparation (de-bulking) prior to PDT.78,79 
Laser or incoherent light sources may be used for a successful ALA/MAL-PDT. 
Pulsed laser light sources matching one of the Q-bands at 585 nm were reported to 
have similar results as compared with those using an incoherent light source in the 
treatment	of	AK.80 Although not ideally matching the porphyrin absorption spectrum, 
the use of a long-pulsed dye laser at 595 nm (V-beam, Candela Corporation, Wayland, 
MA,	USA)	was	also	reported	to	be	effective	for	treating	AK.81 In contrast to lasers, 
light	 sources	 with	 wide	 illumination	 fields	 enable	 the	 simultaneous	 irradiation	 of	
larger areas. Here, incoherent light sources such as lamps (PDT 1200L, Waldmann 
Medizintechnik, Villingen- Schwenningen, Germany) or light emitting diodes (LEDs) 
(Aktilite,	Galderma,	France;	Omnilux	PDT,	Phototherapeutics,	Altrincham,	UK),	which	
match the absorption maxima of the ALA- or MAL-induced porphyrins are preferred. 
80,82-84 	A	broad-spectrum	red	 light	(580–700	nm)	dose	of	100–150	J/cm2 (100–200	
mW/cm2)	is	chosen	for	treating	malignant	tumors.	The	values	are	significantly	lower	
(37–80	J/cm2) for the more narrow emission spectra of the LED systems (bandwidth 
approximately 30 nm). The light intensity should not exceed 200 mW/cm2 to prevent 
hyper-thermic effects.80,82 A	light	dose	of	10–40	J/cm2	and	a	light	intensity	of	50–70	
mW/cm2	(broad-spectrum	red	light)	is	recommended	for	inflammatory	dermatoses.	
During irradiation, both the patient and clinic staff should be wearing protective 
goggles in order to avoid the risk of eye damage.85 Since proliferating, relatively iron-
deficient	tumor	cells	of	epithelial	origin	are	highly	sensitized	by	ALA	or	MAL,	tissue	
damage is mostly restricted to the sensitized cells almost omitting the surrounding 
tissue,	especially	cells	of	the	mesenchymal	origin	such	as	fibroblasts	resulting	in	an	
excellent cosmesis. 86  The	same	applies	for	the	cells	in	inflammatory	dermatoses.	It	
was reported that fractionated laser light (on-off) was more effective than continuous 
illumination at the same power density and using the same photo-sensitizers. 87,88  A 
fractionated illumination of 20 + 80 J/cm2 separated by a 2-hour dark interval after a 
single	application	of	20%	ALA	in	treatment	of	superficial	BCC,	Bowen’s	disease	and	
AK	lesions	achieved	high	complete	response	rates	after	a	2-year	follow-up	period.88 
It was suggested by Braathen et al89 and Christansen et al90  that shorter incubation 
times	may	be	sufficient	for	a	successful	treatment.	
Until	recently,	clinically	approved	indications	were	restricted	to	AK,	superficial	and	nodular	
BCC and Bowen’s disease. The range of indications has been expanding continuously. 
Nowadays, PDT is also used for the treatment of non-malignant disorders such as acne 
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vulgaris, verrucae vulgaris, leishmaniasis and skin ageing.91 Various guidelines on PDT 
have been published, but no complete consensus has been reached as yet .92,93 
Adverse effects of PDT 94: 
- Pain of varying intensity is experienced by most patients undergoing PDT. 
The pain is described as a burning, stinging or a prickling sensation in the 
treatment area during illumination. The mechanism behind the PDT-induced 
pain is probably a consequence of nerve stimulation or damage by reactive 
oxygen	species	generated	during	illumination.	The	subsequent	inflammatory	
reaction may also contribute to the long-term pain sensation. Measures 
such as topical anesthetic to reduce the pain during PDT have no effect.95-97 
Unilateral	peripheral	nerve	block	appeared	to	be	very	efficient	 in	reducing	
MAL-PDT induced pain and did not affect clinical outcome.98  Subcutaneous 
infiltration	 anesthesia	 was	 significantly	 more	 effective	 in	 reducing	 5-ALA	
PDT-related pain than oral analgesics.99 Administration of oral analgesics 
may	be	indicated,	especially	if	the	irradiation	field	is	extended.	A	significant	
reduction in pain score during PDT treatment was reported when cold air 
analgesia 100  and cooling by fans or spraying water on the lesion were used. 
It was reported that the pain during illumination depended on the location, 
the size and the histological type of the lesion. Large lesions on the face and 
the scalp were most painful.101 Localized erythema and edema in the treated 
area are usually seen after PDT, followed by a dry necrosis restricted to the 
treated area over the next days after tumor treatment.69 
- Post-treatment photo-toxicity up to 48 hours.
- Contact allergy to MAL (approximately 1 % risk).102 
2.2.5 Fluorescence  detection (FD)
After application, 5-ALA is taken up actively at higher concentrations in tumor cells 
than in normal cells leading to a concentration ratio of PpIX. This ratio can be used 
in	 PDT	 to	 selectively	 destroy	 the	 diseased	 tissue	 and	 in	 fluorescence	 detection	
to visualize the diseased tissue (Figure 9).103 PpIX absorbs light entering into the 
excited state. The molecule leaves the excited state via 3 different pathways. The 
first	2	options	are	the	return	to	the	ground	state	by	either	 transforming	the	stored	
light	 into	heat	or	 by	emitting	 the	energy	as	 light,	 the	 so-called	 fluorescence.	The	
fluorescence	 is	shifted	 to	 the	 longer	wavelength	 (600-700	nm)	as	compared	with	
the excitation light (400 nm). The third pathway is the cross-over to the intermediate 
state of the photo-sensitizer and the subsequent generation of ROS for PDT. The 
fluorescence	quantum	yield	is	the	percentage	of	molecules	that	convert	the	absorbed	
light	energy	 into	fluorescence.	The	fluorescence	quantum	of	PpIX	 is	only	15%	so	
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that the molecules must be excited with light at 400 nm, which coincides with their 
maximum absorption. Light emitting diodes are spectrally centered at 405 nm and 
have a spectral half-width of 20 nm. The LED light is transformed by PpIX into red 
fluorescence.	The	fluorescence	is	detected	using	a	digital	camera.	A	special	optical	
filter	 in	 the	 front	 of	 the	 camera	 	 blocks	 the	 unwanted	 blue	 light	 imaging	 the	 red	
PpIX	fluorescence	only.	A	normal	color	image	of	the	skin	area	under	investigation	is	
possible	for	diagnostic	use	without	this	filter.	Blue	light	penetrates	the	skin	to	a	depth	
of 1- to 2-mm. Excitation using deeper penetrating wavelengths such as green- or 
red light (Q- bands) is theoretically possible, but these bands are 10- to 20-fold 
smaller than the Soret-band (blue light).103 The light intensity is kept at values of 
lower than 1 mW/cm2  to prevent any PDT effect.
The	 traditional	 fluorescence	 aided	 detection	 of	malignant	 and	 pre-malignant	 skin	
lesions is a three- step process as follows:
Application of a photo-sensitizer such as 5-ALA 20% in moisturizing cream, 1. 
methyl ester of 5-ALA 16% (Metvix) or 5-ALA 20% in propylene glycol and 
alcohol	(Kerastick	–	USA)	under	occlusion.
2.  Blue light (417 nm) delivered to the tumor and the immediate vicinity
3.  Fluorescence detection at wavelengths  above 600 nm.
An	incoherent	light	source	is	sufficient	for	exciting	the	porphyrins	in	the	skin	lesions	
of	 interest	after	 topical	application	of	ALA.	The	fluorescence	 is	excited	by	a	flash	
lamp emitting light in the spectral range of 380 nm to 450 nm at a repetition rate 
of	about	10	Hz.	The	area	of	interest	is	immediately	exposed	to	the	excitation	flash	
and	the	fluorescence	of	the	lesion	is	monitored	by	a	CCD-camera	triggered	by	the	
flash	 lamp.	This	pulsed	system	enables	a	dermatologic	fluorescence	diagnosis	 in	
an ambient light situation (Dyaderm, Biocam GmbH, Regensburg, Germany). The 
camera is connected to a personal computer and provides the normal RGB-image 
and	the	fluorescence	images	at	the	same	time.	These	images	are	displayed	in	real-
time	on	a	PC	screen.	Moreover,	the	fluorescence	images	are	processed	by	analyses	
routines, which help to estimate the size of each lesion. Additionally, the resulting 
fluorescent	 area	 is	 false	 color-coded	and	 superposed	on	 the	 normal	RGB-image	
to show the exact position and the size of the lesion in the clinical image of the 
skin.103 Calibration using the surrounding tissue allows one to enhance the contrast 
of	 the	 lesion	with	 respect	 to	 the	background	fluorescence	 in	a	single	 image.	The	
fluorescence	intensity	is	thus	given	as	a	ratio	between	the	lesion	and	the	reference.	
The non-homogeneous irradiation of the investigated skin by the light source can 
also be corrected for by using a quantitative read-out. Additional parameters such 
as	 the	 age,	 the	 skin	 type,	 the	 pigmentation	 and	 the	 inflammation	 that	 influence	
the	measured	fluorescence	 intensity	can	thus	be	considered	and	corrected	for	by	
employing	various	algorithms.	Multiplication	of	the	resulting	fluorescence	image	with	
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the	specific	adjustable	parameters	enables	one	to	make	optimum	use	of	the	dynamic	
range of the CCD-camera in order to obtain the highest possible contrast. The false 
color presentation then makes it easier for the investigator to evaluate the distribution 
of	the	fluorescence	intensity.	In	addition,	the	false	color-coded	fluorescence	image	
can	be	superposed	on	the	clinical	image.	Thus,	the	fluorescence	contrast	and	the	
white	light	images	of	the	lesion	are	combined	in	a	single	image.	The	fluorescence	
detection system is limited by the penetration of the used chromophore and the 
penetration depth of the excitation light.104 The image processing described above 
enabled	the	detection	of		the	suspected	areas,	which	showed	a	fluorescence	ratio	of	
> 2.0 for a neoplastic transformation as compared with the surrounding peri-lesional 
tissue.	Fluorescence	detection	may	also	be	used	to	estimate	the	efficacy	of	PDT.	
The digital image processing allows quantitative and user-independent analyses of 
the	detected	fluorescence	intensities,	which	significantly	enhances	the	fluorescence	
contrast between the tumor and the surrounding tissue.103 
2.3 Liposomes 
Liposomes are microscopic vesicles formed from phospholipids as biological 
membranes. A fundamental feature of cell membranes is the organization of lipids 
into bi-layers  providing permeability barriers between the exterior and the interior 
compartments. A large group of biological membrane lipids that spontaneously form 
bi-layers in water are the phospholipids. A class of phospholipids commonly used 
to construct liposomes for drug delivery is phosphatidylcholine (lecithin).105 The 
ability of phospholipids to form a bi-layer structure is because of their amphipathic 
character resulting from the presence of a polar or hydrophilic (water-attracting) 
head-group region and a non-polar or lipophilic (water-repellent) tail. The hydrophilic 
head groups orientate toward the aqueous phase and the lipophilic tails orientate 
to each other in the presence of water.105 Therefore, liposomes contain a lipophilic 
compartment within the bi-layer membranes and hydrophilic compartments between 
the membranes. Under the right conditions, water-soluble substances can be stored 
into the water phase and lipophilic substances into the lipid phase.106 In general, 
phospholipids spontaneously form large multi-lamellar liposomes and special process 
conditions and post-process steps are required to produce appropriately sized (uni-)
lamellar	 liposomes.	 Liposomes	may	be	 small,	 uni-lamellar	 vesicles	 (SUVs	25–50	
nm	in	diameter),	large,	uni-lamellar	vesicles	(LUVs	50–500	nm	in	diameter)	or	large	
multi-lamellar	vesicles	(LMVs	500–10,000	nm	in	diameter).	SUVs	are	less	suitable	for	
drug delivery because they lack stability and their volume is too small for entrapping 
drugs. The penetration of liposomes through the stratum corneum decreases with 
increasing diameters. Therefore, the preferred structures for drug delivery are 
LUVs	that	are	50–500	nm	in	diameter.105 Next to the preferred sizes, an essential 
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characteristic of liposomes for penetration through the stratum corneum is their state 
in a liquid crystal phase. The lipid bi-layer passes from a gel into a liquid crystal 
phase at a critical phase transition temperature (cptT). At the cptT, the head groups 
become fully hydrated and the lipid chains become freely mobile in the membrane. 
The cptT is determined by the length and the saturation of the paired lipid chains.107 
(Lipids such as phosphatidylcholine, form bi-layers at cptT below room temperature. 
This liquid crystal state is essential for liposomes to interact simultaneously with the 
lipid and the aqueous compartments of the stratum corneum, and for delivering the 
entrapped drugs into the skin.108 The similarity in the lipid composition of liposomes 
and the membranes of the intercellular lamellae and the keratinocytes enables the 
liposomes and the drugs encapsulated into them to penetrate into the epidermal 
barrier to a higher extent than that with other forms of application.109 This may result 
in an increased absorption, but a decreased clearance of drugs from the epidermis 
thereby promoting  a prolonged sustained release of drugs in the epidermis and a 
lower absorption of drugs into the blood circulation. Therefore, liposomes may not 
only act as drug transporters, but also as drug localizers.110 Fluorescent liposomes 
applied to the skin were found inside the epidermal keratinocytes.111 Liposomes 
fuse with the outer cell membrane and deliver their contents into the cytoplasm via 
endocytosis.112  It is possible to introduce even large molecules into the cytoplasm of 
keratinocytes by using liposomes as intracellular transporters after which they may 
prove	 their	 efficacy.113 Moreover, ‘empty’ liposomes (without encapsulated drugs) 
hydrate the skin simply by providing lipids to the stratum corneum.114  This hydration 
capacity	may	be	of	benefit	in	the	treatment	of	xerosis	cutis	and	atopic	dermatitis.115 
2.4 Summary of laser basics relevant in this study:116  
a. Thickness of the compartments of the human skin:
-	 Stratum	corneum	10	μm	=	0.01	mm
-	 Epidermis	100	μm	=	0.1	mm
-	 Papillary	dermis	200	μm	=	0.2	mm
-	 Reticular	dermis	2.800	μm	=	2.8	mm
- Total dermis = 3.0 mm.
b. The main chromophores in the skin are:
- Water present in all the tissues, absorption wavelengths above 
 1.300 nm
- Oxy-hemoglobin in the blood vessels absorption wavelengths 400 nm 
 to 600 nm
- Melanin in the epidermis, the dermis and the hair follicles preferentially   
absorbs wavelengths of between 600 nm and 1.300 nm.
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c. Selective Photothermolysis  
 Thermal injury is restricted to a given target without damaging the    
surrounding tissues, if:
- The wavelength of the laser light corresponds to the absorption peak of   
the target
- The pulse duration is shorter than the thermal relaxation time of the target
-	 The	energy	delivered	during	exposure	is	sufficient	to	destroy	the	target
- The effective penetration depth of the laser light encompasses the    
entire target. The effective skin penetration of the PDL 585 nm is 1.2 mm.
d.	 Thermo-kinetic	selectivity	(TKS)
- Large targets of the same chromophore retain heat longer than the   
smaller ones 
- High energy required to damage a large target will spare a smaller    
structure if the energy is infused for a period that exceeds the required   
time for the smaller structure to release its absorbed heat. For example:   
The TRT has to be between the TRT of the epidermis (3-10 msec) and the 
TRT of the hair follicle ( 40-100 msec) to heat the melanin in the hair follicles 
sufficiently	to	damage	the	hair	follicle,	but	without	damaging	the	epidermis	by	
heating the epidermal melanin. Thus, the pulse durations of  between 10 and 
50	msec	are	sufficient	to	destroy	hair	follicles	while	minimizing	the	undesired	
epidermal injury.
e. Extended Theory of Selective Photothermolysis and Thermal Damage Time 
(TDT). Chromophores such as melanin in the hair follicles and oxy-hemoglobin 
in the larger blood vessels may be used as a source of heat, which may destroy 
the target by conduction to the outer (non-chromophore containing) structures. 
The pulse width has to be long enough to avoid damage to the chromophore, 
and must be long enough to heat and damage the surrounding structures (the 
bulge of the hair follicle, the wall of blood vessels). This is called Thermal 
Damage Time (TDT).
f.        Absorption of energy by a chromophore results in the conversion of that energy 
into thermal energy  
- A very short pulse of intense laser light will cause an explosive expansion of 
the tissue and is referred to as photomechanical (or photo-acoustic) reaction
- A longer pulse of less intense laser light causes rapid heating and denaturation 
of the tissue and is referred to as photo-thermal effect
- Lower intensities applied for longer times may result in photochemical tissue 
reactions.
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Positive effects of sunlight Negative effects of sunlight
Photosynthesis Induction of skin cancer
Ability of vision Cataract of the eye lens
Warmth Sunburn
Vitamin D production Ageing of the skin (helio-dermatosis):
=> prevention of : - wrinkles
- rickets and osteoporosis - hyper-pigmentation
- multiple sclerosis, DM Type I, ,  - hypo-pigmentation
  hypertension rheumatoid arthritis - hyperkeratosis
- carcinoma (prostate, mamma, ovary, - actinic keratosis
  colon
- non-Hodgkin’s lymphoma
=> improvement of:
- mental depression
- schizophrenia
Inhibition of virulent viruses and bacteria Induction or exacerbation of
 - discoid or systemic LE
 - rosacea
 - porphyria
Improvement (therapy) of skin diseases: Photo-dermatosis
- tuberculosis - polymorphous light eruption
- acne - solar urticaria
- psoriasis - photo-allergic skin reactions
- eczema - photo-toxic skin reactions
- vitiligo - phytophoto-dermatitis
Table	1.	Light	and	shadow	sides	of	sunlight	(modified	Ferguson	1).
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Epoch Country Worship
Second millennium B.C. Egypt Ra the sun god
Thirteenth century B.C.   Amenhotep III earthly messenger and mortal  
  link conducting solar power to the earthlings
Tenth century B.C. Greece Zeus (all-powerful deity) 
  His son Apollo (sun god and father of  
  medicine)
  Aesculapius (mortal son of Apollo) became a  
  famous physician and his staff, intertwined  
  by a serpent became the symbol of medical  
  profession
Sixth century B.C Persia Teaching of Zoroaster:
  Ahura Mazda (god of wisdom) 
  Mithras (deity of truth and light = sun god),  
  asserted the victory of good over evil, of light  
  over darkness
  Day of rest = Sunday
Second century B.C. Pergamum, Utopia of Aristonicus “Commonwealth of the 
 (Asia minor) sun” 
  Sun as symbol for justice and equality by  
  shedding light and warmth upon all people
Fifteenth century North America Tonatiuh (powerful sun god) whose face  
  forms the center of the Aztec calendar
1643-1715	 France	 Louis	XIV	King	of	France	selected	the	sun	as		
  his symbol of authority and required that his  
  subjects regard him as a sun god
Nineteenth	century	 Europe	 Tanned	skin	=	poverty	(working	in	the	fields)
  Pale skin = wealth (no need to work in the  
	 	 fields)
Twentieth century Western  world Tanned skin = wealth (no need to work in  
  factories, plenty of recreation time) 
  Pale skin = troublesome life
Twenty-first	century	 Whole	world	 Sunburn	is	stupid
  Solar energy replacing fossil energy 
Table	2.	Historical	overview	of	human’s	attitude	to	sunlight	(modified	Harber).
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Ancient Egyptians 8-methoxypsoralen (8-MOP)+ sunlight: treatment of vitiligo
1901 Max Planck introduced the quantum theory and the concept of photons
Early nineties Finsen lamp: tuberculosis of the skin
1917 Einstein stimulation of light emission LASER
1925 Goeckermann crude coal tar + ultraviolet light-B (UVB): psoriasis
1960 Maimann Ruby laser: pigmentation disorders
1964	Goldman	first	publication	on	laser	surgery
1970 Broad-band UVB: psoriasis
1974 Psoralen (8-methoxpsoralen) + Ultraviolet light A (PUVA) systemic treatment, followed by topical 
treatment (bath PUVA): psoriasis
1975 Argon laser: port-wine stain
1983 Anderson and Parrish Selective Photothermolysis: Pulsed Dye Laser fort port-wine stain
1985 Narrow-band UVB: psoriasis and eczema
 CO2-laser and Erbiumlaser for skin ablation
1989 Retinoin-PUVA: psoriasis
1996 Pulsed Dye Laser: psoriasis
2000 Photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) and blue light (USA) or PDT 
with methylaminolaevulinate and red light (Europe) for actinic keratosis
2009 Acne treatment with 5-ALA 0.5% liposomale spray and IPL, vitiligo treatment with khellin 0.005% 
liposomes and UVAB, Fluorescence Detection with 5-ALA 0.5% liposomale spray and blue light.
Table 3. History of light in Dermatology.
Figure 1. Wavelength is the distance between two corresponding points on each 
successive wave. Frequency (v) is the number of waves that passes a point per 
second.	Einstein:	 λ	 x	 v	 is	 equal	 to	 the	 speed	of	 light	 (300.000	 km	per	 sec).	The	
energy of a photon is inversely proportional to the wavelength.
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Figure 2.  The electromagnetic spectrum.
Figure 3.  Absorption curves of melanin, oxy-hemoglobin and water.
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Figure 4.   Design of the Pulsed Dye Laser.
Figure 5.  Penetration depth of lasers depends on the wavelength: 
 NBUVB light penetrates only into the epidermis 
	 PDL	light	penetrates	into	the	superficial	dermis	
 Diode light penetrates into the mid-dermis 
 Erbium and CO2 light is absorbed by water
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Figure 6.  Photon absorption raises molecules to the singlet excited state *S1, energy 
dissipation	 include	 fluorescence,	 phosphorescence,	 triplet	 *T1 state formation and 
formation of photoproducts.
Figure 7. Absorption spectrum of a molecule.
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Figure 8.   Protoporphyrin IX absorption spectrum.
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Figure	9.	Photodynamic	therapy	(PDT)	and	fluorescence	detection	(FD).
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Chapter 3 
3.1 Psoriasis
3.1.1 History, epidemiology and clinical aspects
 
The term psoriasis is derived from the Greek word psora meaning scale and was 
first	used	by	the	Greek	physician	Galen	to	describe	a	scaly	skin	condition	(129-99	
B.C.).	This	affliction	 included	probably	 true	psoriasis,	but	also	skin	diseases	such	
as eczema, scabies and leprosy. The confusion between psoriasis and leprosy 
continued for many centuries. People suffering from psoriasis were isolated from 
their community as lepers, the church declared them dead and in the 14th century 
Philip the Fair even ordered them to be burnt at the stake. Ferdinant von Hebra 
definitely	separated	the	clinical	features	of	psoriasis	from	those	of	leprosy	in	1841.1 
In	1908,	Robert	Willan	specifically	described	psoriasis	as	a	recognizable	entity.
Psoriasis	 is	 a	 chronic	 inflammatory	 and	 proliferative	 skin	 disease	 that	 affects	
approximately 2% of the world’s population.2,3  Different prevalence of psoriasis was 
reported for different countries, geographical regions and ethnic groups. Its prevalence 
ranges from 0% in Samoa to 4.6% in the USA, but is only 0.7% in African Americans. 
The estimated prevalence in Europe is 2-3%, and 0.7% in India, Nigeria and East 
Africa. Psoriasis is very rare in American Indians, Eskimos, Greenland Inuit Eskimos 
and Australian aboriginals. The risk of incurring psoriasis is about 20% if one parent 
has psoriasis, and is about 75% if both parents are affected. If one monozygotic twin 
suffers from psoriasis, the probability is more than 55% that the other will be affected 
too.4	No	significant	gender	differences	have	been	reported.	In	psoriasis	two	distinct	
patient cohorts have been recognized. Type I is characterized by a peak age of 
onset of psoriasis at between 16 and 21 year and type II onset occurs at about the 
age of 55 years. Type I patients are more likely to show widespread and recurrent 
disease as compared with late onset patients. They also have a history with affected 
parents (44% in type I and 0% in type II), and have a higher frequency of HLA 
Cw6 as compared with late onset patients (85% vs 14%) and for HLA DR7 (70% vs 
30%).2,5 Although only rarely life-threatening, psoriasis is disabling, incurable and the 
cause	of	significant	morbidity	and	of	a	poor	quality	of	life	of	the	patient.6  Plaque-type 
psoriasis (Figure 10) is the most common form of the disease (occurring in more 
than 80% of the cases), which is characterized by the presence of symmetrical, well-
demarcated, raised and erythematous scaly plaques.7  These plaques are commonly 
situated on the scalp and the extensor surfaces of the limbs. However, any skin 
site may be affected. Psoriasis usually runs a remitting course, its clinical behavior 
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varying between patients and also in the affected patient at different times. Active 
disease is distinguished by plaques increasing in size and number, whereas the most 
acute form, pustular psoriasis, is characterized by localized or widespread areas of 
superficial	cutaneous	postulation.7 
Other types of psoriasis are as follows:
Psoriasis guttata, a common form of psoriasis in children, associated - 
with preceding upper respiratory infection and raised anti-streptolysin 
titer indicating the relevance of streptococcal infections. The lesions 
vary from 2-mm to 1-cm in diameter and are round or oval. They are 
distributed more or less evenly over the body, particularly on the trunk
and the proximal part of the limbs.8 
-	 Psoriasis	 inversa	 (flexural	 psoriasis)	 characterized	 by	 red,	 sharply	
demarcated thin plaques in body folds such as the axillae, sub-mammary 
region,	groins	and	the	inter-gluteal	cleft	(often	a	central	fissure	is	seen).
Psoriasis palmoplantaris (Figure 11) exhibits red symmetric, sharply - 
bordered plaques with very adherent yellow-white scale and frequently 
with	painful	fissures.	In	psoriasis	pustulosa	of	the	palms	and	the	soles,	
the scaly erythematous plaques are admixed with sterile pustules and 
yellow-brown macules. 
Psoriasis of the nails affects about 30-50% of the psoriasis patients. The - 
numbers are even higher in those with psoriasis arthritis. The most typical 
sign is pitting when the nail matrix is involved. Psoriatic changes in the 
nail bed result in the “oil spot” phenomenon. Sub-ungual hyperkeratosis 
and distal onycholysis are due to the parakeratosis of the nail bed. 
Psoriatic arthritis occurs in 5-30% of the patients with cutaneous - 
psoriasis.
Psoriatic erythroderma represents the generalized form of the disease - 
that affects the whole body. 
Although generally associated with cutaneous morbidity only, extensive skin 
involvement may be accompanied by systemic disturbances in the thermo-regulation, 
the	fluid	balance	and	the	protein	metabolism.9 
Psoriasis follows a precarious course with regard to the age of onset, the morphology, the 
distribution, the exacerbations and the remissions as well as the response to treatment. 
Exacerbations may be triggered by stress10-12, alcohol consumption & smoking,13  physical 
trauma	(Koebner’s	phenomenon),4	medications		such	as	β-blockers,	lithium,	chloroquine,	
non-steroidal	 anti-inflammatory	 agents,	 tetracyclines,	 interferons,	 imiquimod14 and 
infections. 8,11,14 
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Figure 10. Plaque type psoriasis
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Figure 11. Psoriasis palmoplantaris
3.1.2 Histopathology
Psoriasis is histologically characterized by hyperproliferation of the epidermal 
keratinocytes,	 hyperkeratosis	 and	 infiltration of immunocytes accompanied by 
angiogenesis resulting in a typical thickening and scaling of the erythematous skin. 
The mitotic activity of basal keratinocytes is increased by a factor of 50 in the psoriatic 
skin resulting in an increased number of keratinocytes, the thickening of the spinous 
layer (acanthosis) and the elongation of the epidermal rete. The keratinocytes 
migrate	 	 from	 the	basal	 layer	 to	 the	cornified	 layer in about 4 days instead of the 
normal  28 days. (Figure 12).4 There is an aberrant expression of cytokeratins 6, 16 
and 17 that are associated with the hyperproliferation in the psoriatic epidermis.15 
The increased recruitment of keratinocytes in the psoriatic epidermis is visualized 
by	staining	 for	 the	Ki67	nuclear	antigen,	which	 is	a	 representative	marker	 for	 the	
growth fraction of the keratinocytes.16. The differentiation of keratinocytes is highly 
altered in psoriasis and parallels the ‘regenerative maturation’, an alternative cell 
differentiation program that occurs transiently during wound repair. The granular 
layer of the epidermis where the terminal differentiation begins is highly reduced 
or totally absent in psoriatic lesions. Consequently, the stratum corneum forms 
from incompletely differentiated keratinocytes that aberrantly retain a cell nucleus 
(parakeratosis).	 Scaling	 and	 thickening	 of	 the	 cornified	 layer	 (hyperkeratosis)	 is	
caused by the failure of psoriatic corneocytes (terminally differentiated keratinocytes) 
to stack normally. They secrete extracellular lipids and adhere to one another (Figure 
12).17  Other histological features of psoriasis include the presence of neutrophils 
within	small	foci	in	the	stratum	corneum	and	significant	mononuclear	infiltrates	in	the	
epidermis, which are detectable with immunostaining. In addition, there is a marked 
infiltration	of	mononuclear	leukocytes	such	as	T	cells	and	dendritic	cells	(DCs)	into	
the dermis. Blood vessels in the papillary dermal region are elongated and show 
hyperplasia. Marked dilation of these vessels causes the visible redness of psoriatic 
skin lesions. Many lymphocytes, monocytes and neutrophils clearly adhere to the 
endothelial cells that acquire characteristics of high endothelial venules, which are 
usually found in lymph nodes.18 Leukocytes may enter the skin parenchyma by 
transmigration through the reactive vessels, but resident skin leukocytes may also 
proliferate	resulting	in	the	dense	infiltrates	observed	in	the	psoriatic	lesions.17 
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3.1.3   Pathogenesis
3.1.3.1  Genetics. 
The pathogenesis of psoriasis is not completely elucidated. The development of 
psoriatic lesions depends on multiple interactions between the susceptibility genes 
and the environmental factors.19 Molecular genetic studies indicate that there are 
multiple susceptibility loci (PSORS1-8) present throughout the human genome. A 
number	of	genetic	loci	have	been	identified	by	genome	wide	linkage	scans	and	two	
loci have been replicated: PSOR1 on chromosome 6, within the MHC, including 
HLA-Cw6, HLA-B13 and HLA-Bw57 and PSOR2 on chromosome 17q.20,21 
3.1.3.2  Innate and adaptive immune response
As a primary defense organ, the skin forms a major barrier for the external elements and 
is thus permanently exposed to microbial, chemical and physical insults. Therefore, 
the skin has the capacity to generate both the innate as well as the adaptive immune 
responses.22 The innate immune response mediates the initial protection against 
infections and the adaptive immune response develops more slowly and mediates 
the later, even more effective, defense against infections. The innate response 
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Figure 12. Histopathology of psoriasis
Keratinocytes	require	28	days	un	the	normal	skin,	but	only	4	days	in	the	psoriatic	
skin to migrate from the stratum basale (str. bas.) to the stratum corneum (str. corn) 
resulting in:
- Hyperkeratosis and scaling
- Incompletely differentiated keratinocytes that aberrantly retain a cell 
nucleus in the str. corn
- Reduction or absence of the stratum granulare (str. gran)
- Thickening of the stratum spinosum (str. spin)
-	 Infiltration	of	immunocytes	and	granulocytes	into	the	epidermis	and	the	
dermis 
- Dilation, elongation and hypertrophy of vacular plexus resulting in sharply 
demarcated, elevated, red, scaly patches.
is	 antigen	 non-specific,	 lacks	 immunological	memory	 and	 involves	 the	 actions	 of	
keratinocytes,		DCs,	macrophages,	natural	killer	(NK)	cells	and	cytokines.	The	cell-
mediated	adaptive	immune	response	is	antigen	specific,	has	the	ability	to	recognize	
and respond to many different microbes, provides enhanced responses to recurrent 
or persistent infections and prevents injurious immune responses against host cells 
and tissues and involves the action of antigen-presenting cells (APCs), macrophages, 
DCs and T-lymphocytes.22 Innate and adaptive immune responses do not operate 
as separate or parallel systems, but represent a single highly integrated biological 
system designed to respond to infectious insults in a complementary fashion.
It is critical that a proper balance between the innate and the adaptive responses 
be maintained because on the one hand, septic shock may result from a cutaneous 
bacterial infection if the innate response is inadequate, whereas on the other hand, 
an	exaggerated	innate	response	may	result	in	a	chronic	autoimmune	inflammatory-
type response.23 
3.1.3.3  Toll-like receptors
Toll-like receptors (TLRs) are phylogenetically well conserved type I transmembrane 
proteins representing the major pattern recognition receptors of the innate immune 
system for various pathogen-associated molecular patterns (PAMPs).24 Toll-like 
receptor	 signaling	 leads	 to	 the	 activation	 of	 the	 nuclear	 factor	 kappa	 B	 (NF-κB)	
through the adaptor protein MyD88-dependent pathway and induces a battery 
of	 immune	 adjuvant	 effects,	 which	 are	 principally	 mediated	 by	 pro-inflammatory	
cytokines. To date, 11 TLR family members together with their agonists have been 
identified.	TLR3	binds	double-stranded	RNA	synthesized	by	viruses,	TLR4	recognizes	
bacterial	lipopolysaccharides,	TLR5	accepts	bacterial	flagellin	and	TLR9	is	activated	
by bacterial and viral DNA. TLR7 and TLR8 are triggered by imiquimod and their 
innate antiviral and anti-tumor effects are because of the induction of type I interferon 
(IFN). Type I IFNs also shape the adaptive arm of the immune response by driving 
TH1 responses. In human peripheral blood, the principal producer of type I IFNs 
in response to imiquimod is represented by plasmacytoid dendritic cell precursors 
(PDCs), a novel subset of lymphoid-related cells selectively expressing high levels 
of TLR7 and TLR9. PDCs are the key players in innate antiviral immunity because 
of their unique ability to produce large amounts of type I IFN. In addition, PDCs 
differentiate	into	DCs	with	the	ability	to	stimulate	T	cell–mediated	adaptive	immunity	
upon viral stimulation. TLR-mediated activation of innate immunity is involved not only 
in the host defense against pathogens, but also in immune disorders.24  Activation 
of	innate	immunity	is	a	crucial	step	in	the	development	of	antigen-specific	acquired	
immunity.25 	Psoriasis	is	a	chronic	and	relapsing	T	cell–mediated	autoimmune	disease,	
in which type 1 cytokine secretion by T cells induces keratinocyte hyperproliferation 
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in genetically predisposed individuals. In recent years, the observation that psoriatic 
plaques are resistant to microbial infection despite a compromised skin barrier has 
led to growing interest in the role of the innate immune system in psoriasis. It was 
shown that exacerbation of chronic psoriasis plaque may follow a repeated topical 
application of the TLR7 agonist imiquimod. A TLR7-mediated effect was indicated by 
the	massive	induction	of	lesional	type	I	IFN	after	imiquimod	therapy.	Keratinocytes,	
as non-professional APCs  possess a remarkable production repertoire of pro-
inflammatory	cytokines	and	constitutively	express	TLR1,	-2,	 -3,	 -5	and	-9,	but	not	
TLR7. Among professional APCs, TLR7 is principally expressed by PDCs, which in 
addition to their unique ability to produce large amounts of type I IFN in response 
to viral infection, also represent the principal producer of type I IFN in response to 
imiquimod. PDCs classically described in blood, secondary lymphoid organs, bone 
marrow,	 and	 thymus	 have	 also	 been	 described	 in	 inflammatory	 skin	 lesions	 and	
large	 numbers	 of	 PDCs	 have	 been	 identified	 in	 the	 dermal	 infiltrate	 in	 psoriasis.	
PDCs may represent key cellular mediators of innate immune responses driving the 
pathogenic events leading to psoriasis.24 TLR9 is the only known receptor to detect 
immunostimulatory DNA such as bacterial DNA.26  Activation of TLR9 leads to the 
activation of IFN-regulatory factor 5 (IRF5), tumor necrosis factor receptor-associated 
factor	6	(TRAF6),	and	NF-κB	and	the	rapid	production	of	inflammatory	cytokines	and	
chemokines including interleukin (IL)-8/CXCL8,	tumor	necrosis	factor	(TNF)-α,	IL-6,	
IL-12, and type I IFNs.27 IL-8 stimulates proliferation of keratinocytes and is also a 
chemoattractant for neutrophils.28 	Keratinocytes	express	functional	TLRs	and	play	
an	important	role	in	initiating	and	fine-tuning	innate	and	adaptive	immune	responses	
in the skin via secretion of cytokines and chemokines in addition to killing microbes 
by	producing	antimicrobial	peptides	(β-defensins).29 	Human	β-defensin-2	(HBD-2)	
is	 induced	as	a	part	of	 the	 inflammatory	 response	 in	 the	skin,	which	 in	psoriasis,	
is a part of the regenerative maturation process involving hyperproliferation and 
induction	 of	marker	 genes	 such	 as	 those	 encoding	 elafin	 and	 cytokeratins	 6,	 16	
and	17.	 It	was	reported	that	HBD-2	and	other	skin	β-defensins	have	cytokine-like	
properties in addition to their antimicrobial activity. The central role of these proteins 
in	the	innate	immune	system	of	the	skin	 indicated	that	β	-defensin	genes	may	be	
candidate genes for psoriasis susceptibility.30 
3.1.3.4  Apoptosis 
Apoptosis is the general name for physiologic cellular suicide caused by activation of 
an energy-dependent suicide program.31 -33  This process can be triggered by various 
stimuli including cytokines, hormones, viruses and toxic insults. Changes at the cell 
surface include the externalization of phosphatidylserine and other alterations that 
promote recognition by the phagocytes. Intracellular changes include the degradation 
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of the chromosomal DNA into the high molecular weight oligonucleosomal fragments 
and	the	cleavage	of	a	specific	subset	of	cellular	polypeptides.	This	cleavage	is	now	
known to be accomplished by a specialized family of cysteine-dependant aspartate-
directed proteases called caspases, which has been referred to as “executioner” 
proteins because of their roles in apoptosis. Some caspases are also required in 
the immune system for the maturation of cytokines. Failure of apoptosis is one 
of the main factors in the development of tumors and autoimmune diseases.34,35  
Therapeutic modalities such as UVB phototherapy and PUVA for psoriasis were 
reported to induce apoptosis of lesional T lymphocytes.36,37 	Keratinocytes	undergo	
terminal	differentiation	and	finally	cornification	during	their	normal	migration		to	the	
epithelial	surface.	This	differentiation	process	is	morphologically	characterized	first	
by cellular enlargement followed by shrinkage of the cytoplasm and nucleus within 
the	 upper	 part	 of	 the	 spinous	 layer.	 Their	 chromatin	 is	 finally	 degraded	 and	 the	
remaining nuclear structure dissolved within the stratum granulosum. The molecular 
mechanism of this process, called anoikosis resembles the apoptotic pathway. UVB-
phototherapy induced keratinocyte apoptosis with an increase in caspase-3 activity 
in time after irradiation, reaching a maximum at 12 hours, after which it declined 
slightly but still remained at a high level.38  Caspase-3 is one of the key executioners 
of apoptosis as it is either partly or totally responsible for the proteolytic cleavage of 
many key proteins leading to the characteristic “DNA ladder” seen in the apoptotic 
cells. 34  Induction of apoptosis by PDL was not observed in an experimental study 
using hamster skin.39  
3.1.3.5  Immune cell kinetics
Antigen-reactive T cells enter the skin at sites that harbors antigen during the course 
of a normal cutaneous immune reaction. Subsequently, the antigen is eliminated 
by an immune mechanism appropriate to the eliciting antigen (Ag). The initial step 
of	 every	 specific	 immune	 reaction	 to	 an	Ag	 is	 the	 recognition	 and	 the	 uptake	 of	
the Ag by professional APCs such as the DCs or the macrophages. The DCs are 
a rather unique cell type in that they may function in both innate and adaptive 
immunity. The second step is the migration of the cells to the T cell areas of local 
draining lymph nodes, the processing of the Ag and the presentation of selected 
Ag fragments (peptides) on the surface of the DCs to naïve T cells.40 The third step 
is the migration of mature T cells to the skin and the various roles played by the 
cytokines released from these T cells and other cells.41	In	normal,	non-inflamed	skin,	
immature Langerhans cells (LCs) are present as a three-dimensional network in 
the suprabasal layers where they can monitor the environment as sentinel cells on-
guard to detect foreign intruders. The immature LC is well suited for this task as it can 
phagocytose	and	then	process	antigen,	and	begins	an	efficient	migratory	pathway	
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towards the draining lymph node to initiate an immune response as a fully mature 
dentritic APC.23  Upon antigenic stimulation by the APCs, the naïve CD4+  T cells 
are activated, expand and differentiate into three different effector subsets termed 
T helper 1(Th1) , T helper 2 (Th2) and T helper 17 (Th17), which are characterized 
by the production of distinct cytokines and effector functions.42 Th1 cells produce 
interferon-γ	(IFN-γ),	and	lymphotoxin	(LT)	and	can	mobilize	the	cellular	arm	of	the	
immune system to combat intracellular pathogens. Th2 cells secrete IL-4, IL-13 and 
IL-25, which are essential for the generation of appropriate classes of antibodies and 
for the elimination of extracellular phatogens.43 Th17 cells play an important role in 
the	host’s	defense	against	extracellular	pathogens,	which	are	not	efficiently	cleared	
by Th1-type and Th2-type response.42	 	While	these	subsets	have	specific	effector	
functions in clearing infections, unregulated expansion of CD4+ Th effector T cells 
causes immunopathology. Excessive Th1 responses are associated with various 
autoimmune	and	inflammatory	disorders,	whereas	enhanced	Th2	cytokine	production	
is involved in atopic diseases including allergies and asthma. The cutaneous immune 
reaction is  overstrained in psoriasis.18,40  The Th17 cytokines IL-17, IL-21 and IL-22 
are	highly	pro-inflammatory	and	Th17	cells	with	specificity	for	self-antigens	lead	to	
severe autoimmunity. 42 IL-17 expression has been detected in the target tissue in 
human autoimmune disease such as rheumatoid arthritis and psoriatic lesions.44  
IL-12 and more recently, IL-23 have both been implicated in the pathogenesis of 
psoriasis. IL-12 plays an important role in the cell-mediated immune response, which 
is responsible for the defense against certain intracellular bacterial and parasitic 
infections. IL-12 is composed of a covalently linked heavy chain (IL-12p40) and a 
light chain (IL-12p35). The receptor comprises two transmembrane subunits, IL-
12Rß1 and IL-12Rß2. 45  IL-12 is produced by the DCs cells and the macrophages. 
It	induces	differentiation	of	CD4	naïve	T	cells	to	Th1	cells	and	activates	NK	cells. 46 
These	Th1	cells	and	activated	NK	cells	produce	interferon	IFN-γ	and	other	type	1	
cytokines	such	as	IL-2	and	TNF-ß.	IFN-γ	plays	a	critical	role	in	the	pathogenesis	of	
psoriasis	by	facilitating	T	cell	infiltration	into	the	epidermis	and	induce	keratinocyte	
proliferation.47 IL-23 is a more recently described cytokine that is structurally closely 
related to IL-12. Both cytokines are heterodimers that share the common subunit IL-
12p40 (IL-12p40 + IL-23p19 = IL-23; IL-12p40 + IL-12p35 = IL-12). Furthermore, the 
receptor for IL- 23 shares the common subunit, IL-12Rß1, to which the common IL-
12p40 subunit binds. The dominant role of IL-23 involves the stimulation of a subset 
of CD4+ T cells (sometimes called IL-17 T cells) to produce IL-17.48  IL-17 induces 
the	production	of	pro-inflammatory	cytokines	predominately	by	the	endothelial	cells	
and	the	macrophages.	It	is	believed	that	IL-17	and	IFN-γ	synergize	to	increase	the	
production	of	pro-inflammatory	cytokines	by	the	keratinocytes,	which	is	important	for	
the	development	of	inflammation	in	the	skin	seen	in	psoriasis.49  IL-12 and IL-23 are 
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important	in	the	pathogenesis	of	psoriasis.	However,	IL-12	and	IL-23	deficiencies	in	
human beings and knockout mice indicate a potential risk for increased susceptibility 
to infection, particularly with Mycobacterium and Salmonella species in patients 
treated with IL-12p40 targeting agents.50  
3.1.3.6  Vascular changes
The	 first	 microscopically	 visible	 events	 in	 developing	 psoriatic	 plaques	 are	 the	
superficial	 peri-vascular	 infiltration	 of	 lymphocytes	 and	 monocytic	 cells	 and	 the	
dilation of the blood vessels in the dermal papillae.51 T cells and macrophages appear 
in	 the	 dermal	 infiltrates	 of	 psoriatic	 lesions	 before	 the	 development	 of	 significant	
epidermal changes.52  The	migration	 of	 lymphocytes	 into	 the	 site	 of	 inflammation	
begins with the adhesion of the lymphocytes to the dermal papillary vascular 
endothelium via cell-cell interactions.7,41 The passage of leukocytes from the blood 
vessels	into	the	tissue	occurs	in	five	steps.	Endothelial	cells	play	a	decisive	role	in	
these	steps.	 In	 the	first	 step	 (rolling),	 leukocytes	 roll	along	 the	blood	vessel	wall.	
Rolling	reduces	the	flow	velocity	of	the	leukocytes	and	is	mediated	by	the	interaction	
between P- and E-selectin expressed by the endothelial cells and the selectin 
ligands expressed by the leukocytes.  E-selectin is the endothelial ligand for CLA on 
memory T cells, which is responsible for skin-homing of memory T cells. E-selectin 
is normally not expressed on the endothelial cells of the cutaneous microvessels, 
but	it	is	up-regulated	during	cutaneous	inflammation	facilitating	the	accumulation	of	
T cells in the psoriatic skin.53,54   Endothelial cells express both P- and E-selectin in 
the uninvolved skin, but their expression is highly enhanced in the psoriatic skin. In 
the	second	step	of	skin	infiltration,	the	immune	cells	rolling	along	the	blood	vessel	
wall recognize chemokines presented by the endothelial cells and are activated 
(triggering).	The	third	step	of	skin	infiltration	is	characterized	by	the	formation	of	tight	
adhesions between the endothelial cells and the immune cells (adhesion). This is 
achieved by integrins expressed on the immune cells and their ligands expressed 
on the endothelial cells. Chemokines induce the integrin-dependent adhesion of 
the immune cells to the endothelial cells and cause the rapid arrest of the immune 
cells.	Lymphocyte	function	antigen-1	(LFA-1,	CD11a	⁄	CD18)	is	an	important	integrin	
for skin homing. It binds to ICAM-1(CD54) and ICAM-2 (CD102) expressed by the 
endothelial cells. The passage of the immune cells through the endothelial wall is 
called diapedesis (fourth step) and occurs via pores formed between the endothelial 
cells. Endothelial cells in psoriatic lesions express a number of leukocyte-related 
adhesion proteins (CD31, CD34 and addressin) that are normally associated with 
high endothelial venules in lymph nodes by the action of T cell triggered vascular 
endothelial growth factor (VEGF). These venules have fenestrations allowing naïve 
cells entry into chronic lesions of psoriasis.18  This is the last step is the migration into 
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the target tissue. The number of T cells in non-lesional psoriatic skin is higher than 
that in the skin from healthy participants.55  In psoriatic skin lesions, CD8+ T cells 
primarily home into the epidermis, whereas CD4+ cells are mainly present in the 
dermis.56 The reasons for these different anatomical homing patterns may be caused 
by the varied expression of chemokine receptors such as CXCR3 and integrins such 
as CD103 on CD4+ and CD8+ T cells. CD45RO+ T cells constitute 36.6% of the 
proliferating dermal cells in involved skin.57 Once keratinocytes synthesize ICAM-1 it 
is	possible	for		LFA-1	positive	T	cells	to	migrate	into	the	inflamed	epidermis	through	
LFA-1/ICAM-1 interaction. T cells may be able to migrate into the epidermis by 
adhesive	interactions	between	αεβ7	integrin,	which	is	expressed	on	the	epidermal	T1	
cells and E-cadherin synthesized by the keratinocytes. Cytokines from intradermal T 
cells can trigger keratinocytes to synthesize and release IL-8, the main chemotactic 
signal for the recruitment of neutrophils into the epidermis from the vascular stores. 
Once arrived in the epidermal regions, the activated T cells release Th1 cytokines 
including	IFN-γ,	 IL-2	and	TNF-α.	 IL-2	 is	associated	with	psoriasis	and	 is	a	known	
T-cell growth stimulator.58  TNF-α	 is	 a	 potent	 inducer	 of	 ICAM-I,	CD40	and	major	
histocompatibility complex (MHC) class II proteins on the epidermal keratinocytes 
and stimulates  angiogenesis.18  Persistence of mature LCs, which produce abundant 
IL-12 provides the background for direct stimulation of Th1 cell subsets in the lesional 
psoriatic skin.18	 In	 normal	 skin,	 the	 superficial	 microvasculature	 is	 composed	 of	
capillary loops, which arise from the terminal arterioles in the upper horizontal dermal 
vascular plexus, pass up into the dermal papilla and arch back to connect with post-
capillary venules in the horizontal plexus.59 Non-lesional skin has short lengths of 
microvessels	 in	 the	superficial,	papillary	dermis,	whereas	 lesional	psoriatic	skin	 is	
characterized	by	dilated	and	elongated	superficial	capillaries	passing	into	the	dermal	
papillae, representing exaggerated tortuosity, coiling of the apical segment of the 
capillary loop,  neo-angiogenesis and high endothelial venule (HEV) formation.60-62 
HEV	formation	may	be	important	for	the	extravasation	and	trafficking	of	the	activated	
T cells in the psoriatic lesions.62	 	Vascular	defects	in	psoriasis	are	confined	to	the	
superficial	 capillary	 loops.	 Factors	 secreted	 by	 the	 epidermis	 such	 as	 the	VEGF	
govern the vascular changes in order to support the increased nutritional requirement 
during the disease activity.63,64 If the hypothesis that the reduced resistance of the 
expanded	capillary	bed	is	responsible	for	the	elevated	blood	flow	in	psoriatic	plaques	
is	true,	then	elimination	of	this	capillary	component	should	normalize	blood	flow.	The	
diameter measurements of psoriatic capillaries vary from 6- to 17-micrometer.61,65,66  
An	average	basal	 flux	of	 35.15	±	40.38	AU	was	 recorded	 in	port	wine	stain	 skin	
using	laser	Doppler	flowmetry.67	This	was	less	than	the	basal	flux	values	recorded	in	
psoriatic	plaque	skin	(269.79	±	232.37).68 These results indicated that the capillary 
expansion	by	itself	 is	not	sufficient	to	generate	a	substantially	elevated	blood	flow	
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and further supports the hypothesis that other factors such as an increased number 
of resistant vessels and/or chronic structural widening of pre-existing arterioles may 
contribute	in	the	grossly	elevated	blood	flow	in	psoriatic	plaque	skin.	
During the last decade, the lymphatic system has been the subject of increasing 
interest	with	the	discovery	of	specific	factors	among	which	are	the	lymphatic	growth	
factors VEGFC and VEGF-D.69 Their tyrosine kinase receptor VEGFR3 found in 
venous and lymphatic endothelial cells during embryogenesis becomes restricted to 
lymphatic cells early in the postnatal period except for the fenestrated blood vessels 
of some organs such as endocrine glands.70  The activation of VEGFR3 by VEGF-C 
or VEGF-D leads to the proliferation of the lymphatic endothelial cells while targeted 
deletion of VEGF-C in mice impairs the development of small lymphatic vessels.69 
Lymphatic vessels are expanded in psoriasis, but little is known on the mechanism 
of their development in the lesions and the potential alterations in the non-involved 
skin of patients with psoriasis. Vascular volume and the expression of  ICAM-1 and 
E-selectin were reported to be increased in the non-lesional psoriatic skin. 71, 72  These 
observations indicated the presence of a pre-psoriatic phenotype in the distant non-
lesional	skin,	but	little	is	known	on	their	potential	significance	in	the	patho-mechanisms	
in psoriasis.73  The expression of the different isoforms of VEGF-A, VEGFR2, VEGF-C, 
VEGFR3 and prox-1 are higher in lesional psoriatic skin than in non-lesional skin.73 
There	is	a	four-fold	increase	in	the	endothelium	of	the	superficial	microvasculature	in	
lesional psoriatic skin, but not in the deeper vasculature indicating that microvascular 
expansion is restricted to the upper plexus.74  Current evidence such as the rapid 
response of psoriasis to cyclosporine, which inhibits T cell activation and cytokine 
release indicates that psoriasis is primarily a T cell-dependent disease.75  However, 
the prominent increase in the dermal microvasculature in the lesional skin indicates 
that psoriasis is also angiogenesis-dependent.76-78 
3.1.4 Treatment of psoriasis, adverse effects and Pulsed Dye Laser (PDL)
Traditional therapies for psoriasis have focused on the inhibition of epidermal 
proliferation	and/or	suppression	of	 inflammation.	Treatments	 include	monotherapy	
or combinations of topical vitamin D analogues, tazarotene, corticosteroids, anthralin 
tar and salicylic acid, phototherapy (broad-band and narrow-band UVB and Psoralen- 
UVA) and systemic treatments with retinoids, methotrexate (MTX), cyclosporine 
CsA), fumaric acid esters and more recently biologicals. Limiting factors are that none 
of these agents is effective in all patients. Each treatment may also have adverse 
effects and the effects of the treatment generally decrease over time.79,80  On the one 
hand, topical therapy is less effective as compared with photo-(chemo) therapy and 
systemic treatments, but on the other hand, adverse effects of topical treatments are 
generally less severe than those of photo-(chemo) therapy and systemic treatments 
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(Table 4). Combinations of treatments associated with increased toxicity are bone 
marrow suppressants (e.g., methotrexate, hydroxyurea and 6-thioguanine) and 
drugs that may increase the risk of skin cancer (e.g. cyclosporine and PUVA). 
The	treatment	with	the	most	optimum	efficacy/adverse	effect	profile	for	the	particular	
patient should be chosen because of the diverse presentations of psoriasis, the 
patient’s individual needs and other coexistent factors.
The alterations in the capillaries have been neglected as a possible therapeutic target, 
although it was  reported that in a new psoriasis lesion one of the earliest observable 
changes is an increase in the dermal papillary vasculature.76-77,78,81  The clinical 
improvement during the treatment is preceded by micro-vascular improvement.82 This 
indicated,	 that	 the	 expanded	 superficial	 micro-vascular	 bed	 in	 psoriasis	 skin	 is	 an	
essential component for maintaining clinical lesions.82 These observations have led to 
the hypothesis, that in psoriasis selective destruction of the dilated papillary vessels by 
selective	photothermolysis	may	reduce	the	transmigration	of	inflammatory	cells	resulting	
in the clearing of the psoriasis plaques (Figures 13 and 14).83  Selective photothermolysis, 
destroying only the dilated papillary vessels, but sparing the normal sized vessels and 
without causing damage to the epidermis became a reality after the introduction of 
the PDL machine.84,85  Partial and total clearance of psoriasis after PDL treatment was 
reported in several studies.86-91 	Efficacy	and	safety	aspects	of	PDL	treatment	of	plaque	
type psoriasis were studied in this thesis.
Figure 13.    A.  Psoriasis palmaris, woman 22 years old, duration of 
  psoriasis 8 years.
                     B. PD-laser after 5 treatments with concomitant calcipotriol ointment, 
stable with 1 PDL treatment per 3 months.
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Figure 14. Psoriasis PDL treatment before and after pictures.
  Side effect: hyperpigmentation
Topical therapy Common adverse effects
Salicylic acid Risk of salicylate toxicity with application to more than 
 20% body surface area
Vitamin D3 derivatives Skin irritation; risk of hypercalciuria and hypercalcemia 
Calcipotriol at more than 100 gram a week 
Calcitriol
Vitamin A derivative  Tazarotene is a pregnancy category X drug
Tazarotene Not registered in the Netherlands
Topical corticosteroids Skin atrophy, striae distensae, teleangiectases, purpura,  
 acne, skin infections, Cushing’s syndrome, 
 hypothalamic-pituitary-adrenal axis suppression
Tars Skin irritation, folliculitis, phototoxic reactions, staining
 of skin and clothes, odor, carcinogenicity following 
	 tar	application	in	psoriatics	remains	unconfirmed,	renal		
 dysfunction during large body surface treatment
Dithranol (anthralin) Skin irritation, burning, erythema, staining of skin and  
 clothes 
Phototherapy  Common adverse effects 
Narrow-band UVB Erythema and burning from overexposure, premature aging  
 of the skin, carcinogenic risk
PUVA Phototoxic reactions, lentigines, induction of photo-aging,  
 increased risk of squamous cell carcinoma and malignant  
 melanoma, ingestion of oral psoralen may produce nausea,  
 oral psoralen is a pregnancy category X drug
Systemic therapy  Common adverse effects
(conventional)
Fumaric acid esters Flushing, nausea, vomiting, stomachache, diarrhea, 
 depression, edema in the legs, anemia, leucopenia,  
 thrombocytopenia, hepato- and renal toxicity, contra- 
 indicated during pregnancy and lactation (pregnancy  
 category X drug)
Methotrexate Hepato-toxicity, gastrointestinal symptons, malaise, 
 headache, reactivation of phototoxic reactions, ulcerative  
 stomatitis, myelosuppression, anemia, pneumonitis, 
	 pulmonary	fibrosis,	induction	of	lymphomas,	teratogenicity,	
 methotrexate is a pregnancy category X drug.
Cyclosporin Renal toxicity, hypertension, gastrointestinal symptons, 
	 flu-like	symptoms,	hypertrichosis,	gingival	hypertrophy,		
 increase in cutaneous malignancies, cyclosporine is a  
 pregnancy category C drug
Acitretin Teratogenicity, hepato-toxicity, hyperostosis, hyperlipidemia,  
 mucocutaneous adverse effects, such as dry skin, cheilitis  
 sicca, dermatitis and alopecia, arthralgias and myalgias, 
 pseudo-tumor cerebri, acitretin is a pregnancy category X  
 drug and should not be used during breast-feeding
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Systemic therapy Common adverse effects
(biologicals)
Infliximab	 Upper	respiratory	tract	infections,	acute	infusion	reactions		
 with fever, chills, chest pain, hypotension, nausea and 
 dyspnea, anaphylactoid reactions, reactivation of latent 
 tuberculosis, six-fold greater risk of lymphomas, increase 
 of liver enzymes, de-myelinating diseases, cardiac
	 insufficiency,	leucopenia,	thrombocytopenia,	pancytopenia,	
 lupus-like syndrome 
Etanercept Transient injection-site reactions with itching, pain,
 erythema and swelling, infections of the upper respiratory 
 tract, bronchitis, skin infections, lupus-like syndrome and
  positive ANA, lymphoma, de-myelinating disorders of the
  central nervous nervous system, congestive heart failure
Efalizumab Removed from the market by the EMEA because of 
 progressive multi-focal leucoencephalopathy
Adalimumab Pain at the injection site, infections, malignancy, 
 development of anti-nuclear antibodies
Alefacept T-lymphocyte depletion. Not approved by the EMEA in 
 Europe
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Table 4.  Overview of anti-psoriatic therapies and their adverse effects. 
Category C: drugs in which risk cannot be ruled out during pregnancy and lactation 
because of inadequate data, two-thirds of all drugs fall in this category. Category 
X: drugs that are absolutely contra-indicated during pregnancy. EMEA = European 
Medicines Agency.
3.1.5 References
Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol 1986; 14: 863-1. 
866.
Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp 2. 
Dermatol 2001; 26: 314-320. 
Roenigh HH, Maibach HI. Psoriasis third edition, 1998, Marcel Dekker, inc. pp 3. 
112-113, 543-557.
Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899-19124. 
5. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA. Psoriasis of 
early and late onset: A clinical and epidemiologic study from Spain. J Am Acad 
Dermatol 2002; 46: 867-873.
6.	 Finlay	AY,	Khan	GK,	Luscombe	D,	Salek	MS.	Validation	of	sickness	 impact	
profile	and	psoriasis	disability	 index	 in	psoriasis.	Br	 J	Dermatol	1990;	123:	
751-756. 
Lebwohl M. Psoriasis. The lancet 2003; 361: 1197-12047. 
McFadden JP, Baker BS, Powles AV, Fry L. Psoriasis and streptococci: the 8. 
natural selection of psoriasis revisited. Br J Dermatol 2009; 160: 929-937.
Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. 9. 
Angiogenesis 2002; 5: 231-236.
Farber EM, Nickoloff BJ, Recht B, Prahi JE. Stress, symmetry and psoriasis: 10. 
possible role of neuropeptides. J Am Acad Dermatol 1986; 14:305-311.
Naldi L, Peli L, Parazzini F, France Carrel C. Family history of psoriasis, 11. 
stressful	 life	events,	and	recent	 infectious	disease	are	risk	factors	for	a	first	
episode of acute guttate psoriasis: results of a case-control study. J Am Acad 
Dematol 2001; 44: 433-438
Schmid-Ott	G,	Jaeger	B,	Boehm	T,	Langer	K,	Stephan	M,	Raap	U,	Werfel	T.	12. 
Immunological effects of stress in psoriasis. Br J Dermatol 2009; 160: 782-
785. 
Poikolainen	K,	Reunala	T,Karvonen	J.	Smoking,	alcohol	and	life	events	related	13. 
to psoriasis among women. Br J Dermatol 1994; 130: 473-477.
Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. 14. 
Clin	Dermatol	2007;	25:	606–615.
Leigh	IM,	Navsaria	H,	Purkis	PE,	McKay	IA,	Bowden	PE,	Riddle	PN.	Keratins	15. 
(Kl6	and	Kl7)	as	markers	of	keratinocyte	hyperproliferation	in	psoriasis	in	vivo	
and in vitro. Br J Dermatol 1995; 133: 501-511.
Ando	 M,	 Kawashima	 T,	 Kobayashi	 H,	 Ohkawara	 A.	 Immunohistological	16. 
detection	of	proliferating	cells	 in	normal	and	psoriatic	epidermis	using	Ki-67	
monoclonal antibody. J Dermatol Sci 1990; 1: 441-446.
Lowes	MA,	Bowcock	AM,	Krueger	JG.	Pathogenesis and therapy of psoriasis. 17. 
71
Nature 2007; 445: 866-873.
Krueger	JG.	The	 immunologic	basis	 for	 the	treatment	of	psoriasis	with	new	18. 
biologic agents. J Am Acad Dermatol  2002; 46: 1-23.
Jullien D, Barker JN. Genetics of psoriasis. J Eur Acad Dermatol Venereol 19. 
2006;	20	(Suppl.	2):	42–51.
Barker JNWN. Genetic aspects of psoriasis. Clin Exp Dermatol. 2001; 26: 20. 
321-325.
Bowcock AM, Barker JN. Genetics of psoriasis: The potential impact on new 21. 
therapies. J Am Acad Dermatol 2003; 49: S51-56.
Schwarz T. Skin immunity. Br J  Dermatol 2003; 149 (Suppl. 66): 2-4.22. 
23		Nickoloff	BJ.	Cutaneous	dendritic	cells	in	the	crossfire	between	innate	and			
adaptive immunity. J Dermatol Sci 2002; 29: 159-165.
24  Gilliet M, Conrad C, Geiges M, Cozzio A, Thürlimann W, Burg G,
  Nestle FO, Dummer R Psoriasis triggered by Toll-like receptor 7 agonist  
 Imiquimod in the presence of dermal plasmacytoid dendritic cell
 precursors. Arch Dermatol. 2004; 140: 1490-1495. 
25  Arancibia SA, Beltran CJ, Aguirre IM, Silva P, Peralta AL, Malinarich F,
		 Hermoso	MA.	Toll-like	Receptors	are	Key	Participants	in	Innate	Immune		 	
Responses. Biol Res 2007; 40: 97-112.
26 Pivarcsi A. Toll-Like Receptor 9 independent suppression of skin    
Inflammation	by	oligonucleotides.	J	Invest	Dermatol	2007;	127:	746-748.
27  Vollmer J. TLR9 in health and disease. Int Rev Immunol 2006; 25:155–181.
28 Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute 
	 inflammation	in	T-cell	mediated	immune	dermatosis,	psoriasis:	a
		 neutrophil-associated	inflammation-boosting	loop.	
 Exp Dermatol 2000; 9: 1-10.
29.	Nagy	I,	Pivarcsi	A,	Koreck	A,	Szell	M,	Urhan	E,	Kemeny	L.	Distinct	strains		 	
of propionibacterium acnes induce selective human beta-defensin-2 and   
interleukin-8 expression in human keratinocytes through toll-like receptors.  
J Invet Dermatol 2005; 124: 931-938.
30. Hollox EJ, Huffmeier U, Zeeuwen PLJM, Palla R, Lascorz J, Rodijk-Olthuis D, 
van	de	Kerkhof	PCM,	Traupe	H,	de	Jongh	G,	den	Heijer	M,	Reis	A,		Armour	
JAL,	Schalkwijk	J.	Psoriasis	is	associated	with	increased	β	-defensin	genomic	
copy number. Nature Genetics 2008; 40: 23-25. 
31. Cohen JJ. Apoptosis. Immunol today. 1993; 14: 126-130.
32.  Raskin CA. Apoptosis and cutaneous biology. J Am Acad Dermatol. 1997;   
36:	885–896.	
33. Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. J 
Invest Dermatol 1993; 101: 107-112.
72
34.		Earnshaw	WC,	Martins	LM,	Kaufmann	SH.	Mammalian	caspases:			 	
structure, activation, substrates, and functions during apoptosis. Annu Rev  
Biochem 1999; 68: 383-424.
35. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281:  
1312-1316.
Krueger	JG,	Wolfe	JT,	Nabeya	RT,	Vallat	VP,	Gilledeau	P,	Heftler	NS,	Austin	LM,	36. 
Gottlieb AB. Successful ultraviolet B treatment of psoriasis is accompanied by a 
reversal of keratinocyte pathology and by selective depletion of intraepidermal 
T cells. J Exp Med 1995; 182: 2057-2068.
37.	Coven	TR,	Walters	IB,	Cardinale	I,	Krueger	JG.	PUVA-induced	lymphocyte	
 apoptosis: Mechanism of action in psoriasis.. Photodermatol   
Photoimmunol Photomed 1999: 15: 22-27. 
38.	Mass	P,	Hoffmann	K,	Gambichler	T,	Altmeyer	P,	Mannherz	HG.	Premature			
keratinocyte death and expression of marker proteins of apoptosis in   
human skin after UVB exposure. Arch Dermatol Res 2003; 295: 71-79.
39.	Babilas	P,	Shafirstein	G,	Baumler	W,	Baier	J,	Landthaler	M,	Szeimies	RM,			
Abels C. Selective Photothermolysis of blood vessels following Flashlamp-  
Pumped Pulsed Dye Laser irradiation: In vivo results and mathematical   
modelling	are	in	agreement.	J	Invest	Dermatol	2005;	125:	343	–352.		
40.	Sabat	R,	Philipp	S,	Höflich	C,	Kreutzer	S,	Wallace	E,	Asadullah	K,	
	 Volk	HD,	Sterry	W,	Wolk	K	
	 Immunopathogenesis	of	psoriasis.	Exp	Dermatol	2007,	16,	779–798.
41	 Mehlis	 SL,	 Gordon	 KB.	 The	 immunology	 of	 psoriasis	 and	 biologic	
immunotherapy. J Am Acad, Dermatol 2003; 49: S44-50. 
42.	Bettelli	E,	Korn	T,	Kuchroo	VK.	Th17: the third member of the effector T cell  
trilogy Current Opion Immunol 2007; 19: 652-657.
43. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Ann Rev Immunol 1989; 7: 
145-173.
44.	Steinman	L.	A	brief	history	of	T(H)17,	the	first	major	revision	in	the	T(H)	1/T(H)2	
hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.
45. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with 
divergent functions. Nat Rev Immunol 2005; 5: 521-531.
46. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications 
in cancer treatment. Oncologist 1996; 1: 88-97. 
47.	Hong	K,	Chu	A,	Ludviksson	BR,	Berg	EL,	Ehrhardt	RO.	IL-12,	independently	
of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-
like skin disorder. J Immunol 1999; 162: 7480-7491
48. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 
73
promotes a distinct CD4 T cell activation state characterized by the production 
of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
49.	Teunissen	 MB,	 Koomen	 CW,	 de	 Waal	 Malefyt	 R,	 Wierenga	 EA,	 Bos	 JD.	
Interleukin-17 and interferon-gamma synergize in the enhancement of 
proinflammatory	 cytokine	 production	 by	 human	 keratinocytes.	 J	 Invest	
Dermatol 1998; 111: 645-649.
50. Torti DC,  Feldman SR. Interleukin-12, interleukin-23, and psoriasis: Current 
prospects. J Am Acad Dermatol 2007; 57: 1059-1068.
51. Ragaz A, Ackerman A B. Evolution, maturation and regression of lesions of 
psoriasis.	New	observations	and	correlation	of	clinical	and	histologic	findings.	
Am	J	Dermatopathol	1979:	1:	199–214.
52.	Bjerke	JK,	Krough	HK,	Matre	R.	Characterization	of	mononuclear	cell	infiltrates	
in psoriatic lesions. J invest Dermatol 1978; 71: 340-343.
 53. Groves RW, Allen MH, Barker JNWN, Haskard DO, MacDonald DM. 
Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous 
inflammation.	Br	J	Dermatol	1991;	124:	117-23.
	54.	Picker	LJ,	Kishimoto	TK,	Wayne	Smith	C,	Warnock	RA,	Butcher	EC.	ELAM-1 
is an adhesion molecule for skin-homing T cells. Nature 1991; 349: 796-799. 
55. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-alpha and inducible 
nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with 
efalizumab	(anti-CD11a).	Proc	Natl	Acad	Sci	USA	2005:	102:	19057–19062.
56. Bos JD,	 Hagenaars	 C,	 Das	 PK,	 Krieg	 SR,	 Voorn	 WJ,	 Kapsenberg	 ML.	
Predominance of ‘memory’ T cells (CD4+, CDw29+) over ‘naive’ T cells (CD4+, 
CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989: 
281:	24–30.
57.	Morganroth	GS,	Chan	LS,	Weinstein	GD,	Voorhees	JJ,	Cooper	KD.	Proliferating	
cells in psoriatic dermis are compromised primarily of T cells, endothelial cells, 
and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol 1991; 96(3): 
333-340.
58. Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA. Interleukin 2 and 
psoriasis. Arch Dermatol 1988; 124: 1811-1815.
59. Yen A, Braverman IM. Ultrastructure of the human microcirculation: the 
horizontal plexus of  the papillary dermis. J Invest Dermatol 1976; 66: 
 131-142.
60. Braverman IM, Yen A. Ultrastructure of the capillary loops in the dermal   
papillae of psoriasis. J  Invest Dermatol 1977; 68: 53-60.
61. Bull RH, Bates DO, Mortimer PS. Intravital video-capillaroscopy for the   
study of the circulation in psoriasis. Br J Dermatol 1992; 126: 436-445. 
62. Guenther LC, Ortonne JP. Pathophysiology of psoriasis: science behind 
74
therapy. J Cutan Med Surg 2002; 6: 2-7.
63.	Detmar	M,	Brown	LF,	Claffey	KP	et	al.	Overexpression of vascular permeability 
factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp 
Med 1994; 180: 1141-1146.
64.	Detmar	M,	Yeo	KT,	Nagy	JA.	et	al.	Keratinocyte-derived	vascular	permeability	
factor (vascular  endothelial growth factor) is a potent mitogen for dermal 
microvascular endothelial cells. J. Invest Dermatol 1995; 105: 44-50. 
65. Mordovstev VN, Albanova VI. Morphology of skin microvasculature in Psoriasis. 
Am J  Dermatopathol 1989; 11 :33-42 
66. Bravermann IM. The cutaneous microcirculation: ultrastructure and 
microanatomical organisation. Microcirculation 1997; 4: 329-340.    
67.		Jernbeck	J,	Malm	M.	Calcitonin	gene-related	peptide	increases	the	blood	flow	
of port wine stains and improves continues wave dye laser treatment. Plast 
Reconstr Surg 1993; 91: 245-251.    
68. Hern S, Stanton AWB, Mellor RH, Harland CC, Levick JR, Mortimer PS. Blood 
flow	in	psoriatic	plaques	before	and	after	selective	treatment	of	the	superficial	
capillaries. Br J Dermatol 2005; 152: 60-65.
69.	Karkkainen	M,	Haiko	P,	Sainio	K	et	al.	Vascular	endothelial	growth	factor	C	is	
required	for	sprouting	of	the	first	lymphatic	vessels	from	embryonic	veins.	Nat 
Immunol	2004;	5:	74–80.
70. Partanen TA, Arola J, Saaristo A et al. VEGF-C and VEGF-D expression 
in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood 
vessels	in	human	tissues.	FASEB	J	2000;	14:	2087–2096.
71.			Barton	SP,	Abdullah	MS,	Marks	R.	Quantification	of	microvascular	changes	in	
the	skin	in	patients	with	psoriasis.	Br	J	Dermatol	1992;	126:	569–574.
72.   De Boer OJ, Wakelkamp IMJ, Pals ST et al. Increased expression of adhesion 
receptors in both lesional and non-lesional psoriatic skin. Arch Dermatol Res 
1994;	286:	304–311.
73. Henno A, Blacher S, Lambert C, Colige A, Seidel , Noël  A, Lapière, de 
la Brassinne M,  Usgens BV. Altered expression of angiogenesis and 
lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. 
Br J Dermatol 2009; 160: 581-590.
Creamer D, Allen MH, Sousa A, Poston R, Barker JNWN. Localisation of 74. 
endothelial proliferation and microvascular expansion in active psoriasis. Br J 
Dermatol 1997; 136: 859-865.
75.  Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH et al. 
Cyclosporine for plaque-type psoriasis. results of a multidose, double-blind 
trial. N Engl J med 1991; 324: 277-284.
76   Pinkus H, Mehregan AH. The primary histologic lesion of seborrhoeic dermatitis 
75
and psoriasis. J Invest Dermatol 1966; 46:109-116.
77			Goodfield	M,	Macdonald	Hull	S,	Holland	D	et	al.	Investigations	of	the	“active”	
edge of plaque psoriasis: Vascular proliferation precedes changes in epidermal 
keratin. Br J Dermatol 1994; 131: 808-813. 
78. Barker JNWN. Pathophysiology of psoriasis. Lancet 1991; 338: 227-230. 
79. Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad 
Dermatol 2005; 53: s59-69.
80.	Macdonald	Hull	S,	Goodfield	M,	Wood	EJ,	Cunliffe	WJ.	Active	and	 inactive	
edges of psoriatic plaques:	identification	by	tracing	and	investigation	by	laser-
Doppler	flowmetry	and		 immunocytochemical	techniques.	J	Invest	Dermatol	
1989; 92: 782-785.
Heng	 MCY,	 Allen	 SC,	 Haberfelde	 G,	 Song	 MK.	 Electronmicroscopic and 81. 
immunohistochemical studies of the sequence of events in psoriatic plaque 
formation following tape-stripping. Br J Dermatol 1991; 125: 548-556. 
Hacker	S,	Rasmussen	J.	The	effect	of	flash	lamp-pulsed	dye	laser	on	psoriasis.	82. 
Arch Dermatol 1992; 128: 853-855.
Anderson RR, Parrish JA. Microvasculature can be selectively damaged using 83. 
dye lasers: a basic theory and experimental evidence in human skin. Lasers 
Surg Med 1981; 1: 263-276.
Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery 84. 
by selective absorption of pulsed radiation. Science 1983; 220: 524-527.
Ros AM, Garden JM, Bakus AD, Hedblad MA. Psoriasis response to the 85. 
pulsed dye laser. Lasers Surg Med 1996; 19: 331-335.
Katugampola	GA,	Rees	AM,	Lanigan	SW.	Laser	treatment	of	psoriasis.	Br	J	86. 
Dermatol 1995; 133: 909-913.
Zelickson BD, Mehregan DA, Wendelschfer-Crabb G et al. Clinical and 87. 
histologic	evaluation	of	psoriatic	plaques	treated	with	a	flashlamp	pulsed	dye	
laser. J Am Acad Dermatol 1996; 35: 64-68.
Bjerring	 P,	 Zachariae	 H,	 Søgaard	 H.	 The	 flashlamp-pumped	 Dye	 Laser	88. 
and	 dermabrasion	 in	 Psoriasis-	 Further	 studies	 on	 the	 reversed	 Köbner	
phenomenon. Acta Derm Venereol (Stockh) 1997; 77: 59-61.
Hern S., Allen M.H., Sousa A.R., Harland C.C., Barker J.N.W.N., Levick J.R., 89. 
Mortimer P.S. Immunohistochemical evaluation of psoriatic plaques following 
selective	photothermolysis	of	the	superficial	capillaries.	Br	J	Dermatol	2001;	
145: 45-53.
Erceg	A,	Bovenschen	HJ,	Kerkhof	van	der	PCM,	Seyger	MMB.	Efficacy	of	90. 
the pulsed dye laser in the treatment of localized recalcitrant plaque type 
psoriasis: a comparative study. Br J Dermatol 2006; 155; 110-114.
Norobio	R,	Kurokawa	M,	Kabayasi	K,	Morita	A.	Evaluation	of	the	clinical	and	91. 
76
						immunohistological	efficacy	of	the	585-nm	pulsed	dye	laser	in	the	treatment	
 of psoriasis.  J Eur Acad Dermatol 2009; 23: 420-424.
3.2     Vitiligo 
3.2.1 Epidemiology and clinical aspects
Vitiligo is an acquired disease characterized by scattered, sharply demarcated white 
macules. These de-pigmented macules often appear symmetrically, usually on the 
face (Figure 15), the nape, the axillae, the elbows, the hands (Figure 16), the knees 
and the genitals. Vitiligo usually occurs in a localized or generalized pattern, but 
rarely in a dermatomic area. Epidermal and mucosal variants occur. The course of 
vitiligo is usually one of slow progression, but it may exacerbate rapidly or stabilize. 
Vitiligo may also re-pigment spontaneously, but only partially.1 Histopathological and 
histochemical examinations showed a reduction in the number and the function of 
melanocytes in vitiligo lesions.2 Usually, the diagnosis is clinically obvious and often 
skin biopsies for the histopathological evaluation is unnecessary. The prevalence 
of vitiligo in the general population is 1% to 2%, without race or gender predilection 
and with an onset peak at an age of between 10 and 30 years. A genetic component 
is likely because there is a positive family history in about 30% of the patients.3,4  
Vitiligo is commonly considered to be only a cosmetic problem, but the implications 
of vitiligo are beyond the limits of a cosmetic disease. The impact on the quality of 
life of the patient is comparable with that in psoriasis on the emotional and socially 
functioning scales.5-8  In addition, many patients experience phototoxic reactions in 
the de-pigmented macules after exposure to sunlight in some patients in spite of the 
use of high sun protection factor agents.
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Figure15. Facial vitiligo
3.2.2 Pathogenesis
The exact etiology of vitiligo remains obscure to date, but many factors including 
infections, stress, neural abnormalities, melatonin receptor dysfunction, impaired 
melanocyte migration and genetic susceptibility  have been implicated in the 
development of the disease.9,10 The cause of vitiligo is not yet fully understood. 
However, it is clear that there is a lack of functional melanocytes in the affected 
skin. There are several hypotheses on the pathogenesis of vitiligo, but none of them 
fully explain the disease. Four hypotheses are particularly important.11 These are as 
follows:        
1). The autoimmune hypothesis is based on the observation that several autoimmune 
diseases such as autoimmune thyroid disease and type I diabetes mellitus often 
accompany vitiligo. Moreover, vitiligo patients may have elevated serum levels of 
antibodies against melanocytic antigens such as tyrosinase and tyrosinase-related 
proteins 1 and 2. Several studies have reported a role for both cellular and humoral 
immunity in the pathogenesis of vitiligo.12-14 
2). The neural hypothesis assumes that the altered reactions of melanocytes 
towards neuropeptides, catecholamines and their metabolites are responsible for the 
destruction of melanocyte. A close contact between melanocytes and nerve endings 
that is rarely seen in normal skin is observed in the de-pigmented skin. In addition, 
degenerated	 and	 regenerated	 autonomous	 nerve	 fibers	 and	 thickened	basement	
membranes of Schwann cells are present at the center and at the periphery of the 
de-pigmented skin lesions. Nerve endings at such sites show aberrations in the 
expression of nerve growth factor (NGF) and neuropeptides.11 
3). The self-destruct hypothesis states that melanocytes destroy themselves because 
of the defects in the protective mechanisms that are responsible for eliminating toxic 
melanin precursors. These defects lead to the accumulation of indole derivatives 
and free radicals, which are melanotoxic. 
4). The biochemical hypothesis argues that the destruction of melanocytes 
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Figure 16.   Vitiligo of the hands
destruction is because of the accumulation of toxic metabolites of melanogenesis, 
the breakdown of free-radical defense and an excess of hydrogen peroxide.15  The 
biochemical hypothesis assumes an over-synthesis of hydrobiopterin, a cofactor of 
tyrosine hydroxylase, resulting in an increased synthesis of catecholamine. This also 
results in an increase in the reactive oxygen species (ROS) toxic for melanocytes. 
Moreover, reduced levels of catalase in combination with higher concentrations of 
hydrogen peroxide were found in affected and unaffected skin of vitiligo patients.16 
Ultimately, all of these different factors may act independently or together to yield the 
same effect, namely the disappearance of melanocytes from the skin and this was 
proposed in the convergence theory.10  For example, autoimmunity may arise as a 
secondary phenomenon following the self-destruction of pigment cells and this may 
then amplify the damage to the melanocytes. Different pathogenic mechanisms may 
account for the various clinical types of vitiligo. The neural theory is usually related to 
the segmental vitiligo, whereas the autoimmune hypothesis is thought to be involved 
in the generalized (non-segmental) form of the disorder. Indeed, non-segmental 
vitiligo is characterized by an association with autoimmune diseases and with 
unstable results after autologous melanocyte grafting.17  Vitiligo is often associated 
with other autoimmune conditions such as autoimmune thyroid disease, autoimmune 
poly-endocrine syndrome types 1 and 2, pernicious anemia, type 1 diabetes mellitus, 
Addison’s disease, alopecia areata, systemic lupus erythematosus, rheumatoid 
arthritis, psoriasis and myasthenia gravis.9  Furthermore, these same autoimmune 
diseases	 occurred	 at	 an	 increased	 frequency	 in	 the	 first-degree	 relatives	 of	 the	
patients.18,19 
Histological examination of skin biopsies from vitiligo patients showed that 
inflammatory	cells	were	most	prominent	at	the	periphery	of	the	vitiligo	lesions.20  The 
dermal	and	the	epidermal	infiltrate	consisted	of	cytotoxic	and	helper	T	cells	that	were	
closely associated with the areas of melanocyte depletion. Expression of the MHC 
class	II	antigen	HLA-DR	indicated	that	many	of	the	infiltrating	T	cells	were	activated	
and	a	significant	number	of	T	cells	at	the	edges	of	the	vitiligo	lesions	also	showed	
high levels of the expression of CLA antigen, which is typical for skin-homing T cells. 
20,21 
In	addition,	there	was	evidence	for	the	expression	of		IL-2	and	IFN-γ	receptors	on	the	
lymphocytic	infiltrate. 22	Although	these	findings	do	not	distinguish	between	whether	
the	immune	infiltrate	is	the	result	or	the	cause	of	the	disease,	the	results	indicate	the	
involvement of local immune reactivity in melanocyte destruction.9 
There is evidence that both cellular and humoral immunity can act together in 
vitiligo pathogenesis. Firstly, both T and B cells were found to be simultaneously 
increased in patients with recent onset vitiligo. 23  Secondly, both autoantibodies 
and T lymphocytes reduced the number of pigment cells in an in vitro experiment 
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in a dose-dependent manner.24  Re-pigmentation in vitiligo patients treated with 
immunosuppressive agents such as corticosteroids, ultraviolet (UV) radiation with 
psoralen	(PUVA),	and	cytotoxic	drugs	like	5-fluorouracil	indirectly	supports	the	idea	
that an autoimmune-mediated process is involved in vitiligo pathogenesis. 25-27
UV	radiation	can	induce	the	expression	of	anti-inflammatory	cytokines,	modulate	the	
expression of ICAM-1, interleukin (IL) receptors (R) 1 and 2 and induce apoptosis 
of	skin-infiltrating	T	lymphocytes.28-30  Furthermore, HLA-DR antigens, Fc and C3b 
receptors are decreased on Langerhans cells (LCs) after UV treatment which 
may adversely affect the role of LCs. Following PUVA therapy, a reduction in the 
number of LCs was noted in vitiligo patients and a decrease in the expression of a 
vitiligo-associated melanocytic antigen was observed, which could have inhibited 
the antibody-dependent cell-mediated cytotoxicity (ADCC) against pigment cells.31,32 
Tacrolimus exerts an immunosuppressive effect on T cells by blocking the action of 
the cytokine gene-activating cofactor calcineurin. Topical application of tacrolimus 
to vitiligo lesions resulted in successful re-pigmentation.33,34  This treatment again 
indicated the role of immune reactions in vitiligo pathogenesis.
The	final	result	of	all	the	pathogenic	mechanisms	involved	during	the	de-pigmenting	
process in vitiligo is melanocyte destruction and an absence of pigmentation.35 
However, the melanocytes in the hair follicles usually remain unaffected. During the 
process of re-pigmentation, these melanocytes proliferate and mature to an active 
state as they migrate into the epidermis.36 
3.2.3 Treatment
Therapeutic approaches are aimed at reversing the progressive loss of melanocytes 
and reconstituting normal skin coloration, but none is uniformly effective and adverse 
effects may occur. Most common treatments are topical corticosteroids, tacrolimus, 
systemic and topical psoralen ultraviolet-A light (PUVA), narrow- and broad-band 
ultraviolet-B (NB-UVB and BB-UVB, respectively) and topical khellin with UVA 
(KUVA).1,37,38   NB-UVB was reported to be effective in the treatment of vitiligo with an 
overall re-pigmentation of 75% in 53% of the patients and a stabilization of the disease 
in 80% of the patients.39			Khellin	(ami	visnaga),	a	furanochromone	with	a	chemical	
structure resembling that of the psoralen family (Figure 17), is activated by UVA 
and UVB.40 Khellin	has	been	used	to	treat	vitiligo,	because	it	has	phototherapeutic	
properties that are similar to those of the psoralens, but it has substantially lower 
phototoxic and mutagenic effects.40,41 The current status on the position of khellin for 
treating vitiligo was recently reported and it was concluded that the research into this 
area remains inconclusive and at times contradictory.38  In a study comparing khellin 
or	placebo	under	the	influence	of	natural	sunlight,	12	of	the	30	patients	with	vitiligo	in	
the khellin group showed more than 50% re-pigmentation compared with none in the 
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placebo group.42 A left versus right study in 72 patients comparing khellin with UVA 
versus UVA alone concluded that re-pigmentation was because of the UVA and not 
the khellin.43  There was no difference between the khellin and the placebo groups in 
a left versus right study comparing khellin plus sunlight with vehicle plus sunlight in 
41 vitiligo patients.44   However, in a later study the same authors compared a khellin 
gel and UVA with UVA alone and reported that both groups responded, but khellin 
plus UVA was superior to UVA alone (P < 0.01).45  A study in 33 patients compared 
topical khellin plus UVA with PUVA and reported that khellin plus UVA may induce re-
pigmentation that was comparable with that induced by systemic PUVA, but required 
a longer period.46 
The selection of the vehicle in which khellin is incorporated is highly important for the 
adequate availability of khellin in the skin because of its very low solubility in water.45 
Khellin	encapsulated	in	phosphatidylcholine	liposomes	facilitates	the	availability	of	
khellin in the epidermis and in the hair follicles.47,48 
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Figure	18.		Before	and	after	Khellin-Liposomal-	Ultraviolet	(KLUV)	treatment.
Figure 17.  Molecular structure formula of khellin and psoralen
3.2.4 Surgical treatment
Surgical treatment is limited to vitiligo maculae, refractory to the aforementioned 
treatments. An important condition for surgical therapy is the stability of the diseas.35 
In stable vitiligo (such as segmental unilateral vitiligo), the outcome of transplantation 
therapy is usually excellent. In some cases, transplantation may indeed be the only 
effective treatment.49  Unfortunately, to date there is no reliable test to predict the 
activity and the outcome of melanocyte transplantation treatment in patients with 
vitiligo. Vitiligo can be active in one skin area and inactive or even in regression in 
another	area	at	 the	same	time	and	fluctuations	 in	 time	are	often	seen.49  Thus, it 
may	be	difficult	to	draw	conclusions	from	patient’s	anamnesis	and	from	performing	
a few test grafts prior to more extensive treatments as an approach to predict 
stability.	While	 there	 is	 no	 consensus	on	definite	 parameters	 for	 stability,	 various	
recommendations indicate a period of disease inactivity ranging from 6 months to 
two years.50  Njoo et al recommended a 6-point scale on which the disease activity 
by history was scored by means of the “vitiligo disease activity score (VIDAscore)” 
before and after 12 months of therapy. This is a scoring system of the patient’s own 
opinion of the present disease activity within the time periods indicated as follows: 
active in the past 6 weeks (score +4); active in the past 3 months (score +3); active 
in the past 6 months (score +2); active in the past year (score +1); stable for at least 
1 year (score 0); and stable for at least 1 year with spontaneous re-pigmentation 
(score	–1).	The	term	“active”	is	defined	as	the	expansion	of	the	existing	lesions	or	the	
appearance of new lesions. “Stable” refers to the condition when these symptoms 
are not present.51 
Methods of surgical modalities for vitiligo include both tissue grafts and cellular 
grafts. Both these techniques have their own advantages and disadvantages (Table 
5) according to the recently published guidelines.50  Tissue grafts comprises punch 
grafting, suction blister epidermal grafting and split-thickness grafting. Cellular grafts 
represent methods, which require specialized trained personnel and appropriate 
laboratory facilities and are expensive.50,52  In vitiligo surgery the most frequently 
reported complication is the lack of take or the survival of grafts and the absence of 
re-pigmentation. De-pigmentation of grafts may also occur (often as a result of vitiligo 
instability) in spite of a good take of the graft. Another problem may be the quality of 
the preparation of the melanocytes before transplantation. In vitro cultured autologous 
skin cells have been chemically and mechanically prepared and/or cultured. For cell 
preparation it is important to use a medium containing a minimum of foreign proteins 
and if they have to be used, they should be from the safest possible source. These 
precautionary measures are taken in order to reduce the risk of transmitting slow 
viruses, prions and similar agents to the recipient site.49  Liquid nitrogen, sandpaper, 
suction devices, topical methoxsalen followed by PUVA, CO2 laser and Erbium-YAG 
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lasers were used for preparing the recipient site.53,54 The disadvantage of preparing 
the recipient site with liquid nitrogen and topical methoxsalen followed by PUVA is 
that	it	is	difficult	to	control	the	final	result.	Today,	lasers	are	a	good	means	to	ablate	
the skin in a controlled fashion. It was reported that the Erbium-YAG laser-assisted 
ablation resulted in more  pigment spread around the graft than areas prepared with 
topical methoxsalen followed by PUVA.54 
The	first	 investigation	on	vitiligo	described	in	this	thesis	involved	the	evaluation	of	
the	efficacy	and	 the	safety	of	 the	 treatment	of	vitiligo	with	khellin	encapsulated	 in	
liposomes	 in	combination	with	UV	 light	 therapy	(KLUV).	The	second	 investigation	
involved a surgical approach for transplanting of suction blister roof epidermal grafts 
and Erbium laser ablation for re-pigmentation of refractory and stable vitiligo patches. 
The third study involved additional surgery for refractory vitiligo patches, particularly 
on the ‘emotionally charged’ body sites such as the face, the head, the neck and the 
hands	after	1	year	of	KLUV	treatment.	
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Table 5.  Advantages and disadvantages of surgical methods in the treatment of  
 vitiligo.
Surgical methods Advantages Disadvantages
Punch grafting Easiest and least  Only suitable for small areas
 expensive Scars at donor and recipient  
  sites (cobblestone effect)
Suction blister epidermal Excellent cosmetic  Large areas require several 
grafting results Minimum chances treatments
 of scarring at donor and 
 recipient sites
Split-thickness grafting Treating a relatively large  Scares at donor site
 area in a short period of time Color mismatch
  Milia
  Peri-graft  de-pigmentation 
  halo 
  Stuck-on appearance of 
  recipient site
Transplantation of  Fairly large area can be Requires a well-equipped
autologous epidermal  treated with a donor-to- laboratory and trained personnel
cell suspension recipient expansion ratio 
 ranging from 5 to 10 fold
Transplantation  Treating a relatively large Safety concerns on the use of
of cultured autologous  area in a short period cultured autografts. This
melanocytes of time method is expensive and 
  requires a tissue culture 
  laboratory setup 
Autologous cultured  Treating large areas Requires both specialized
epithelial grafts  equipment and personnel and  
  is expensive
3.2.5 References
1.	 Kovacs	S.	Continuing	medical	education:	vitiligo.	J	Am	Acad	Dermatol	
1998; 38: 647-666.
2.	 LePoole	IC,	Das	PK.	Microscopic	changes	in	vitiligo.	Clin	Dermatol 1997; 
15:	863–873.
3.	 Handa	S,	Kaur	I.	Vitiligo:	clinical	findings	in	1436	patients.	J	Dermatol	
1999;	26:	653–657.
4.	 Halder	RM.	Childhood	vitiligo.	Clin	Dermatol	1997;	15:	899–906.
5.	 Kent	G,	al-Abadie	M.	Factors	affecting	responses	on	Dermatology	Life	
Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996; 21: 
330-333.
6.	 Parsad	D,	Pandhi	R,	Dogra	S,	Kanwar	AJ,	Kumar	B.	Dermatology Life 
Quality Index score in vitiligo and its impact on the treatment outcome. Br J 
Dermatol 2003; 148: 373-374.
7. Sampogna F, Picardi A, Chren MM et al. Association between poorer quality 
of life and psychiatric morbidity in patients with different dermatological 
conditions. Psychosom Med 2004; 66: 620-624.
8.	 Ongenae	K,	van	Geel	N,	De	Schepper	S,	Naeyaert	JM.	Effect of vitiligo on 
self-reported health-related quality of life. Br J Dermatol 2005; 152: 1165-
1172.
9.	 Rezaei	 N,	 Gavalas	 NG,	 Weetman	 AP,	 Kemp	 EH.	 Autoimmunity	 as	 an	
aetiological	factor	in	vitiligo.	J	Eur	Acad	Dermatol	Venereol	2007;	21,	865–
876.
10.	 Le	Poole	 IC,	Das	PK,	 van	 den	Wijngaard	RMJG,	Bos	 JD,	Westerhof	W.	
Review of the etiopathomechanism of vitiligo: a convergence theory. Exp 
Dermatol 1993;	2:	145–153.
11. Forschner	T,	Buchholtz	S,	Stockfleth	E.	Current	state	of	vitiligo	 therapy	–	
evidence-based  analysis of the literature J Dtsch Dermatol Ges 2007;  5: 
467–476.
12. Ochi Y, DeGroot LJ. Vitiligo in Graves’ disease. Ann Intern Med 1969; 71: 
935–940.		
13.	 Naughton	 GK,	 Eisinger	 M,	 Bystryn	 JC.	 Antibodies to normal human 
melanocytes in vitiligo. J Exp Med 1983;	158:	246–251.
14. Ogg GS, Dunbar PR, Romero P, Chen JL, Cerundolo V. High frequency 
of	skin-homing	melanocyte-specific	cytotoxic	T	lymphocytes	in	autoimmune	
vitiligo. J Exp Med 1998;	188:	1203–1208.
15.	 Pawelek	J,	Korner	A,	Bergstrom	A,	Bologna	J.	New	regulation	of	melanin	
biosynthesis and autodestruction of melanoma cells. Nature 1980; 286: 
617–619.
85
16.	 Schallreuter	KU,	Wood	JM,	Berger	J.	Low	catalase	levels	in	the	epidermis	of	
patients with vitiligo. J Invest Dermatol 1991;	97:	1081–1085.
17. Taeib A. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell 
Res 2000; 13 (Suppl.	8):	41–47.
18. Alkhateeb A, Fain PR, Thody A, Bennet DC, Spritz RA. Epidemiology of 
vitiligo and associated autoimmune diseases in Caucasian probands and 
their relatives. Pigment Cell Res 2003;	16:	208–214.
19.	 Laberge	G,	Mailloux	CM,	Gowan	K,	Holland	P,	Bennet	DC,	Fain	PR,	Spritz	
RA. Early onset and increased risk of other autoimmune diseases in familial 
generalised vitiligo. Pigment Cell Res 2005;	18:	300–305.
20. Al Badri AMT, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Goudle RB. 
An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 
1993;	170:	149–155.
21.	 Van	 den	 Wijngaard	 R,	 Wankowicz-Kalinska	 A,	 Le	 Poole	 C,	 Tigges	 B,	
Westerhof W, Das P. Local immune response in skin of generalised vitiligo 
patients. Destruction of melanocytes is associated with the prominent 
presence of CLA+ T cells at the perilesional site. Lab Invest 2000;	80:	1299–
1309.
22.	 	Abdel	Naser	MB,	Kruger-Krasagakes	S,	Krasagakis	K,	Gollnick	H,	Abdel	
Fattah A, Orfanos CE. Further evidence for involvement of both cell mediated 
and humoral immunity in generalised vitiligo. Pigment Cell Res 1994; 7: 
1–8.
23.	 	Hann	 SK,	 Park	 YK,	 Chung	 KY,	 Sungbin	 IM,	 Won	 JH.	 Peripheral	 blood	
lymphocyte	imbalance	in	Koreans	with	active	vitiligo.	Int J Dermatol 1993; 
32:	286–289.
24.	 Wankowicz-Kalinska	A,	van	den	Wijngaard	RM,	Tigges	BJ,	Westerhof	W	et	
al. Immunopolarization of CD4+ and CD8+ cells to Type-1-like is associated 
with melanocyte loss in human vitiligo. Lab Invest 2003;	83:	683–695.
25. Parrish JA, Fitzpatrick TB, Shea C, Pathak MA. Photochemotherapy of 
vitiligo: use of orally administered psoralens and a high intensity long wave 
ultraviolet light system. Arch Dermatol 1976;	112:	1531–1534.
26.	 Kumari	J.	Vitiligo	treated	with	topical	clobetasol	propionate.	Arch	Dermatol 
1984;	120:	631–635.
27.	 Tsuji	T,	Hamada	T.	Topically	administered	fluorouracil	in	vitiligo.	Arch	Dermatol 
1983;	119:	722–777.
28.	 Krutmann	J,	Morita	A.	Mechanisms	of	ultraviolet	(UV)	B	and	UVA	phototherapy.	
J Invest Dermatol Symp Proc 1999;	4:	70–72.
29.	 Duthie	MS,	Kimber	 I,	Norval	M.	The	effects	of	ultraviolet	 radiation	on	 the	
immune system. Br J Dermatol 1999;	140:	995–1009.
86
30. Halder RM, Young CM. New and emerging therapies for vitiligo. Dermatol 
Clin	2000;	18:	79–89.
31.	 Kao	CH,	Yu	HS.	Comparison	of	 the	effect	of	8-Methoxypsoralen	(8-MOP)	
plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro. J 
Invest	Dermatol	1992;	98:	734–740.
32. Viac J, Groujon C, Misery L, Staniek V, Faure M, Schmitt D, Claudy A. 
Effect of UVB 311 nm irradiation on normal human skin. Photodermatol 
Photoimmunol	Photomed	1997;	13:	103–108.
33. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients 
with	 vitiligo:	 results	 of	 a	 prospective	 patient	 series.	Cutis	 2003;	 71:	 158–
162.
34. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB et al. A 
double-blind randomised trial of 0.1% tacrolimus vs 0.05% clobetasol for the 
treatment	of	childhood	vitiligo.	Arch	Dermatol	2003;	139:	581–585
35. Falabella R. Surgical treatment of vitiligo: why, when and how. J Eur Acad 
Dermatol	Venereol	2003;	17:	518–520.
36. Cui J, Shen L, Wang G. Role of hair follicles in the repigmentation of vitiligo. 
J Invest Dermatol 1991; 97: 410-416.
37.	 Antoniou	G,	 Katsambas	A.	Guidelines	 for	 the	 treatment	 of	 vitiligo.	 Drugs	
1992; 43: 490-498.
38. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I,  Whitton ME, Watts MJ, 
Anstey	AV,	Ingham	J,	K.	Young.	Guideline	for	the	diagnosis	and	management	
of vitiligo. Br J Dermatol 2008; 159: 1051-1076.
39. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children 
with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 
42: 245-253. 
40. Morliere P, Honigsmann H, Averbeck D, Dardalhon M, Hüppe G, Ortel B, 
Santus R, Dubertet L. Phototherapeutic, Photobiologic and Photosensitizing 
properties of khellin. J Invest Dermatol 1988; 90: 720-724. 
41.  Ortel B, Tanew A, Honigsmann H. Treatment of vitiligo with khellin and 
ultraviolet A. J Am Acad Dermatol 1988; 18: 693-701.
42.  Abdel-Fattah A, Aboul-Enein MN, Wassel GM, El-Menshawi BS. An approach 
to	treatment	of	vitiligo	by	khellin.	Dermatologica	1982;	165:	136–40.
43. Procaccini EM, Riccio G, Montfrecola G. Ineffectiveness of topical khellin in 
photochemotherapy	of	vitiligo.	J	Dermatol	Treatment	1995;	6:	117–120.
44. Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight 
in vitiligo. Dermatology 1992; 184: 120-123.
45. Orecchia G, Sangalli ME, Gazzaniga A., Giordano F. Topical 
photochemotherapy of vitiligo with a new khellin formulation: preliminary 
87
results. J Dermatol Treatment 1998; 9: 65-69.
46. Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin 
and UVA: comparison with systemic PUVA. Clin Exp Dermatol 2004; 29:180-
184.
47.	 Lieb	 LM,	 Ramachandran	 C,	 Egbaria	 K,	 Weiner	 N.	 Topical	 delivery	
enhancement  with multilamellar liposomes into pilosebaceous units. J. 
Invest Dermatol 1992; 99:108-113.
48. Hoffman RM. Topical liposome targeting of dyes, melanins, genes, and 
proteins selectively to hair follicles. J Drug Target 1995: 67-74.
49. Olsson MJ. What are the needs for transplantation treatment in vitiligo, and 
how good is it? Arch Dermatol 2004; 140: 1273-1274
50. Parsad D, Gupta S. Standard guidelines of care for vitiligo surgery. Indian J 
Dermatol Venereol Leprol 2008; 74: s37-45.
51.	 Njoo	 MD,	 Das	 PK,	 Bos	 JD,	 Westerhof	 W.	 Association	 of	 the	 Kobner	
phenomenon with disease activity and therapeutic responsiveness in vitiligo 
vulgaris. Arch Dermatol 1999; 135: 407-413.
52. Falabella R. Surgical therapies for vitiligo. Clin Dermatol 1997; 15: 927-
939.
53.		 Oh	CK,	Cha	JH,	Lim	JY,	Jo	JH,	Kim	SJ,	Jang	HS,	Kwon	KS.	Treatment	of	
vitiligo with suction epidermal grafting by the use of an ultrapulse CO2 laser 
with a computerized pattern generator. Dermatol Surg, 2001; 27(6):  565-
568.
54.	 Pai	GS,	Vinod	V,	Joshi	A.	Efficacy	of	erbium	YAG	laser-assisted	autologous	
epidermal grafting in vitiligo. J Eur Acad Dermatol Venereol, 2002. 16: 604-
606.
3.3 Acne vulgaris
3.3.1 Epidemiology and clinical aspects.
Acne	vulgaris	is	one	of	the	most	common	disorders	of	the	skin	with	70–96%	of	the	
population suffering from it at some point in their life and may have a considerable 
impact on the quality of life.1,2  For many patients, acne has the characteristics 
conform	the	definition	of	chronic	disease,	psychological	sequels	that	do	not	always	
correlate with the clinician’s assessment of the severity at one point in time.3  
These characteristics are a prolonged course, a pattern of recurrence or relapse, 
manifestation as acute outbreaks or slow onset, and a psychological and social impact 
that affects the sufferer’s quality of life.4  Acne vulgaris is clinically characterized by 
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non-inflammatory	comedonal	lesions,	inflammatory	acne	papules,	pustules,	nodules	
or cystic lesions.5 
The histopathological picture of acne depends on the stage of genesis. Early lesions 
are seen as microcomedones, which show mildly distended follicles and narrowed 
follicular openings. The follicular distention increases and passes into a compact 
cystic structure containing an eosinophilic, keratinaceous debris, hair, and bacteria 
in closed comedones. Open comedones have broad follicular openings with a peri-
vascular	mononuclear	cell	infiltrate	surrounding	the	distended	follicle.	The	sebaceous	
glands become atrophic. The follicular contents may rupture into the dermis following 
the	follicular	distension	and	induce	an	inflammatory	response.	In	the	acute	phase	
of	 inflammation	 neutrohils	 first	 appear	 creating	 a	 pustule.	As	 the	 lesions	mature,	
foreign-body	granulomatous	inflammation	engulfs	the	follicle	and	end-stage	scarring	
often results.6 
Clinical classification of acne: 5 
1. Neonatal acne is characterized by multiple small, erythematous, closed  
comedones on the nose, the forehead and the cheeks of a neonate with an 
onset frequently at between 0 and 6 weeks of age. Nearly 1 in 5 neonates 
has	mild	 acne.	 Neonates	 have	 open	 comedones,	 inflammatory	 papules,	
or pustules less often. Neonatal acne lesions predominantly resolve 
spontaneously within 1 to 3 months and don not need treatment. 
Infantile acne that is seen later in infancy has an onset beginning in months 2. 
3	to	6	and	is	classified	as	 infantile	acne.	It	 is	 less	common	than	neonatal	
acne	 and	 is	 characterized	 by	more	 numerous	 inflammatory	 papules	 and	
pustules with an occasional presentation of nodular acne. Scarring from 
infantile acne is a risk. Patients with infantile acne may run an increased risk 
of developing severe acne vulgaris during the teenage years. 
Acne vulgaris 3. 
- Teenager acne is often related to the hormonal changes before 
and during puberty. Teenaged boys are more often affected than 
teenaged girls, with some estimates indicating that 100% of the 
teenaged boys are more or less affected by acne.  After peaking 
during the teenage years, the prevalence of acne progressively 
decreases. 
- Adult acne affects approximately 8% of the adults aged 25 to 34 
years and only 3% of the adults aged 35 to 44 years. Young adult 
acne may be a continuation of teenage acne or start de novo. Most 
teenaged boys with acne may anticipate a clearing by the age of 20 
to 25 years. In contrast, women may continue to have acne well into 
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their adult life, up to and even beyond the age 40 years. Acne may 
persist into adult years in as many as 50% of the individuals.7 Eighty-
five	percent	of	the	women	experienced	a	premenstrual	flare	of	their	
acne. 
-	 Acne	 papulopustulosa	 is	 characterized	 by	 non-inflammatory	
comedones,	 inflammatory	 papules,	 pustules	 with	 occasional	
presence of nodules and cicatrices (Figure 19A)
- Acne conglobata is a severe, eruptive nodulocystic variant of acne 
without systemic manifestations (Figure 19B).6 
- Acne fulminans is the most severe form of cystic acne and is 
characterized by the abrupt onset of nodular and suppurative acne 
in association with varying systemic manifestations. Both forms of 
cystic	acne	are	characterized	by	the	formation	of	deep	inflammatory	
lesions that often cause scarring. 6 
- Acne cosmetica is most commonly found in women between the 
ages of 20 to 40 years and is associated with the use of cosmetics 
containing comedogenic substances. It is characterized by persistent, 
low-grade closed comedones that resolve slowly once the causing 
product is no longer used.6 
- Pomade acne is a variation of acne cosmetica seen almost exclusively 
in AfricanAmericans and Europeans. It is associated with the use of 
greases and oils applied on the scalp and the face. The lesions are 
closely packed closed comedones found only at the site of pomade 
application.5 
Physical scars or persistent hyper-pigmentation are both not uncommon sequels of 
acne	and	are	usually	expensive	and	difficult	to	treat	effectively.	Adverse	psychological	
effects including anxiety, depression and social withdrawal have all been reported 
in individuals with acne and acne scars.8,9 The effects of acne can persist for many 
years, even in individuals who had self-limited adolescent acne.10 Other micro-
organisms are involved in acne-like diseases such as rosacea and Gram-negative 
folliculitis. Acneiform lesions may be also be induced by medicaments such as 
corticosteroids, iodides, bromides, lithium, isoniazid and others (drug-induced 
acne).	An	 abrupt,	monomorphous	 eruption	 of	 inflammatory	 papules	 distinguishes	
drug-induced acne from the heterogeneous morphology of acne vulgaris. Acne 
mechanica occurs secondary to the repeated mechanical and frictional obstruction 
of the pilosebaceous outlet resulting in comedo formation. Linear and geometric 
distribution of comedones and papulopustels is sometimes accompanied by hyper-
pigmentation	and	lichenification	indicating	acne	mechanica.6 
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3.3.2 Acne pathogenesis
The formation of an acne lesion begins with the microcomedo. This lesion, which is 
not yet clinically visible forms when excess sebum collects in the follicle and abnormal 
epithelial desquamation occurs along with proliferation of Propionibacterium (P.) 
acnes. The microcomedo is the precursor of all acne lesions such as comedones 
and papules/pustules.11 Four major factors are responsible for the development of 
acne lesions.10 
1. Sebum production by the sebaceous gland
2. Follicular colonization by P. acnes
3. Alteration in the keratinization 
4.	 Release	of	inflammatory	mediators	into	the	skin
Ad 1. Sebaceous lipids are regulated by peroxisome proliferator-activated 
receptors (PPARs) and sterol response element binding proteins.12,13  PPARs are 
members of the nuclear hormone receptor family that alter sebaceous lipid production 
in concert with retinoid X receptors to regulate epidermal growth, differentiation and 
lipid metabolism.12  Sterol response element binding proteins mediate the increase in 
sebaceous lipid formation induced by insulin-like growth factor-1.13  The sebaceous 
gland acts as an independent endocrine organ in response to changes in androgens 
and hormones.14  	This	aspect	of	sebaceous	gland	 function	 is	primarily	 influenced	
by corticotrophin-releasing hormone and corticotrophin receptors. Corticotrophin-
releasing hormone levels change in response to stress and its role in regulating 
sebaceous gland function is a likely link in the brain-skin connection that is thought 
to	explain	the	relationship	between	stress	and	skin	disorders	with	an	inflammatory	
component such as acne.15-17  In addition, the sebaceous gland has both direct and 
indirect antibacterial activities. Palmitoleic acid isomer, a lipid in sebum, has innate 
antimicrobial activity against Gram-positive bacteria and is up-regulated by activation 
of TLR-2 by skin bacteria.18, 19  
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Figure 19.  A. acne papulopustulosa            B. acne conglobata
Ad 2.	 Interaction	between	P.	acnes	and	TLR-2	triggers	an	inflammatory	response,	
which	induces	the	synthesis	of		TNF-α	and	IL-1.20-22		These	inflammatory	cytokines	
amplify the signaling pathways that activate the activator protein (AP)-1 transcription 
factor.23  Activation of AP-1 induces matrix metalloproteinase (MMP) genes whose 
products degrade and alter the dermal matrix.23  Retinoids are known to inhibit AP-
1.24 Retinoids may induce monocytes to develop into CD209+ macrophages that 
phagocytose P. acnes bacteria.25	These	data	further	support	the	anti-inflammatory	
activity of currently available treatments such as topical retinoids in acne.
Ad	3.	 Immune	changes	and	inflammatory	responses	occur	before	hyperproliferation	
of keratinocytes, with a pattern similar to a type IV delayed hypersensitivity response.26  
Oxidized squalene can stimulate hyperproliferative behavior of keratinocytes indicating 
that this lipid may be responsible for comedo formation.27  It has been hypothesized 
that	 lipoperoxides	 exert	 a	 proinflammatory	 effect	 on	 the	 pilosebaceous	 duct.28,29  
Lipoperoxides produce leukotriene B4, which is a powerful chemoattractant that can 
recruit		neutrophils,	macrophages	and	stimulate	the	production	of	proinflammatory	
cytokines.26, 28,30 Matrix metalloproteinases (MMPs), which include collagenases, 
gelatinases, stromelysins, and matrilysins originate in keratinocytes and sebocytes 
and	have	a	prominent	role	in	both	inflammatory	matrix	remodeling	and	proliferative	
skin disorders.31  Oral isotretinoin can reduce the concentrations of MMPs in sebum 
paralleling the clinical improvement.30 
Ad 4. The immune response is led by CD4+  lymphocytes and macrophages.26 
Subsequent productions of cytokines activate local endothelial cells, up-regulating 
inflammatory	 vascular	markers	 such	as	E-selectin,	VCAM-1,	 ICAM-1	and	human	
leukocyte antigen-DR (HLA-DR) in the vasculature around the pilosebaceous 
follicle26 and the subsequent attraction of lymphocytes and leukocytes resulting in an 
inflammation.	Acne	is	a	disease	that	involves	the	innate	and	adaptive	immune	system	
and	 inflammatory	 events.	 Therefore,	 treatment	 that	 targets	 both	 immune	 system	
activation	 and	 inflammatory	 pathways	 is	 desirable.	Many	 of	 the	 agents	 currently	
used	to	treat	acne	have	effects	on	cellular	receptors,	inflammatory	mediators,	and	
other molecular targets.10 
3.3.3 Treatment and side effects
Standard treatment of acne consists of peeling the skin and reducing P. acnes and 
inflammation	 by	 using	 topical	 benzoylperoxide	 gel,	 azelaic	 acid	 cream,	 tretinoin	
cream, adapalene gel and topical antibiotics. Systemic antibiotics and anti-androgens 
(in	female	patients)	are	used	when	this	approach	is	not	efficacious.	Antibiotics	were	
the	first	effective	treatment	for	acne.	However,	the	efficacy	of	antibiotic	treatment	is	
progressively reduced by increasing resistance of the bacteria to the used antibiotics. 
Adverse	effects	may	also	limit	their	use	(Table	6).	When	other	treatments	fail,	the	final	
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remedy is oral isotretinoin, which is very effective, but its use is even more limited by 
moderate to serious adverse effects (Table 6). Patients with acne are often treated 
with	multiple	antibiotics	and	their	flora	is	exposed	to	a	significant	selective	pressure	
for resistance development. It has been observed that patients with acne treated 
with antibiotics had 2.15 times higher risk of developing an upper respiratory tract 
infection than patients with acne who were not treated with antibiotics.32  In addition, 
there have been an increasing number of reports of infections caused by P. acnes 
and include arthritis, endocarditis and endophthalmitis.33-35  Even an increased risk of 
(fatal) breast cancer by cyclins was reported.36  Current guidelines and publications 
emphasize the need to limit antibiotic use, both frequency and duration, and to add 
the non-antibiotic antimicrobial agent benzoylperoxide (BPO) gel when long-term 
antibiotic	use	is	necessary	because	BPO	is	a	highly	efficient	bactericidal	agent	that	
minimizes the development of resistance at sites of application.37-40  Strategies have 
been developed to limit antibiotic resistance in acne management:10
- Since acne is a multi-factorial disease, multiple classes of drugs are used in 
the	clinical	setting.	Combination	therapy	is	now	recommended	as	the	first-line	
choice.
- Combination of a topical retinoid such as tretinoin and adapalene with an 
antimicrobial (oral or topical) agent because of the complementary modes of 
action that have been observed clinically.
- Oral antibiotics must be discontinued when there is no further notable 
improvement and should ideally be used for no longer than 3 months.  
- Replacing oral and topical antibiotics by a topical BPO-containing base 
because BPO reduces the possibility of antibiotic resistance of P. acnes and 
rapidly reduces the number of sensitive and resistant strains of P. acnes at the 
site of application.40 
- The use of  topical retinoids for maintenance therapy with added BPO  for an 
antimicrobial effect if needed. Maintenance therapy is an effective strategy to 
minimize the risk of relapse.41 
- Avoiding of the use of antibiotics for maintenance therapy.
 This approach may have several problems in the clinical setting:
- Discontinuation of antibiotic treatment may often lead to an exacerbation 
of acne in spite of the replacement of topical BPO and the continuation of 
topical retinoids. In such cases, most of the patients are willing to continue the 
antibiotic treatment for longer than 3 months for good reason. 
- Patients may have aversion to the use topical BPO because of the white 
discoloration of clothes.
- Adverse effects such as burning, itching, redness, dry skin, scaling, cracks, 
crusting, blistering and allergic contact dermatitis of BPO may limit its use. 
93
-  Concerns on the long-term carcinogenesis effect of BPO.42  
- Adverse effects such as burning, itching, dry skin, redness, desquamation, 
contact allergy, crustation, hypo- and hyper-pigmentation and photo-
sensitization are also possible during the use of tretinoin and to a lesser extent 
also during the use of adapalene.
The increasing antibiotic resistance of P. acnes and the growing awareness on the 
adverse effects of topical and systemic drugs in the treatment of acne vulgaris by 
physicians	and	patients	motivated	the	search	for	new	efficacious	and	safe	treatment	
modalities such as light-based therapies.
Light-based treatments have three primary therapeutic targets.43-46 These are as 
follows: 
Reduction of P. acnes levels1. 
Disruption of sebaceous gland function and subsequently reduction of 2. 
sebum production
Reduction	of	inflammation	via	action	on	inflammatory	cytokines	3. 
Acne	often	improves	after	exposure	to	sunlight	or	artificial	 light	sources.43  As part 
of its normal metabolism, P. acnes produces light-sensitive porphyrin compounds 
such as uroporphyrin, coproporphyrin III and protoporphyrin IX (PpIX). PpIX absorbs 
visible light at several wavelengths of between 400 and 700 nm. Absorption of light 
excites the PpIX, causing formation of singlet oxygen and ROS resulting in phototoxic 
reactions and destruction of bacteria47 and damage to the sebaceous glands.48 
The	activation	of	PpIX	is	visualized	by	the	phenomenon	of	PpIX-fluorescence	with	
fluorescence	 photography	 	 (Figures	 19	 and	 20).	 The	 theoretically	 most	 effective	
wavelength for photo-activation of PpIX is 415 nm. Red light (635 nm) is less 
absorbed by photo-activating porphyrins, but penetrates more deeply into the tissue 
and	may	also	have	anti-inflammatory	effects	by	influencing	the	release	of	cytokines	
from macrophages.49  Initially, light-based systems for treating acne emitted blue light, 
50 red light or a combination of blue- and red light. 47  However, clinical improvement 
was limited and multiple sessions were required. Photodynamic therapy (PDT) after 
application of photo-sensitizers such as 5-ALA or MAL has the potential to damage 
the sebaceous gland by the action of free oxygen radicals because of the higher 
availability of PpIX. The initial disruption of the sebaceous glands accompanied by 
the	temporary	release	of	pro-inflammatory	mediators	may	help	to	explain	why	acne	
can	flare	after	initiation	of	therapy.	The	subsequent	reduction	of	the	sebaceous	gland	
function eliminates or reduces sebum production for prolonged periods.51  Therefore, 
PDT with 5-ALA or MAL was introduced to achieve more effectiveness with fewer 
treatment sessions.52 	Studies	on	the	efficacy	and	the	tolerability	of	PDT	differ	in	the	
used light source, the treatment schedules, the parameters and the concentration of 
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5-ALA.53-59  In those studies, adverse effects such as pain, erythema, crusts (Figure 
3) and post-treatment hyper-pigmentation were encountered highlighting the need 
for optimizing PDT for the treatment of acne. Split-face studies using 5-ALA and 
IPL reported that the combination of 5-ALA and IPL was more effective than IPL 
alone.52,53,55
Liposomes are used in the treatment of hair follicle- and sebaceous gland-associated 
disorders because of their potential to carry lipophilic drugs and hydrophilic drugs 
such as 5-ALA into the pilosebaceous structures.60-63  Promising results were obtained 
with liposomal encapsulated drugs in the treatment of acne. 64-67  Christiansen et 
al	performed	a	study	on	the	fluorescence	distribution	patterns	of	normal	skin	after	
topical application of 20% 5-ALA in a moisturizing cream and after application of 
low concentrations of 5-ALA (0.5% and 1%) encapsulated in liposomes. The 5-ALA 
concentration could be lowered by a factor of 40 by changing the vehicle for delivering 
the 5-ALA from a moisturizing cream to liposome encapsulation while inducing the 
same	level	of	fluorescence	in	the	skin.	The	need	for	occlusion	was	eliminated	at	the	
same	time.	The	low	post-treatment	fluorescence	also	significantly	reduced	the	risk	of	
post-treatment phototoxicity.68  It was not substantiated that follicular obstruction was 
reduced by PDT. The combination of a topical retinoid and an antimicrobial agent 
is currently the preferred approach for almost all patients with acne.10 The rational 
for this combination is that it attacks 3 of the 4 major pathogenic factors of acne: 
abnormal	 desquamation,	 P.	 acnes	 colonization	 and	 inflammation.	 Retinoids	 are	
anticomedogenic,	comedolytic,	and	have	some	anti-inflammatory	effects,	whereas	
antibiotics	have	anti-inflammatory	and	antimicrobial	effects	and	BPO	is	antimicrobial	
with some keratolytic effects. The combination of topical retinoids and PDT promises 
an attack on all 4 major pathogenic factors of acne including the normalization of 
keratinization, destruction of P. acnes, reduction of sebum excretion and reduction 
of	inflammation.	The	efficacy	of	photodynamic	therapy	(PDT)	of	acne	vulgaris	using	
5-ALA 0.5% liposomal spray and Intense Pulsed Light (IPL) in combination with 
topical keratolytic agents (Li-PDT-PC) was investigated in the study described in this 
thesis.
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Topical drugs
Figure 20. Before and after PDT treatment using 5-ALA 0.5% liposomal spray and 
Intense Pulsed Light in combination with topical keratolytic agents (Li-PDT-PC).
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Non-melanoma skin cancer
3 4.1 Epidemiology
Non-melanoma skin cancer (NMSC) is the most common cancer in Caucasians 
and its incidence is of epidemic proportions worldwide.1-5 Although, the term NMSC 
covers all cutaneous cancers excluding melanomas, it is normally used to refer to 
two major types of skin cancers namely basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC). These two types of skin cancer account for more than 95% 
of all NMSC.5 BCCs arise de novo, which means there are no known precursor 
lesions.5	SCCs	may	arise	from	actinic	keratoses	(AKs).	Actinic	keratoses	have	been	
often considered to be pre-malignant precursor lesions by some authors6-8, whereas 
according	to	other	authors,	AKs	are	true	epithelial	neoplasmata	from	the	beginning.3,9 
From	this	standpoint	of	view,	the	evolution	from	AK	to	SCC	represents	progression	
rather	 than	 transformation,	 and	 therefore,	AK	 should	 be	 recognized	 as	 incipient	
SCC.10		It	has	been	estimated	that	6%	to	10%	of	AKs	develop	into	invasive	SCC.11,12 
This	highlights	the	value	of	AK	as	a	marker	for	SCC.3 Thus, if these high-risk patients 
with	AKs	are	monitored	closely,	invasive	tumors	that	develop	could	be	treated	at	an	
early stage when cure rates are high, morbidity low, mortality non-existent and costs 
of treatment are limited.3 The average annual increase of NMSC in the Caucasians 
in Europe, the United States, Canada and Australia has been 3% to 8% since the 
1960s.4  Today, the incidence of NMSC is higher than all other cancers combined and 
NMSC	is	among	the	five	most	costly	cancers	reported	in	the	USA.13  There are many 
reasons for the worldwide increase in the incidence of NMSC.
In the Netherlands, the total number of skin cancer patients calculated over a period 
of 15 years is expected to increase from 20,654 cases in 2000 to 37,342 cases in 
2015 (an increase of 81%).14 The number of cases of BCC is expected to increase 
by 78%. The highest increase is expected in those aged 15-64 years (males, 66% 
increase; females, 94% increase), especially at sites other than the head and the 
neck. An overall increase of 80% in SCC is expected. An increase of 79% is expected 
in older males and females and an increase of 93% is expected in middle-aged 
females	aged	35–64	years.14 
There are many reasons for the worldwide increase in the incidence of NMSC. 
Etiological factors that underlie the development of skin cancer are of endogenous 
origin as well as of exogenous origin.4  Major endogenous factors are the age, the 
genetic pre-disposition such as the skin type (especially skin types I, II and III) and 
hereditary diseases such as xeroderma pigmentsum. The key environmental risk 
factor	for	NMSC	is	the	ultraviolet	(UV)	radiation	from	exposure	to	sunlight,	artificial	
tanning lamps,15-18 iatrogenic exposure to psoralen & ultraviolet A (PUVA) and 
ultraviolet B (UVB) modalities often used for the treating psoriasis and vitiligo.19,20 
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Those with occupational or recreational outdoors exposure such as commercial 
fisherman,	construction	workers,	park	rangers,	 farmers,	aircraft	pilots,	yachtsmen,	
golfers,	skiers,	mountaineers	and	sun-addicts	have	a	higher	incidence	rate	of	AKs	
than those who are indoors.21-24  Other exogenous factors include carcinogens such 
as arsenic, pesticides, tar, certain industrial oils, dyes, solvents, ionizing radiation, 
human papilloma viral infections.25 and immunosuppression, especially in organ 
transplant recipients.26 Tobacco smoking has also been recently linked to SCC.27  In 
2002, more than 1 million cases of NMSC were diagnosed in the United States.28  More 
than 20% of the metastatic diseases and deaths in NMSC are from SCC. Therefore, 
the ability of a physician to distinguish pre-cancerous lesions with a high degree of 
accuracy is very important and will decrease the morbidity and mortality from SCC.29 
The	differential	diagnosis	of	NMSC	includes	many	benign	and	(superficial)	malignant	
lesions (Table 4).12,29 The diagnostic accuracy or the positive predictive value (PPV) 
of	the	clinical	diagnosis	of	AKs	made	by	specialized	physicians	appeared	to	be	only	
74% after histological evaluation.29  An increasing problem is posed by a particular 
cancerous area with multiple (pre)malignant lesions diffusely spread over UV-
exposed skin. Today, physicians often need to take multiple biopsies from clinically 
suspected	malignant	lesions,	which	can	be	a	significant	burden	for	the	patient.30 
3.4.2 Clinical features NMSCs
- Actinic keratosis: solitary or multiple, red, scaly papules or plaques, 2- to10-
mm in diameter, occurring in sun-exposed sites, may bleed and become 
hypertrophic.29 
- Squamous cell carcinoma in situ: solitary or multiple, sharply demarcated, 
scaling, or hyperkeratotic macule, papule or plaque, often pink or red in 
color, erosions and crusts may be present.
- Differentiated squamous cell carcinoma: red, yellow or skin-colored, 
indurated plaque, papule or nodule, with adherent scaling or hyperkeratosis, 
erosion,	ulceration,	crust	in	the	center	and	a	firm,	hyperkeratotic	border.
-	 Undifferentiated	 squamous	 cell	 carcinoma:	 red,	 fleshy,	 granulating,	 easily	
bleeding, erosive, crusting papules, nodules papillomatous vegetations and 
ulceration with a necrotic base.
-	 Superficial	basal	cell	 carcinoma:	 red,	shiny	or	slightly	scaly,	 thin	plaques,	
often	with	a	fine	pearly	border.
-	 Superficial	multi-centric	basal	cell	carcinoma	appears	as	multiple,	thin,	pink	
or	red	plaques	with	fine	teleangiectasia.
- Nodular basal cell carcinoma: translucent or pearly papule or nodule, 
sometimes with black, brown or blue hyper-pigmentation.
-	 Morphea-like	basal	 cell	 carcinoma:	whitish,	 sclerotic	patch	with	 ill-defined	
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borders and sometimes with pearly colored papules at the periphery.
-	 Cystic	basal	cell	carcinoma	may	present	as	firm,	 translucent	papules	and	
noduli occasionally with a depressed (umbilicated) center.
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Differential diagnosis of  actinic keratosis
Benign Malignant
Kerarosis	(	seborrheic,	stucco,	arsenical,		lichenoid	)	 Bowen’s disease
Porokeratosis  Basal cell carcinoma
Keratoacanthoma	 Squamous	cell	carcinoma
Lentigo solaris
Discoid lupus erythematosus
Psoriasis
3.4.3 Dermatoscopy
Dermatoscopy is a noninvasive method that allows the in vivo evaluation of colors 
and microstructures of the epidermis, the dermoepidermal junction, and the papillary 
dermis not visible to the naked eye.
Dermatoscopic characteristics of NMSC:
Actinic keratosis:  
- Uniform pink or tan-colored background.
- Prominent keratin (white or yellow scale).31 
Morbus Bowen:
- Irregular ‘glomerular vessels’ are characteristic.
- Scaly surface.32 
Basal cell carcinoma:
- Arborizing vessels
-  Grey-blue ovoid nests
-  Maple leaf-like areas 
-  Spoke wheel areas
-             Ulceration 
-  Small brown globules and/or homogeneous pigmentation.32,33,.34 
Dermatoscopic characteristics of benign skin disorders, which may show positive 
fluorescence	after	application	of	5-ALA:
Sebaceous hyperplasia:
- Solitary or aggregated white or yellow nodules 
- The nodules are surrounded by groups of orderly winding, scarcely branching 
vessels extending towards the center, but never crossing it: “crown vessels”. 
34,35,36 
Poriasis:
- Vessels are tiny red dots in a homogenous pattern
- Light pink background
-	 Non-adherent	scaling	(in	flakes).32 
Common wart:
- Papilliform structure
- Thrombosed capillaries. 
  
3.4.4 Fluorescence detection of NMSCs
Following topical application of 5-ALA, PpIX is induced selectively in epithelial tumor 
cells with high metabolism. The tumor becomes visible upon irradiation with light and 
can be delineated from the surrounding tissue.37	This	method	is	called	fluorescence	
diagnosis	(FD).	The	contrast	of	the	acquired	fluorescence	images	can	be	significantly	
enhanced by using a highly light sensitive charged couple device (CCD) camera 
system together with a specially designed digital imaging (Dyaderm system, Biocam 
GmbH, Regensburg, Germany).30,37,38   
The	 clinical	 differential	 diagnosis	 between	 AK,	 (superficial)	 SCC,	 (superficial)	
BCC	 and	 certain	 benign	 skin	 disorders	 may	 be	 difficult	 as	 already	 mentioned.	
Dermatoscopy is very helpful, but is time-consuming for examining large areas of 
the skin. The advantage of FD is that it indicates the “points of most interest“ for 
determining the optimal site for dermatoscopic examination or for taking a biopsy. 
This results in a considerable reduction of procedure time. FD is also a helpful tool 
for	evaluating	the	efficacy	of	PDT	or	for	marking	the	boundaries	of	the	tumor	for	pre-
operative planning. Although promising, the results up till now were limited because 
of technological constraints in terms of the application of 5-ALA, the illumination and 
the	observation	of	fluorescence.	
A new FD system with a purpose-made digital camera and software in combination 
with the application of 5-ALA encapsulated in liposomes was evaluated in the studies 
described in this thesis in order to improve the detection of early NMSCs (clinically 
visible as well as non-visible lesions) on the face, the neck, the chest, the back and 
the hands of patients treated with UV and outdoor workers.
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Summary
In	psoriasis,	the	earliest	changes	before	the	occurrence	of	inflammation	and	epidermal	
hyperproliferation are in the dermal papillary vasculature. Previous investigations 
have demonstrated a reduction of psoriasis after selective photothermolysis of the 
dermal vasculature with the pulsed dye laser. This laser was used to treat 74 patients 
with chronic plaque type psoriasis unresponsive to conventional topical therapies. 
After laser treatment, improvement appeared to be good to very good in 73% of 
patients.
Introduction
Psoriasis is histologically characterized by epidermal keratinocyte hyperproliferation, 
an	intradermal	and	intraepidermal	inflammatory	infiltrate	composed	mainly	of	T	cells,	
accumulation of neutrophil granulocytes, increased numbers of dendritic cells and 
mast cells, and	expansion	of	the	superficial	dermal	vasculature.	Traditional	therapies	
for psoriasis have generally focused on inhibition of epidermal proliferation and /or 
inflammation.	The	abnormities	in	the	capillary	vasculature	have	therapeutically	been	
neglected, although it has been reported that in a new psoriasis lesion the earliest 
observable changes are in the dermal papillary vasculature. 1,2,3 These changes include 
increased vascular dilatation and proliferation, increased tortuosity of capillaries, 
swelling of endothelial cells, and widening of the gaps between endothelial cells. 2,3 
In psoriasis skin capillary loops display the morphological characteristics of venous 
capillaries, including bridged fenestrations of the endothelial cell layer, facilitating the 
exchange between the vessel and the interstitium.4 In addition,T-helper cells adhere 
to dermal papilla capillary endothelium in psoriatic but not in normal kin.5 These 
studies have led to the hypothesis that selective destruction by photothermolysis of 
the dilated papillary vessels leads to elimination of the extravasation of mediators of 
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inflammation	in	the	interstitium	resulting	in	clearing	of	psoriasis	plaques.6 
The Pulsed Dye laser (PDL) is very suitable for selective photothermolysis of 
dermal vessels.7 This machine has been proven to be effective in the treatment of 
teleangiectasia and port wine nevi. 8,9,10 Previous studies have demonstrated partial 
and total clearance of psoriasis with the PLD.6,11,12,13
Katugampola	 et	 al	 treated	 8	 patients	 with	 chronic	 plaque	 type	 psoriasis.	 An	
improvement of more than 50% was shown in 5 patients at week 10 after the last 
of 3 treatment sessions. A complete remission of the treated plaques was seen in 1 
patient. 6
Ros et al observed a clinical improvement after 1 to 3 treatment sessions in 6 of 10 
patients.	Pathohistologic	findings	of	biopsies	from	treated	skin	of	3	patients	revealed	
no epidermal damage. 11
In an elegant study performed by Zelickson et al, a psoriasis plaque was divided 
into 2 halves, one half was treated with PDL, the other half was not treated. The 
authors demonstrated a remission of psoriasis after 2 treatments, while the non-
treated half did not show any improvement at all. After 13 months an expansion of 
psoriasis was seen from the non-treated half into the treated half of the plaque. The 
remission time of psoriasis plaques treated by PDL appeared to be considerable 
longer than the remission time of psoriasis plaques treated by triamcinolon cream. 
Confocal microscopy demonstrated normalisation of diameter and tortuosity of 
papillary vessels in psoriasis skin after PDL treatment.12
Bjerring et al compared the results of PDL treatment in 11 patients with chronic 
plaque type psoriasis with the results of simultaneous treatment with dermabrasion 
in 6 of the 11 patients. Complete remission was seen in 3 patients after PDL and in 
5 patients after dermabrasion. Partial remission was observed in 6 patients treated 
by PDL and in 1 patient treated by dermabrasion. The PDL treatment appeared to be 
less damaging than dermabrasion.13
The purpose of this open prospective study was to evaluate the effectiveness and 
the safety of pulsed dye laser treatment in 74 patients with plaque type psoriasis.
Patients and methods
Selection of the patients
The study group comprised 74 patients with stable plaque type psoriasis or psoriasis 
pustulosa circumscripta on the hands and feet, which was resistant to previous 
topical treatments (calcipotriol, corticosteroids, tar, broadband UVB,and topical 
psoralen-UVA). Patients with photointolerance (toxic or allergic), on medication 
with phototoxic or photoallergic drugs, who were pregnant, or with pre-existent or 
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manifest cutaneous malignancy were excluded.
All included patients provided written informed consent to participate in the study.  
Four patients did not show up, 1 patient because of intercurrent mamma carcinoma 
and	the	other	3	patients	without	any	definite	reason.
methods
Laser treatment: Patients were treated with PDL equipment (MultiCare, VLS 
Cynosure, Chelmsford, Mass, USA) that had adjustable settings for wavelengths 
from 585 to 600 nm; pulse durations of 450 and 1500 microseconds; and 3-, 5-, 7-, 
and	10-mm	spot	diameters.	Depending	on	the	spot	size,	fluences	up	to	20-J/cm2 are 
possible. In this study a wavelength of 585 nm and a pulse duration of 0.450 msec 
was	used.	Treatment	fluences	ranged	from	6	to	8	J/cm2 for 5-mm spot size, 5 to 6 J/
cm2 with a 7-mm spot diameter. The patients were treated once every 4 to 6 weeks 
with an overlap of ± 20% of the spot size, treating the entire lesion with a margin 
of about 5 mm in the surrounding skin. During the treatment the skin was cooled 
with cold air (Cryo 5, Zimmer Elektromedizin GmbH, Ulm, Germany). Patients were 
requested to report any adverse events immediately.
In each patient the initial PDL treatment was carried out with a spot diameter of 5 
mm	and	a	fluence	of	6.0	J/cm2.	At	following	visits	the	fluence	was	increased	with	0.5	
to 1.0 J/cm2 in case the psoriasis lesions showed a lower improvement than 50%, 
up	till	a	maximum	fluence	of	8.0	J/cm2.		Psoriasis	lesions	with	thick	infiltration	and/or	
abundant	scales	were	treated	with	a	spot	diameter	of	7mm	and	initial	fluence	of	5.0	
J/cm2,	and	the	fluence	was	raised	on	indication	up	till	a	maximum	of	7.0	J/cm2.
The PDL treatment was terminated in those cases, which did not show an improvement 
of more than 30 % after 5 treatments.
Comedication
To promote the penetration of the laser light into the skin, scaly psoriatic lesions of 
the patients were initially treated with calcipotriol ointment between laser treatments. 
However, soon we noticed that there was more hyperpigmentation in patients after 
they had received a combination of calcipotriol ointment and laser therapy than after 
laser therapy alone. Replacement of calcipotriol ointment by salicylic acid 5% to 10% 
in	petrolatum	ointment	resulted	in	sufficient	keratolysis	and	less	hyperpigmentation.	
The patients were also instructed to discontinue any other medication.
Evaluation of PDL treatment
Treatment	efficacy	was	evaluated	by	blinded	comparison	of	photographs	(Fotofinder,	
TeachSreen Software GmbH, Bad Birnbach, Germany) of the lesions taken in each 
patient at inclusion time and every control visit before PDL treatment. Changes of 
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lesions were assessed concerning erythema, desquamation and size by experienced 
dermatologists. The results were recorded as follows (Table 1):  
Results
Of the 74 treated, 54 patients (73%) achieved greater than 70% improvement after 
an improvement average of 2.5 treatments, 35 of the patients (47%) achieved 
a clearance between 91% and 100%, 19 of the patients (26%) an improvement 
between 71% and 90%, and 11 of the patients (15%) an improvement between 31% 
and 70% clearance (Table 2). All 9 patients (12%) exhibiting 30% and less clearance 
were deemed treatment failures for purposes of the study. Improvement of lesions 
and outcomes were well correlated to the number of treatments received (Figure 1). 
Of those receiving four or more treatments, only one (6%) had improvement less 
than 70%.
Of those exhibiting greater than 70% improvement in their lesions, the duration of 
remission	averaged	14.7	months	following	the	final	treatment	(Figure	2).	Those	with	
90-100% improvement exhibited the longest duration of remission, up to 36 months 
with an average of 17.2 months. Those with between 70 and 90% improvement 
exhibited up to 24 moths of remission with an average of 10.8 months. The degree 
of improvement was well correlated with duration of remission.
Side effects of the PDL treatment were post laser treatment purpura in all the 
patients with spontaneous resolution in 1 to 2 weeks, non-severe pain during and 
shortly after the laser treatment (local anesthesia was seldom necessary), transient 
hypopigmentation in 3% of the patients, transient hyperpigmentation in 27% of the 
patients, and transient crustae in 3% of the patients. Scarring was not observed. There 
were no dropouts because of adverse events associated with PDL treatment.
Summery of the results: 73% of the patients suffering from recalcitrant plaque type 
psoriasis who were treated with the pulsed dye laser showed an improvement of 
71%	to	complete	clearance	after	1	–	5	treatment	sessions	(Figures	3	–	6).	The	mean	
time of psoriasis remission appeared to be 14 months. Serious side effects were not 
observed. 
Discussion
The pathogenesis of psoriasis is not yet entirely known, although present evidence 
indicates	 that	 psoriasis	 is	 primarily	 a	 T	 cell–dependent	 immunological	 disease.14 
Problems may often be encountered in the course of treatment of psoriasis. Topical 
treatment using calcipotriol, corticosteroids, tar and ultraviolet light (UV) is not always 
effective and side effects of topical anti-psoriasis agents may limit their use. In those 
cases	that	topical	treatment	does	not	work	sufficiently,	the	next	step	is	to	change	to	
systemic treatments with fumarates, retinoids, methotrexate or cyclosporine. Although 
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these	systemic	agents	are	more	efficacious	than	the	topical	agents,	they	may	have	
even more serious side effects. Every expansion of the therapeutic armamentarium 
with methods minimizing side effects is welcome. 
Laser light with a wavelength of 585 nm passes through the epidermis without 
damaging epidermal structures, because the epidermis contains no chromophores 
for 585 nm light.11	Lack	of	epidermal	damage	prevents	the	Köbner	phenomenon	to	
occur.13 Only abundant melanin in sun tanned skin and in skin type 4 to 6 absorbs 585 
nm light, which may result in hyper-and hypopigmentation. The thermal relaxation 
time (TRT) of blood vessels in the skin vary from 0.2 msec for vessels with a diameter 
of 10 micrometer up till 3 msec for larger vessels with diameter of 40 micrometer.15 
Thus, the pulse duration of the pulsed dye laser (0.450 msec) is longer than the 
TRT of the small vessels and therefore long enough to avoid damage to the small 
vessels. The pulse duration of 0.450 msec is short enough to eliminate the dilated 
vessels with diameters of about 20 micrometer in the stratum papillare of psoriatic 
skin. 15	 	 Zelickson	 et	 al	 did	 not	 observe	 a	 significant	 difference	 in	 the	 efficacy	 of	
PDL light with a pulse duration of 0.450 msec compared with a pulse width of 1.5 
msec. In this study best clinical results were achieved using the 5-mm spot diameter, 
which is in accordance with previous studies. Penetration of laser light increases 
with increasing spot diameter making a spot diameter of 7-mm more suitable for 
more	infiltrated,	thick	psoriasis	lesions.	
The 7-mm spot diameter has also the advantage of shorter treatment duration. 
PDL treatment using the 10 mm spot diameter appeared to be  less effective than 
treatment using 5-mm and 7-mm spot sizes. This is probably due to the lower energy 
per mm3 on the level of the papillary vessels in the skin column provided by the 
10-mm spot size compared with the energy in the 5-mm and 7-mm skin column, 
because the 10-mm spot size light penetrates deeper into the skin than the 5-mm 
and 7-mm spot size light. 
The	fluence	of	the	PDL	has	to	be	high	enough	for	photothermolysis	of	the	dilated	
vessels	in	psoriatic	skin.	For	5-mm	spot	size	fluences	of	6	to	8	J/cm2 are appropriate, 
and in recalcitrant cases even 9 J/cm2.	A	spot	diameter	of	7-mm	requires	fluences	
of 5 to 7J/cm2.	If	the	fluence	is	chosen	to	low,	no	purpura	will	be	seen.	Therefore,	
the	appearance	of	purpura	during	PDL	treatment	indicates	the	appropriate	fluence.	
Cooling the skin during treatment using an air-cooled device reduces discomfort and 
should be a standard procedure. No analgesia is required and treatments are well 
tolerated. The treatment of a psoriasis lesion sized 100 cm2  takes about 10 minutes
Therefore, the treatment of wide spread psoriasis is to time-consuming Additional 
daily application of salicylic acid 5% in petrolatum removes much of the scaling 
associated with psoriatic plaques, thereby improving the amount of energy delivered 
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to the dermal vasculature. The application of salicylic acid ointment was stopped 
2 days before each PDL treatment, because of its photo-protective capacity. 
Calcipotriol ointment has also keratolytic capacity, but it causes more post laser 
hyperpigmentation than salicylic acid ointment does. 
Conclusion:
Seventy-three percent of patients with plaque type psoriasis resistant to traditional topical 
treatments achieved between 70% and 100% remission in the treated lesions. A mean 
duration of remission appeared to be 14 months. PDL treatment is indicated for patients 
with persistent plaque type psoriasis, not responding to usual treatments (particularly 
on ‘‘non-covered body’’ sites), plaque type psoriasis complicated by side effects of 
medication, psoriasis palmoplantaris, psoriasis inversa, patients not willing to use topical 
corticosteroids or systemic treatment, and patients at risk for skin cancer provocation by 
UVB therapy or immunosuppression.
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91%  to  100% change complete remission Score 4
71% to  90% change good improvement Score 3
31%  to  70% change moderate improvement Score 2
11%  to  30% change some improvement Score 1
0%  to  10% change no improvement Score 0
Number of
treatments score 4 score 3 score 2 score 1 score 0 Total
1 9.46% 1.51% 2.70% 1.35% 2.70% 29.73%
2 13.51% 6.76% 6.76% 4.05% 2.70% 33.78%
3 6.76% 4.05% 4.05% 0.00% 1.35% 16.22%
4 12.16% 1.35% 1.35% 0.00% 0.00% 5.41%
5 5.41% 0.00% 0.00% 0.00% 0.00% 5.41%
Total 47.3% 25.68% 14.86% 5.41% 6.76% 100.00% 
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Table 1.
Table 2.
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Figure 1. Results after 1 to 5 PDL treatments
Figure 2. Remission periods in relation with treatment scores
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Figure 3. Score 4: improvement 95% after 2 PDL treatments
Figure 4. Score 4: improvement 100 % after 5 PDL treatments
Figure 5. Score 4: improvement 95% after 2 PDL reatments
A B
Figure 6. Score 3: improvement  71- 90 % after 2 PDL treatments
  Side effect hyperpimentation
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abstract
Background: Psoriasis of the hands and feet is a chronic disease which is often 
resistant to the usual topical therapies. It has considerable morbidity and seriously 
affects the quality of life of patients.
Objective:	We	sought	to	prospectively	evaluate	the	efficacy	and	safety	of	pulsed	dye	
laser (PDL) treatment of psoriasis of the hands and feet.
Methods: In all, 41 patients with therapy-resistant psoriasis of the hands and feet were 
treated once every 4 to 6 weeks with PDL at 585-nm wavelength, 450 microsecond 
pulse	duration,	7-mm	spot	diameter,	and	5-	to	6.5	J/cm2	fluence.	Calcipotriol	ointment	
and salicylic acid 5% to 10% ointment were used as keratolytic agents. Treatment 
efficacy	was	evaluated	by	blinded	comparison	of	photographs	of	the	lesions	taken	
before and after PDL treatment in each patient.
Results: A good to very good improvement in the lesions was observed in 76% of 
the patients after treatment. An average duration of remission was 11 months. Side 
effects were transient purpura, moderate discomfort during the treatment, transient 
hyperpigmentation or hypopigmentation, and incidental transient crustae.
Limitations: This was an open prospective study with a limited number of patients 
who were concomitantly treated with calcipotriol and salicylic acid ointment. Patients 
with photointolerance, on medication with phototoxic or photoallergic drugs, and with 
widespread psoriasis were excluded.
Conclusions: Concomitant treatment with PDL and topical calcipotriol, salicylic acid, 
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or both was a satisfactory modality for treating psoriasis of the hands and feet. There 
was a subjective improvement in the symptoms and quality of life in all patients.
Introduction
Psoriasis	is	a	chronic	disease	causing	significant	morbidity	and	poor	quality	of	life	
in many patients.1,2 In particular, psoriasis of the hands and feet is a distressing 
and	disfiguring	disease,	often	resistant	to	treatment,	especially	in	case	of	pustulosis	
palmoplantaris. Topical and systemic treatments are not always adequately effective 
and their use may be limited by side effects. Therefore, clinicians have sought 
alternative methods and have turned to lasers for treating psoriasis.3 Traditional 
therapies for psoriasis have focused on the inhibition of epidermal proliferation, 
inflammation,	or	both.	The	earliest	changes	noted	 in	a	new	psoriatic	 lesion	are	 in	
the capillaries.4-7 These studies have led to the idea that selective destruction of the 
dilated papillary vessels by selective photothermolysis eliminates the extravasation 
of	 inflammatory	 mediators	 into	 the	 interstitium	 resulting	 in	 clearing	 of	 psoriatic	
plaques.8
The theory of selective photothermolysis stipulates that selective target destruction 
can be achieved by selection of a wavelength optimally absorbed by the chosen 
target, a pulse duration of less than the inherent thermal relaxation time of the target, 
and	a	fluence	that	is	sufficient	to	cause	nonrepairable	injury.9
Selective photothermolysis of cutaneous blood vessels can be achieved with the 
flashlamp-pumped	pulsed	dye	laser	(PDL).10-12 Previous studies have demonstrated 
partial and total clearance of psoriasis by selective photothermolysis of dermal 
vessels with PDL.13-17 The aim of this open prospective study was to evaluate the 
efficacy	and	safety	of	PDL	 treatment	 in	patients	with	psoriasis	manuum	et	pedis.	
Changes in the disease-related symptoms and the quality of life after treatment were 
also assessed.
methods
Patients
The study group comprised 41 patients (23 female, 18 male) aged 11 to 70 years 
(mean: 46.4 years) with clinical and histologic features of plaque-type psoriasis and 
psoriasis pustulosa on the hands and feet, which was resistant to previous topical 
treatments (calcipotriol, corticosteroids, tar, broadband UVB, topical psoralen-UVA). 
Patients with photointolerance (toxic or allergic), on medication with phototoxic or 
photoallergic drugs, who were pregnant, or with pre-existent or manifest cutaneous
malignancy were excluded. And institutional review board approved this study. 
All included patients provided written informed consent to participate in this open 
prospective study.
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Laser treatment 
Patients were treated with PDL equipment (MultiCare, VLS Cynosure, Chelmsford, 
Mass) that had adjustable settings for wavelengths from 585 to 600 nm; pulse 
durations of 450 and 1500 microseconds; and 3-, 5-, 7-, and 10-mm spot diameters. 
Each patient was treated with the PDL at a 585-nm wavelength, 450-microsecond 
pulse	 duration,	 7-mm	 spot	 size,	 and	 5-	 to	 6.5-J/cm2	 fluence.	 The	 patients	 were	
treated once every 4 to 6 weeks with an overlap of 20% of the spot size, treating 
the entire lesion with a margin of about 5 mm in the surrounding skin. During the 
treatment the skin was cooled with cold air (Cryo 5, Zimmer Elektromedizin GmbH, 
Ulm, Germany). Patients were requested to report any adverse events immediately.
Comedication
To promote the penetration of the laser light into the skin, scaly psoriatic lesions of 
the patients were initially treated with calcipotriol ointment between laser treatments. 
However, soon we noticed that there was more hyperpigmentation in patients after 
they had received a combination of calcipotriol ointment and laser therapy than after 
laser therapy alone. Replacement of calcipotriol ointment by salicylic acid 5% to 10% 
in	petrolatum	ointment	resulted	in	sufficient	keratolysis	and	less	hyperpigmentation.	
The patients were also requested to discontinue any other medication. 
Evaluation of PDL treatment
Treatment	efficacy	was	evaluated	by	blinded	comparison	of	photographs	(Fotofinder,	
TeachSreen Software GmbH, Bad Birnbach, Germany) of the lesions taken before 
and after PDL treatment in each patient. Experienced dermatologists subjectively 
assessed the photographs. Improvement was scored as follows: no improvement, 
0% to 10% clearance; poor improvement, 11% to 30% clearance; moderate 
improvement, 31% to 70% clearance; good improvement, 71% to 90% clearance; 
and very good improvement, 91% to 100% clearance. 
PDL treatment was discontinued after complete clearance of the psoriatic lesions or 
after 5 treatment sessions if the improvement was not better than 30%.
The follow-up in each patient was continued for up to 36 months to determine the 
duration of remission once the psoriatic lesions had cleared completely. During 
the follow-up period the patients were permitted to use calcipotriol, salicylic acid 
ointment, or both.
Results
In all, 41 patients with psoriasis manuum et pedis participated in this open 
prospective study. The results of the treatment are summarized in Table I.	Briefly,	
31 (76%) of the 41 patients who were treated achieved more than 71% clearance 
123
after an average of 4.2 treatment sessions (Table II). A representative example of 
the photographs taken before and after 4 treatment sessions from these 31 patients 
are shown in Figs 1 and 2. The remaining 10 (24%) patients who showed less than 
70% improvement were considered as treatment failures for the purposes of this 
study. Representative examples of the photographs from these 10 patients taken 
before and after 5 treatment sessions are shown in Fig 3. The duration of disease 
remission was also assessed in all 31 patients who showed an improvement of 
more than 71% during a follow-up period of 36 months. The results of remission are 
summarized in Table II. The duration of remission averaged 10.7 months after the 
final	treatment	in	patients	who	showed	an	improvement	of	more	than	71%	in	their	
lesions. An average duration of remission of 12 months was noted in patients with 
91% to 100% improvement in their lesions. Side effects of the PDL treatment were 
postlaser treatment purpura in all the patients with spontaneous resolution in 1 to 2 
weeks, nonsevere pain during and shortly after the laser treatment (local anesthesia 
was seldom necessary), transient hypopigmentation in 3% of the patients, transient 
hyperpigmentation in 27% of the patients, and transient crustae in 3% of the patients. 
There were no dropouts because of adverse events associated with PDL treatment. 
All the patients verbally commented on the subjective improvement in their quality of 
life and a reduction in the symptoms of their disease at each visit.
Discussion
The exact cause of psoriasis has not yet been elucidated.18 Psoriasis is histologically 
characterized by epidermal keratinocyte hyperproliferation, intradermal and 
intraepidermal	 inflammatory	 infiltrate	 composed	 mainly	 of	 T	 cells,	 and	 vascular	
dilation and proliferation in the papillary dermis.3 The question still remains whether 
it	 is	the	epidermal	proliferation	that	triggers	inflammation	and	vascular	changes	or	
whether it is the reverse. The changes in the capillary vasculature of psoriasis have 
been therapeutically neglected, although it was reported that these were the earliest 
observed changes both in a new psoriatic lesion and at the margin of an extending 
lesion.1-3 Laser light with a wavelength of 585-nm penetrates the epidermis without 
causing epidermal damage because the keratinocytes have no chromophore 
absorbing	 this	 wavelength	 whereby	 Koebner´s	 phenomenon	 is	 prevented	 from	
occurring.11 The thermal relaxation time of the capillary vessels is around 200 
microseconds	for	 the	smallest	vessels	with	a	diameter	of	10-μm.	The	diameter	of	
the	dilated	psoriatic	 vessels	 is	about	20-μm.	The	pulse	duration	of	 the	PDL	 (450	
microseconds) is short enough to destroy the psoriatic vessels, but long enough to 
spare the normal capillary vessels.16 The	fluence	must	be	high	enough	to	destroy	
the psoriatic vessels. The destruction of the vessels is visible as purpura, so that the 
appearance	of	purpura	is	an	indication	that	the	fluence	has	been	correctly	chosen.	
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This postlaser purpura disappears 1 to 2 weeks after treatment.
It	appeared	 that	a	5-mm	spot	diameter	 required	a	fluence	of	 	6	 to	8	J/cm2	 to	be	
effective	and	a	7-mm	spot	diameter	required	a	fluence	of	5	to	6.5	J/cm2.	The	results	
of both those treatments were more or less equal.14 In this open prospective study, 
we	chose	 treatment	with	7-mm	spot	diameter	and	fluence	of	5	 to	6.5	J/cm2.	The	
PDL treatment was generally well tolerated by all patients. Although there was some 
discomfort, local anesthesia was not required in most of the patients. The pain may 
be reduced by pretreatment with lidocain-prilocain cream under occlusion, oral 
paracetamol tablet, or both. This is especially useful in patients with psoriasis of 
the palms and soles. Hypopigmentation was most common in patients with tanned 
skin. Hyperpigmentation may be because of sunlight exposure after PDL treatment. 
Therefore,	patients	were	requested	to	avoid	exposure	to	(artificial)	sunlight	6	weeks	
before and 6 weeks after PDL treatment. Hyperpigmentation is also often seen after 
the combination of calcipotriol ointment and PDL treatment. To remove the scales 
from the psoriatic lesions, salicylic acid ointment does well without augmenting the 
risk of post-PDL treatment hyperpigmentation. 
Cooling of the skin during PDL treatment is obligatory to reduce the pain and the 
risk	 for	pigment	changes.	Koo	and	Lebwohl19 examined the duration of remission 
reported with many therapies currently used for psoriasis. The remissions varied from 
1 month to 1 year depending on the therapeutic modality. In many clinical studies, 
‘‘remission’’	 and	 ‘‘relapse’’	 are	 not	 actively	 defined.	Not	 all	 the	 investigators	 tend	
use	 the	same	definitions	even	when	 these	 terms	are	defined.	The	 least	stringent	
definition	of	relapse	involves	a	recurrence	of	psoriasis	to	50%	of	the	baseline.	The	
strictest	definition	involves	any	recurrence	of	psoriasis	after	clearing.20 We	defined	a	
relapse as recurrence of psoriasis to 30% or more of the baseline. During remission, 
patients were allowed to use emollients or calcipotriol ointment. The mean duration 
of remission in our study in 31 patients with improvement of 71% to 100% was 10.7 
months	after	the	final	treatment,	whereas	the	mean	duration	of	remission	in	the	22	
patients with 91% to 100% improvement was 12 months.
Almost identical clinical results were recently reported by Feldman et al, 21 who 
treated 30 patients with psoriasis using the excimer laser (308-nm, 10 mJ pulse, 
3.2-cm2 spot) (PhotoMedex XTRAC, Montgomeryville, Pa) twice weekly, starting at 
2	to	4	minimum	erythema	dose,	increasing	it	if	there	was	no	response	after	the	first	
treatment. An improvement of 75% was achieved in 72% of patients after an average 
of 6.2 treatment sessions. Common adverse events were erythema, blistering, 
hyperpigmentation, and erosions. At 12 months, 24% of the patients showing 
improvement were remission free. In our study, patients were treated once every 4 
to 6 weeks with PDL. After an average of 4.2 treatment sessions, more than 71% 
clearance was achieved in 76% of the patients. In these patients, the mean duration 
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of remission was 10.7 months. Crustea were noted in only 3% of the patients and 
no blistering was observed in any of the patients. Furthermore, the wavelength of 
308-nm (excimer laser) is potentially carcinogenic in the long term, whereas the 
wavelength of 585-nm (PDL) is noncarcinogenic. These differences argue in favor 
of treating patients with psoriasis using PDL. Good candidates for PDL treatment 
appeared to be patients with limited plaque-type psoriasis resistant to other topical 
treatments; patients in whom other treatments caused adverse events; and patients 
with disseminated psoriasis in important areas such as the hands, arms, legs, and 
genital	area	where	prolonged	treatment	is	difficult	to	sustain.14
In conclusion, the results of this open prospective study showed that concomitant 
calcipotriol, salicylic acid ointment, or both and PDL treatment was effective. 
However,	 there	 were	 limitations	 to	 the	 study	 reported	 here.	 Briefly,	 the	 limited	
number	 of	 included	 patients	 and	 the	 concomitant	 treatment	 restrict	 any	 definite	
recommendations concerning its routine use for treating therapy-resistant psoriasis 
of the hands and feet. This can only be established in large well-designed clinical 
studies.
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Follow-up in 31 patients after successful pulsed dye laser treatment
Improvement No of patients Mean No. of PDL Mean duration of
  treatment sessions remission, mo
71%-100% 31 (76%) 4.2 10.7
91%-100% 22 (54%) 4.9 12
Table II. All patients were followed up for 36 months. Improvement of 71% to 100% 
and 91% to 100% in the patients with the corresponding mean number of PDL 
treatment sessions and the mean duration of remission are shown. 
Improvement  No of patients Patients %
0%-10%  3 7
11%-30%  1  2
31%-70%  6 15
71%-90%  9  22
91%-100%  22 54
Total 41 100
Table I. Improvement in scores in the 41 patients after pulsed dye laser treatment.
Improvement of less than 71% was regarded as pulsed dye laser treatment failure.
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Fig 1. A, Girl aged 14 years with duration of psoriatic lesions for 6 years before 
pulsed dye laser (PDL) treatment. B, Lesions improved by 95% in same patient after 
4 PDL sessions. Lesions were in remission with one treatment each 6 months.
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Fig 3.    A, Woman aged 44 years with duration of psoriatic lesions for 18 
years before pulsed dye laser (PDL) treatment. 
B, There was only 50% improvement in lesions of same patient after 
5 PDL sessions.
Fig 2. A, Woman aged 22 years with duration of psoriatic lesions for 8 years before 
pulsed dye laser (PDL) treatment. B, Improvement in hand and foot lesions in same 
patient of 90% and 70%, respectively, after 4 PDL sessions. Lesions were still in 
remission after 36 months.
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abstract
Background: Narrow-band Ultraviolet-B and Pulsed Dye Laser both affect psoriasis, 
but via different pathways. 
Objective: To compare the results of Pulsed Dye Laser with Ultraviolet-B therapy 
and to look for synergism of both therapies in patients with plaque type psoriasis.
Methods: In each eligible individual four similar target plaques were selected and 
halves of these plaques were treated either by Pulsed Dye Laser, Ultraviolet-B, 
combination of Pulsed Dye Laser and Ultraviolet-B, or not treated. Results were 
recorded single-blind using the Physician’s Global Assessment-score at study 
enrolment and at week 13. Non-parametric, paired statistical tests were used to 
test for differences within and between therapies.The results were also analysed 
after dichotomisation of the changes in the Physician’s Global Assessment-score 
into responsive and non-responsive to treatment. 
Results:  A	significant	improvement	of	the	psoriasis	lesions	was	noted	at	Week	13	
(p<.001)	 	 with	 each	 therapy.	 No	 significant	 differences	 were	 noted	 between	 the	
therapies. Synergism of Pulsed Dye Laser and Ultraviolet-B was not observed. 
Conclusions:  Pulsed Dye Laser is safe for treating plaque type psoriasis, but its 
efficacy	 is	 limited	 to	 a	 sub-group	 of	 patients.	 Combining	 Pulsed	 Dye	 Laser	 with	
Ultraviolet-B	has	no	additional	benefit.
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Introduction
Epidermal hyperproliferation with epidermal thickening, parakeratosis and hyperkeratosis, 
an	intra-dermal	and	intra-epidermal	inflammatory	infiltrate	composed	mainly	of	T	cells,	
accumulation of neutrophil granulocytes, increased numbers of dendritic cells and mast 
cells,	 and	 expansion	 of	 the	 superficial	 dermal	 vasculature	 histologically	 characterize	
psoriasis.1	 	 	 In	normal	 skin,	 the	superficial	microvasculature	 is	 composed	of	 capillary	
loops that arise from terminal arterioles in the upper horizontal dermal vascular plexus, 
pass up into the dermal papillae and arch back to connect with the postcapillary venules 
in the horizontal plexus.2 Non-lesional skin has short lengths of microvessels in the 
superficial,	papillary	dermis,	whereas	dilated	and	elongated	superficial	capillaries	passing	
into the dermal papillae, representing exaggerated tortuosity and coiling of the apical 
segment of the capillary loop, characterize lesional psoriatic skin.3,4  The endothelium of 
the	superficial	microvasculature	in	lesional	skin	is	four	times		thicker	than	in	normal	skin	
but not in the deeper vasculature, indicating that microvascular expansion is restricted 
to the upper plexus.5 Although, present evidence indicates that psoriasis is primarily a 
T cell-dependent disease, the prominent increase in the dermal micro-vasculature in 
lesional skin indicates that psoriasis is also angiogenesis-dependent.6-8  Most traditional 
therapies for psoriasis have focused on the inhibition of epidermal proliferation and 
suppression	of	inflammation.	Limiting	factors	are	that	none	of	these	treatments	is	effective	
in	all	patients,	each	may	have	serious	side	effects,	and	the	efficacy	generally	decreases	
over time.9,10 The alterations in the capillaries have been neglected as a possible 
therapeutic target, although it has been reported that, in a new psoriasis lesion, one of 
the earliest observable changes is an increase in the dermal papillary vasculature.6-8,11,12 
During treatment, microvascular improvement precedes clinical improvement.13 
This	 indicates	 that	 the	expanded	superficial	microvascular	bed	 in	psoriasis	skin	 is	an	
essential component for maintaining clinical lesions.13 These observations have led to 
the hypothesis that, in psoriasis, selective destruction of the dilated papillary vessels by 
selective	photothermolysis	may	reduce	the	transmigration	of	inflammatory	cells	resulting	
in clearing of psoriasis plaques.14 Selective photothermolysis, destroying  only the dilated 
papillary vessels, sparing the normal- sized vessels and without causing damage to 
the epidermis, became an effective procedure once the Pulsed Dye Laser (PDL) was 
introduced.15,16 Partial and total clearance of psoriasis after PDL treatment was reported 
in several studies.14, 17-22 Narrow-band ultraviolet-B light therapy (UVB), which is highly 
efficacious	against	psoriasis,	23-28  appeared to be superior to broad-band UVB therapy 
28,29 and nearly as effective as psoralen ultraviolet-A (PUVA) therapy, and  because  there 
are no photosensitizer-related adverse reactions and a possible lower long-term cancer 
risk, it can be considered to be the standard light therapy.30  UVB inhibits the proliferation 
of keratinocytes and induces immunosuppression.31-34 UVB targets primarily structures 
in the epidermis, whereas PDL light passes through the epidermis and targets primarily 
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the	superficial	vessels	 in	 the	dermis,	 indicating	 that	UVB	and	PDL	clear	psoriasis	via	
different	pathways.	The	aim	of	this	study	was	to	evaluate	the	efficacy	and	the	safety	of	
PDL treatment in plaque type psoriasis, to compare the results of PDL treatment with the 
results of the UVB treatment and with those of the PDL+UVB treatment, and to look for a 
synergistic effect of PDL+UVB treatment on psoriasis. 
materials and methods
Subjects 
Patients were recruited from the outpatient dermatology clinic of the Erasmus MC, 
University Medical Center, Rotterdam. Adult patients with stable plaque psoriasis with 
at least four psoriasis plaques were considered eligible. Patients who were intolerant to 
light (toxic or allergic), were using drugs with photo toxic or photoallergic potency, were 
younger than 18 years, were pregnant or had preexistent or manifest skin malignancy 
were excluded. A wash-out period of 2 weeks was indicated for topical drugs and of 4 
weeks for photo (chemo) - therapy and systemic drugs, except for emollients. All included 
patients provided written informed consent to participate in the study. The Medical Ethical 
Committee of the Erasmus MC, University Medical Center, Rotterdam approved this 
study. The study was started in October 2004 and ended in March 2006. 
materials
PDL treatment was performed using the V Star PDL (Cynosure Inc., Chelmsford, MA, 
USA). The active medium is a rhodamine dye that emits yellow light at a wavelength 
of 585-nm. During treatment, the skin was cooled with cold air from the Zimmer 6 
air cooler (Zimmer Elktromedizin, Neu-Ulm, Germany).35 PDL treatment parameters 
were wavelength 585-nm, pulse duration 0.450 ms, spot diameter 7-mm, spots 
overlapping	±	20%	and	fluences	between	5.5-	and	6.5	J/cm².	
Ultraviolet 311-nm treatment was performed with the UVB-TL01 S (wavelength 311-
nm) handheld device (Cosmedico Medizintechnik GmbH, Villingen-Schwenningen, 
Germany). Mean irradiance 19.4 mW/cm². During treatment the aperture of the 
appliance (5.0 cm x 10.0 cm) was held against the skin, the implication being, that 
the distance between the device and the skin was constant in every patient. Minimal 
erythema dose (MED) was determined by placing a metal cover with 6 test squares 
(each 1 cm²) on the MultiCare device. The squares allowed the penetration of 100%, 
83%, 65%, 49%, 34% and 17% of UVB-TL01 irradiance of the device (19.4 mW/cm²). 
After 24 hours the test squares were examined. The square showing just observable 
erythema was considered as MED. Mean MED was 0.86 J/cm² (range 0.34-1.2 J/
cm²). 
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Treatment schedule 
In each patient, four plaques were randomly allocated, divided into two halves, and 
treated as shown in Figure 1. This paired approach enabled us to assess the effect 
of UVB, PDL and UVB+PDL at Week 13 and to compare the effect of UVB and PDL 
with control sides in plaque b and in plaque c. The sides of plaques a and b that 
were not treated with UVB were protected with metal foil during exposure. Plaque d 
was treated with the combination of UVB and PDL (PDL+UVB) on both sides, and 
the effect was compared with that of UVB (plaque b) and PDL (plaque c). Therefore, 
four plaques were available for blind observation: two plaques treated on both sides 
(plaque a, plaque d) and two plaques treated on one side (plaque b, plaque c). In 
some patients, the psoriatic lesions were too small to divide into two halves. In these 
cases, two separate, comparable, nearby plaques were selected as substitutes. The 
four target plaques were selected, as much as possible, on symmetrical sites of the 
right arm, the left arm, the right leg and the left leg. A clock wise rotation schedule of 
the various above-mentioned treatments, of plaque a through plaque d, was used in 
which, in every new included patient, the schedule started on a different body site. 
The remaining plaques in patients who presented with more than the four study 
plaques were treated as follows: half of the body with UVB-TL01, the other half with 
PDL, following a rotation model according to the sequence of inclusion.
Patients were treated with PDL every 3 weeks for 10 weeks, in total four treatments 
(Table 1). During laser treatment, the patient’s skin was cooled with cool air to reduce 
the pain and to prevent damage to the melanocytes due to overheating.
UVB treatment parameters were wavelength 311 nm, start dose 70% of the MED, 
dose increments each treatment 20% of previous treatment until erythema threshold 
or clearing of the lesion was reached, three  weekly treatments for 11 weeks (in total 
30-33 treatments) (Table1).36,37 Mean initial dose was 0.62 J/cm² (range 0.24-0.86 J/
cm²), cumulative dose 84 J/cm² (range 40-120 J/cm²). 
Concomitant topical treatment with salicylic acid 5% in petrolatum was permitted for 
all plaques to reduce scattering of the laser beam by scales but was discontinued 2 
days prior to PDL treatment.
Clinical assessment
Specialized dermatological nurses recorded clinical results single-blind using the 
Physician’s Global Assessment (PGA) score38 (Table 2) at Week 13. This moment 
was chosen 2 weeks after cessation of the UVB treatment and 3 weeks after the 
last PDL treatment (ensuring that the post-laser purpura had totally disappeared) 
(Table 1). Although two PGA scores were recorded for the PDL+UVB treated lesions 
(plaque d) to maintain blind assessment, we restricted the analysis to the right side 
of the treated plaques. 
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Definition of response to treatment
An improvement of 3 points or more from baseline on the PGA score (maximum 
score 5) or a total clearance (PGA score of 0) in plaque-sides selected for this study 
was	defined	as	response	to	treatment.
Statistical analyses
The	Friedman’s	 test	was	used	 to	 test	 for	statistically	significant	differences	 in	 the	
change of PGA scores of the UVB-, PDL- and PDL+UVB-treated plaques at Week 
13. We also assessed the difference in the degree of PGA score change after each 
of these therapies in different plaques within the same patient. For UVB and PDL, 
change in PGA score was compared with the control side of the same plaque at 
week 13. For each of these paired statistical tests, the Wilcoxon signed rank test was 
used. Good clinical response (change of 3 levels of PGA score or clear at week 13) 
between the three therapy regimens was compared using the McNemar’s test.
Results
Study population
In this single-centre, single-blind, prospective, paired randomized controlled study 
27 patients (17 men and 10 women), aged 20 to 65 years (mean 44.4 years), with 
skin types I to IV, and stable plaque psoriasis with at least four psoriasis plaques 
were included ((in total 108 plaques). The mean duration of psoriasis was 14 years 
(range 4 to 35 years). The distribution of the baseline PGA scores in each of the 
treatment groups was comparable (Figure 2)
Direct Paired Comparison Between Baseline and Week 13
The	PGA	scores	after	treatment	with	UVB,	PDL,	and	PDL	+	UVB	were	significantly	
reduced at Week 13 (p <0.0001) (Table 3 and Fig 2). For each therapy, in about 20% 
of plaques no improvement was achieved, more than 60% showed improvement of 
two levels in the PGA score and less than 20% showed an improvement of three or 
more levels in the PGA score (Figure 3). No statistical differences were observed in 
treatment induced PGA score changes between these three therapies (Table 3). A 
comparison between PGA scores of the UVB- or PDL- treated halves and the control 
halves	of	the	psoriasis	plaques	showed	no	significant	differences	(p=0.47	and	0.42,	
respectively). In plaque a, a clearly visual difference between UVB treatment and 
PDL treatment was seen in 6 patients in favour of UVB and in 4 patients in favour of 
PDL (Figure 4).
Analyses of PGA-scores in the Sub-group of Plaques that Responded to 
Treatment.
Good	clinical	response	(improvement	of	≥	3	points	in	the	PGA	score	from	baseline	
or clearing of psoriasis) was achieved in seven (25.9%) UVB-treated, nine (33.3%) 
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PDL-treated,	five	(18.5%)	PDL+UVB-treated	and	two	(7.4%)	non-treated	(NT)	halves	
of the 27 psoriasis plaques. 
Total	 clearance	 (PGA	 score	 of	 0)	was	 achieved	 in	 the	UVB-treated	 sides	 of	 five	
(18.5%)	plaques,	in	the	PDL-treated	sides	of	five	(18.5%)	plaques,	in	the	PDL+UVB-
treated side of two (7.4%) plaques, and in a non-treated side of one (3.7%) plaque. 
In one patient, total clearance was obtained after PDL mono-therapy and UVB mono-
therapy. Total clearance was achieved after PDL treatment in four plaques and after 
UVB treatment also in four plaques. 
Side effects of treatment
Regarding side effects of the PDL therapy, all patients reported transient purpura 
(occasionally accompanied by crusts) during 1 to 2 weeks, 20 (74%) reported 
moderate discomfort (which is considerably reduced by cooling the skin during 
treatment), and 20 (74%) reported evident, but transient hyperpigmentation after 
therapy. Although hypopigmentation and atrophic scarring were reported in some 
studies,16,18 these side effects were neither reported in a recent study22 nor observed 
in our study. Regarding side effects of the UVB treatment, nine (33%) patients 
reported pain, 15 (55%) reported photo-dermatitis, and 20 (74%) reported some 
hyperpigmentation. Regarding side effects of PDL+UVB therapy,   all patients 
reported purpura, 17 (63%) reported pain, 13 (48%) reported photo-dermatitis, and 
19 (70%) reported hyperpigmentation.
Discussion
Recent breakthroughs in the treatment of psoriasis have led to better understanding of 
the pathogenesis of this disease.34,39,40  Although major advances in the development 
and the use of targeted biologicals for controlling psoriasis have been made, the need 
to develop more safe and cost-effective cures remains. Potential targets for future 
drugs	are	cytokines	involved	in	T-cell	activation	and	T-cell	trafficking.40 Inhibition of 
immunocyte	 trafficking	by	selective	photothermolysis	of	 the	elongated	and	dilated	
papillary	blood	vessels	by	PDL	was	demonstrated	to	be	efficacious	in	plaque	type	
psoriasis.13,16-22 The PDL was developed on the concept of selective absorption of a 
brief	radiation	pulse	that	generates	and	confines	heat	to	oxy-haemoglobin,	resulting	
in the destruction of the dilated papillary blood vessels, while minimizing damage to 
the normal-sized papillary blood vessels and to the surrounding structures .14, 15, 20  
Two wavelengths, 585- and 595-nm, are currently used for treating skin disorders, 
which are accompanied by vascular dilatation. Controversy exists as to which 
wavelength induces greater photo-thermal damage to the blood vessels and 
subsequent resolution of the particular skin disorder.41,42  Before laser irradiation 
oxy-haemoglobin absorbs 4.8 times more light with a wavelength of 585-nm than 
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light with a wavelength of 595-nm. However, during laser irradiation the absorption 
increases more for 595-nm than for 585-nm, yielding a 585- to 595-nm ratio of 1.2. 
This is due to bathochromic (red) shift in blood-absorption and conversion of oxy-
haemoglobin to met-haemoglobin, which reduces the 585-nm light absorption and 
increases that of 595-nm compared with native oxy-haemoglobin, both caused by 
heating of the blood during irradiation. The remaining small disparity between 585-
nm	 and	 595-nm	 can	 easily	 be	 corrected	 by	 augmenting	 the	 fluence.	 Therefore,	
similar results may be obtained with the wavelengths of 585-nm and 595-nm. The 
purpura level for both wavelengths is a good indicator of the proper vascular damage 
that has been achieved.43  
According to the principles of photothermolysis the optimal pulse-duration to treat 
dilated capillary vessels in a psoriasis plaque is considered to be in the range of 
0.450- to 1.5- msec (less or equal to the Thermal Relaxation Time of the vessels),18 
which is short enough to damage the dilated psoriasis vessels and long enough to 
spare the normal-sized capillary blood vessels. 
The optimal spot diameters for destroying psoriasis vessels are 5-and 7-mm. The 
7-mm spot diameter has the advantage that the number of pulses required to treat the 
clinical area is 35% lower than when treating with the 5-mm spot diameter, reducing 
the time of treatment, and that the penetration of the laser light is slightly deeper.44 
The	beam	profile	of	 the	PDL	machine	has	a	Gaussian-like	distribution	of	energy,	
resulting in considerable more light energy in the centre of the beam compared with 
the border.45 In order to obtain a uniform pattern of applied energy, overlapping of 
the spots by about 20% is imperative. From this point of view it is likely that without 
overlapping,	the	inhibition	of	the	immunocyte	trafficking	in	psoriasis	is	sub-optimal,	
resulting in decreased clinical responses.
In order to have a correct simultaneous comparison between the results of UVB 
and	PDL,	the	endpoint	of	the	study	was	chosen	to	be	just	after	±	30	treatments	with	
UVB, which is a standard number of treatments, and 3 weeks after 4 treatments with 
PDL. An universal evidence-based standardized protocol concerning time-intervals 
for PDL therapy is not yet available.
The PGA scoring system was chosen instead of the PASI scoring system, because 
in the observation of individual plaques the percentage of the total surface area 
involvement is not an issue, the PGA scoring is far less time-consuming than the 
PASI scoring, and also because the blinded observers (research nurses) were better 
trained in scoring the PGA than the PASI. In addition it has been shown, that PGA 
and PASI are highly correlated and share a high overall reliability38. 
In the statistical data analyses of all included patients PDL and UVB, as well as the 
combination	 therapy	PDL+UVB	resulted	 in	a	significant	 improvement	 (p	<	0.0001	
for all 3 treatment modalities) in the PGA scores at T13 compared with T0 (Figure 
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2,	Table	3).	However,	there	were	no	statistically	significant	differences	between	the	
three treatment modalities mutually (Table 3). After dichotomising the changes in 
PGA scores into responsive and non-responsive to treatment, PDL scored better 
than UVB and UVB better than PDL+UVB, but according to the McNemar’s test these 
differences	were	not	statistically	significant.	This	indicates	that	in	terms	of	response,	
PDL was statistically as effective as UVB treatment, but there was no synergistic 
effect of combining PDL treatment with UVB treatment in the sub-group of patients 
who responded to treatment. A speculative explanation for this lack of synergism 
may be that the inhibition of vessel-active cytokines produced by keratinocytes and 
immunocytes by UVB-treatment normalises the diameters of the papillary blood 
vessels, whereby these vessels no longer form a target for PDL. A total clearance of 
psoriasis after both UVB and PDL was seen in only 1 patient. Complete clearance 
after UVB, but not after PDL was achieved in 4 patients and after PDL, but not after 
UVB also in 4 patients, indicating that patients who do not respond to UVB may 
respond to PDL and vice versa.
The non-treated sides of the study plaques also showed an unexpectedly good 
response. The differences between the UVB-treated and the non-treated sides, and 
between	the	PDL-treated	and	the	non-treated	sides	were	not	significant	(p	=	0.47	
and P = 0.42, respectively).  A putative explanation for this phenomenon is that the 
non-treated	sides	could	have	benefited	 from	 the	UVB-	and	 the	PDL	 treatment	of	
the neighbouring sides, although in a previous study it was suggested that there 
was no carry-over effect between the side treated with PDL and the non-treated 
side.18	 In	 contrast,	 the	 differences	 between	 the	 improvements	 reflected	 in	 the	
PGA scores of the NT sides seen in the Figures 5, 6, and 7 indicate an inverse 
relationship between improvement and the distance between PDL treated sides and 
NT sides, indicating an effect of PDL in a limited area around the irradiated site. 
This observation is supported by Babilas and colleagues who demonstrated tissue 
damage and thrombus formation in and also outside the irradiated area of hamster 
skin 24 hours after PDL treatment.46 Although the carry-over effect in PDL warrants 
further	study,	our	findings	indicate	that	overlapping	spot	sizes	may	not	be	necessary	
in	the	PDL	treatment	of	psoriasis.	This	implies	multiple	benefits	such	as	a	reduction	
in the duration of treatment, less discomfort to the patients, and lower costs. Other 
possible	mechanisms	by	which	the	non-treated	sides	could	have	benefited	are	via	
a systemic effect of the treatment of the remaining plaques with UVB and PDL, and/
or a non-expended good effect of the permitted concomitant treatment with salicylic 
acid ointment. A spontaneous remission was not likely, because the majority of the 
patients (19) were treated during the winter.  
Taibjee and colleaques47 conducted a trial on the treatment of localized plaque 
psoriasis	in	which	the	efficacy	of	the	excimer	laser	was	compared	with	the	efficacy	
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of the PDL laser (wavelength 595-nm, spot diameter 7-mm, pulse width 1.5 msec 
and	fluence	10	J/cm²).	They	reported	a	complete	clearance	in	41%	of	the	patients	
in the excimer group after 17 treatments and in 27% of the patients in the PDL 
group, requiring 3.2 treatments. Many patients in that study found PDL to be a 
very convenient treatment modality because of monthly hospital visits. Side effects 
caused by the excimer were blistering in 68% and hyperpigmentation in 41% of 
the patients versus 0% blistering and 9% hyperpigmentation caused by the PDL.47 
Those results are in good agreement with the results presented here.
During the laser treatment, cooling of the skin is imperative in order to reduce the 
pain, to protect the melanocytes in the epidermis from damage, and to prevent 
activation of epidermal effector T cells via pericapillary heat diffusion after treatment, 
which will tend to promote the persistence of clinical lesions.20
Better results of PDL treatments may be obtained by increasing the number of 
sessions,	reducing	the	time	intervals	between	treatments,	increasing	the	fluence	and	
the pulse width to respectively 10 J/cm² and 1.5 msec (Taibjee and colleagues)47, 
applying mineral oil immediately prior to PDL treatment and by concomitant treatment 
with calcipotriol ointment.48
Conclusions and limitations
All	tested	treatment	modalities	appeared	to	be	efficacious	in	the	treatment	of	plaque	
type	psoriasis.	There	were	no	statistically	significant	differences	between	the	efficacy	
of PDL treatment and UVB treatment. A combination of PDL and UVB treatment 
had no additional value because of lack of synergism. Surprisingly, no statistically 
significant	differences	were	seen	between	UVB	treatment	and	PDL	treatment	on	the	
one hand and the non-treated sides on the other hand. There is no clear explanation 
for this, but an unexpected carry-over effect (although a previous study suggested 
otherwise)18 from the neighbouring PDL- and UVB-treated sides is supported by 
the observation of an inverse relationship between improvement of NT sides on the 
one hand and the distance between the PDL treated sides and the NT sides on the 
other hand. Another possibility is a systemic effect of the treatment of remaining 
plaques. After all, it seems likely that dividing of plaques is not the best approach to 
study	the	efficacy	of	topical	therapies,	but	if	pursued,	then	the	treatment	has	to	be	
strictly restricted to study plaques, without treatment of other remaining plaques. In 
the present study, patients with a complete clearance of the target lesion appeared 
to be divided into either PDL responders or UVB responders, indicating that patients 
who do not respond to UVB may respond to PDL and vice versa. Treatment with PDL 
resulted only in mild and transient side effects and therefore appeared to be safe. 
PDL treatment is certainly not the panacea for every psoriasis patient and should not 
be used in widespread psoriasis or in patients who respond adequately to simple 
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topically applied treatments. PDL treatment should be reserved for patients with 
persistent plaque type psoriasis, not responding to usual treatments (particularly 
on “non-covered body” sites), plaque type psoriasis complicated by side effects of 
medication, psoriasis palmoplantaris, psoriasis inversa, patients not willing to use 
topical corticosteroids or systemic treatment and patients at risk for skin cancer caused 
by actinic damage or immunosuppression. Most patients in our study preferred PDL 
therapy above UVB (20 versus 7 patients) because of the less frequent treatment 
sessions, the subjective improvement in the quality of life, and the lack of reports 
on carcinogenesis due to PDL treatment, whereas long-term side effects including 
carcinogenesis caused by excimer UVB and narrow-band UVB remain uncertain. 
With	regard	to	the	patient’s	preference	and	the	efficacy,	the	PDL	treatment	should	be	
considered as a serious option in the treatment of plaque type psoriasis.
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0 = clear: No evidence of erythema, but there may be residual discolourations 
(e.g. hyperpigmentation and pigmented macules), no evidence 
for scaling and induration (no plaque elevation above normal 
skin levels)
1 = minimal Considering all involved areas, the overall clinical picture shows 
plaques with slight erythema with discrete induration (possible 
trace	elevation	above	normal	skin)	and	occasional	fine	scaling	
over <5% of lesions
2 = mild Considering all involved areas, the overall clinical picture shows 
plaques	with	red	colouration,	slight	but	definite	induration	(slight	
but	definite	elevation	of	plaques	above	normal	skin)	and	a	fine	
thin scaling
3 = moderate Considering all involved areas, the overall clinical picture shows 
plaques	 with	 definite	 red	 colouration,	 moderate	 induration	
(moderate elevation from normal skin to plaques with rounded or 
sloped edges), and coarse scaling
4 = severe Considering all involved areas, the overall clinical picture shows 
plaques with very bright red colouration, marked induration 
(marked elevation with hard sharp edges to plaques), and a 
coarse, thick scaling
5 = very severe Considering all involved areas, the overall clinical picture shows 
plaques with dusky to extreme deep red colouration, very marked 
induration (with very hard sharp edges between normal skin and 
plaques) and very severe, tenacious, coarse, thick scaling
Table 2:   Physician’s Global Assessment-score
Week 0 1 2 3 4 5 6 7 8 9 10 11 12 13
PDL  X   X   X   X
UVB  3X 3X 3X 3X 3X 3X 3X 3X 3X 3X 3X
Score X             X
Table 1: Schedule of actions
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Within therapies+ In favour of T13 In favour of T0 Equal effect at T13 p-value
UVB T13 vs UVB T0 20 0 7 <0.0001
PDL T13 vs PDL T0 20 1 6 <0.0001
PDL+UVB T13 vs  21 1 5 <0.0001
PDL+UVB T0
Between therapies#  In favour of In favour of  Equal effect of p-value
 1st therapy 2nd therapy therapies
UVB vs PDL 9 12 6 0.52
UVB vs PDL + UVB 10 9 8 0.82
PDL vs PDL + UVB 9 7 11 0.63 
Compared with control†  In favour of In favour of  Equal effect of p-value
 1st therapy 2nd therapy therapies
UVB vs control 10 7 10 0.47
PDL vs control 8 5 14 0.42
Abbreviations: UVB = ultraviolet-B; PDL = pulsed dye laser, vs = versus.
*   Wilcoxon signed ranks test
+  Comparison of the PGA-scores of the same psoriasis plaque between baseline (T0)  
 and at week 13 
#   Comparison of degree of change in PGA-scores of psoriasis plaques between  
 different therapies at week 13 within the same patient.
†   Comparison of degree of change in PGA-scores of the halves of treated and 
 non-treated psoriasis plaques at week 13.
Table 3.  Comparison* of within and between therapies at Week 13 (T13) of the   
 study. 
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Figure 1:  Treatment schedule of 4 plaques in each patient.
  PDL = Pulsed Dye Laser, UVB = Ultraviolet-B TL01,
  PDL+UVB = combination therapy, NT = no treatment
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Figure 3.  For each therapy, the distribution of the degree of change in Physician’s 
Global Assessment score at week 13. Proportion of plaques (%) (n=27).
Figure 2:  For each therapy, the distribution of Physician’s Global Assessment sco-
res at baseline (T0) and after 13 weeks (T13) of treatment.
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Figure	4:	 Two	confluent	plaques	right	lower	leg.	A.	Pre-treatment.	B.	Post-treatment	
PDL side. C. Post-treatment UVB side. VII = UVB, VIII = PDL
Figure 5:  One plaque divided into two halves on the left elbow. A. Pre-treatment. B. 
Post-treatment. III = PDL, IV = NT. Considerable improvement of NT side adjacent to 
PDL side. 
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Figure	6:		Two	 almost	 confluent	 plaques	 on	 the	 dorsum	 of	 the	 left	 hand.	A.	 Pre-
treatment. B.  Post-treatment. VII = PDL, VIII = NT. Some improvement of NT side 
near PDL side.
Figure 7:  Two small plaques separated from each other by non-psoriatic skin on the 
right upper leg. A. Pre-treatment. B. Post-treatment of the NT side. C. Post-treatment 
of the PDL side. V = NT, VI = PDL. No improvement of NT side separated from PDL 
side by non-psoriatic skin. 
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Chapter 7
Cellular and molecular effects of pulsed dye laser and local 
narrow-band UVB therapy in psoriasis
E.	Rácz,	J.	de	Leeuw,	E.	M.	Baerveldt,	M.	Kant,	H.A.M.	Neumann,		E.	P.	Prens.
Submitted for publication
abstract
Background: Pulsed dye laser (PDL) therapy is effective in clearing psoriasis 
plaques, but the mechanism of action is only partially understood. Local Narrow-
band	ultraviolet	B	(NB-UVB),	which	has	a	better	defined	mode	of	action	is	an	effective	
standard treatment for psoriasis. 
Objectives:  To evaluate the cellular and the molecular effects of PDL and compare 
them with those of local NB-UVB in order to gain further insight into their mechanisms 
of action in psoriasis.
Patients and Methods:  Nineteen patients with stable plaque-type psoriasis were 
treated either with PDL or NB-UVB. Lesional punch biopsies were obtained from all 
the patients before treatment. Additional biopsies were obtained at 3 hours and 24 
hours after PDL treatment in 5 of these patients. In 14 patients additional biopsies 
were taken after 7- and 13 weeks of treatment. Samples were  histopathologically 
examined	 for	 the	 level	of	dermal	T	cell	 infiltrate,	and	 the	expression	of	epidermal	
β-defensin 2, immune cell-derived tumor necrosis factor (TNF)-α, endothelial 
E-selectin, VEGFR2 and VEGFR3, and the expression of Interleukin (IL)-23 before 
and after treatment.  
Results: The expression of VEGFR2, VEGFR3 and E-selectin was decreased 
in clinically high responders within 24 hours after PDL treatment. The expression 
of  IL-23, TNF-α	mRNA	and	E-selectin	 protein	were	 significantly	 reduced	after	 2	
PDL treatments, whereas the expression of epidermal markers and dermal T cell 
infiltrates	 had	 normalized	 after	 4	 PDL	 treatments.	 The	 expression	 of	 epidermal	
activation	markers	and	E-selectin	were	significantly	reduced	after	13	weeks	of	NB-
UVB treatment.
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Conclusions: The expression of epidermal activation markers and the dermal T cell 
infiltrates	were	decreased	after	both	the	treatments.	The	decreased	expression	of	
VEGFR2 and VGFR3 followed by the down-regulation of TNF-α and IL-23p19 may 
be	contributory	factors	in	the	efficacy	of	PDL	in	stable	plaque-type	psoriasis.
Introduction
The dilation and proliferation of the dermal papillary microvasculature is one of the 
early changes seen in a new psoriatic plaque.1  The increased dermal microvasculature 
facilitates	the	trafficking	of	leukocytes	from	the	circulation	into	the	skin	and	therefore	
plays	an	important	role	in	maintaining	inflammation	in	psoriasis.2 Interference with 
leukocyte	trafficking	via	a	selective	destruction	of	the	dilated	capillaries	may	be	an	
effective therapeutic intervention in psoriasis. Selective targeting of blood vessels 
may	be	achieved	with	 the	flash-lamp	pumped	pulsed	dye	 laser	 (PDL).3 The PDL 
technique is based on the selective absorption of short pulses of 585 nm light by 
oxy-hemoglobin inducing photothermolysis of capillaries leaving the other nearby 
structures in the skin undamaged.4
Several studies reported that psoriatic plaques were partly or completely cleared by 
PDL treatment.5-8	In	a	comparative	study,	PDL	showed	a	significantly	higher	efficacy	
than a class II topically applied corticosteroid.8 PDL was also effective in clearing 
recalcitrant psoriatic plaques,9 whereas palmoplantar psoriasis responded well to 
treatment with PDL alone or in combination with topical calcipotriol or salicylic acid.10 
NB-UVB therapy is a standard treatment modality for psoriasis. The mechanism 
of action of NB-UVB has been investigated more thoroughly than that of PDL. It is 
known that NB-UVB targets the epidermal compartment inhibiting the proliferation 
of keratinocytes, abrogating antigen presentation, migration of Langerhans cells11 
and inducing apoptosis of activated skin-homing T cells.12,13 Prolonged exposure to 
NB-UVB and a high cumulative dose may result in premature ageing of the skin and 
lead to a higher risk of skin cancer. However, recent follow-up studies in patients 
receiving NB-UVB for psoriasis did not report any increase in the incidence of skin 
cancer as compared with controls. 14,15 Long-term side effects of PDL treatment have 
not yet been reported. 
No	significant	differences	 in	 the	clinical	efficacy	between	PDL	and	NB-UVB	were	
reported in a single-blind, prospective, paired randomized controlled study,16 
indicating that PDL is a valid treatment modality for psoriasis. However, to date 
there is only a poor insight into the cellular and the molecular mechanisms that are 
affected	by	PDL	explaining	its	efficacy	in	psoriasis.	The	aim	of	the	present	study	was	
to investigate the effects of PDL treatment on the cellular and the molecular markers 
of disease activity in psoriasis using immunohistochemical  and quantitative real 
time (RT)-PCR techniques and lesional skin biopsies taken before, during and at the 
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end of the treatment and compare them with those of NB-UVB treatment. 
materials and methods
Patients and biopsies
Nineteen patients with stable plaque type psoriasis were enrolled into the study after 
they had provided written informed consent. The study was approved by the Medical 
Ethical Committee, Erasmus MC, University Medical Center, Rotterdam (approval 
nr: MEC-2004-154).  Patients intolerant to light (toxic or allergic), using drugs with 
phototoxic or photo-allergic potency, younger than 18 years, were pregnant, or with 
pre-existing or manifest skin malignancy were excluded. A wash-out period of 2 
weeks was indicated for topical drugs and of 4 weeks for photo (chemo) therapy 
and systemic drugs. Emollients were allowed.  
The most representative psoriasis plaque was selected for a punch biopsy before 
treatment (baseline) in each patient. In 5 patients (2 women and 3 men aged 45 to 
59 years) additional 3-mm punch biopsies were taken at 3 hours and 24 hours after 
the	first	PDL	treatment	for	examining	the	short-term	effects.	The	psoriasis	plaques	
were randomly selected and treated either with PDL or with NB-UVB or left untreated 
in the remaining 14 patients (7 women and 7 men aged 20 to 65 years).  Two 3-mm 
punch biopsies, one from a PDL-treated site and one from a NB-UVB-treated site 
were taken at week 7 (after 2 treatments of PDL and 15 treatments with NB-UVB) 
and at week 13 (after 4 treatments of PDL and 30 to 33 treatments of NB-UVB) from 
each of these14 patients. The punch biopsies were snap-frozen in Tissue-Tek OCT 
(Miles, Elkhart, IN, USA) and stored at -80°C until further processing. 
Treatments
The V Star PDL (Cynosure Inc., Chelmsford, MA), emitting yellow light at a wavelength 
of 585 nm was used for PDL treatment. The skin was air-cooled using a Zimmer 6 
air cooler (Zimmer Elktromedizin, Neu-Ulm, Germany) during the treatment. The 
PDL treatment parameters were: pulse duration 0.50 ms, spot diameter 7-mm, spots 
overlapping	±	20%,	and	fluences	between	5.5	and	6.5	J/cm2. Patients were treated 
with the PDL every 3 weeks for 10 weeks, a total four treatments. The UVB-TL01 S 
(wavelength 311 nm) handheld device (Cosmedico Medizintechnik GmbH, Villingen-
Schwenningen, Germany) was used for the NB-UVB treatment. Mean UV-output was 
19.4 mWatt/cm2. The devices were calibrated with the Optometer P 9710 (Gigahertz 
Optik, Puchheim, Germany) before the treatment. The aperture of the appliance (5.0 
× 10.0 cm) was held against the skin assuring that the distance between the device 
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and the skin was constant in each patient during the treatment. Minimal erythema 
dose (MED) was determined in each patient prior to the study. Mean MED NB-
UVB was 0.86 J/cm2	(range	0.34–1.2	J/cm2). NB-UVB treatment (3 times per week) 
parameters were: a start dose of 70% of the MED, dose increments of 20% of the 
previous treatment until persistent erythema appeared or clearing of the lesion was 
achieved.	A	total	30–33	treatments	were	given	during	11	weeks.	Mean	initial	dose	
was 0.62 J/cm2	 (range	0.24–0.86	J/cm2), mean cumulative dose 84 J/cm2 (range 
40–120	J/cm2).
Plaques were randomly chosen and treated with PDL, NB-UVB or only with emollient 
in each patient. Concomitant topical treatment with salicylic acid 5% in petrolatum was 
permitted	for	all	plaques	in	between	the	treatments	sessions	to	reduce	reflectance	
of the PDL and the NB-UVB beam by scales, but was discontinued 2 days before 
the	PDL	treatment	and	directly	before	the	NB-UVB	treatment.	Clinical	efficacy	was	
assessed as described previously (16).
Immunohistochemistry
Cryostat sections (6 µm) were cut from each punch biopsy, mounted on glass slides, 
fixed	in	acetone	and	stained	for	markers	of	psoriasis	using	antibodies	shown	in	Table	
1. Endogenous peroxidase activity was neutralized using 4-chloro-1-naphtol. The 
slides were washed in phosphate-buffered saline (PBS) containing 0.05% Tween 
20 and 0.5% bovine serum albumin (BSA) and incubated with the appropriate 
dilution of the primary antibodies (Table 1) for 1 hour at room temperature. They 
were subsequently incubated with biotinylated secondary antibodies (rabbit-anti-
mouse IgG (Dako, 1:400) or donkey-anti-rabbit IgG (Amersham Biosciences, 1:800)) 
for 30 minutes and with horseradish peroxidase (HRP)-linked streptavidin (Dako, 
High	Wycombe,	UK)	for	1	hour	at	room	temperature.	Any	non-specific	staining	was	
prevented by adding unlabeled (normal) secondary antibody and normal human AB 
serum. HRP activity was visualized with amino-9-ethylcarbazole (Sigma-Aldrich, St. 
Louis, MO, USA) as a chromogen, resulting in a bright red staining. Sections were 
counter-stained with hematoxylin and mounted in glycerin-gelatin (Dako). 
A representative region was selected in each glass slide and photographed at 100x 
magnification	using	an	AxioCam	MRc5	camera	(Zeiss,	Goettingen,	Germany).	The	
acquired images were analyzed by computer-assisted image analysis using the 
WCIF VisionJ (http://rsb.info.nih.gov/ij) software. The area occupied by the stained 
tissue was expressed as a fraction of the total area of interest (i.e. epidermis or 
dermis). For statistical analysis of the quantitative data, the Wilcoxon Signed Ranks 
test	 and	 the	Kruskal-Wallis	 test	were	 used	 for	 unpaired	 and	 paired	 sets	 of	 data,	
respectively.
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RNA extraction and RT-PCR
The total RNA extraction was as follows. Twenty 10 µm cryostat sections were cut 
under RNAase-free conditions from each punch biopsy, directly placed in RNA lysis 
buffer (Sigma) followed by mRNA extraction. RNA was transcribed into cDNA and 
RT-PCR was performed using newly designed primers and probes. ABL1 was used 
as a housekeeping control gene. Primer and probe sequences are listed in Table 2.
Results
Clinical assessment
The Physician’s Global Assessment (PGA) score was used to establish clinical 
improvement. The PGA score is a 5 point scoring system, where score 0 denotes 
symptom-free	 state,	 whereas	 scores	 1-5	 represent	 increasing	 severity.	 Definition	
of each score, as well as the clinical outcomes of the study have been reported in 
more detail elsewhere (16). The results of the present study showed that the mean 
clinical improvement (mean reduction in the PGA score) at week 13 was 46% for the 
PDL-treated plaques and 52% for the NB-UVB-treated plaques indicating that the 
clinical	efficacy	of	both	treatments	were	comparable.	Six	high	responders	(defined	
as a PGA reduction > 50%) were selected from the 14 patients in order to evaluate 
the effects of both treatments. Clinical improvement as assessed by the PGA score 
in the whole group and in the 6 high responders during both the treatments is shown 
in Figure 1.
Early effects of the PDL
Early changes (within 24 h) in psoriasis plaques after PDL treatment were investigated 
in order to elucidate its mechanism of action. No changes were observed in mRNA 
expression levels of markers of the activated epidermal psoriasis phenotype such 
as β-defensin	2	(HBD2)	and	keratin	17	(KRT17),	TNF-α  and vascular endothelial 
growth factor (VEGF)-A in biopsies taken 3- and 24 hours after PDL treatment 
(results not shown). The expression of the anti-apoptotic, heat-regulated molecule 
Bcl 2 also remained unaltered at the same time points   (results not shown). The 
expression	of	the	endothelial	molecules	E-selectin	and	VEGFR2	were	significantly	
decreased in the biopsies taken 3 hours after the PDL treatment (Figures 2a & b). 
The expression of E-selectin was still reduced, whereas the expression of VEGFR2 
returned to baseline indicating that the reduction of VEGFR2 was transient (Figures 
2a & b) in the biopsies taken at 24 hours. Interestingly, the expression of the mRNA 
of the lymphatic marker VEGFR3 showed an alteration that was similar to that of 
VEGFR2	(Figure	2c).	The	expression	of	IL-23p19	mRNA	was	significantly	reduced	
at	3	hours	and	remained	reduced,	although	not	significantly	at	24	hours	after	 the	
PDL treatment (Figure 2d). 
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The PDL treatment affected the expression of VEGFR2 and VEGFR3 mRNA as early 
as	3	hours,	whereas	E-selectin	expression	was	significantly	reduced	24	hours	after	
treatment. The expression of IL-23p19 mRNA was also affected by PDL treatment, 
although	not	significant	at	24	hours.
Long-term alterations at the mRNA level
Selected psoriasis plaques were treated either with PDL or with NB-UVB in 14 
patients. The PDL treatment was carried out every 3 weeks for 10 weeks (a total four 
treatments), whereas NB-UVB treatment was three times weekly with increasing 
doses. The mRNA expression of keratinocyte-, immune cell- and endothelial cell-
associated activation markers was assessed by quantitative RT-PCR in punch 
biopsies taken before, at week 7 and at week 13 of therapy in the group of clinical 
responders in order to determine the course of the molecular changes during the 
treatment. The expression of keratin 17 and β-defensin	2	decreased	significantly	in	
the PDL-treated punch biopsies corresponding with the clinical improvement. There 
were	no	significant	alterations	in	the	expression	of	keratin	17	and	β-defensin 2 after 
the NB-UVB treatment in responders (Figures 3 a-d).
The expression of TNF-α	mRNA	was	decreased	significantly	in	the	biopsies	after	the	
PDL treatment, but not after the NB-UVB treatment (Figures 3e & f). The expression 
of IL-23p19 mRNA was suppressed in the punch biopsies at week 7 of the PDL 
treatment, but returned to the baseline levels after 13 weeks, whereas there were no 
significant	alterations	in	the	expression	of	IL-23p19	mRNA	in	the	clinical	responders	
after the NB-UVB treatment (Figures 3g & h).
The expression of VEGFR2 mRNA was up-regulated during both the treatments 
indicating an activated angiogenesis (Figures 3i & j). In addition, a reduced expression 
of the anti-apoptotic molecule Bcl 2 was observed in the biopsies after the PDL 
treatment (results not shown).
In the 6 clinical responders, the PDL treatment resulted in the decreased expression 
of TNF-α and IL-23p19 mRNA at 7 weeks, and the decreased expression of 
β-defensin 2 (HBD2), keratin 17 and Bcl 2 at 13 weeks, whereas the expression of 
the angiogenic molecule VEGFR2 was induced. The expression of mRNA of these 
markers in the punch biopsies varied considerably between the patients treated with 
the NB-UVB.
Immunohistochemical alterations 
Punch biopsies from all the 14 patients were analyzed by immunohistochemistry. The 
expression	of	transglutaminase	K	(TGK),	an	early	differentiation	marker	with	strong	
expression in psoriasis was assessed in order to follow any epidermal alterations. 
The	level	of	T	lymphocyte	infiltrates	(CD3)	in	the	dermis	was	determined	to	assess	
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the	 inflammatory	 components	of	 the	disease	activity.	Changes	 in	 the	 contents	 of	
the blood vessels were followed by staining for the von Willebrand’s factor (vWF), 
whereas endothelial activation was assessed by the expression of E-selectin. 
Global improvement of the psoriatic pathology as assessed in the hematoxylin and 
eosin (H&E)-stained sections was observed in about 50% of the patients corresponding 
with	 the	clinical	 improvement	 in	psoriasis.	No	significant	 changes	were	observed	
in	 the	PDL-treated	plaques,	whereas	 the	expression	of	TGK	and	E-selectin	were	
significantly	decreased	in	the	NB-UVB-treated	plaques	(Figure	4)	after	13	weeks	of	
treatment in the group of 14 patients (responders and non-responders).  
We	analyzed	punch	biopsies	from	6	clinically	high	responders	(defined	as	a	PGA	
reduction > 50%) for epidermal and dermal markers of psoriasis in order to evaluate 
the effects of both treatments.	The	expression	of	epidermal	TGK	and	the	dermal	T	
cell	infiltrates	were	markedly	reduced	by	both	treatments	(Figures	5a-d)	in	these	6	
patients	after	13	weeks.	The	expression	of	vWF	was	significantly	decreased	in	the	
NB-UVB-treated	 plaques;	 a	marked,	 but	 not	 significant	 decrease	was	 also	 noted	
after PDL treatment (Figures 5e & f). The expression of the endothelial activation 
marker	E-selectin	showed	a	significant	decrease	in	the	PDL-treated	punch	biopsies	
after	7	weeks,	but	this	change	did	not	reach	significance	at	week	13.	The	expression	
of E-selectin showed a gradual persistent decrease in the NB-UVB-treated lesional 
punch biopsies (Figures 5g & h). 
Discussion
The results of this study showed that the clinical improvement of psoriasis after the 
PDL treatment was accompanied by alterations in certain classical markers of disease 
activity. The observed effects at the mRNA level were comparable in responders 
to	 the	PDL-	 and	 the	NB-UVB	 treatment.	The	 relatively	 low	 clinical	 efficacy	 (52%	
improvement versus minimally 60% reported for total body irradiation) of NB-UVB 
in this study may be explained by the fact that local NB-UVB treatment was used 
instead of total body irradiation. It is assumed that total body NB-UVB irradiation may 
also exert a systemic effect.17
A hallmark of psoriatic skin is the remarkable transformation in the local microvascular 
system characterized by the dilation and the tortuosity of capillaries, increased 
permeability, and high endothelial venule formation, which is usually observed 
in lymph nodes.18 Active angiogenesis in psoriatic lesions evidenced by the up-
regulation of VEGF and VEGFR2 is accompanied by endothelial cell activation as 
observed by the up-regulation of ICAM-1, vascular cell adhesion molecule-1 (VCAM-
1) and E-selectin. During this process, vascular endothelial growth factor (VEGF) 
signaling on endothelial cells represents the major rate-limiting step.18 VEGF acts 
by engaging with its tyrosine kinase receptors VEGFR1 and VEGFR2 in endothelial 
157
cells. Although VEGF binds to both receptors, it appears that most of its biological 
functions are mediated via VEGFR2.18,19 
Our observation that the early effects of the PDL treatment involve the decreased 
expression of the endothelial molecules VEGFR2 and E-selectin corresponds with 
its proposed primary target. However, an additional early effect was also noted 
on VEGFR3 (FLT4), a lymph-endothelial marker.20 Lymphatics are expanded in 
psoriasis and the expression of VEGFR3 is increased in both the involved as well 
as the uninvolved psoriatic skin.19  The decreased expression of VEGFR3 early after 
PDL	treatment	may	contribute	to	its	efficacy	in	psoriasis.	
Interestingly, the expression of VEGFR2 was up-regulated at later time points 
indicating re-activation of angiogenesis. This active angiogenesis may counteract 
the	anti-psoriatic	effect	of	the	PDL	treatment	and	may	explain	the	insufficient	clinical	
response in some patients. Another possibility may be that the main source of VEGF 
in psoriatic lesions, the activated keratinocyte, is not targeted by the PDL treatment. 
Therefore, activated lesional keratinocytes are less inhibited and may continue to 
stimulate the lesional microvasculature. The up-regulation of VEGFR2 may explain 
the	enhanced	efficacy	of	the	PDL	treatment	when	combined	with	calcipotriol	ointment,	
which targets activated keratinocytes.10 
TNF-α	and	 IL-23	mainly	produced	by	 the	 inflammatory	dendritic	cells	 (DC)	 in	 the	
dermis are critical cytokines in the pathogenesis of psoriasis.21, 22 Their importance is 
underlined by the fact that biologics targeting TNF-α and IL12/IL23p40 are effective 
in treating psoriasis.23 Furthermore, both the cytokines are down-regulated during 
the treatment with other effective modalities.24 The results of the present study 
showed that after 7 weeks of the PDL treatment, TNF-α and IL-23 mRNA were 
down-regulated in psoriatic skin, whereas IL-23 was already observed to be down-
regulated within 3 hours after the PDL treatment. In combination with the observed 
decreased number of dermal CD3+ T cells, it may indicate that the vascular damage 
induced by the PDL treatment may also affect the peri-vascular immune cells.
Markers of keratinocyte activation and of the psoriasis phenotype were only 
significantly	reduced	at	the	end	of	the	series	of	the	PDL	and	the	NB-UVB	treatment	
sessions.	Keratin	17	expression	 is	high	 in	 the	psoriatic	epidermis	correlating	with	
the clinical severity.25	 Keratin	 17	 is	 considered	 to	 be	 a	 candidate	 auto-antigen	 in	
psoriasis.26 Human β-defensin 2 (HBD2) is a molecule with antimicrobial activity 
expressed	 by	 epidermal	 keratinocytes	 under	 inflammatory	 conditions	 such	 as	
psoriasis.27 Patients with psoriasis have higher genomic copy numbers of the gene 
encoding β-defensin 228 and have higher serum β-defensin 2 levels than healthy 
controls. Serum β-defensin 2 levels were shown to correlate positively with the 
disease severity.29 Since the PDL treatment does not target the epidermis primarily, 
it is conceivable that the PDL-associated decrease in the expression of epidermal 
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keratin 17 and HBD2 is secondary to the dermal blood vessel damage and to the 
subsequent	reduction	in	the	inflammatory	infiltrate	and	their	mediators.
Our	finding	that	the	PDL	treatment	is	effective	in	approximately	50%	(a	subgroup)	
of patients has also been reported by others.30 In our study, the group of PDL-
responders	could	not	be	distinguished	from	the	non-responders	in	terms	of	specific	
baseline expression patterns (results not shown) or immunohistochemical alterations 
induced by the treatment. Further studies are essential for identifying the prognostic 
markers of PDL-responsiveness in psoriasis.
In conclusion, PDL and local NB-UVB treatment are clinically equally effective in 
stable plaque-type psoriasis. At the end of the treatment period, both the treatments 
resulted in the decreased expression of epidermal markers of keratinocyte activation 
as	 well	 as	 decreased	 dermal	 T	 cell	 infiltrates.	 This	 indicated	 that	 alterations	 in	
the expression of markers of psoriasis activity do not clearly disclose the clinical 
treatment	modality	used	and	may	just	reflect	the	clinical	improvement	in	the	disease.	
Furthermore, we observed early effects of the PDL treatment on VEGFR2, VEGFR3 
and the down-regulation of TNF-α and IL-23p19. These are previously unrecognized 
factors	for	the	efficacy	of	the	PDL	treatment	in	psoriasis.	
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Figure 1. Clinical improvement in the psoriatic lesions during the PDL 
and the NB-UVB treatment from baseline to week 13. In each patient, stable 
psoriatic plaques were randomly selected and treated with PDL or NB-UVB. Clinical 
improvement was evaluated using the Physician’s Global Assessment (PGA) score. 
The average clinical improvement in the 14 patients (1a & b).  The average clinical 
improvement in 6 patients with high clinical response (1c & d). Error bars represent 
the standard error of the mean (SEM).
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Figure 2. The effects of the PDL treatment on the expression of the vascular 
endothelial growth factor receptors, E-selectin and IL-23p19 in psoriatic skin. 
The expression of VEGFR2 (a), VEGFR3 (b), E-selectin (c) and IL-23p19 (d) was 
determined by RT-PCR in punch biopsies taken from psoriatic lesions before, 3- and 
24 hours after the PDL treatment in 5 patients with psoriasis. The Figures depict 
the expression in the individual patients relative to the baseline. At each time point, 
the mean +/- SEM are marked. p-values are shown as calculated with the Wilcoxon 
signed ranks test. 
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Figure 3. The effects of the PDL and the NB-UVB on the expression of the 
psoriasis markers in lesional psoriatic skin. The expression of mRNA of β-defensin 
2 (a & b), keratin 17 (c & d), IL-23p19 (e & f), TNF-α (g & h) and VEGFR2 (i & j) was 
determined by the quantitative RT-PCR in punch biopsies from 6 patients. ABL1 was 
used as a housekeeping control gene. Bars show average expression levels relative 
to the baseline, error bars represent SEM. p-values are shown as calculated with the 
Wilcoxon signed ranks test. 
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Figure 4. Immunohistochemical staining. Punch biopsies from 14 patients 
with psoriasis were taken before and 13 weeks after the start of the treatment. 
Immunohistochemical staining of the cryostat sections for epidermal transglutaminase 
K	(TGK),	CD3,	von	Willebrand’s	factor	(vWF)	and	E-selectin	(E-sel)	was	performed.	
The	level	of	staining	was	quantified	using	digital	image	analysis.	The	level	of	staining	
for	CD3	was	 quantified	 separately	 in	 the	 dermis	 (DCD3).	Bars	 show	 the	 level	 of	
staining at 13 weeks relative to the baseline. Error bars represent the SEM. 
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Figure 5. Immunohistochemical staining in punch biopsies from clinical 
responders. Cryostat sections of punch biopsies from 6 clinical responders taken 
before the start of treatment and 7 and 13 weeks later were stained using antibodies 
against	transglutaminase	K	(a	&	b),	CD3	(c	&	d),	von	Willebrand’s	factor	(e	&	f)	and	
E-selectin	(g	&	h).	The	level	of	staining	was	quantified	using	digital	image	analysis.	
Figures depict the level of the expression in individual patients relative to the baseline. 
At each time point, the mean +/- SEM are marked. p-values are shown as calculated 
with the Wilcoxon signed ranks test.
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1 Probe numbers of the Exiqon probe library system (Exiqon, Vedbaek, Denmark).
Table 2. Primers and probes for quantitative real-time PCR.
 Forward primer Reverse primer Probe 1
RT17 TTGAGGAGCTGCAGAACAAG AGTCATCAGCAGCCAGACG 76
HBD2 TCAGCCATGAGGGTCTTGTA GGATCGCCTATACCACCAAA 35
TNF-α	 CAGCCTCTTCTCCTTCCTGAT	 GCCAGAGGGCTGATTAGAGA	 29
IL-23p19 GTTCCCCATATCCAGTGTGG TCCTTTGCAAGCAGAACTGA 76
E-selectin ACCAGCCCAGGTTGAATG GGTTGGACAAGGCTGTGC 86
VEGF-A TGCCCGCTGCTGTCTAAT TCTCCGCTCTGAGCAAGG 1
VEGFR2 GCTCAAGACAGGAAGACCAAG GGTGCCACACGCTCTAGG 27
VEGFR3 CAAGAAAGCGGCTTCAGGTA GCAGAGAAGAAAATGCTGACG 8
Bcl2 CAACACGCAGAGAATGTAAAGC GGTAGGAGCTGTGGCGACT 45
ABL1 TGGAGATAACACTCTAAGCA GATGTAGTTGCTTGGGACCCA CCATT  
 TAACTAAAGGT  TTTGG  
   TTTGG  
   GCTTC  
   ACACC  
   ATT
antibody Target molecule Supplier Species Titer
anti-TGK	 Transglutaminase	K	 Biomedical	 Mouse	 1:200
  Technologies Inc.
anti-CD3 CD3, a cell surface 
 molecule on T lymphocytes Dako Rabbit 1:100
anti-vWF von Willebrand’s factor, a  Abcam Rabbit 1:25000
 coagulation factor syn-
 thesized by endothelial cells    
anti-E-selectin E-selectin (CD62E), an  R&D systems Inc Mouse 1:20
 adhesion molecule on 
 endothelial cells .  
anti-ICAM-1 Intercellular adhesion  R&D systems Inc. Mouse 1:50
 molecule 1 (CD54), 
 expressed on endothelial 
 cells and keratinocytes 
Table 1.  antibodies used in the study
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abstract
Liposomes	are	vesicles	consisting	of	spherical	phospholipid	bi-layers	with	specific	
properties making them useful for topical application of drugs. Liposome research 
has expanded considerably over the last 30 years and nowadays, it is possible to 
construct a wide range of liposomes varying in size, phospholipids composition and 
surface	characteristics	to	suit	the	specific	application	for	which	they	are	intended.	In	
dermatology, the topical application of liposomes has proven to be of therapeutic value. 
Liposomes can be used as carriers for hydrophilic as well as lipophilic therapeutic 
agents because of their amphipathic character. They may improve stabilization of 
instable drugs by encapsulating them and serve as penetration enhancers facilitating 
the transport of compounds that otherwise cannot penetrate the skin. Liposomes 
help in reducing skin irritation by sustaining the release of drugs and by hydration of 
the epidermis. They also have the potential to target drugs into the pilosebaceous 
structures and hence they have an additional advantage for treatment of hair follicle-
associated disorders. Clinical data indicate that 5-ALA encapsulated in liposomes 
improves the quality of Fluorescence Diagnosis by ALA-induced Porphyrins (FD) 
and optimizes the results of Photodynamic Therapy (PDT).
Introduction
The skin is an organ, which is directly accessible for topical application of drugs. 
However, this does not imply that drugs incorporated in conventional transport media 
such as creams and ointments are delivered at the optimal concentration to the right 
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target structure in the skin. Optimum topical delivery of drugs into the skin requires 
penetration of the vehicle through the stratum corneum, liberation of the drug from 
the vehicle, absorption of the drug through the different layers of the skin, adsorption 
of the drug to the tissue structure(s) involved in the pathological process and 
permeability of the drug through the cell membrane in case of intended intracellular 
action. Safety aspects of topical drug delivery include the reduction of the risk of 
local and systemic side-effects by using appropriate drug concentrations, optimal 
vehicles and valid treatment schedules.1 Liposomes were already described in 1965 
by Bangham et al., who noticed the spontaneous aggregation of phospholipids into 
vesicles after addition of water to phospholipids.2 These vesicles, called liposomes, 
were initially used as a model for membrane system studies.3  Since 1970, liposomes 
have received considerable attention as a system for delivering drugs to the target 
tissue (drug targeting).3 The delivery of liposomal agents seemed to be superior 
to	their	conventional	counterparts	in	certain	fields	(e.g.	reducing	tumour	burden	in	
squamous cell lung carcinoma).4 The active or passive targeting by liposomes offered 
new	approaches	in	the	therapy	of	neoplasms	(e.g.	Kaposi’s	sarcoma,	 leukaemias	
and myelomas).4 Liposomes may be effective in the therapy of micrometastases 
when liposomes are taken up by surrounding tissue from the blood vessels during 
angiogenesis.4 In spite of promising prospects, the systemic application of liposomal 
drugs has been limited to just a few indications, but the topical application of liposomal 
preparations has attracted increasing attention in dermatology.3,5 
Liposomes are microscopic vesicles formed from phospholipids as biological 
membranes. A fundamental feature of cell membranes is the organization of 
lipids into bi-layers, providing permeability barriers between exterior and interior 
compartments. A large group of biological membrane lipids that spontaneously form 
bi-layers in water are the phospholipids. A class of phospholipids commonly used to 
construct liposomes for drug delivery is phosphatidylcholine (lecithin; Fig. 1).5  The 
ability of phospholipids to form a bi-layer structure is because of their amphipathic 
character resulting from the presence of a polar or hydrophilic (water-attracting) 
head-group region and a non-polar, lipophilic (water-repellent) tail. The hydrophilic 
head groups orientate toward the aqueous phase and the lipophilic tails orientate 
to each other in the presence of water (Fig. 1).5 Therefore, liposomes contain a 
lipophilic compartment within the bi-layer membranes and hydrophilic compartments 
between the membranes. Under the right conditions, water-soluble substances can 
be stored into the water phase and lipophilic substances into the lipid phase (Fig. 
1).6 In general, phospholipids spontaneously form large multilamellar liposomes 
and special process conditions and post-process steps are required to produce 
appropriately sized (uni)lamellar liposomes. Liposomes may be small, unilamellar 
vesicles	 (SUVs	25–50	nm	 in	diameter),	 large,	unilamellar	vesicles	 (LUVs	50–500	
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nm	in	diameter)	or	large	multilamellar	vesicles	(LMVs	500–10	000	nm	in	diameter).	
SUVs are less suitable for drug delivery because they lack stability and their volume 
is too small for entrapping drugs. The penetration of liposomes through the stratum 
corneum decreases with increasing diameters. Therefore, the preferred structures 
for	 drug	delivery	 are	LUVs	 that	 are	50–500	nm	 in	diameter	 (Fig.	 1).5 Next to the 
preferred sizes, an essential characteristic of liposomes for penetration through the 
stratum corneum is their state in a liquid crystal phase. The lipid bi-layer passes from 
a gel into a liquid crystal phase at a critical phase transition temperature (cptT). At 
the cptT, the head groups become fully hydrated and the lipid chains become freely 
mobile in the membrane. The cptT is determined by the length and the saturation of 
the paired lipid chains.7
Lipids, such as phosphatidylcholine, form bi-layers at cptT below room temperature. 
This liquid crystal state is essential for liposomes to interact simultaneously with 
the lipid and the aqueous compartments of the stratum corneum, and for delivering 
entrapped drugs into the skin.8 Cell membranes contain many more classes of lipid 
than phosphatidylcholine, and the next, quantitatively important phospholipid is 
phosphatidylethanolamine. This lipid, in isolation, does not form a bilayer but adopts a 
structure known as the hexagonal (H11) phase. The ability of lipids to adopt structures 
other	than	the	bilayer	configuration	upon	hydration	is	known	as	lipid	polymorphism.	
A	 generalized	 shape	 property	 can	 be	 ascribed	 to	 lipid	molecules,	 which	 reflects	
the phase structure they prefer in excess water. The bilayer phase lipids exhibit a 
cylindrical geometry, whereas H11 phase lipids can be considered cone shaped in 
that the acyl chains subtend a larger cross-sectional area than the polar head-group 
region. The reverse cone shape is adopted by detergens-type lipids which form 
micelles.5 Evidence is accumulating that inverted H11 structures act as intermediates 
in membrane fusion and that LUVs made from lipid mixtures containing
unsaturated phosphatidylethanolamine can fuse and mix with the skin lipids to loosen 
their structure providing a penetration enhancing effect.5,9  Standard nanocarriers 
encompassed pure phosphatidylcholine vesicles (non-rigid), phosphatidylcholine 
vesicles with cholesterol (membrane stabilized liposomes), and two rigid vesicles of 
dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylcholine with cholesterol. 
The	 ultradeformable	 (flexible)	 vesicles	 include	 phosphatidylcholine	 with	 sodium	
cholate, phosphatidylcholine with Span 80 and phosphatidylcholine with Tween 
80. All types of liposomes improve deposition into and permeation through the 
epidermis of encapsulated drugs compared with a saturated aqueous control. The 
ultradeformable vesicles are better than the standard liposomes with respect only 
to	transepidermal	drug	flux.9 The majority of the conventional liposome preparation 
techniques involve the application of volatile organic solvents or detergents. These 
solvents	may	 influence	 the	 stability	 of	 vesicles,	 leading	 to	 leakage	of	 drugs	 from	
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the liposomes. They may also exert toxicity towards molecules dissolved in the 
aqueous phase of the liposomes and towards membranes of cells. Because of these 
disadvantages,	removal	of	the	solvents	and	the	detergents	by	gel	filtration	or	dialysis	
are required.10 Recently, a new method for the production of liposomes without 
the use of solvents and detergents has been described. This method involves the 
hydration of liposome components in an aqueous medium followed by the heating of 
these components in the presence of glycerol.11 
The skin acts as a two-way barrier, controlling the inward and outward passage of 
water and electrolytes. This barrier is situated in the stratum corneum and consists 
of	 the	 cornified	material	 of	 the	 terminal	 differentiated	 keratinocytes,	 proteins	 and	
intercellular lipids. Filaggrin is a crucial protein in the formation of the protective 
stratum corneum and has been indicated to play a role in determining the degree 
of dryness of human skin.12 Filaggrin	aggregates	the	keratin	filament	cytoskeleton,	
causing	 the	 collapse	of	 the	granular	 cells	 into	 flattened	 squames.	This	 collapsed	
cytoskeleton, together with its attachment proteins and membrane components, 
undergoes	 extensive	 cross-linking	 to	 form	 the	 cornified	 cell	 envelope.	 The	main	
function	 of	 the	 cornified	 envelope	 is	 to	 form	 the	 outermost	 barrier	 layer	 of	 the	
skin, which prevents water loss and keeps out allergens and infectious agents.12 
Intercellular lipids are produced by ovoid lamellar bodies, which are provided by the 
Golgi area in the keratinocytes in the stratum spinosum. In the ovoid lamellar bodies, 
lipids	are	arranged	in	bi-layer	discs,	which	represent	flattened	unilamellar	liposomes.	
In the stratum granulosum, the ovoid lamellar bodies migrate to the cell periphery, 
fuse with the cell membranes and discharge their contents into the intercellular 
spaces. After extrusion, the discs become arranged parallel to the cell membranes 
and then fuse to form uninterrupted sheets of water-retaining lipid bi-layers between 
the corneocytes.13,14 Thus, the stratum corneum contains hydrophilic and lipophilic 
compartments, which act as a buffer to retard both water loss and absorption of 
water.15 These	lipid-rich	structures	might	also	influence	the	desquamation	process	in	
the stratum corneum.16,17 Three mechanisms of the penetration of liposomes into the 
skin have been described:
1. Via lateral diffusion of liposomes in the stratum corneum. The molecular 
structure of liposomes is similar to that of endogenous skin lipids. Lipid 
exchange between human membranes is a common physiological 
phenomenon. The exchange occurs via molecular diffusion from one 
membrane to the other.5 The rate of phospholipid exchange depends upon 
the relative sizes of the hydrophobic portions of the molecule. In general, 
phospholipids with short acyl chains (< 16 carbons long) exchange rapidly 
(minutes to hours), whereas longchain phospholipids move slowly between 
membranes into the stratum corneum (many hours to days).18,19
173
2. Via a trans-epidermal osmotic gradient and hydration force through which 
liposomes are sucked into the epidermis. In accordance with this putative 
mechanism is the observation that an effective penetration of liposomes into 
the skin requires a dry skin surface. Under occlusion (maximal hydration), no 
penetration of liposomes occurs.20,21
3. Via the pilosebaceous units.22–24
The similarity of lipid composition of liposomes and membranes of intercellular 
lamellae and keratinocytes enables the liposomes to penetrate into the epidermal 
barrier to a greater extent as compared with other application forms and so do the 
compounds encapsulated into these liposomes.25 This may result in an increase of 
drug absorption into the epidermis and decrease of drug clearance from the epidermis, 
promoting longer sustained release of drugs in the epidermis and lower absorption 
of drugs into the blood. This is why liposomes may act not only as drug transporters, 
but also as drug localizers.3 Fluorescent liposomes applied to the skin have been 
found inside the keratinocytes of the epidermis.26 Liposomes fuse with the outer cell 
membrane and deliver their contents to the cytoplasm via endocytosis (Fig. 2).27 It 
is possible to introduce even large molecules into the cytoplasm of keratinocytes by 
using liposomes as intracellular transport system after which these molecules may 
unfold	their	efficacy.28
Mezei	 and	 Gulaskharam	 were	 the	 first	 to	 report	 that	 triamcinolone	 acetonide	
in liposomes, applied topically to rabbit skin resulted in a higher concentration 
of triamcinolone acetonide in the epidermis and lower triamcinolone acetonide 
concentrations in the blood and urinary excretion as compared with triamcinolone 
acetonide applied in a gel formulation.29,30 A similar effect was also shown in the 
human skin using liposome encapsulated tertracaine 31 and hydrocortisone.32,33 
Moreover, ‘empty’ liposomes (without encapsulated drugs) hydrate the skin simply by 
providing lipids to the stratum corneum.34 This	hydration	capacity	may	be	of	benefit	in	
the treatment of xerosis cutis and atopic dermatitis.35
Indications for liposomes as drug carriers in dermatology
Acne
Acne is one of the most common disorders of the skin and has a considerable 
impact on the quality of life of adolescents. Standard treatment today consists of 
peeling	the	skin,	eliminating	the	corynebacterium	acnes	and	reducing	inflammation	
by using topical benzoyl peroxide (BPO), tretinoin, adapalene and antibiotics. If 
this	 approach	 is	 not	 efficacious,	 systemic	 antibiotics	 and	 antiandrogens	 are	 the	
next	step.	However,	the	efficacy	of	antibiotic	treatment	is	progressively	reduced	by	
increasing resistance of bacteria to antibiotics, and side-effects may also limit their 
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use.	In	case	of	failure	of	treatment	the	final	remedy	is	oral	isotretinoin,	which	is	very	
effective, even in recalcitrant acne, but its use is limited by moderate to serious side-
effects.	The	efficacy	and	safety	profiles	of	certain	antiacne	drugs	may	be	improved	
by encapsulating them into liposomes.
The superiority of liposome-encapsulated 1% clindamycinsolution vs. 1% clindamycin-
solution in the treatment of acne was demonstrated in 73 patients. No side-effects 
were reported.36
Topical tretinoin is an anti-acne agent especially for reducing the size and the number 
of comedones. 
Its use is limited by skin irritation, with erythema, scaling, burning sensation and 
increased susceptibility to sunlight at the sites of application. In a doubleblind study, 
the	efficacy	and	the	local	tolerability	of	liposomal	tretinoin	0.01%	were	compared	with	
those of a commercial gel preparation with either 0.025% or 0.05% in 20 patients 
with	uncomplicated	acne	vulgaris.	The	efficacy	of	liposomal	tretinoin	appeared	to	be	
equipotent to the reference gels, but liposomal tretinoin was superior with respect to 
skin irritancy.37
A comparative double-blind study in 30 patients demonstrated a 1.5-fold enhancement 
of	drug	efficacy	and	a	marked	decrease	in	all	side-effects	associated	with	tretinoin	
therapy for liposomal tretinoin gel compared with conventional tretinoin gels after 3 
months of treatment.38
BPO is an effective topical agent in the treatment of acne and acts by inhibition of 
the propionibacterium acnes in the pilosebaceous units. Although resistance to BPO 
is not evident, local irritation with burning and erythema, and also bleaching of dyed 
clothing may limit patient compliance. A comparative doubleblind study of liposomal 
BPO	vs.	conventional	BPO	in	30	patients	demonstrated	a	significant	improvement	
in the therapeutic response (about 2-fold) after 3 months of treatment with liposomal 
BPO as compared with a conventional BPO gel, with marked reduction in adverse 
symptoms and bleaching of clothing.39 In	 another	 study,	 a	 significantly	 higher	
antibacterial effect of a BPO liposome formula was observed as compared with 
commercial BPO formulations.40
Photodynamic therapy (PDT) is widely used to treat acne. However, there are 
only	 a	 few	 studies	 in	 the	 literature	 regarding	 treatment	 efficacy	 and	 treatment	
parameters.41–44	Hyper-pigmentation was more often seen at higher doses of light, 
and pain was experienced more often by the patients when higher doses were used. 
The authors concluded that PDT could be an alternative treatment for acne and that 
the lowest possible light dose should be used for minimal side-effects.43 Considering, 
the information provided by these publications, the need for optimizing PDT for 
treatment	 of	 acne	 is	 justified,	 especially	 concerning	 discomfort	 and	 side-effects	
during	and	after	treatment.	Christiansen	et	al.	performed	a	study	on	the	fluorescence	
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distribution patterns of normal skin after topical application of 20% 5-aminolevulinic 
acid (5-ALA) in a moisturizing cream and after application of low concentrations 
ALA (0.5% and 1%) encapsulated in liposomes. Changing the 5-ALA vehicle from 
a moisturizing cream to liposome encapsulation, the 5-ALA concentration could be 
lowered	by	a	factor	of	40,	and	still	induced	the	same	skin	fluorescence	and	at	the	same	
time eliminated the need for occlusion.45,46 The	low	post-treatment	fluorescence	also	
significantly	reduced	the	risk	of	post-treatment	pototoxicity.45 In a preliminary study 
16 patients with moderate to severe acne were treated with 0.5% ALA in a liposomal 
spray (each 10 min for 1 h) and subsequent illumination with an intense-pulse laser 
(IPL;	400–720	nm)	3×3.5–3×4.5	J/cm2,	every	4–6	weeks,	and	concomitant	treatment	
with tretinoin 0.02% cream at night. Topical or systemic antibiotics were not used. 
The clinical results appeared to be promising without any side-effects (de Leeuw, 
unpublished observation; Fig. 3).
Ichthyosis vulgaris, xerosis cutis, and atopic skin
Recently,	mutations	 in	the	filaggrin	gene	(R501X	and	2282del4)	were	 identified	in	
patients with ichthyosis vulgaris and were shown to be an important predisposing 
factor for atopic dermatitis. These mutations, which are found in 10% of those of 
European	origin,	may	lead	to	(in)-complete	absence	of	filaggrin	expression.	12 This 
results in a disturbance of the outermost barrier layer of the skin, which normally 
prevents water loss and keeps out allergens and infectious agents.47,48 In atopic 
skin, more nonextruded lamellar bodies remain undelivered within the uppermost 
stratum granulosum cells, resulting in reduced delivery of pro barrier polar lipids in 
the intercellular space. This affects water permeability, leading to increased trans-
epidermal water loss.16,49 Healthy skin has the ability to regulate disturbed barrier 
function by increased lipid synthesis. This ability is reduced in atopic patients because 
of	 the	 (in)-complete	 absence	 of	 filaggrin	 expression	 and	 the	 altered	 extruding	
mechanism	of	 lamellar	 bodies.	Environmental	 influences	 such	 as	 central	 heating	
systems, increased washing, increased use of detergents,  environmental pollutants, 
and	many	other	influences	on	the	epithelial	barrier	may	increase	the	susceptibility	
of the skin leading to exacerbation of atopic dermatitis.48 Increased lamellar body 
secretion was demonstrated with coincidental clinical improvement after wet-wrap 
dressing treatment of atopic eczema.50 Similar effects on the restoration of the 
skin barrier were described after application of liposomes on the skin. Due to the 
similarity between the structure of the liposomes and the lipid layers of the stratum 
corneum, the liposomes bind to the keratin layer of the stratum corneum and form 
a	 thin	occlusive	film,	which	 reduces	 trans-epidermal	water	 loss	giving	 the	patient	
immediate relief from the discomfort associated with dry skin.51 Additionally, the 
water content of liposomes promotes further hydration of the skin.18 The wet-wrap 
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treatment is very time-consuming, needs training and is not well tolerated by every 
patient. Application of liposomal spray is a fast, easy to use and requires no training. 
Moreover, a doubleblind study showed that the patient’s acceptance for liposomes
containing	preparations	was	significantly	higher	than	that	for	commercially	available	
moisturizing preparations.52
Atopic dermatitis, irritant and allergic contact dermatitis
Topically	 applied	 corticosteroid	 therapy	 is	 the	 first	 choice	 of	 treatment	 for	 atopic	
dermatitis and irritant and allergic contact dermatitis in addition to restoration of 
the damaged skin barrier and recognizing and elimination of a causative agent. 
Liposomes promote the restoration of the skin barrier resulting in a reduction of 
penetration of irritant- and allergenic substances and subsequently in a reduction 
of	 inflammation.18,35 Furthermore, pharmacokinetic evaluation of triamcinolone 
acetonide and hydrocortisone showed higher drug levels in the skin and lower 
systemic availability following application of liposomal corticosteroids as compared 
with conventional preparations.29,30,32,33 Higher and sustained concentrations of a 
corticosteroid	in	the	skin	promise	higher	efficacy,	less	side-effects	from	absorption	of	
corticosteroids into the blood and lower frequency of application.3,53
Psoriasis
Recent breakthroughs in the treatment of psoriasis have led to improved understanding 
of the pathogenesis of this disease.54,55 Although major advances in the development 
and the use of targeted biologicals for controlling psoriasis have been made, the 
need to develop safe, cost-effective and disease-effective cures remains. 
Vitamin D3 analogues such as calcipotriol, calcitriol and tacalcitol have antipsoriasis 
capacities	due	to	suppression	of	inflammation	and	hyper-proliferation	and	promotion	
of epidermal differentiation. Calcitriol was tested at concentrations of 5, 15 and 20 
μg/g in liposomes and in petrolatum in a mouse tail test.
The highest increase in the orthokeratosis indices was observed for calcitriol 5 μg/g 
in liposomes as compared with 15 and 20 μg/g in liposomes and 5, 15 and 20 μg/g 
in petrolatum. Similar results were also observed with tacalcitol in liposomes. The 
authors suggested that by using a liposomal preparation, the vitamin D3 concentration 
can be reduced as compared with that of currently available commercial preparations 
without	sacrificing	therapeutic	effect	and	meanwhile	reducing	local	side-effects	such	
as skin irritation and systemic side-effects.56 Dithranol generally used as short contact 
therapy	is	safe	and	efficacious	in	the	treatment	of	plaque	type	psoriasis.	However,	its	
use is inconvenient and troublesome because of its side-effects such as skin irritation, 
burning sensation, staining and necrotizing effect on normal as well as the diseased 
skin. The entrapment of dithranol in liposomal vesicles promotes its bioavailability 
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in the epidermis, which makes it possible to reduce the dose and in turn, the dose-
dependent side-effects.57 In a double-blind study, the superiority of 0.5% dithranol 
encapsulated in a liposomal gel as compared with a conventional cream containing 
1.15% dithranol, 1.15% salicylic acid and 5.3% coal tar was reported.58 Cyclosporine 
A	 (CyA),	 a	 potent	 immunosuppressive	 drug	 is	 highly	 efficacious	 in	 the	 treatment	
of psoriasis and other skin disorders. However, systemic administration of CyA is 
associated with serious side-effects, especially nephrotoxicity. Topical delivery 
of CyA is hindered by its physicochemical properties and the barrier property of 
statum corneum. CyA liposomal vesicles containing 10% and 20% ethanol showed 
statistically enhanced deposition of CyA into the stratum corneum, as compared 
with vesicles prepared without ethanol. These results can be considered as a step 
forward for the topical delivery of CyA using liposomes as a tool for the treatment of 
inflammatory	skin	diseases	like	psoriasis.59
Systemic methotrexate can be used for controlling recalcitrant psoriasis. However, 
the systematic use may provoke a number of side-effects, notably hepatotoxic 
effects. In order to overcome these side-effects, clinical studies have been pursued 
with topical application of methotrexate. A major problem in topical application of 
methotrexate is that the drug is hydro-soluble and is mostly in the dissociated form, 
thereby limiting its capacity for passive diffusion. However, by applying methotrexate 
in a liposomal preparation, 50% of the administered dose was found in the skin 
indicating that liposomes may be valuable in the topical application of methotrexate 
in the treatment of psoriasis.60,61 It	was	confirmed	that	psoriasis	can	be	treated	by	
topical	application	of	liposomalentrapped	methotrexate-paraffin	wax	in	a	small	clinical	
trial. This preparation was applied once a day on the psoriatic lesions, while the 
psoriasis plaques in the control group of patients were treated with free methotrexate 
and	empty	liposomes	in	paraffin	wax.	After	2	weeks	of	treatment,	all	plaques	treated	
with liposomal methotrexate showed total clearance, whereas those receiving free 
methotrexate did not improve.62
Vitiligo
Vitiligo is an acquired de-pigmentation disorder affecting about 1% of the population. 
It may have an important negative impact on the quality of life, particularly of those 
with pigmented skin.
Autoimmunity, destroying the melanocytes in the epidermis, is the most accepted 
pathogenic mechanism, although other mechanisms have also been proposed. The 
inactive melanocytes in the outer root sheath of the hair follicles are not affected. 
Phosphatidylcholine liposomes are able to target molecules like khellin into the hair 
follicles.22,23  After khellin is activated by ultraviolet A (UVA) and UVB, the inactive 
melanocytes proliferate and mature to an active state as they migrate into the 
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epidermis.63 The results of systemic khellin in combination with UVA are comparable 
with the rates reported from psoralen photochemotherapy (PUVA).64 The major 
advantage of khellin is that it does not induce photo-toxic skin erythema and does 
not induce detectable DNA mutations in contrast to PUVA, but side-effects such as 
liver dysfunction have been reported.64 Topical photochemotherapy of vitiligo with 
khellin has also been reported	 to	 be	 efficacious.65 The	 efficacy	 and	 the	 safety	 of	
topical treatment with 0.005% khellin encapsulated in L-phenylalanine stabilized 
phosphatidylcholine	liposomes	in	combination	with	UVA/UVB	light	(KPLUV)	therapy	
was demonstrated in 74 patients with vitiligo in a retrospective open trial.66
Actinic keratoses and skin cancer
Skin cancer is the most common cancer in white people. 67 Basal cell carcinoma and 
squamous cell carcinoma are the most frequently occurring skin cancers.68 Squamous 
cell carcinoma has the potency to metastasize. Actinic keratosis is believed to be 
premalignant. The change of progression to invasive squamous cell carcinoma is 
about 8%, and many patients with squamous cell carcinoma have multiple actinic 
keratoses.69 Skin cancer incidence rates have steadily increased over the last 
decades and are expected to keep on rising.70 Exposure to solar UV radiation is the 
main environmental factor linked to the formation of skin cancers.70 Sun-addicts are 
particularly at risk as are patients treated for skin disorders with UVB and PUVA. Other 
contributing factors are the ageing of the population and the increasing consumption 
of immunosuppressive drugs by organ transplant recipients and by individuals on 
treatment for autoimmune disorders, malignancies and skin disorders. Wavelengths 
especially in the UVB (280- to 320-nm) range damage DNA in the cells of human 
skin. Un-repaired UV-induced lesions such as cyclobutane pyrimidine dimers (CPD) 
in the DNA may lead to mutations involved in skin tumorgenesis.71
The bacteriophage T4 produces a DNA repair enzyme (T4 endonuclease V), which 
is able to substitute the UV-damaged enzyme complex in humans to initiate excision 
repair.72 It has been shown in preclinical studies that T4 endonuclease V encapsulated 
in liposomes (T4N5 liposomes) cross the stratum corneum and  were present in the 
epidermis 1 hour after application of a lotion containing T4N5 liposomes to mouse 
skin.73 T4N5 liposomes, leading to a reinforcement of DNA repair, were observed 
in the cytoplasm and in the nuclei of keratinocytes in mouse and human skin. 26,74 
T4N5 liposomes are antimutagenic not only because they remove CPD, but also 
because the re-synthesis step is less subject to error.73 In addition, T4N5 liposomes 
have the ability to suppress the upregulation of tumour necrosis factor-α	 (TNF-α) 
and interleukin-10 (IL-10) after UVB irradiation of the skin. TNF-α is responsible for 
inflammatory	and	 immunosuppressive	 responses	by	 the	 immune	system.	 IL-10	 is	
also induced by UVB and shifts the cellular immune response from an active Th1 
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mode to a suppressive Th2 mode. It was reported that T4N5 liposomes, applied after 
UV exposure penetrate human skin and deliver T4 endonuclease into keratinocytes 
and epidermal Langerhans cells in 15 volunteers with preceding skin cancers.75 
In	the	same	study,	a	significant	reduction	of	TNF-α and IL-10 gene transcription, a 
reduction of IL-10 protein and also an increase in DNA repair was demonstrated in 
biopsies taken 6 h after the T4N5 liposome application.75 A reduction (45%) of UV-
induced skin cancer in mice by topical application of T4N5 liposomes to the skin 
was already demonstrated in 1995.76 Patients with xeroderma pigmentosa have an 
autosomal-recessive genetic defect in the pathway that repairs suninduced damage 
to DNA.77 
As a result, the rates of (pre) malignancies of the skin are much higher than in the 
general population. This defect in DNA repair has been overcome in cell culture by 
the intracellular delivery of the bacterial DNA incision repair enzyme T4 endonuclease 
V. Daily applications of T4N5 liposome lotion for 1 years to sun-damage skin of 30 
xeroderma pigmentosa patients (with a history of skin cancer or actinic keratosis) 
lowered	the	rate	of	new	actinic	keratoses	and	basal	cell	carcinomas	significantly.78 
In summary, T4N5 liposomes protect the skin against UV-induced carcinogenesis by 
promoting the DNA repair and by inhibiting immunosuppression. 
PDT, employing 5-ALA, was initially used in the treatment of actinic keratoses 
and	later	on	also	in	the	treatment	of	superficial	basal	cell	carcinomas	and	morbus	
Bowen.79–83	The mechanism of ALA- PDT is based on the selective accumulation of 
5-ALA in malignant cells (and also in non-malignant cells with increased metabolism) 
as compared with normal adjacent tissue, and transformation of 5-ALA into the 
photosensitizer protoporphyrin IX (PpIX). PpIX induces phototoxicity and tissue 
destruction upon absorption of light of an appropriate wavelength and dose.84  The 
hydrophilic nature of the ALA molecule limits the penetration through the skin as 
well as the cell membranes. Hence, ALAinduced PpIX formation is often restricted 
to	 superficial	 layers.85 In	 order	 to	 improve	 the	 efficacy	 of	 5-ALA,	 particularly	 in	
thicker lesions, a number of options have been investigated. Higher PpIX levels 
have been obtained in cell cultures by using the lipophilic methylester of 5-ALA 
methylaminolevulinate (MAL) compared with 5-ALA.86 Higher PpIX levels have also 
been demonstrated using penetration enhancers, iron chelators, iontophoresis, and 
also after curettage prior to 5-ALA treatment.87 To optimize the topical delivery system, 
the in vitro delivery performance of liposomes containing 5-ALA in the epidermis 
and the dermis without stratum corneum was studied. A higher skin retention and 
a lower skin permeation of 5-ALA was demonstrated as compared with 5-ALA in 
aqueous solution.87 Another study assessed the tissue distribution and the kinetics 
of porphyrin synthesis after topical application of 5-ALA encapsulated in liposomes 
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to tumour bearing mice. In contrast to the kinetics of porphyrins formed from free 
5-ALA, tumour and overlying skin produced maximal amount of porphyrins 24 hour 
after liposomal application.85 The results of these studies indicated that 5-ALA in 
liposomes may be adequate for the 5-ALA PDT treatment of skin cancer because the 
liposomes deliver 5-ALA to the target skin layers (viable epidermis and dermis).87 
Early tracing of (pre) malignancies is important for reducing the extensiveness of 
subsequent medical interventions, resulting in less patient discomfort, higher cure 
rates and reducing the costs of more extensive interventions and increased chances 
of side-effects. Actinic keratoses may be clinically detected as red and rough papules 
and plaques by inspection and palpation. However, diagnostic approaches have been 
unsatisfactory to date and there is a great demand for non-invasive clinical methods.88 
Fluorescence diagnosis by ALA-induced porphyrins (FD), a technique based on 
PDT, was developed to distinguish various types of tissues and cells on the basis 
of	 differences	 in	 fluorescence.	 Recently,	 laserinduced	 fluorescence	 spectroscopy	
at 410-nm excitation has been shown to be effective as a non-invasive method for 
objective evaluation of non-melanoma skin cancers.89 The depth of penetration of 
5-ALA into the skin is a major limitation in the diagnosis, especially in hypertrophic 
and hyperkeratotic actinic keratosis lesions, and in psoriasis.90–92 The mechanical 
barrier by the stratum corneum is responsible for the diffusion rate of ALA and/or 
penetration of light.92 Liposomes provide an enhanced passage of 5-ALA through 
the stratum corneum, resulting in a more precise targeting of drugs into the diseased 
cells. Liposomeencapsulated 5-ALA transformation into PpIX is also higher in actinic 
keratosis and basal cell carcinoma cells as compared with the cells in the normal 
adjacent skin. This is why liposomes may contribute toward improved diagnostic and 
therapeutic results. This property of liposomes as a targeting method is not available 
in other topical applications.45
Thrombophlebitis
Superficial	 vein	 thrombosis	 is	 generally	 considered	 to	 be	 relatively	 harmless.	
However,	 deep	 venous	 thrombosis	 and	pulmonary	 embolism	 following	 superficial	
vein thrombosis have been reported.93
Therefore, the importance of treatment with low molecular weight heparin (LMWH) in 
addition to compression therapy has increased, mainly because of the antithrombotic 
and antiphlogistic actions of heparin.94 Topical liposomal heparin spray-gel appeared 
to	 be	 equally	 efficacious	 in	 reduction	 of	 pain,	 erythema	 and	 thrombus	 size	 as	
compared with subcutaneous injections of LMWH.94
Subcutaneous injections and applications of topical LMWH in ointment, cream and 
gels are painful (rubbing into the skin at the site of the thrombophlebitis) in contrast 
with	liposomal	heparin	spray-gel.	In	a	double-blind	study,	124	patients	with	superficial	
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vein thrombosis were treated. One half of the patients were treated with liposomal 
heparin spray and the other half of the patients with placebo liposomal spray. All 
the patients were also treated with ambulant compression therapy. Remarkably, 
better	efficacy	was	observed	in	the	patients	treated	with	liposomal	heparin	spray	as	
compared with those treated with the placebo liposomal spray. All patients underwent 
Doppler scanning of the deep venous
system. Thrombus propagation was not encountered in any case during the three 
weeks observation period.95
Hair removal
Unwanted facial and body hair can represent a severe cosmetic disturbance with 
social and psychological implications often strong enough to motivate patients, 
especially women, to seek dermatologic treatment. The goal of laser hair removal 
is to damage stem cells in the bulge of the follicle or to replace the hair follicle at 
the level of the dermis with connective tissue through thermal injury. The primary 
mechanism of laser hair removal is selective photothermolysis whereby follicular 
melanin is the target chromophore for destruction by light energy. Laser hair removal 
of white, blond and grey hair is often unsuccessful due to the lack of melanin in 
the hair follicle. Melanin-encapsulated liposomes have demonstrated to deliver 
melanin selectively to the hair follicle and the hair shaft. (Hoffman 1998) Melanin-
encapsulated liposomes (Lipoxome®) are used for staining hair follicles of people with 
blond,	white	or	grey	hair.96,97	Histological	studies	have	confirmed	the	presence	of	
new deposits of melanin in the hair follicle after application of melanin-encapsulated 
liposomes. Pre-treatment with melanin liposomal spray improved the results of 800-
nm diode laser therapy in 38 hirsute women and 2 men with light blond, white and 
grey	hair.98	Lipoxome®	spray	was	applied	6–8	times	a	day,	during	14	days	prior	to	
laser	treatments	with	an	800-nm	diode	laser	(treatment	intervals	6–8	weeks).	At	6	
months after the last laser treatment, 90% of patients experienced a permanent hair 
reduction of over 75% within 10 treatments. A correlation was found between the 
quantity of Lipoxome® applied to the area in the 14-day pretreatment period and 
the	extent	of	laser	hair	removal	(correlation	of	0.785	at	a	significant	level	of	99.9%)	
In the control group, 20 hirsute women also having light blond, white and grey hair, 
were only treated with the 800-nm diode laser. At the last control visit, 6 months after 
the last laser treatment, these patients hardly showed any notable hair reduction. 
Side-effects were seen in both groups: transient discomfort, erythema, perifollicular 
oedema, crusting and transient hyperand hypopigmentation.98 Pretreatment with 
Lipoxome® spray improved also the results of long pulsed Nd:Yag laser treatment 
for pigmented underarm hair. At 6 months after three laser treatment sessions, the 
percentage of hair reduction was 73% with the combined therapy and 43% with laser 
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treatment alone.99
Topical anaesthesia for intravenous cannulation and superficial surgery
In contrast with EMLA® cream, there is no need for occlusion after application of 
tetracaine 5% or lidocaine 4% in liposomal cream. Adequate anaesthesia is already 
obtained after 30 min, vasoconstriction does not occur and there is no association 
with methemoglobinemia.100–105
Skin rejuvenation
It became apparent that PDT of (pre) malignant disorders rejuvenated the adjacent 
skin in the irradiated area, which was clinically seen as a reduction of wrinkles, 
solar lentigines, scars and large skin pores.106,107 In double-blind, split-face studies, 
a	significantly	higher	clinical	 improvement	was	demonstrated	on	 the	 facial	halves	
receiving topical 5-ALA and IPL as compared with the facial halves receiving only 
IPL.108,109 The concentrations of 5-ALA and MAL used in PDT, respectively, 20% and 
16%, were originally chosen for the photodynamic treatment of precancerous and 
superficial	malignant	skin	disorders,	at	which	 the	side-effects	were	acceptable	 for	
the	beneficial	clinical	efficacy.	However,	in	cosmetic	treatments,	the	safety	and	the	
lack of discomfort are of primary importance, side-effects such as pain, oedema, 
erythema,	desquamation	and	phototoxicity	during	24–48	hour	after	3	hour	of	20%	
5-ALA and 16% MAL treatments are not acceptable.45 This is why attempts have been 
made	to	reduce	discomfort	and	at	 the	same	time	maintain	or	augment	efficacy	of	
PDT by reducing incubation time to 1 hour84,107 and even to 30 min110 and/or reducing 
5-ALA concentration to 5%.79 Since these studies demonstrated that 0.5- to 1-hour 
incubation	times	of	20%	5-ALA	cream	under	occlusion	was	sufficient	to	obtain	a	skin	
rejuvenation effect, comparable clinical results are to be expected from 1 to 2-hour 
application of 5-ALA 0.5% liposomal solution without occlusion. 
Instead of PDT or in addition to PDT, tretinoin can be used to treat acne, for skin 
rejuvenation, to treat sun-damaged skin and to prevent epithelial (pre)malignancies 
because of its ability to regulate sebum production, collagen synthesis and epithelial 
cell growth and differentiation.111,112 It has been demonstrated that the hydration of 
the epidermis and the storage of tretinoin in the epidermis is strongly promoted by 
incorporation	of	tretinoin	in	negatively	charged	liposomes	resulting	in	more	efficacy	
and less irritation of the skin as compared with tretinoin in a conventional cream.113
Conclusions
Liposome research has expanded considerably over the last 30 years, and 
nowadays, it is possible to construct a wide range of liposomes varying in size, 
phospholipids	composition	and	surface	characteristics	to	suit	the	specific	application	
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for which they are intended.114 Liposomal formulations should have high entrapment 
efficiencies,	 narrow	 size	 distributions,	 long-term	 stabilities	 and	 ideal	 release	
properties. Consequently, the production method requires the potential to produce 
liposomes using a wide range of ingredients of molecules (e.g. lipids/phospholipids) 
that promote liposome stability. In addition, liposomes should be free of toxic solvents 
and detergents. There are numerous lab-scale and a few large-scale techniques 
for liposome preparation giving rise to vesicles of different sizes and consisting of 
one or more bi-layers. However, most of these techniques are not suitable for the 
encapsulation of sensitive substances because of their exposure to mechanical 
stresses, harmful chemicals (e.g. volatile organic solvents and detergents) or low/high 
values of pH during the preparation. Conventional and novel preparation techniques 
have been introduced, each with its own advantages and possible limitations. Topical 
application of liposomal preparations is rational, based on clinical data and also from 
a pharmacologic point of view because of their advantages concerning drug delivery 
and restoration of skin barrier, including:
1. The similarity of lipid composition of liposomes and membranes in the 
epidermis enables the    liposomes to penetrate into the epidermal barrier 
to a higher extent as compared with other application forms and so do the 
compounds encapsulated into the liposomes. This may result in an increased 
drug absorption into the epidermis and a decreased clearance of drug 
from the epidermis resulting in a much longer sustained drug release and 
reduction of drug absorption into the blood. This is why liposomes may act 
as drug transporters as well as drug targeters.3 This may lead to increased 
effectiveness, reduction in side-effects and a higher compliance of patients
to treatment.3 Liposomes have also the potential to target drugs into the 
pilosebaceous structures and hence they can be employed for treatment of 
hair follicle- and sebaceous gland-associated disorders.22–24 So, liposomes 
may serve as penetration enhancers facilitating the transport of compounds 
through the epidermis. The use of conventional penetration enhancers (e.g. 
dimethylsulphoxide or propylene glycol) leads on the one hand, to an improved 
transport rate through the epidermal barrier but, on the other hand, to more 
unwanted side-effects because of an increased systemic drug level115 In 
addition, irritant- and allergic reactions to penetration enhancers have been 
reported leading to the conclusion that addition of penetration enhancers 
does not always mean an advantage in topical drug administration.3,115 Side-
effects from liposomes are not to be expected because liposomes are similar 
to epidermal lipids, biodegradable and non-toxic.116
2. Liposomes can be used as carriers for hydrophilic as well as lipophilic drugs 
because of their amphipathic character.4,5 Compounds like methotrexate and 
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cyclosporin which cannot penetrate the epidermis may be usable for topical 
application when encapsulated in penetrating liposomes.59,60,117 Liposomes 
may also improve stabilization of instable drugs by encapsulating
them.116–118
3. ‘Empty’ liposomes (without encapsulated drugs) hydrate the skin simply 
by contributing lipids to the stratum corneum.18,19,35,51 Additionally, the water 
content of liposomes promotes further hydration of the skin. In contrast 
with the ‘wet-wrap’ method, application of liposomal spray is a fast, easy 
procedure without any need of training.51,52 Liposomes will help to reduce 
skin irritation to drugs (e.g. tretinoin) by hydration of the epidermis.37,38,118,119
4. Promising results have been obtained with liposomal encapsulated drugs 
in the treatment of acne,36–40 xerosis,51,52 atopic dermatitis,53 psoriasis,57,58 
vitiligo,66	superficial	vein	thrombosis94,95  and hair removal.96–99
5. T4N5 containing liposomes protect the skin from UVinduced carcinogenesis 
by promoting the DNA repair and by inhibiting immunosuppression.26,72–77 
T4N5 liposomes protect against the development of basal cell carcinoma 
and actinic keratoses in patients with xeroderma pimentosa.78,120
6.	 PDT	 is	 widely	 used	 to	 treat	 actinic	 keratoses	 and	 superficial	 basal	 cell	
carcinoma. In addition, PDT is increasingly used to treat acne and for skin-
rejuvenation. Side-effects limit patient’s acceptance, especially in case of 
non-malignant skin disorders. Changing the 5-ALA vehicle from a moisturizing 
cream to liposome encapsulation, the 5-ALA concentration can be lowered 
by	a	factor	of	40	and	still	induce	the	same	skin	fluorescence	and	at	the	same	
time eliminate the need for occlusion.45
7. Liposomes provide the opportunity for a more precise targeting of drugs into 
diseased	cells	and	may	contribute	 to	optimize	 the	quality	of	 fluorescence	
diagnosis. This property of liposomes as a targeting method is not available 
in other topical applications.45 It may be evident, that this review does not 
provide a complete detailed overview on the production and the usage of 
liposomal preparations in medicine. Based on what is already known, our 
view is that liposomal preparations have rightly earned a place in topical 
dermatological	treatment	and	that	future	studies	may	show	the	benefits	of	
these preparations for other indications.
It may be evident, that this review does not provide a complete detailed overview on 
the production and the usage of liposomal preparations in medicine. Based on what 
is already known, our view is that liposomal preparations have rightly earned a place 
in	topical	dermatological	treatment	and	that	future	studies	may	show	the	benefits	of	
these preparations for other indications.
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Figure 1. Top left structural formula of the phophatidylcholine molecule. In the 
presence of water phopholipid bilayers are formed, which create vesicles, enclosing 
an aqueous core. Lipid soluble substances can be stored in the outer lipid phase 
(yellow ring) and water soluble substances in the inner aqeous phase (blue centre).
Figure 2. Liposomes fuse with the outer cell membrane and deliver their contents to 
the cytoplasm of cells via endocytosis.
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Figure 3. Female patient: a. and b. before treatment, c. and d. after 7 treatments with 
0.5% ALA in a liposomal spray and subsequent illumination with an IPL (400 nm to 
720 nm) every 4 to 6 weeks, concomitant treatment with tretinoin cream. Topical or 
systemic abtibiotics were not used.
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Chapter 9
An earlier version of this chapter has been published as
A case study to evaluate the treatment of vitiligo with khellin 
encapsulated in L-phenylalanin stabilized phosphatidylcholine 
liposomes in combination with ultraviolet light therapy
Jaap de Leeuw, Nick van der Beek, Günther Maierhofer, 
Wolfgang-Dieter Neugebauer
European Journal of Dermatology 2003; 13: 474-477.
abstract
Vitiligo destroys the melanocytes in the epidermis; the inactive melanocytes in the 
outer root sheaths are not affected. Phosphatidylcholine liposomes are able to 
target	molecules	contained	in	them	into	the	hair	follicles.	Khellin	is	activated	by	UVA	
and	previous	 studies	have	 shown	 that	 a	 combination	of	 khellin	 and	UVA	 (KUVA)	
can be effective in the treatment of vitiligo. The aim of this study was to determine 
in	 an	 open	 trial	 the	 efficacy	 and	 safety	 of	 treatment	with	 khellin	 encapsulated	 in	
L-phenylalanine stabilized phosphatidylcholine liposomes in combination with UVA/
UVB	light	therapy(KPLUV)	in74	subjects	with	vitiligo.	After	a	mean	treatment	period	of	
12 months (range 10-14 months) 72% of the treated locations had a repigmentation 
response of 50% to 100%. Repigmentation of 75-100% was achieved on the face 
in 63%, the back in 59%, the arms in 58%, the trunk in 57%, the legs in 56% and 
on	 the	hands	 in	4%	of	 the	patients.Side	effects	were	not	 seen	with	KPLUV.	The	
patients in the control group, only treated with UVA/B - light, hardly showed any 
repigmentation (Figure 2). This indicates that the exposure of the skin to UV light 
alone	is	not	responsible	for	the	results	of	KPLUV.	
Introduction
Vitiligo, an acquired depigmention disorder affecting about 1% of the population,1, 2 
may be a psychosocial disaster, particular in people with pigmented skin, especially in 
those countries where there is confusion of vitiligo with leprosy in the public mind.3 
Vitiligo is histologically characterized by the absence of melanocytes in the epidermis. 
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Inactive melanocytes in the outer root sheaths of the hair follicles are not affected. 
During the process of repigmentation, these inactive melanocytes proliferate and 
mature to an active condition as they migrate into the epidermis.4
Therapeutic approaches are aimed at reversing the progressive loss of melanocytes 
and reconstituting normal skin coloration, but none is uniformly effective and side 
effects may occur. Most common treatments are topical corticosteroids, systemic and 
topical PUVA, broad- and narrowband UVB, systemic and topical L-phenylalanine 
with UVA (PAUVA)5-9,	 systemic	 and	 topical	 khellin	 with	 UVA	 (KUVA).10-14 Surgical 
treatment is limited to small and stable vitiligo maculae.1
Khellin,	a	furanochromone	with	a	chemical	structure	closely	resembling	that	of	the	
psoralen family, is activated by UVA (365 nm).10
Liposomes are small vesicles of membrane lipids. They can be used as microscopic 
carrier	 capsules	 for	 selective	 delivery	 of	 drugs	 into	 a	 specific	 disease	 site.	
Phosphatidylcholine-based liposomes have a high potential for selectively targeting 
molecules contained in them into the hair follicles.15, 16, 17 Encapsulating khellin in 
phosphatidylcholine liposomes may enhance the penetration of khellin into the area 
of the inactive melanocytes in the hair follicle in order to provide optimal availability 
of khellin to stimulate the inactive melanocytes. L-phenylalanine is added to the 
formula in order to promote the stability of the solution. L-phenylalanine was also 
chosen because of its reputation to be effective, both orally and topically, together with 
UVA therapy in the treatment of vitiligo.8, 9  Schallreuter has suggested that oxidative 
stress plays a role in the pathomechanism of vitiligo18 and because L-phenylalanine 
has anti-oxidant properties this may be the way it works.19 The Arimed B light source 
has a UV spectrum approximating that of sunlight (approximately UVB 5% and 
UVA 95%). It can be argued that such a simulated sunlight source represents a 
more cautious approach to home therapy than conventional broad spectrum UVB 
therapy.20 The advantage of home therapy is that the high social and economic costs 
of hospital visits are reduced. The disadvantage of home therapy is that medical 
supervision is less frequent.
In	 this	 open,	 retrospective	 study	 the	 efficacy	 of	 topical	 treatment	 of	 vitiligo	 with	
khellin encapsulated in L-phenylalanine stabilized phosphatidylcholine liposomes 
in	 combination	 with	 ultraviolet	 light	 therapy	 (KPLUV)	 as	 home	 phototherapy	 is	
determined.
Subjects and methods
65 patients (50 females and 15 males) with vitiligo vulgaris and 9 patients (5 
females and 4 males) with vitiligo universalis were included in the study. The 
average age was 43 years (range 12-75 years). Mean duration of vitiligo was 15 
years (range 4-60 years). All patients had been treated before with topically applied 
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corticosteroids, 48 patients also with PUVA and 18 patients with broadband-UVB, 
without notable repigmentation. Exclusion criteria were phenylketonuria, pregnancy 
and breastfeeding, impaired hepatic and renal functions, malignant skin diseases, 
history of exposure to arsenates or ionizing radiation and photo-induced diseases. 
The patients were instructed to apply twice a day, in the morning and half an hour 
prior to the UVA therapy, a spray containing khellin in a concentration of 0.005% 
encapsulated in phosphatidylcholine liposomes, stabilized with L-phenylalanine 
0.1%. The light source (Arimed B Cosmedico, Stuttgart, Germany) has a spectrum 
from 295 to 400 nm and peak emissions at 317 and 356 nm. The phototreatment 
schedule started with one minute daily 5 times a week raising the exposure time 
by one minute every week until the erythematic dose was reached. The treatment 
was continued with the suberythema dose. The exposure time was never more than 
l5 minutes. The light source was given to the patients for treatment at home as a 
panel and not as a booth in order to save space, so that patients with vitiligo on the 
frontal and dorsal parts of the body underwent two exposures. As soon as a marked 
improvement was achieved, the treatment schedule was reduced from 5 times a 
week to 3 times a week.
This study is a case-study and not a placebo-controlled, randomized study. The 
control group consisting of 30 patients used the same UVA/B light source (Arimed 
B Cosmedico), with the same photo treatment schedule, but not in combination with 
the application of the khellin and phenylalanine containing liposomal solution. The 
liposomal vehicle of the spray has an absorption spectrum from 190- to 210-nm. 
This is out of the range of the emission spectrum of the used UVA/B light source, 
excluding	the	need	to	use	the	vehicle	in	the	control	group.	Photographs	(Fotofinder,	
TeachScreen Software GmbH, Germany) of the subjects were taken at the 
beginning of the therapy and than once every two months for one year. The extent of 
repigmentation was recorded by visual comparison of the successive photographs, 
making use of planimetry. 
The before-and-after evaluation was performed by 2 experienced clinicians, who did 
not know whether the patients were treated with UVA/B light therapy in combination 
with topical liposomal solutions (study group) or with UVA/B as monotherapy (control 
group).
Results
After a mean treatment period of 12 months (range 10 to 14 months) 72% of treated 
locations had a repigmentation response of 50% to 100%. The repigmentation was 
not equal for different parts of the body. Repigmentation of more than 50% was 
achieved on the face in 79%, the trunk in 73%, the arms in 76%, the legs in 70%, 
and on the hands in 65%. Repigmentation of 75%-100% was achieved in the face 
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in 63%, the arms in 58%, the trunk in 73%, the legs in 56% and the hands in 4% 
(Figure1). Surprisingly eight out of the nine patients (88%) with vitiligo universalis 
showed a repigmentation of more than 75%. The patients in the control group treated 
with only Uvlight (Arimed B), without the use of the khellin spray, hardly showed any 
repigmentation (Figure 2). 
Mean cummulative annual Joules doses of UVA 679 J/cm2 and of UVB  25.9 J/cm2 
(table 1).
Discussion
The treatment of vitiligo can be frustrating to patients and doctors. A standard 
modality that cures every patient does not yet exist.1, 2 Topical corticosteroids, 
topical- and systemic PUVA, broad- and narrow-band UVB light therapy are the 
most common methods, although they are not always effective and side effects 
may limit the therapeutic options.5-9 Narrow-band UVB is effective in the treatment 
of vitiligo. An overall repigmentation of 75% in 53% of the patients and a stabilization 
of the disease in 80% has been seen.21 But not all investigators came to the same 
conclusion.22  Surgical treatment is limited to small and stable vitiligo maculae.1 
The results of systemic khellin in combination with UVA11-14 are comparable to 
the rates reported from psoralen phototherapy.1 The major advantage of khellin is 
that it does not induce phototoxic skin erythema and it does not induce detectable 
DNA mutations in contrast to PUVA.11,12 Ortel et al. studied the effect of oral khellin 
in combination with UVA light in 26 patients. A repigmentation of more than 70% 
was achieved in 41 % of the patients who had received 100 to 200 treatments. 
A mild elevation of liver transaminases was observed in 28% of the patients on 
oral treatment. Of three patients who were treated with topical khellin and UVA, two 
patients had a repigmentation of only 30%.12 In our study with topically administered 
khellin in liposomes, a repigmentation between 50% and 100% was seen in 72% of 
the patients. Hofer et al. performed a study to assess the effectiveness and short-
term	and	long-term	safety	of	oral	khellin	plus	UVA	light	therapy	(KUVA)	in	patients	
with vitiligo. Of 17 patients, 41 % had a response of more than 70% repigmentation 
after a mean of 194 treatments. Short term side effects were episodes of nausea in 
29% of the patients, elevated liver enzymes in 7% and gastritis in 7% of the patients. 
Long-term side effects have not been seen, no skin cancer or actinic damage of 
vitiliginous	 skin	 was	 found	 in	 any	 patient.	 Their	 data	 indicate	 that	 KUVA	 seems	
to be safe as well as effective for vitiligo, provided treatment is administered long 
enough.13 Orecchia et al. concluded from their study that topically applied khellin is 
effective in the treatment of vitiligo, but that the results are vehicle dependant.14 A 
potential concern is the hepatotoxic side effect of khellin. The low active ingredient 
concentration of 0.005% khellin in the topically applied spray would tend to exclude 
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this risk. Vitiligo destroys only the active melanocytes in the epidermis; inactive 
melanocytes in the outer root sheath of the hair are not affected. During the process 
of repigmentation, these inactive melanocytes proliferate and migrate from the outer 
root sheath to the epidermis, meanwhile maturing from the inactive phase to an 
active state.4 
The ideas behind the treatment of vitiligo with khellin in L-phenylalanine stabilized 
liposomes as described in this article are based on:
-  Enhancing the penetration of khellin by carrier liposomes into the hair follicles 
in order to provide optimal availability of khellin in the area of the inactive, 
nonaffected melanocytes.
-  Stimulation of the melanogenesis by using topical khellin and UVA light.
-  Avoidance of side effects by using only topical- and not systemic khellin   
 treatment.
-  L-phenylalanine was added to the formula because of its stabilizing effect on 
the solution, and its anti-oxidant properties.
-  The safe light source and the fact that topically applied khellin has a very low 
phototoxic effect makes this approach suitable for home therapy.
-  Home therapy is cost reducing and comfortable for the patients.
This	study	demonstrates	that	KPLUV	is	effective	(Figures	3A+B	and	4A+B)	and	safe	
in the treatment of vitiligo.
An open study has many shortcomings and further investigation is needed to 
determine the optimal combination of the ingredients in the spray and the optimal 
application frequencies.
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Figure	1.		 KPLUV	group:	%	of	repigmentation	of	vitiligo	spot	sizes	for	different		 	
 parts of the body.
Figure 2.  Control group: % of repigmentation of vitiligo spot sizes for different   
 parts of the body: almost no repigmentation
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 UVA  J/cm2 UVB  J/cm2
Mean 679 25.9
Maximum 1680 61,7
Minimum 180 7,2
Table 1. Cummulative annual Joules doses of UVA and UVB.
 Figure 3A. 14 year-old female patient Figure 3B.  14 year-old female patient 
                    before treatment  after treatment
Figure 4A.  41 year-old male patient            Figure 4B.  41 year-old male patient 
 before  treatment.  after treatment.
205
Chapter 10
Epidermal blister grafts for vitiligo 
Y. J. Assen, J. de Leeuw, P. Bjerring, H.A.M. Neumann.
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abstract
Vitiligo is commonly encountered in dermatology. A variety of surgical and non-
surgical treatment modalities have been described. Surgical techniques such as the 
epidermal blister graft transplantation may be effective in re-pigmenting the lesions 
in stable or refractory vitiligo. Our objective was to re-pigment vitiligo lesions using an 
easy technique without scarring. It can replace techniques that do cause scarring.
Introduction
Vitiligo is a common disease characterized by areas of de-pigmentation. It is widely 
accepted that the functional melanocytes disappear.1 Although vitiligo is sometimes 
regarded as a cosmetic problem, the impact on the quality of life is considerable.2-4 
A variety of surgical and non-surgical treatment modalities have been described to 
treat vitiligo. Surgical interventions are based on transplanting functional melanocytes 
to the de-pigmented areas.5 Surgical techniques are generally reserved for stable 
and refractory vitiligo. 0ne of the promising surgical techniques, besides minigrafts 
using punch biopsies, split-thickness grafts and transplantation of non-cultured cell 
suspension or cultured melanocytes, is blister roof transplantation in which epidermal 
blister grafts are transplanted onto the prepared de-pigmented areas.5 We used 
this technique in patients with a clinical diagnose of vitiligo with a stable disease. 
This technique was observed to be effective, safe and easy to use and caused no 
scarring.
Technique
The blister roofs are the donor source of melanocytes in epidermal blister graft 
transplantation.	The	transplantation	is	performed	in	three	phases.	In	the	first	phase	
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the blisters are created with a suction device, connected to a rectangular plastic 
block. This block divides the negative pressure over 28 holes each with a diameter of 
5-millimetre (mm) and is attached to a skin area with normal pigmentation, preferably 
the patient’s upper arm (Figures 1 and 2). It takes about one to one and a half hours 
to obtain manageable blisters using a vacuum of 300-mm of mercury. The second 
phase	consists	of	creating	superficial	erosions	with	diameters	of	4-mm	to	5-mm	in	
the	recipient	area	by	ablation	with	an	Erbium-YAG	laser	with	a	fluence	of	4.8	J/cm2 
(Figure 3). In the third phase, the blister roofs are removed with a pair of scissors 
and smooth forceps and transferred to the erosions on the recipient area (Figures 4 
and 5). Smooth forceps are used because the blister roofs tend to stick in the ridges, 
interfering with the removal from the serrated forceps.
The transplants in the recipient area are protected with silicone sheeting, which is 
covered	with	standard	gauze	and	fixed	with	an	adhesive	bandage	(fixomull	stretch)	
to prevent it from shifting. It is important that the graft remains stationary during the 
first	few	days.	The	bandage	is	carefully	removed	after	a	week	and	replaced	by	a	new	
bandage for another week. Additional therapy such as phototherapy can be started 
two weeks after the transplantation. 
The	 donor	 site	 re-pigments	 spontaneously.	 This	 is	 confirmed	 by	 the	 histological	
examination of a biopsy of the suction blister. The melanocytes are equally distributed 
between the roof and the bottom of the blister (Figure 6).
Discussion
We discuss our views on the choices we made within the options of this technique. 
We comment on the position of this technique in the range of surgical techniques 
available for vitiligo.
Choice of parameters
Various techniques have been used for blister roof transplantation. Previous studies 
reported that transplantation of epidermal blister grafts in vitiligo was effective.1,5.6 
Liquid nitrogen and suction devices were used for preparing the donor site.7 Application 
of liquid nitrogen is not only painful, but may easily damage the melanocytes. The 
medial side of the upper arm was chosen as the donor site because it is a relatively 
inconspicuous area in case of a temporary discoloration and it is easily accessible. 
It enables patients to move freely during the creation of the blisters with the block on 
their arm and the suction device on a cord over their shoulder.
A larger area as compared with the sum of the individual graft surface can be re-
pigmented as a result of the post-operative peripheral spreading of the pigment. 
A blister roof with a diameter of 5-mm corresponds to a surface area of 0.2 cm2. 
Generally, the peripheral pigment spread around a transplanted graft is 1-mm to 
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2-mm resulting in an expansion rate of the surface area by a factor 2 to 3 In the 
case where grafts are used with a diameter of 10-mm corresponding to a surface 
area of 0.79 cm2, the peripheral spreading of pigment of 1-mm to 2-mm increases 
the expansion rate of the surface area by a factor 1.4 to 1.9.8 Therefore, 5-mm grafts 
provide optimum tissue and also have the advantage that they are easier to handle 
than the 10-mm grafts. The erosions caused by the laser ablation in the de-pigmented 
areas are about 2-mm apart from each other because of the expanding of pigment 
into the periphery. The Erbium laser ablation is stopped at the moment pin-point 
hemorrhages appear indicating that the ablation has reached the papillary dermis. 
Laser ablation may be painful and often requires topical anesthesia with lidocaine 
1%-2%. Adrenalin is not used to prevent the masking of the pin-point hemorrhages.
A variety of techniques, besides the Erbium-YAG laser are used for preparing the 
recipient site. Generally used techniques are liquid nitrogen, sandpaper, suction 
devices, diamond fraise, topical methoxsalen followed by PUVA and CO2 lasers.
6,9 
The	disadvantages	of	these	techniques	are	the	difficulty	to	control	the	final	result	and	
the chances of scarring. Today, lasers are a good method to dermabrade the skin 
in a controlled fashion. In our opinion the Erbium laser is superior to the CO2 laser 
because it causes less thermal damage in the recipient area than the CO2 laser. 
Comparison with other surgical techniques
Besides blister roof transplantation, other known surgical techniques are the Thiersch 
split-thickness skin grafts, the cell suspension technique and the punch grafts. 
Thiersch grafts are known to cause scarring at both the donor- and the recipient site.10 
Moreover, a cosmetic treatment should have no or only a limited chance of aesthetic 
complications. In the above mentioned epidermal blister transplantation technique 
scarring has not yet been encountered. A temporary hyper- or hypopigmentation 
may occur at the donor site. 
The cell suspension technique seemed to result in a good re-pigmentation rate, 
but the donor skin was harvested with a dermatome, so that there was a chance 
of scarring at the donor site. It also requires a laboratory that can process the cell 
suspension. It is important to prepare cell suspension in medium containing a 
minimum of foreign proteins and  adequate precautionary measures must be taken 
to reduce the risk (even theoretical) of transmitting slow viruses, prions, and other 
pathogens to the recipient site.11 Punch grafting is a simple technique and that is 
probably the reason for its wide use. It is know that punch grafts are effective in re-
pigmentation, but they often cause a cobblestone effect.12 According to the literature 
both epidermal blister grafts and punch grafts have the same re-pigmentation rate.9. 
However, punch grafts result in more scar formation and thus justify treating vitiligo 
with the blister roof transplantation. It is our experience that epidermal blister grafts 
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leave no scarring either at the donor- or the recipient sites as compared with other 
surgical techniques. However, more studies are necessary to exactly establish its 
rightful place in the treatment of vitiligo. 
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Figures 1  Suction device block Figure 2  Evoking blisters by suction.
Figure 3 Erosions made by ablation with an Erbium-YAG laser
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Figure 4.  Removal of the blister roofs with forceps and scissors.
Figure 5.  Transplantation of the blister roofs onto the erosions on the recipient   
 area.
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Figure 6.  Distribution of the melanocytes in the roof and the bottom of the blister   
	 (Melan-a	stain)	(original	magnification	x	40).
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Treatment of vitiligo with khellin liposomes, ultraviolet light 
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Abstract
Background: Various surgical and non-surgical methods are available to treat 
vitiligo. Surgical techniques such as epidermal blister graft transplantation may 
be	effective	 for	 the	 re-pigmentation	of	 stable,	 but	 refractory	 vitiligo	areas.	Khellin	
has phototherapeutic properties that are similar to those of the psoralens, but with 
substantially lower phototoxic effects and DNA mutation effects. Its penetration into 
the hair follicles is enhanced by encapsulating it into liposomes. This facilitates the 
stimulation of melanocytes in the hair follicles by ultraviolet light-activated khellin.
Objective: The	first	objective	was	to	evaluate the surplus value of combining blister 
roof transplantation (BRT) with treatment using khellin in liposomes and ultraviolet 
light	 (KLUV)	 in	 the	 treatment	of	 recalcitrant	vitiligo	patches.	The	second	objective	
was to assess patients’ satisfaction.
methods and materials: Nineteen patients with vitiligo lesions non-responding to at 
least	1	year	of	KLUV	treatment	were	included	for	BRT	followed	by	KLUV.	Locations	
where randomly assigned. The transplantation was performed by creating the blisters 
with a suction device, preparation of the recipient with Erbium laser ablation and the 
actual transplantation. In each subject non-transplanted vitiligo patches were used 
as controls. A blinded observer established the results.
Results: Seventy-five	percent of	the	patients	were	satisfied	with	the	cosmetic	result.	
All	of	the	patients	would	recommend	the	treatment	to	other	vitiligo	patients.	Fifty-five	
percent of the patients showed more than 75% re-pigmentation of vitiligo areas as 
was concluded from the single blinded evaluation of the photographs taken before 
and after the treatment. 
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Introduction
Vitiligo is an acquired disease characterized by sharply demarcated macules of de-
pigmentation. It is a  relatively common disease with a prevalence of about 1-2%. 
The course of vitiligo is usually one of slow progression, but it may exacerbate 
rapidly or stabilize. Spontaneous re-pigmentation may also occur sometimes. It 
is widely accepted that melanocytes disappear from the involved skin areas, but 
the exact pathogenesis has not yet been established.1 During the de-pigmenting 
process in vitiligo, the ultimate consequence of all the pathogenic mechanisms is 
the destruction of melanocytes and thus the absence of pigmentation. Initially, only 
the epidermal melanocytes are affected, but as the condition progresses, the most 
important pigment cell reservoir, the hair follicle, may also become involved and 
leucotrichia develops. The hair follicle is unable to provide new melanocytes for 
pigmentation from that moment.2 However, the melanocytes in the hair follicles are 
generally not affected. During the process of re-pigmentation, these melanocytes 
proliferate and mature to an active state as they migrate into the epidermis.3 Vitiligo 
is commonly considered to be only a cosmetic problem, but the implications of 
vitiligo are beyond the limits of a cosmetic disease. Its impact on the quality of life 
of the patient is comparable with psoriasis on the emotional and socially functioning 
scales.4-7 Therapeutic approaches in vitiligo are aimed at reversing the progressive 
loss of melanocytes and reconstituting the normal skin coloration. However, none 
of the approaches is uniformly effective and side effects may occur. Most common 
methods for treatment are topical corticosteroids, tacrolimus, systemic and topical 
psoralen ultraviolet-A light (PUVA), broad- and narrow-band ultraviolet-B (BB-UVB, 
NB-UVB)	and	topical	khellin	with	UVA	(KUVA).1,8.9,10.11	Khellin,	a	furanochromone	with	
a chemical structure resembling that of the psoralen family is activated by UVA and 
UVB.12	Khellin	has	been	used	to	 treat	vitiligo,12,13 because it has phototherapeutic 
properties that are similar to those of the psoralens, but it has substantially lower 
phototoxic and mutagenic effects.14,15  The current status on the position of khellin in 
the treatment of vitiligo was recently reported and it was concluded that the research 
into this area remains inconclusive and at times contradictory.11 In a study comparing 
khellin	or	placebo	under	the	influence	of	natural	sunlight,	12	of	the	30	patients	with	
vitiligo in the khellin group showed more than 50% re-pigmentation compared with 
none in the placebo group.16 A left versus right study in 72 patients comparing khellin 
with UVA versus UVA alone concluded that re-pigmentation was because of the UVA 
and not the khellin.17 There was no difference between the khellin and the placebo 
groups in a left versus right study comparing khellin plus sunlight with vehicle plus 
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sunlight in 41 vitiligo patients.18  However, in a later study the same authors compared 
a khellin gel and UVA with UVA alone and reported that both groups responded, but 
khellin plus UVA was superior to UVA alone (P < 0.01).19 A study in 33 patients 
compared topical khellin plus UVA with PUVA and reported that khellin plus UVA may 
induce re-pigmentation that was comparable with that induced by systemic PUVA, 
but required a longer period.20 
The selection of the vehicle in which khellin is incorporated is highly important for the 
adequate availability of khellin in the skin because of its very low solubility in water.19 
Liposomes are small vesicles of membrane lipids.21,22 They are used as microscopic 
carrier	capsules	 for	 the	selective	delivery	of	drugs	 to	a	specific	disease	site	such	
as the hair follicles.23,24 Encapsulating khellin in phosphatidylcholine liposomes 
enhances the availability of khellin in the hair follicles facilitating the stimulation 
of the melanocytes. The MultiCare SP 04 light source (Figure 1a) has emission 
peaks at 311 nm and 365 nm and is used as a handheld device, which makes it 
suitable for treatment at home. The advantage of home therapy is that the high 
social and economic costs of hospital visits are reduced. The disadvantage of home 
therapy is that medical supervision is less frequent.25 In a retrospective, single blind, 
comparative study 74 vitiligo patients were treated with a spray containing khellin 
encapsulated in liposomes in combination with a UVA and UVB emitting light source 
(KLUV	group).	The	control	group	consisted	of	30	patients	and	was	treated	with	the	
same light source and the same photo treatment schedule, but not in combination 
with khellin liposomal spray (UV group). After one year of treatment, re-pigmentation 
of	75%-100%	was	achieved	in	61%	of	the	KLUV	patients	(excluding	the	results	of	the	
hands). The patients in the control (UV) group hardly showed any re-pigmentation. 
No side effects were observed.26  
Surgical treatment is limited to vitiligo maculae, refractory to the aforementioned 
treatments. An important condition for surgical therapy is the stability of the disease.2 
In stable vitiligo (such as segmental unilateral vitiligo) the outcome of transplantation 
therapy is usually excellent. In some cases, transplantation may indeed be the only 
effective treatment.27 Unfortunately, to date there is no reliable test to predict the 
activity and the outcome of melanocyte transplantation treatment in patients with 
vitiligo. Vitiligo can be active in one skin area and inactive or even in regression in 
another area at the same time.27	Thus,	it	may	be	difficult	to	draw	conclusions	from	
patient’s anamnesis and from performing a few test grafts prior to more extensive 
treatments	as	an	approach	to	predict	stability.	While	there	is	no	consensus	on	definite	
parameters for stability, various recommendations indicate a period of disease 
inactivity ranging from 6 months to two years.28 
Methods of surgical modalities for vitiligo include both tissue grafts and cellular grafts. 
Both these techniques have their own advantages and disadvantages according 
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to the recently published guidelines (Table 1).28 Tissue grafts comprises of punch 
grafting, suction blister epidermal grafting and split-thickness grafting. Cellular grafts 
require specialized trained personnel and appropriate laboratory facilities and are 
expensive.28,29 In vitiligo surgery the most frequently reported causes of failure are 
the lack of take, the survival of the grafts and the absence of re-pigmentation in spite 
of the good take. De-pigmentation of grafts after initial pigmentation may also occur 
(often as a result of vitiligo instability). Another problem may be the quality of the 
preparation of the melanocytes before transplantation. In vitro cultured autologous 
skin cells have been chemically and mechanically prepared and/or cultured. For cell 
preparation it is important to use a medium containing a minimum of foreign proteins 
and if they have to be used, they should be from the safest possible source. These 
precautionary measures are taken in order to reduce the risk of transmitting slow 
viruses, prions and similar agents to the recipient site.27  Liquid nitrogen, sandpaper, 
suction devices, topical methoxsalen followed by PUVA, CO2 laser and Erbium-
YAG lasers have been used for preparing the recipient site.30,31 The disadvantage 
of preparing the recipient site with liquid nitrogen and topical methoxsalen followed 
by	PUVA	 is	 that	 it	 is	 difficult	 to	 control	 the	 final	 result.	 Today,	 lasers	 are	 a	 good	
means to ablate the skin in a controlled fashion. It was reported that the Erbium-YAG 
laser-assisted ablation resulted in more pigment spread around the graft than areas 
prepared with topical methoxsalen followed by UVA.31  
The	aim	of	 this	 study	was	 to	evaluate	 the	efficacy	and	 the	patient	 satisfaction	of	
epidermal blister graft transplantation in combination with khellin encapsulated in 
liposomes	and	ultraviolet	light	(KLUV)	treatment	before	and	after	transplantation	in	
patients with vitiligo.
Subjects and methods
Inclusion
Nineteen	patients	(9	women	and	6	men),	mean	age	44	years	(25	–	68	years)	who	
were	treated	with	KLUV	for	at	least	one	year	and	who	showed	refractory	and	stable	
vitiligo lesions on the hands, the arms (in one patient also the shoulders), the neck, 
and the face were included for blister roof transplantation after providing informed 
consent (Table 2). Exclusion criteria were pregnancy, lactation, history of allergy 
to sunlight, photo-induced diseases, medication with drugs known to have potency 
for light toxicity or light sensitization, phenylketonuria, impaired hepatic and renal 
functions, malignant skin diseases, history of exposure to arsenates and ionizing 
radiation. In each patient two lesions where selected to be suited for blister roof 
transplantation. Of these lesions one was randomly chosen to be treated with blister 
roof	transplantation	combined	with	KLUV	therapy	and		the	other	lesions	being	treated	
with	a	KLUV	mono-therapy.
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KLUV treatment
The patients were instructed to apply a spray containing khellin at a concentration 
of 0.005% encapsulated in phosphatidylcholine liposomes, stabilized with 
L-phenylalanine 0.1%, twice a day in the morning and in the evening. UV phototherapy 
was carried out with the MultiCare SP 04 light source (MultiCare, Hoge Naarderweg 
7h, Hilversum, The Netherlands). This device has peak emissions at 311 nm and 365 
nm and is used as a handheld device (Figure 1a), which is in contact with the skin 
resulting in a constant lamp-skin distance. The illumination schedule started with 
one minute 3 times a week raising the exposure time by 50% every 2 treatments 
until redness appears on the treated skin area, which lasted for more than 24 
hours (erythematous dose). From then onwards, the light treatment was continued 
3 times a week with the sub-erythematous dose (the dose of light just below the 
erythematous dose). The spray was applied in the morning and half an hour prior 
to the UV treatment for the 3 days a week of light therapy. The exposure time per 
session was never more than 15 minutes. The treatment schedule was gradually 
reduced from 3 times a week to 1 time a week or stopped as soon as a marked 
improvement was achieved. Patients were advised to avoid sun exposure on the 
days of the UV treatment.
Blister roof transplantation
The blister roofs were the donor source of melanocytes in epidermal blister graft 
transplantation. The transplantation was performed in three phases. These were 
creating the blisters, preparation of the recipient site and the actual transplantation. 
In	 the	 first	 phase	 the	blisters	were	 created	with	 a	 suction	device	 connected	 to	 a	
rectangular plastic block (Figure 1b). This block divides the negative pressure over 
28 holes each with a diameter of 5-millimetres (mm), and is attached to a skin area 
with normal pigmentation, preferentially the patient’s upper arm (Figure 1b). It takes 
about one to one and a half hours to obtain manageable blisters using a vacuum of 
300-mm of mercury (Figure 1c). This procedure is painless and topical anesthesia 
is	 unnecessary.	The	 second	 phase	 consisted	 of	making	 superficial	 erosions	with	
diameters of 5- to 6-mm in the recipient area by ablation with an Erbium-YAG laser 
(Dornier Medilas E, Meditech, Munich, Germany), with a 4-mm diameter spot, energy 
400- to 600 mJ/cm2 and frequency of 3- to 5 Herz (Figure 1d). The laser ablation was 
stopped at the moment pin-point haemorrhages appear indicating, that the ablation 
had reached the papillary dermis. This procedure required topical anesthesia with 
lidocaine 1%-2% (without adrenalin). In the third phase the blister roofs were removed 
with a pair of scissors and forceps and transferred to the erosions in the recipient 
area. Smooth forceps were used in order to avoid that the blister roofs sticked to 
the	serrated	forceps,	which	makes	it	difficult	to	remove	the	blister	from	the	forceps.	
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Finally, the transplants in the recipient area were protected with sillicone sheeting 
(Mepitel Mölnlycke Health Care AB, Göteborg, Sweden), which was covered with 
standard	gauze	and	fixated	with	an	adhesive	bandage	(Fixomull	stretch	BSN	medical	
GmbH, Hamburg, Germany) to prevent it from shifting. The blister roof grafts were 
too thin to be stitched to the laser ablation erosions. The bandage technique has to 
be optimal to keep the transplants in place and movements of the recipient body site 
have to be restricted because it is important that the grafts remain stationary during 
the	first	post-operative	week.	Concave	body	areas	were	filled	up	with	synthetic	cotton	
(Artiflex	BSN	medical	Ltd,	Hull,	England).	The	duration	of	the	whole	procedure	for	
the transplantation of 28 blister roofs is one and a half hour for the patient and half 
an hour for the doctor. The bandage was carefully removed after a week using plenty 
of water to detach the silicone sheets from the grafts because wet silicone sheets 
detach more readily from the underlying grafts (Figure 2). Then a new bandage with 
paraffin	gauze	and	standard	gauze	was	placed	to	protect	the	grafts	for	another	week	
after	which	the	bandages	are	no	longer	used.	The	KLUV	treatment	was	re-started	
with a light dose that is 4 steps back in the UV treatment schedule followed by an 
increase of the light dose with one step a week until the optimal dose was reached 
once again (Figure 2). 
Results
Three	 patients	 dropped	 out	 because	 they	 did	 not	 fill-in	 the	 questionnaire	 on	 the	
patient’s	satisfaction	concerning	the	efficacy	and	the	tolerance	of	the	treatment.	The	
remaining	16	patients	(84%)	filled-in	this	questionnaire.	The	results	of	the	combined	
therapy can be broken up as follows: A repigmentation of 70-100% was achieved 
in 2 patients (after 1 and after 6 transplantation sessions). A re-pigmentation of 50-
75% was achieved in 6 patients (after 1 to 10 transplantation sessions). Thus, an 
improvement of 50% or more was achieved in 8 (50%) of the patients. If necessary 
10 (63%) of the patients would undergo re-treatment. There was no graft take in one 
patient,	caused	by	improper	immobilization	of	the	recipient	body	site.	Seventy-five	
percent	of	the	patients	were	satisfied	with	the	cosmetic	result	and	reported	that	the	
treatment had more advantages than disadvantages.  All of the participating patients 
would recommend the treatment to other vitiligo patients (Table 2).
The blinded evaluation of the photographs taken before and after treatment by a 
dermatologist showed an average repigmentation of 67.2 % (st. deviation = 22.4) 
of	 the	 lesions	 treated	 with	 the	 blister	 roof	 transplantation	 and	 KLUV.	 According	
to	 Student’s	 paired	 T-test	 the	 improvement	 was	 statistically	 significant	 (p<0.01).	
The	 change	 in	 pigmentation	 of	 the	 control	 lesions	 treated	 with	 KLUV	 as	 mono-
therapy	showed	no	significant	change.	Additionally	the	difference	in	the	change	in	
pigmentation	of	the	combined	blister	roof	transplantation	and	KLUV	therapy	and	that	
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of	the	KLUV	mono-therapy	was	statistically	significant	(p<0.01).	(Figures	2,	3	and	4).	
The donor sites showed spontaneous re-pigmentation (Figure 5). Scars are rarely 
seen after the epidermal blister transplantation procedure. A temporary hypo- and 
hyper-pigmentation at the donor site is common.
Discussion
Recent guidelines on the treatment of vitiligo recommended the use of potent or 
very potent topical steroids for a trial period of no more than 2 months.111 Although 
benefits	 were	 observed,	 skin	 atrophy	 was	 a	 common	 side	 effect.	 In	 such	 cases	
topical pimecrolimus is an alternative to the use of a topical steroid.11 Narrow-band 
UVB phototherapy should be considered for the treatment of vitiligo only in patients 
who cannot be adequately managed with more conservative treatments, who have 
widespread	vitiligo	or	have	localized	vitiligo	associated	with	a	significant	impact	on	the	
patient’s quality of life (QoL).11 Patients should be monitored with serial photographs.11 
Unfortunately, in many patients refractory areas may remain, particularly on the 
distal body sites such as the dorsal parts of the hands and the feet, but all body 
sites	may	be	involved.	Photo-medical	treatment	such	as	PUVA	and	KLUV	may	be	
efficacious	where	aforementioned	treatment	methods	have	failed.14,17,18,24  It seems 
rational	to	prefer	KLUV	to	PUVA,	because	khellin	has	phototherapeutic	properties	
that are similar to those of the psoralens, but it has substantially lower  phototoxic 
an mutagenic effects than the psoralens.14,15 A potential concern is the hepatotoxic 
side effect of khellin. A mild elevation of liver transaminases was observed in 7% to 
28% of the patients on oral treatment.13,32  The low active ingredient concentration of 
0.005%	khellin	in	the	topically	applied	spray	would	tend	to	exclude	this	risk.	KLUV	
results in disease stability in almost all cases,24 which is an important requirement for 
the success of surgical therapy.2    
A variety of techniques have been tried for blister roof transplantation. Liquid nitrogen 
and suction devices were used for preparing the donor site.33 Liquid nitrogen is a 
painful procedure that may damage the melanocytes. Blister roofs are the donor 
of melanocytes in epidermal blister graft transplantation. This is because the 
melanocytes in suction blisters are more or less equally distributed between the 
blister roof and the bottom of the blister as is seen in the histology of a biopsy of a 
suction blister (Figure 6).34 Due to this phenomenon approximately the same number 
of melanocytes is transported to the recipient area as is left behind in the donor area. 
This results in spontaneous re-pigmentation of the donor site, albeit after a period 
of erythema, followed by transient hypo-pigmentation and hyper-pigmentation. 
The choice for the medial side of the upper arm as the donor site is because this 
area is a relatively inconspicuous site in case of a temporary discoloration and also 
because this area is easily accessible. Patients can move freely during the creation 
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of the blisters with the block on the arm and the suction device with a cord over the 
shoulder. In our experience, the medial side of the upper arm yields superior blisters 
in a shorter period than the lateral side of the arm because of the difference in the 
skin thickness.
After transplantation, melanocytes induce pigmentation in their immediate vicinity, 
but are unable to proliferate continuously until the whole achromic defect becomes 
re-pigmented. Therefore, depending on the size of the de-pigmented area, a number 
of grafts have to be transplanted followed by  phototherapy in combination with 
psoralen or khellin to stimulate the peripheral spreading of the pigment until the whole 
defect becomes repigmented(Figure 2).2,35 A larger area can be treated as compared 
with the total sum of the individual graft surface areas because of this peripheral 
spreading of the pigment. A blister roof with a diameter of 5-mm corresponds with 
a surface area of 0.2 cm2. Generally, the peripheral pigment spread around a 
transplanted graft is 1-mm to 2-mm resulting in an expansion rate of the surface 
area with a factor 2 to 3. In case that grafts with a diameter of 10-mm are used, 
corresponding with a surface area of 0.79 cm2, the peripheral spreading of pigment 
of 1-mm to 2-mm increases the expansion rate of the surface area with a factor 1.4 
to 1.9. Thus, 5-mm grafts provide optimum tissue and also have the advantage that 
they are easier to handle than the 10-mm grafts. The blister roof grafts are placed 
into the erosions (made by laser ablation in the de-pigmented areas) that are about 
2-mm apart from each because the pigment expands into the periphery. The Erbium 
laser ablation is stopped at the moment pin-point haemorrhages appear indicating 
that the ablation has reached the papillary dermis. Laser ablation is painful and 
requires topical anesthesia with lidocaine 1%-2%. Adrenalin is not used to prevent 
masking of the pin-point hemorrhages. Blister roofs are too thin to be stitched on to 
the laser ablation erosions. Careful bandaging and moderate immobilization of the 
recipient	body	site	are	important	for	keeping	the	grafts	in	place	during	the	first	week.	
The bandage is carefully removed after a week and replaced by a new bandage for 
another week. The recipient areas initially show white skin areas with brown dots 
(Figure	9).	Post-surgical	photo-medical	treatment	is	necessary	to	obtain	confluence	
of pigmentation (Figure 9) and to maintain disease stability.
In the research setting the vitiligo area-scoring index (VASI) and the Vitiligo European 
Task force (VETF) assessment tools offer a more accurate measurement of the extent 
of the disease than only the simple clinical photography.11 In therapeutic trials relating 
to vitiligo, researchers should make the patient’s improvement in his/her Quality of life 
(Qol) as the most important outcome measure.11 Serial photographs should still be 
used to record the progress in clinical practice among other things because patients 
may forget their initial condition.11 This may also explain the discrepancy between 
the patient’s view on the treatment result and the evaluations of the photographs 
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by	 the	 researchers.	Therefore,	 the	 judgment	whether	 the	 therapy	 is	efficacious	 is	
somewhere between the physician’s observation and the patient’s view.36
Improvements in the blister roof transplantation technique may be achieved by:
-	Selecting	the	patients	prior	to	BRT	according	to	the	Vido	classification	(Table	3).37
- Application of a corticosteroid cream or a calcineurin cream to the recipient area 
after the grafts have been taken in order to avoid activation of the vitiligo process 
caused	by	the	ablation	procedure	(Köbner	phenomenon)	or	spontaneous	aggravation	
of vitiligo.37
- Using a medical intervention for the underlying causes of melanocyte destruction.27 
Efalizumab may be such remedy.38
- Suction blister roof ablation of the recipient area instead of the ablation with the 
Erbium laser in order to obtain the same thickness of removed skin and transplanted 
skin, but this technique will be limited to smooth skin areas only.
The	policy	of	 treatment	of	 vitiligo	 in	 this	 study	 (Figure	7)	was	 to	 start	with	KLUV	
for stabilizing vitiligo, to reduce phototoxic reactions caused by sunlight and to 
achieve re-pigmentation of the white patches. Additional surgery was considered 
after	1	year	of	KLUV	treatment	for	refractory	vitiligo	patches,	especially	situated	in	
the ‘emotionally charged’ body sites such as the face, the head, the neck and the 
hands.	Post-surgery	photo-medical	treatment	(KLUV)	is	necessary	to	obtain	enough	
peripheral spread of the pigment to cover the entire area of de-pigmentation (Figures 
2, 3 and 4) .
This within-patient controlled blinded study demonstrated, that transplantation of 
suction blister roof grafts on erosions made by Erbium laser ablation in combination 
with	before	and	after	KLUV	 is	 a	 safe	and	 reliable	method	 to	 treat	 refractory	 and	
stable	vitiligo	areas.	The	combined	therapy	of	blister	roof	transplantation	and	KLUV	
therapy	had	better	results	 than	KLUV	alone.	 	This	procedure	 is,	with	 lower	costs,	
easier to perform than epidermal cell suspensions. The most important limitations 
of this method are the (moderate) immobilization of the treated body site and the 
fixation	of	the	grafts	to	the	erosions	in	the	skin	using	bandages.
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Figure 1.  a.  The MultiCare SP 04 light source.
 b.  Suction device attached to the skin.  
 c.  After about 1 hour the blisters are ready for harvesting.  
 d.  Transplantation of the blister roofs into the laser ablated erosions  
  in a vitiligo area.
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Figure	2.	Blister	roof	transplantation	(1	session)	followed	by	KLUV	3	times	a	week:
a. Before transplantation
b. One week after transplantation = replacement of bandage      
c. Four weeks after transplantation
d. Twelve weeks after transplantation (note peripheral spreading of pigment).
Figure 3. Results	BRT	and	KLUV	6	months	after	1	transplantation	session.
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Figure 5. The donor site shows   
 spontaneous repigmentation
Figure 6. Histology of suction blister  
 the melanocytes are more or  
 less equally distributed
Figure 4.	Results	of	BRT	and	KLUV	after	5	transplantation	sessions.
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Figure 7. Flow diagram for the treatment of vitiligo in the present study
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Chapter 12 
Photodynamic Therapy of acne vulgaris using 5-ALA 0.5% 
liposomal spray and Intense Pulsed Light in combination 
with topical keratolytic agents. 
Jaap de Leeuw, Nick van der Beek , Peter Bjerring, H.A. Martino Neumann.
Accepted for publication in the Journal of the European Academy for Dermatology 
and Venerology
Abstract
Background: Increasing antibiotic resistance of Propionibacterium acnes and 
growing awareness on the side effects of topical and systemic drugs in the treatment 
of acne vulgaris by physicians and patients have paved the way for a search into 
new	efficacious	and	safe	treatment	modalities	such	as	photodynamic	therapy	(PDT).	
Although	the	efficacy	of	PDT	using	20%	5-aminolevulinic	acid	(ALA)	cream	has	been	
established, phototoxic side effects limit its use. The 5-ALA concentration can be 
lowered by a factor of 40 by changing the vehicle of 5-ALA from a moisturizing cream 
to liposome encapsulation.   
Objectives:	Assessment	of	the	efficacy	and	the	safety	of	PDT	using	5-ALA	0.5%	in	
liposomal spray and Intense Pulsed Light (IPL) in combination with topical peeling 
agents (Li-PDT-PC) in acne vulgaris. 
Materials and Methods:  Thirty-two patients suffering from acne participated in this 
randomized, prospective, single blind study. All patients were treated with Li-PDT-
PC. ) During the study nine patients were additionally treated with topical or systemic 
antibiotics (Li-PDT-PC-AT.  These patients were removed from the study although 
their results were recorded.   
Results: After a mean period of 7.8 months and a mean number of 5.7 treatments the 
mean total number of lesions dropped from 34.6 lesions to 11.0 lesions, resulting in 
a mean improvement of 68.2%. Side effects were minimal. Additionally, an intention 
to treat analysis was conducted.
Conclusion: Photodynamic therapy of acne vulgaris using 5-ALA 0.5% liposomal 
spray and Intense Pulsed Light in combination with topical peeling agents is safe 
and	efficacious,	even	in	patients	with	acne	recalcitrant	to	standard	therapy.	
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Introduction
Acne	 often	 improves	 after	 exposure	 to	 sunlight	 or	 artificial	 light	 sources.1  
Propionibacterium acnes produces protoporphyrin IX (PpIX), which generates 
reactive oxygen species, upon exposure to light, inducing phototoxic reactions and 
ultimately bacterial destruction2 and damage to the sebaceous glands.3 The activation 
of	PpIX	is	visualized	by	the	phenomenon	of	PpIX-fluorescence 	with	fluorescence	
photography   (Figures 1 and 2). The theoretically most effective wavelength for 
photoactivation of PpIX is 415 nm. Red light (635 nm) is less absorbed by photo-
activating porphyrins, but penetrates more deeply into tissue and may also have 
anti-inflammatory	effects	by	influencing	the	release	of	cytokines	from	macrophages.4 
Initially, light-based systems for treating acne emitted blue light, 5 red light or the 
combination of blue- and red light. 2 However, clinical improvement was limited and 
multiple sessions were required. Photodynamic therapy (PDT) with 5-aminolevulinic 
acid (ALA) or methylaminolaevulinate (MAL) was introduced to achieve better result 
with fewer treatment sessions. 6	Studies	on	the	efficacy	and	the	tolerability	of	PDT	
differ in the used light source, the treatment schedules, the parameters and the 
concentration of 5-ALA. 7-13 In those studies side effects such as pain, erythema, 
crusts (Figure 3) and post-treatment hyperpigmentation were noticed, highlighting 
the need for optimizing PDT for treatment of acne. Split-face studies using 5-ALA 
and Intense Pulsed Light (IPL) have demonstrated that the combination of 5-ALA 
and IPL is more effective than IPL alone.  6,7,9
Liposomes are used in the treatment of hair follicle- and sebaceous gland-associated 
disorders because of their potential to carry lipophilic drugs and hydrophilic drugs 
such as 5-ALA into the pilosebaceous structures.14--17  Promising results were obtained 
with liposomal encapsulated drugs in the treatment of acne. 18-21 Christiansen et al 
performed	 a	 study	 on	 the	 fluorescence	 distribution	 patterns	 of	 normal	 skin	 after	
topical application of 20% 5-ALA in a moisturizing cream and after application of 
low concentrations of 5-ALA (0.5% and 1%) encapsulated in liposomes. The 5-ALA 
concentration could be lowered by a factor of 40 by changing the vehicle for delivering 
the 5-ALA from a moisturizing cream to liposome encapsulation, and still induce the 
same	level	of	fluorescence	in	the	skin.	The	need	for	occlusion	was	eliminated	at	the	
same	time.	The	low	post-treatment	fluorescence	also	significantly	reduced	the	risk	of	
post-treatment phototoxicity.22 It has not been substantiated that follicular obstruction 
is reduced by PDT. 23 Therefore, in this PDT study concomitant treatment was carried 
out using tretinoin cream at night because peeling of the skin is an essential part of 
acne treatment. 24
The	first	objective	of	this	study	was	to	determine	the	efficacy	and	the	safety	of	5-ALA	
0.5% Liposomal PDT in combination with a Peeling Cream (Li-PDT-PC) in patients 
with acne vulgaris. The second objective was to establish the ability of Li-PDT- PC to 
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replace topical- and systemic standard anti-acne treatments. 
Patients and methods 
Patients
 From October 2005 until August 2008, patients with acne vulgaris grade 4-6 on the 
Burton scale  25 (Table 1) were consecutively recruited into the study. They received 
information about all the aspects of acne, including advantages and disadvantages 
of treatment modalities before inclusion. After taking all options into account, the 
patients could freely make up their minds to enroll into the study or to choose for a 
traditional treatment modality. The study protocol (MC 2007-2) was approved by the 
medical ethics committee of the institute prior to the study. After providing informed 
consent 34 patients with acne vulgaris on the face were included in the study. These 
patients were divided into grade 4 (25 patients), grade 5 (8 patients) and grade 6 (1 
patient) using the Burton grading scale (Table 1). Exclusion criteria were pregnancy, 
lactation, history of allergy to sunlight or 5-aminolevulinic acid, patients with diseases 
aggravated by sunlight (such as lupus erythematosus, porfyria cutanea tarda), 
patients	using	anti-inflammatory	drugs	and	drugs	known	to	have	potency	for	photo-
toxicity or photosensitization, topical and/or systemic antibiotics treatment during 
the half year prior to inclusion, and systemic isotretinoin treatment during one year 
before the start of the study (Table 2). The treatments were performed once a month. 
The endpoint of the study in each individual patient was the moment at which no 
further improvement was observed after two consecutive treatments.
Materials
In the present study, an emulsion containing 0.5% 5-ALA encapsulated in 50 nm 
sized unilamellar liposomes, which are the preferred structures for drug delivery, was 
used.21 The liposomal solution was prepared according to the pharmacy-protocol 
written by Dianorm GmbH, München, Germany. These preparations were chemically 
stable for at least 24 months. 
Intense Pulsed Light was delivered by an Intense Pulsed Light (IPL) device (Ellipse® 
Flex	type	9DER0290	Ellipse	A/S,	Agem	Allé	11,	DK-2970	Hørsholm,	Denmark).	The	
IPL	 consisted	 of	 a	 high-energy	 flash	 lamp	 and	 a	 set	 of	 dual	mode	water-cooled	
filters,	 which	 enlarges	 the	 therapeutic	 energy	window	 and	 therefore,	 requires	 no	
changing	of	filters	according	to	the	skin	type	and	the	degree	of	actual	pigmentation. 
The skin was cooled during treatment with the Cryo 5  (Zimmer Elektromedizin, Neu 
Ulm, FRG). Although not an integral part of PDT, cream containing between 0.02% 
and 0.05% tretinoin was applied as a skin peeling agent. Patients who had irritation 
from the tretinoin cream were treated with adapalene gel (1 patient) or salicylic acid 
5% cream (1 patient).
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Procedure
Patients were asked not to apply make-up on the involved area of the skin on the 
day of the treatment. The involved skin area was degreased with acetone before 
treatment. After rinsing and drying the skin, 5-ALA liposomal spray was applied 
every 5 minutes for one hour to the involved skin area. During this phase, the patient 
remained	in	an	artificially	lit	room	at	low	intensity.	After	1	hour	of	applying	the	spray,	
excessive spray on the skin was rinsed off and the skin was dried with gauze. The 
skin was covered by a thick layer of an optical index-matching gel to ensure an 
effective optical coupling between the IPL’s light guiding crystal and the skin before 
the start of IPL treatment. Parameters of IPL treatment were chosen as follows: the 
acne applicator (530 nm to 750 nm) in 2 pulse trains with a pulse duration of 2.5 ms 
and	an	interpulse	delay	of	10	ms	(acne-PDT)	using	fluences	ranging	from	2	x	4.0	J/
cm2 (sensitive skin) to 2 x 6.0 J/cm2 in patients with skin type I to IV. Alternatively, 
the	PL	applicator	(400-nm	to	720-	nm	was	used	with	fluences	ranging	from	3	x	3.0	
J/cm2 up to 3 x 4.0 J/cm2) in patients with skin type V in order to the risk of side 
effects. Different treatment schedules were used depending on the skin type and the 
occurrence of pain. During the IPL treatment the skin was air-cooled using the Cryo 
5	in	order	to	reduce	heat-induced	pain	sensation.	After	finishing	the	PDT	treatment	
the gel residue on the involved skin was rinsed off, the skin was dried with paper 
tissue and a photo-protective cream containing 5% titanium dioxide was applied. 
The procedure took about 1 hour and 15 minutes, including the 15 minutes of active 
participation by the physician. The patients were advised to protect the treated skin 
areas against sunlight for 8 hours after the treatment Photographs of each patient 
were	taken	before	 the	first	 treatment	and	4	weeks	after	 the	 last	 treatment.	These	
photographs were used to evaluate the results of the treatments by a blinded counting 
of the acne lesions on the face by an observer (trained dermatologic assistant 
B.HS). The number of acne lesions per patient was divided into three categories: 
total	lesions,	inflammatory	lesions	and	non-inflammatory	lesions.	Acne	severity	was	
additionally graded using the Burton scale (Table 1).
Clinical improvement was also assessed according to the patient’s subjective 
response to the treatment, using a questionnaire ranking the level of improvement 
as poor = less than 50% (1 patient), as moderate = 50% to 75% (3 patients), as good 
to very good = 75% to 100% 19 patients (Table 3). 
Results 
Eleven patients dropped out of the study, one patient because of pregnancy and 
one patient because of traveling considerations. Nine patients received additional 
treatments during the study, thus violating the study protocol. The results of these 
patients were recorded irrespective of the violation of protocol. The remaining Li-
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PDT-PC group consisted of 23 patients (12 females and 11 men), Fitzpatrick photo 
skin types II to V, acne grade 4 (17 patients) and grade 5 (6 patients) on the Burton 
scale,	completed	the	study.	Mean	age	of	the	patients	was	24	years	(range	15	–	42	
years, SD = 7). Mean duration of acne prior to inclusion was reported by the patients 
to	be	7.2	years	(range	1	–	23	years,	SD	=	4.5).	Both	an	outcome	based	analysis	and	
an intention to treat analysis was conducted.
According to the analysis of outcome, the Li-PDT-TC treatment required a mean 
period of 7.8 months (SD =4.3) and a mean number of 5.7 treatments (SD =1.8). The 
change in the severity of the acne according to the Burton scale is shown in Table 
3. As the Burton scale is an ordinal scale, we used the non-parametric Wilcoxon 
signed ranks test, which showed that the difference in the reported acne severity 
was	statistically	 significant	 (p-value<0.05).	Thus,	 it	was	safe	 to	 conclude	 that	 the	
Li-PDT-TC therapy resulted in a reduction in the severity of acne. The mean total 
number of lesions dropped from 34.6 lesions (SD=25.1) to 11.0 lesions (SD = 10.5), 
resulting in a decrease of 68.2%. The lesions were divided into two subsets based 
on	the	presence	of	an	inflammatory	component.	The	mean	number	of	inflammatory	
lesions	decreased	by	70.6%,	 the	mean	pre-treatment	 inflammatory	 lesions	being	
18.0 (SD = 14.7) and the post-treatment mean being equal to 5.3 lesions (SD = 
5.7).	The	mean	number	of	non-inflammatory	lesions	decreased	by	66.1%,	starting	
from a mean pre-treatment lesions of 16.7 (SD = 15.1), with a mean number of 5.7 
lesions (SD= 5.9) remaining after the treatment. The results are presented in table 
3.	The	samples	fit	the	normal	distribution	according	to	the	Kolmogorov	–	Smirnov	
test,	 so	 that	 the	 significance	of	 the	 difference	 in	 the	 samples	 can	 be	 tested	with	
Student’s T-test for paired samples. The improvement in the total number of lesions 
and	the	number	of	inflammatory	lesions	is	statistically	significant	for	p-value<0.01.	
The	difference	in	the	number	of	non-inflammatory	lesions	is	statistically	significant	
as well for p<0.05.  An improvement of 75% to 100% in all lesions was achieved in 
12 of the patients,	in	the	inflammatory	lesions	in	12	of	the	patients	and	in	the	non-
inflammatory	lesions	in	8	patients	(Table	3).	
The	number	of	drop-outs	 is	considerable	(32.3%).	This	group	did	not	significantly	
differ from the remaining group of patients both in terms of pre-treatment acne severity 
and post-treatment acne severity (non-parametric Mann-Whitney test (p>0.05)). As 
the results of all patients were recorded a intention to treat analysis was performed 
to	assure	that	the	results	are	not	influenced	by	a	bias	in	the	drop-outs.	This	implies	
merging the results of the drop-out group with the results of those patients who 
did	finish	the	therapy.	The	results	of	this	analysis	are	as	follows:	Within	this	group	
of 34 patients, 11 did not follow the protocol and are considered treatment failure, 
although the data extracted from them was used in the analysis. The change in 
mean number of lesions before and after treatment, including standard deviation and 
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improvement percentage is 36.0 lesions (SD=30.1) to 10.5 lesions (SD = 10.6) and 
70.9% for all lesions, 21.7 (SD = 24.8) to 5.0 lesions (SD = 5.6) and 77.1% for the 
inflammatory	lesions	and	14.3	(SD	=	14.3)	to	5.5	lesions	(SD=	5.4)	and	61.7%	for	the	
non-inflammatory	lesions.	The	improvement	in	terms	of	the	change	in	Burton	acne	
severity	scale)	was	significant,	as	was	the	change	in	the	number	of	lesions	(table	3)	
. Remarkably, the outcome of the intention to treat analysis and that of the outcome 
based	analysis	above	could	not	be	shown	to	differ	significantly.	The	outcome	based	
analysis	was	not	influenced	by	a	selection	bias	in	the	drop-outs.	
The patient self-assessment of the therapy is also shown in table 3. The reported 
improvements exceeded those of the objective counting of lesions, with all patients 
reporting an improvement of at least 50%. More importantly, again using the Wilcoxon 
signed ranks test, the self-assessment of the investigated method was shown to be 
statistically different from the self-assessment of previous treatments reported at the 
outset of the study (Tables 2 and 4 ).  All calculations where performed using SPSS® 
15, SPSS inc.
All patients experienced a burning sensation during treatment. Pain symptoms, 
mostly related to the treatment with the acne applicator and not with the PL 
applicator, were generally well tolerated without any topical anesthesia. A reduction 
of	the	fluence	was	necessary	in	3	patients	because	of	pain.	All	patients	showed	post-
treatment erythema for half an hour to one hour. One patient mentioned erythema 
and desquamation, which lasted up to 3 days. Some patients reported acneiform 
exacerbation	after	the	first	treatment.	Serious	side	effects	were	not	noted.	Data	on	
the remission period and the incidence of relapse are not yet available.
Discussion
Phototherapy in the treatment of acne was initially focused on the endogenous 
production of porphyrins by bacteria, such as P. acnes, as a by-product of their 
metabolism. 26	 Fluorescence	 photographs	 may	 show	 no-	 or	 some	 fluorescence	
from acne lesions caused by protoporphyrins produced by the P. acnes (Figure 1a). 
Increased	fluorescence	is	seen	after	5-ALA liposomal spray has been applied over 
5 minutes intervals for one hour, indicating the increase of PpIX in the involved 
skin	 area	 (Figures	 1b	 and	 2).	 	 Split-face	 studies	 demonstrated	 significant	 higher	
reduction	 in	 inflammatory	 lesion	 count	 from	 ALA-PDT	 and	 MAL-PDT	 compared	
with placebo PDT.  6,9,12,27   However, PDT using 20% 5-ALA under occlusion is 
often complicated by side-effects such as pain, erythema, crusts (Figure 3) and 
post -treatment hyperpigmentation.13 Therefore, optimizing PDT for the treatment 
of	acne	is	needed.	Reduction	of	side	effects	is	possible	by	reducing	light	fluences,	
reducing 5-ALA concentrations and/or 5-ALA application times. Another possibility is 
to enhance the penetration of 5-ALA into the sebaceous gland. In this study 5-ALA 
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was incorporated into liposomes, which have the capacity to transport incorporated 
drugs into the sebaceous glands (Figures 1 and 2), at the same time reducing 
the concentration of 5-ALA to 0.5%. The application of the 5-ALA liposomal spray 
augmented	the	fluorescence	from	the	acne	lesion	(Figure	1b).	Following	subsequent	
PDT,	the	fluorescence	in	the	acne	lesion	disappeared	as	a	result	of	the	phenomenon	
of photo-bleaching (Figure 2). The mechanism of action of 5-ALA liposomal PDT and 
IPL on acne is assumed to be an exogenous PDT response occurring in the presence 
of oxygen and light with appropriate wavelengths and intensity. This PDT reaction is 
very	fast	and	is	specific	to	the	sebaceous	gland.  9,28   Another plausible explanation 
for	the	observed	efficacy	is	that	PpIX	acts	as	a	fluorophore	which	absorbs	the	light	
energy and subsequently transports the energy to the P. acnes and the sebaceous 
glands. This may result in the destruction of the bacteria and minimize the production 
of sebum by thermal damage to the sebaceous gland.
In a previous unpublished pilot study, it was observed that acne-PDT may cause 
phototoxicity with crusts and exfoliation in patients with skin type V. In these patients 
no phototoxicity occurred with PL-PDT because of the longer pulse duration 
compared with acne-PDT and the spreading of the light energy over 3 passes with 
lower	 fluence	 per	 pass.	 Serious	 side	 effects	 of	 PL-PDT	 and	 acne-PDT	were	 not	
observed.	Some	patients	reported	acneiform	exacerbation	after	the	first	treatment	
with 5-ALA 0.5% liposomal PDT, comparable with that after the start of systemic 
isotretion therapy.
Standard treatment currently consists of peeling the skin and reducing P.acnes and 
inflammation	 by	 using	 topical	 peeling	 agents,	 topical	 and	 systemic	 antibiotics	 or	
oral	isotretinoin.	However,	side	effects	may	limit	their	use	(table	4)	and	the	efficacy	
of antibiotic treatment is progressively reduced by increasing resistance of the 
bacteria	to	the	used	antibiotics.		The	efficacy	of	most	of	the	previous	standard	acne	
treatments used by the patients in this study was poor, except for isotretinoin (Table 
2). The results and the safety aspects of Li-PDT-PC were very promising (Table 3, 
Figure	4).	The	first	objective	of	the	study	was	met	because	the	severity	of	the	acne	
in	the	patients	receiving	Li-PDT-PC	was	significantly	reduced	after	treatment	and	the	
safety	profile	was	high.	Most	of	the	patients	who	had	experienced	poor	results	from	
previous	treatments	benefited	from	Li-PDT-PC.	Examples	of	 the	treatment	results	
are	provided	in	figures	5	and	6.	The	second	objective	of	the	study	was	met	because	
the	patient	self-assessment	score	of	the	investigated	method	was	significantly	higher	
than	the	reported	efficacy	of	previously	received	anti-acne	treatments.	The	patient	
self-assessment score was even better than the blinded assessment by the observer. 
This	highlighted	the	appreciation	of	the	patients	for	the	efficacy	of	the	treatment	and	
the paucity of side effects in addition to their appreciation of being treated with a 
topical treatment modality instead of systemic treatment. The results of this study 
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suggest that the described treatment has the potential to replace systemic therapy 
and even isotretoin or could serve as a supporting treatment thereby shortening the 
duration of the treatment and exposure to systemic drugs. 
The intention to treat analysis shows that Li-PDT-PC may be a good basis for other 
combination treatments. The fact that the response of the group of nine patients 
receiving additional treatment was comparable with the results of the patients 
receiving Li-PDT-PC treatment is surprising as only 2 of the 9 patients were treated 
with systemic antibiotics for acne vulgaris grade 4 to 6. The 7 other patients would 
have,	according	to	current	acne	treatment	guidelines,	qualified	for	systemic	antibiotics	
or isotretinoin from the beginning of the treatment.24 This would at least indicate that 
further studies comparing systemic antibiotics and/or isotretinoin with Li-PDT-PC are 
of interest. 
At present, it is not yet possible to provide information on the remission period and 
the incidence of relapse. But up till now, it turned out to be that the frequency of 
treatments could be gradually lowered after about 4 treatments. 
In spite of the use of topical keratolytic agents, the improvement of the non-
inflammatory	 lesions	 in	 this	 study	 was	 not	 better	 than	 the	 improvement	 of	 the	
inflammatory	 lesions.	This	may	indicate	that	5-ALA	0.5%	liposomal	PDT	does	not	
contribute to the change in the keratinocyte shedding and hyperkeratosis as was 
previously assumed.23 Therefore the addition of concomitant treatment with keratolytic 
agents to PDT seems rational. The results of Li-PDT-PC with an improvement in total 
acne	lesions	of	68.2%	and	improvement	in	inflammatory	acne	lesions	of	70.4%,	are	
more or less comparable with the results of other studies using 5-ALA 20% PDT: 
improvement in total lesions of 68% 29  improvement in total lesions of 60% and in 
inflammatory	lesions	of	65%	30,	improvement	in	inflammatory	lesions	of	69%15  8 and 
improvement in total lesions of 72%   31. The results of Li-PDT-PC surpassed those 
reported in 16% MAL-PDT studies with an improvement in total lesions of 54%, 
11	 and	 improvement	 in	 inflamed	 lesions	of	68% 11 .Better results may be obtained 
by	performing	double	passes	with	 the	acne-PDT	on	 inflammatory	 lesions	and	by	
reducing treatment intervals to 2 or 3 weeks.
The reported higher appreciation of the current method when compared to earlier 
treatments suggests that indeed Li-PDT-PC could be an effective alternative for 
traditional acne treatment modalities.
Conclusions: Photodynamic therapy of acne vulgaris using 5-ALA 0.5% liposomal 
spray and intense pulsed light in combination with topical peeling agents is safe and 
effective, even in patients with acne recalcitrant to standard therapy and excels in 
paucity of side effects. In many acne patients this topical treatment has the potential to 
replace systemic therapy (even isotretion) or to reduce its duration in case additional 
systemic therapy is still required for optimum results. Target groups for Li-PDT-PC 
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are patients who have poor results from standard topical treatment and who dislike 
to try systemic therapy and patients with known side effects of standard topical or 
systemic remedies.  
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Grade 0:   Total absence of lesions
Grade 1:   Sub-clinical acne with few comedones visible only on close examination
Grade	2:		 Acne	comedonicus:	comedones	with	slight	inflammation
Grade	3:			Mild	acne	with	inflamed	papules	and	erythema
Grade	4:			Moderate	acne	with	many	inflamed	papules	and	pustules
Grade	5:			 Severe	nodular	acne:	inflamed	papules	and	pustules	with	several	
 deep nodular
Grade 6:   Severe cystic acne with many nodular cystic lesions with scarring
Table 1. Burton scale for grading acne
Table 2
Efficacy	and	safety	of	previous	
treatments in the study population 
patients (nr 23)
Poor
Less 
than 
50%
Moderate
50% to 
75%
GOOD
> 75%
Medication 
stop 
because of 
side effects
Topical treatment
Tretinoin cream 7 1
Adapalene cream
Benzoylperoxide gel 3
Salicylic acid cream
Erythromycin lotion 10 1
Clindamycin lotion 1 1
Antibiotic	lotion	not	specified	 1
Systemic treatment
Tetracycline 1
Minocycline 3 4  1
Erythromycin  2  1
Antibiotic	non-specified	 1
Cyproterone/estradiol 3 1
Isotretinoin 1  5 1
Results of 46 previous treatments 
in 23 patients 67,39% 21,74% 10,87% 5%
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Mean number of 
lesions and (standard 
deviation) intention to 
treat analysis
Mean number of 
lesions (standard 
deviation) outcome 
analysis
Pre-treatment lesions 34.6 (25.1) 36.0 (30.1)
Pre-treatment	inflammatory	lesions	 17.9	(14.7)	 21.7	(24.8)
Pre-treatment	non-inflammatory		 16.6 (15.1) 14.3 (14.3)
lesions 
Post-treatment lesions 11.0 (10.5) 10.5 (10.6)
Post-treatment	inflammatory	lesions	 5.3	(5.7)	 5.0	(5.6)
Post-treatment	non-inflammatory		 5.7	(5.9)	 5.5	(5.4)
lesions 
Results according to the Burton scale (no. of patients in class)
Class 6 5 4 3 2 1 0
Pre-treatment (outcome) 0 6 16 1 0 0 0
Post-treatment (outcome) 0 0 0 0 9 9 0
Pre-treatment (i.t.t.) 1 7 23 1 0 0 0
Post-treatment (i.t.t.) 0 0 0 0 15 12 0
Results according to the patient’s subjective response to the treatment
Improvement in % Less than 50 % 50% to 74% 75% to 100%
Number of the patients 1 5 26
Table 3. Results
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Skin and mucosae
Gastro-intestinal
Blood
Pregnancy and 
lactation
Carcinogenicity
Others
salicylic 
acid
Irritation, 
dermatitis, 
contact 
allergic 
eczema
Intoxica-
tion 
following
application 
on large  
skin areas
Intoxica-
tion 
following
application 
on large  
skin areas
Treatment 
of large 
areas and 
under 
occlusion 
contra-
indicated 
in 
pregnan-
cy.
Lactation 
no 
problem
benzoyl-
peroxide
Burning, 
itching, 
erythema, dry 
skin, scaling, 
cracks, 
crusting, 
blistering,  
allergic 
contact 
dermatitis
No problem
Concern about 
carcinogenesis 
in the long-term
White staining 
of clothes
Azelaic 
acid
Burning, 
itching, 
erythema, 
desquamation, 
contact allergy, 
hypopig-
mentation,
photo-
sensitization
No data 
available
tretinoin,
adapalene
Burning, 
itching, 
dry skin,  
erythema, 
desquama-
tion, contact 
allergy, 
crustation, 
hypo- and 
hyperpig-
mentation,
photo-
sensitization
Small 
quantities 
probably no 
problem. 
Treatment of 
large areas 
and under 
occlusion 
contra-
indicated in 
pregnancy and 
lactation
erythromycin, 
clindamycin
Burning, 
itching, dry 
skin,  erythema, 
desquamation, 
contact allergy,
gram-negative
folliculitis
Clindamycin:
Belly ache, 
diarrhea, colitis
No data 
available
Topical drugs
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Skin and mucosae
Gastro-intestinal
Neurological and 
psychologica
Blood
Kidneys
Pregnancy and 
lactation
Carcinogenicity
Other
PDT 5-ALA 
10% to 
20% cream
Pain, stinging, 
itching
erythema, 
oozing, crustae 
and pustules.
Phototoxicity
48 hours after 
treatment
tetracyclin,
doxycyclin,
minocyclin
Urticaria, 
angio-edema, 
phototoxical- and 
photoallergic 
reactions, Sweet’s 
syndrome.
Anemia, 
thrombocytopenia, 
neutropenia.
Doxycycline: 
induction of
hypoglycemia
renal dysfunction
Pregnancy 
category C
Increased risk of 
incident and fatal 
breast cancer
From minocin also 
reported:
-lupus pneumonia
-hypersensitivity
-pneumonia
-progressive  
respiratory
failure
erythromycin
Pruritus, urticaria, 
exanthema, toxic 
epidermal necrosis, 
Stevens-Johnson-
syndrome
Nausea, vomiting, 
diarrhea, glossitis, 
hairy tongue, 
stomatitis, pseudo-
membranous colitis, 
prutitus ani, hepar 
dysfunction
Benign intracranial 
hypertensiona
Contra-indicated 
during pregnancy 
and lactation
Unreliability of 
oral contraceptive 
devices
Anorexia, nausea, 
vomiting, cramps, 
diarrhea,  pseudo-
membranous 
colitis, hepatitis, 
pancreatitis
Impaired hearing
No problem
Increased risk of 
incident and fatal 
breast cancer
Increased risk of 
incident and fatal 
breast cancer
isotretinoin
Xerosis cutis, pruritus, 
dermatitis, exanthema, 
epistaxis, conjunctivitis-, 
blepharitis- and 
cheilitis sicca, alopecia, 
paronychia, nail 
dystrofia, hyperhidrosis, 
hirsutism, vasculitis
Nausea, gastro-
intestinal bleeding, 
intestinal inflam-
mation, hepar 
dysfunction, hepatitis, 
pancrea-titis, malaise.
Headache, benign 
intracranial 
hypertension, 
photophobia, blurred 
vision, disturbance 
dark adaptation, 
cataract, impaired 
hearing, convulsions, 
somnolence, mental 
depression, psychosis, 
suicide.
anemia thrombo-
cytopenia, neutropenia, 
hyperglycemia, 
elevated cholesterol- 
and triglyceride levels, 
low HDL, thrombosis
glomerulonephritis
Absolutely contra-
indicated during 
pregnancy and lactation
                                            Systemic drugs
Table 4. Side effects of anti-acne drugs.
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Figure	2.		 Acne	nodule:		left	clinical	images,	middle	fluorescence	images,	right		 	
pseudo-color images.  
Top	right	before	application	of	5-ALA	liposomal	spray:	no	auto-fluorescence.	
Middle right: after 1 hour of treatment with 5-ALA liposomal spray: clear 
fluorescence	mainly	located	in	the	acne	nodule.		
Bottom	right:	decreased	fluorescence	as	a	result	of	photo-bleaching	by	IPL	
treatment.
Figure 1. Fluorescence photography of a sebaceous gland.
1a.	Spontaneous	auto-fluorescence	from	PpIX
1b.	Increased	fluorescence	after	application	of	5-ALA	liposomal	spray
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Figure 3.  Left: 1 day after PDT with 1 hour application of 5-ALA 0.5%  liposomal 
spray  without occlusion (no side effects). 
Right: 1 day after PDT with 5-ALA 20% cream under occlusion (redness and crusts). 
The parameters of the IPL treatment were the same for both areas.
Figure 4. Reduction of the mean number of all lesions 68.2% (p<0.05), of 
inflammatory	lesions	70.6% (p<0.05) and	of	non-	inflammatory	lesions	66.1%	
(p<0.05).  
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Figure 5.  Left: Before Li-PDT-PC. 
Right: After 6 Li-PDT-PC treatments in 7 months (improvement 80%). No side 
effects. No effect from previous treatments with erythromycin lotion, systemic 
minocycline and systemic isotretinoin.
Figure 6. Left: Before Li-PDT-PC.
Right: After 6 Li-PDT-PC treatments in 6 months (improvement 90%). No side 
effects. No effect from previous treatment with cyproteron/ethinylestradiol and 
systemic minocycline.
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Chapter 13
Published as 
Fluorescence detection and diagnosis of non-melanoma 
skin cancer at an early stage.
Lasers in Surgery and Medicine 2009; 41;  96-103.
Jaap de Leeuw, Nick van der Beek, W. Dieter Neugebauer,  Peter Bjerring, H.A. 
Martino Neumann.
abstract
Background: The occurrence of non-melanoma skin cancer (NMSC), including 
actinic	keratosis	(AK)	is	increasing	all	over	the	world.	The	detection	and	diagnosis	
of NMSC is not optimal in clinical practice. The need for complementary methods for 
detection and accurate demarcation of NMSC at an early stage is large in order to 
limit the damage caused by tumours.
Objective:	The	purpose	of	the	present	study	was	to	use	a	large	area	skin	fluorescence	
detection system to detect early NMSCs (clinical visible as well as non-visible lesions) 
in the face, neck, chest,   back and hands of patients treated with UV and outdoor 
workers.
methods: Fluorescence detection with a purpose-made digital camera and 
software (Dyaderm®) combined with 5-aminolevolinic acid (5-ALA) encapsulated in 
liposomes.
Results: In	93	consecutively	referred	patients	positive	skin	fluorescence	was	detected	
in	61	patients.	After	histological	examination	the	positive	fluorescence	appeared	to	
be correlated to benign lesions in 28 patients (sebaceous gland hyperplasia in 22 
patients) and to (pre-) malignant lesions in 33 patients (actinic keratosis in 29, BCC 
in	3	and	SCC	in	1	patient).	False	negative	fluorescence	was	found	in	only	one	lesion.	
In 5 patients the FD technique used in this study appeared to be more sensitive for 
the	identification	of	(pre-)	malignant	lesions	than	the	clinical	examination	in	contrast	
to FD techniques used in previous studies.
Conclusion: Diagnostic	skin	fluorescence	using	liposomal	encapsulated	5-ALA	and	
a specialized computerized detection and visualization system offers the possibility 
for detection of NMSC at an early, pre-clinical stage. The technique is well suited to 
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examine	large	areas	of	skin.	It	also	identifies	areas	of	most	interest	for	performing	
confirmatory	skin	biopsies,	as	well	as	pre-operative	assessment	of	boundaries	of	
skin	malignancies,	and	finally,	the	technique	is	applicable	in	the	control	and	follow-up	
of skin cancer treatment.
Introduction
Nonmelanoma skin cancer (NMSC) is the most common cancer in Caucasian 
populations and its incidence is of epidemic proportions worldwide.1-5 Although, the 
term NMSC covers all cutaneous cancers excluding melanomas, it is normally used 
to refer to two major types of skin cancer: basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC). These two forms of skin cancer account for more than 95% of 
all NMSC.5 BCCs arise de novo, which means there are no known precursor lesions.5 
SCC’s	 may	 arise	 from	 actinic	 keratoses	 (AKs).	 Often,	 these	 lesions	 have	 been	
considered to be pre-malignant precursors6-8,	but	according	 to	other	authors,	AKs	
are true epithelial neoplasmata from the beginning.3,9 From this standpoint of view, 
the	evolution	from	AK	to	SCC	represents	progression	rather	than	transformation,	and	
therefore,	AK	should	be	recognized	as	incipient	SCC.10,11  It has been estimated, that 
6%	to	10%	of	AKs	develop	into	invasive	SCC.12,13	This	highlights	the	value	of	AK	as	
a marker for SCC.3 Thus, if these high-risk patients are monitored closely, invasive 
tumors that develop could be treated at an early stage when cure rates are high, 
morbidity low, mortality nonexistent, and costs of treatment are limited.3 The average 
annual increase of NMSC in white populations in Europe, the United States, Canada 
and Australia has been 3% to 8% since the 1960s.4   Nowadays, NMSC incidence 
is	greater	than	all	other	cancers	combined	and	NMSC	is	among	the	five	most	costly	
cancers reported in the USA .14  There are many reasons for the worldwide increase in 
NMSC incidence. Etiological factors that underlie the development of skin cancer are 
of endogenous origin as well as of exogenous origin.4 Major endogenous factors are 
age, genetic predisposition, such as skin type (in particular skin type I, II and III) and 
genetic diseases (for example xeroderma pigmentosa).The key environmental risk 
factor	for	NMSC	is	ultraviolet	(UV)	light	radiation	from	exposure	to	sunlight,	artificial	
tanning lamps15-18  and iatrogenic exposure to psoralen and ultraviolet A (PUVA), 
and to ultraviolet B (UVB), modalities often used for the treatment of psoriasis and 
vitiligo.19,20   Persons with occupational or recreational outdoors exposure, such as 
commercial	fisherman,	construction	workers,	park	rangers,	farmers,	aircraft	pilots,	
yachtsmen, golfers, skiers, mountaineers and sun-addicts, have higher incidence 
rates	of	AKs	than	indoor	living	people.21-24  Other exogenous factors include chemical 
carcinogens (such as arsenic, pesticides, tar, certain industrial oils, dyes and solvents), 
ionizing radiation, human papilloma viral infections25 and immunosuppression, 
especially in organ transplant recipients.26 Tobacco smoking has also been recently 
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linked to SCC.27  In 2002, more than 1 million cases of NMSC were diagnosed in the 
United states.28  Squamous cell carcinoma accounts for more than 20% of NMSC 
and most metastatic disease and death due to NMSC. Therefore, the ability of the 
physician to distinguish precancerous lesions with a high degree of accuracy is 
of great importance and will decrease the morbidity and mortality of SCC.29  The 
clinical	 features	 of	AK’s	 are	 nonspecific,	 usually	 described	 as	 red,	 scaly	 papules	
or plaques, 2- to 10- mm in diameter, occurring in sun-exposed sites. They may 
bleed and may become hypertrophic, at which point a biopsy should be performed 
to evaluate for progression to SCC.29 	The	differential	diagnosis	of	AK	includes	many	
benign and malignant lesions (Table 1).13,29  This broad differential underscores the 
highly	 nonspecific	 clinical	 features	 of	AKs.29  The diagnostic accuracy or positive 
predictive	value	(PPV)	of	the	clinical	diagnosis	of	AKs	made	by	specialized	doctors	
appeared to be only 74% after histological diagnosis.29  A sound public health policy 
adapted to the challenges of the 21st century must strive to prevent skin cancer 
development	 through	 risk	 factor	 modification	 (primary	 prevention)	 and	 improved	
disease surveillance and earlier detection (secondary prevention).30  The need for 
complementary methods for detection and accurate demarcation of skin cancers at 
an early stage is large, to limit the damage caused by tumours.31 . 
Besides its usefulness in photodynamic therapy (PDT), 5-aminolevulinic acid (5-ALA) 
and methylaminolevulinic cream (MAL, Metvix®, Galderma) also can be exploited for 
diagnostic purposes. The mechanism of 5-ALA use in PDT is based on intracellular 
transformation of 5-ALA to protoporphyrin IX (PpIX), followed by light exposure, 
which induces phototoxicity. The transformation of ALA can be monitored non-
invasively	by	detection	of	PpIX	fluorescence	at	634-nm.	Fluorescence	from	the	skin	
after application of 5-ALA is a complex interaction of ALA penetration into the skin, 
cellular absorption of ALA, and metabolic transformation of ALA into PpIX. For topical 
application of ALA relatively high concentrations of ALA are necessary, because of 
the low rate of penetration of free 5-ALA into the skin. Generic preparations of 5-ALA 
20% in a moisturizing cream (pharmacy preparations) or methylaminolevulinate 
(MAL) 16% cream (Metvix® Galderma) are used, under an impermeable plastic 
occlusion	film	to	enhance	and	standardize	absorption.	Following	treatment	with	this	
high concentration preparations photosensitization remains for at least 32 hours. 
Exposure to ambient light within this time interval may cause severe clinical signs 
of phototoxicity e.g. swelling, erythema and scaling. Therefore, patients receiving 
this type of treatment are advised to avoid bright light and sun exposure for 24 to 48 
hours after treatment.32 
Liposomes are microscopic vesicles consisting of concentric bilayers formed by 
phospholipids, enclosing an aqueous core. Therefore, liposomes contain lipophilic 
compartments within the bi-layer membranes and hydrophilic compartments 
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between the membranes. Lipophilic substances can be stored into the lipid phase 
and water soluble substances into the water phase. Therefore, liposomes can be 
used as carriers for lipophilic as well as hydrophilic drugs.33 Three mechanisms 
have been described concerning the penetration of liposomes into the epidermis: 
penetration via the pilosebaceous units34, via lateral diffusion of liposomes in the 
stratum corneum35, and via a transepidermal osmotic gradient and hydration force.36 
The similarity of lipid composition of liposomes and epidermis enables the liposomes 
(and also the drugs encapsulated in them) to penetrate into the epidermal barrier to 
a greater extend than lotions, creams and ointments do. In addition, liposomes bind 
to cells and deliver their contents to the cytoplasm of cells by fusion with the outer 
cell membrane or by endocytosis, where upon they are concentrated in lysosomal 
sacs.37 These capabilities make liposomes very useful for the enhancement of the 
penetration of lipophilic as well as hydrophilic drugs (5-ALA is hydrophlic) into the 
epidermis.38 An optimal penetration of liposomes requires a dry skin surface, under 
occlusion (maximal hydration) no penetration of liposomes occurs.36 
The	fluorescence	of	skin	areas	treated	for	more	than	1	hour	with	20%	ALA	cream	
under	occlusion	appears	to	be	very	uniform	and	the	fluorescence	intensity	continues	
to	increase	after	the	end	of	5-ALA	application.	The	maximum	fluorescence	is	reached	
at 8 hours after the end of 20% 5-ALA application.32	The	fluorescence	of	skin	areas	
following non-occluded topical application of liposome-encapsulated 0.5% 5-ALA 
was	heterogeneous	distributed	(heterogeneous	distribution	shows	high	fluorescence	
intensity	from	diseased	tissue	and	low	fluorescence	intensity	from	normal	skin)	and	
reached	a	saturation	 level	after	2	hours.	The	fluorescence	decays	 linearly	shortly	
(within 15 minutes) after the end of application of 0.5% 5-ALA liposomes and was 
back to baseline within 8 hours.32	The	average	skin	surface	fluorescence	induced	by	
the liposome-encapsulated 0.5% 5-ALA applied for longer than 2 hours, is found to be 
equal	to	the	average	measured	skin	surface	fluorescence	obtained	after	30	minutes	
exposure to 20% 5-ALA cream.32 Changing the 5-ALA vehicle from a moisturizing cream 
to liposome encapsulation, the 5-ALA concentration can be lowered by a factor of 40, 
and	still	induce	the	same	skin	fluorescence	and	at	the	same	time	eliminates	the	need	
for occlusion.32  Following topical application of 5-ALA, PpIX is induced selectively 
in cells with high metabolism, such as in epithelial tumor cells. Upon irradiation 
with light the tumor becomes visible and can be delineated from the surrounding 
tissue.39 This	method	is	called	fluorescence	diagnosis	(FD).	By	using	a	highly	light	
sensitive charged couple device (CCD) camera system together with a specially 
designed digital imaging (Dyaderm system, Biocam GmbH, Regensburg, Germany), 
the	contrast	of	the	acquired	fluorescence	images	can	be	significantly	enhanced.39-41 
This allows the determination of the optimal site for a directed biopsy and/or may 
indicate the boundaries of the tumour for preoperative planning when Mohs’ surgical 
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treatment is scheduled.39 Moreover,	FD	 is	also	a	helpful	 tool	 to	prove	 the	efficacy	
of PDT.39 Although promising, the results till now were limited due to technological 
constraints both in terms of application of 5-ALA, illumination and observation of 
fluorescence.42 The current technology deviates from preceding methods in three 
ways.	Firstly,	the	previously	used	flashlamp	is	replaced	by	a	homogeneous	LED	light	
source.  Secondly, the 5%-ALA in a moisturizing cream under occlusion is replaced 
by liposomal encapsulated 5-ALA 0.5%, without occlusion. Thirdly, the Dyaderm® 
system with its relatively limited skin area (which can be investigated in one picture), is 
replaced by a specialized version of the Dyaderm® system. This new system enables 
investigation of large skin areas in one picture, resulting in less time consuming 
procedures. The aim of this study was to establish FD, using liposomal encapsulated 
5-ALA and a specialized version of the Dyaderm© system, as a reliable guide for 
the	detection	of	NMSCs	(including	AKs).	An	additional	objective	was	to	asses	the	
diagnostic	 efficacy	 of	 heterogeneous	 fluorescence	 following	 application	 of	 5-ALA	
0.5% liposomes without occlusion in contrast to homogeneous	fluorescence from 
16% 5-methylaminolevulinic cream (MAL, Metivix©, Galderma) under occlusion.
Materials and Methods
Patients
The study was conducted on a consecutively recruited group of 93 persons with 
a history of chronic UV exposure, such as outdoor professions and long term UV 
therapy, or with a history of treatments for NMSC. The group consisted of 43 females 
and 50 males with an average age of 59 years (standard deviation 11 years). 
Pregnancy, a history of epilepsy, recent peeling or scrubbing or other rejuvenation 
techniques of the skin, and allergy to 5-ALA were exclusion criteria. The study areas 
were limited to highly UV exposed areas such as the face, the scalp, the chest, the 
upper back and the back of the hands. Prior to the FD procedure, the test areas of 
the skin were degreased by wiping with gauze moistened with acetone.
5-ALA Preparation
In the present study an emulsion was used containing 0.5% 5-ALA encapsulated 
in 50 nm sized unilamellar liposomes, which are the preferred structures for drug 
delivery.33 The liposomal solution was prepared according to a pharmacy-protocol 
from Dianorm GmbH (Munich, Germany). The preparation is chemically stable for 
at	least	24	months.	The	concentration	of	0.5%	5-ALA	appeared	to	be	sufficient	for	
fluorescence	 detection,	 meanwhile	 strongly	 reducing	 the	 risk	 of	 post	 procedure	
phototoxicity.32  
The only known side effect of 5-ALA liposomal preparation is that it may induce a 
slight erythema and scaling when applied to skin which has recently been treated 
with a peeling or scrubbing agent or skin which is very dry where the epidermal 
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barrier function is not intact. Attention was given to these potential side-effects during 
application.
Fluorescence detection system
5-ALA is metabolized in mammalian cells to heme, producing protoporphyrin IX 
(PpIX), which absorbs optical energy when subjected to illumination with visible 
light. Absorption peaks exist at 409nm, 509nm, 544nm, 584nm, and 634nm. 
Fluorescence is emitted in the red part of the optical spectrum, with emission peaks 
at	 636nm	 and	 708nm.	 In	 cancer	 cells,	 the	 concentration	 of	 PpIX	 is	 significantly	
higher	than	in	normal	skin	cells,	and	the	intensity	of	the	fluorescence	emitted	from	
the cancerous region will be higher than that emitted from normal skin tissue.31 In 
this	 study	fl uorescence measurements were performed with a specially designed 
version of the DyaDerm®	fluorescence	detection	system,	which	is	a	highly	sensitive	
digital	fluorescence	imaging	system	intended	for	the	analysis	of	larger	skin	areas.	
Each image dimension is 14 by 18 centimetres, giving an imaging skin size of 252 
cm2. A high brightness LED pulsed light source is used, which emits blue light with 
a peak wavelength of 405 nm. Pulse duration is 5 ms and repetition frequency is 1 
Hz.	The	resulting	fluorescence	signal	is	recorded	by	a	10	bit	CCD	camera	mounted	
to an adjustable stand and coupled to a computer system where image acquisition 
and processing is controlled by the DyaDerm  software. Because of the short pulsed 
excitation	 photo-bleaching	 of	 PpIX	 is	 minimized.	As	 PpIX	 fluorescence	 emission	
consists of light in the red spectrum, the red pixels of the CCD camera are used 
to	generate	a	fluorescence	image. The DyaDerm® system can capture and display 
color	images	of	the	skin	and	their	corresponding	fluorescence	images	in	a	live	video	
mode	while	artifacts	due	to	camera	motion	are	suppressed	because	of	using	a	fixed	
stand. These images can be superimposed and pseudo-colored to better highlight 
relevant	parts	of	increased	fluorescence	due	to	malignant	or	pre-malignant	lesions.	
Because images are captured in video mode using both white and blue conditions, 
the	system	is	triggered	to	capture	every	fifth	image	under	fluorescent	 light.	In	this	
way,	both	color	and	fluorescence	images	are	captured	and	transferred	to	the	display.	
After interpolation, both images can be superimposed to allow a physician to localize 
any	 high-fluorescence	 spots	 at	 the	 examined	 skin.	 It	 is	 possible	 to	 present	 the	
fluorescence	 intensity	 in	pseudo-color.	The	human	eye	distinguishes	colors	better	
than different shades of brightness, thus with a pseudo-color image a tumor is much 
easier to localize. By	comparing	 the	 red	 light	 resulting	 from	 the	 red	fluorescence	
of	PPIX	and	 the	green	auto-fluorescence,	which	 is	also	excited	by	 the	used	 light	
source, an accurate and detailed image of the lesions is created, including a relative 
measurement	of	fluorescence	intensity	on	a	cardinal	ranking,	making	 intra-patient	
fluorescence	 comparisons	 possible.	 By	 computing	 the	 relative	 intensities	 of	 the	
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PPIX	and	auto-fluorescence	 image,	 inhomogeneities	 in	 the	fluorescence	 intensity	
due	 to	 imperfections	 of	 the	 excitation	 light	 field	 and	 inhomogeneities	 due	 to	 the	
curvature of the observed object are automatically corrected. The resulting image 
is	referred	to	as	“PPIX	filtered”	and	is	also	presentable	in	pseudo-color	(Fig.1	a-c).43 
These	presentations	support,	amongst	others,	easy	detection	of	AK’s,	as	they	are	
clearly	visible	with	a	well	defined	compact	core	of	high	intensity,	shown	in	red,	and	a	
surrounding	halo	of	intermediate	fluorescence	levels	which	is	also	well	defined	with	
borders sharply demarcated against the normal tissue.  
Comparison of the fluorescence properties of 5-ALA 0.5% liposomal spray with 
5-methylaminolevulinic 16% cream (MAL, Metvix©, Galderma).
MAL16% cream was applied under occlusion on the right side of the forehead for 3 
hours. Liposomal 5-ALA 0.5% spray was applied every 5 minutes on the left side of 
the forehead without occlusion for 2½ hours, followed by a pause of ½ hour to allow 
the 5-ALA liposomes to be absorbed completely into the skin. Immediately after this, 
fluorescence	pictures	were	made	of	both	sides	of	the	forehead.	
Establishment of the efficacy of FD, using liposomal encapsulated 5-ALA and a 
specialized version of the Dyaderm system for the detection of NMSC (including 
AK)
After admission, the patients were situated in a room with dimmed light, where they 
applied the 5-ALA spray every 5 minutes for two and a half hours to the involved 
skin area. Thereafter, the spray was left to be absorbed into the skin for half an hour 
more.	Although	the	intensity	of	the	blue	pulsed	light	emitted	from	the	fluorescence	
detection system is not harmful, theoretically it may trigger a seizure in patients with 
epilepsy. Therefore, patients who either suffered from epilepsy or had a close relative 
suffering from epilepsy were examined wearing dark eye goggles. Subsequently, 
pictures	were	taken	using	the	fluorescence	detection	system.	In	order	to	minimise	
any disturbance from ambient light, the pictures were taken in a completely darkened 
room. The pictures were evaluated by a trained dermatologist. The general threshold 
level	for	demarcating	tumor	from	normal	skin	(fluorescence	ratio)	was	found	to	be	
1.37	times	the	mean	value	of	the	fluorescence	in	the	ALA	treated	area	using	4	hours	
of ALA cream application.44 In this study skin areas showing a red centre surrounded 
by	a	yellow	halo	(intensity	of	fluorescence	in	the	red	centre	above	1.5	compared	with	
the	fluorescence	of	the	surrounding	normal	skin)	were	considered	to	have	a	positive	
fluorescence	pattern.	From	these	skin	areas	of	most	interest,	biopsies	were	taken	
under local anaesthesia with 1% lidocaine-adrenalin for histological diagnosis. 
Ethics
The study protocol and associated information were submitted to and approved by 
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an ethics committee prior to the study. All investigations are in accordance to all 
applicable legal norms and non-legal standards.
Results
The	fl uorescence image of the right (MAL- treated) side of the forehead showed very 
high	and	homogeneous	fluorescence	intensity	in	most	of	the	studied	skin	areas	with	
low discrimination between normal and diseased skin (Fig. 2). The left (ALA-liposome 
treated)	side	showed	 low	autofluorescence	of	 the	normal	skin	and	moderate,	but	
distinct	fluorescence	of	actinic	keratoses,	resulting	in	a	high	discrimination	between	
the normal and the diseased skin (Fig. 3). The 5-ALA-liposome solution seems 
to be highly superior to MAL for discrimination between normal skin and NMSC 
lesions	(Fig	2	and	3).	Moreover,	the	significantly	lower	uptake	of	5-ALA	in	liposomes	
into the normal skin results in lesser degree of photosensitivlty and -toxicity and 
the	 known	 faster	 clearance	of	 5-ALA	ensures	a	much	better	 safety	 profile	 of	 the	
0.5% 5-ALA lipsome preparation compared with MAL cream (8 versus 36 hours of 
photosensitivity) (Fig. 4.). 
A	positive	fluorescence	intensity	was	detected	from	287	(100%)	lesions	in	61	(65.6%)	
of	the	patients.	After	histological	examination	the	positive	fluorescence	appeared	to	
be correlated to 212 (73.9%) benign lesions in 28 (30.2%) of the patients and to 75 
(26.1%) (pre-) malignant lesions in 33 (35.5%) of the patients (Table 2). The benign 
lesion	were	histologically	identified	as	sebaceous	gland	hyperplasia	(204	=	71.1%)	
in	22	(23.7%)	of	the	patients	(fig.	5).	Other	benign	lesions	(8	=	2.8%)	included	viral	
warts,	a	benign	lichenoid	inflammation.	Dysplastic	melanocytic	nevi,	were	found	in	6	
(6.5%) of the patients. The (pre-) malignant lesions were histological diagnosed as 
actinic keratosis (71 = 24.7%) in 29 (31.2%) of the patients. Notably, these lesions 
could readily be recognised by a high intensity core with well circumscribed peripheral 
medium	intensity	fluorescence	(fig.	6	and	7).	In	4	(4.3%)	patients	4	(1.4%)	malignant	
lesions	were	histologically	confirmed	to	be	3	BCCs		(Fig.1)	and	1		SCC.
False	 negative	 fluorescence	 was	 found	 in	 only	 one	 lesion	 (a	 negative	 result	 by	
fluorescence	detection	of	a	lesion	clinically	suspected	and	histologically	confirmed	
to	be	an	AK).	This	lesion,	situated	on	the	vertex	of	the	head	was	noted	by	the	patient	
because	of	a	thick	hyperkeratosis	and	was	clinical	identified	as	actinic	keratosis	by	
the examining doctor (Fig. 8 and 9). 
In	 5	 (5.4%)	 of	 the	 patients	AKs,	 not	 noted	 by	 the	 patients	 nor	 by	 the	 examining	
doctors	were	identified	by	fluorescence	detection	and	later	confirmed	by	histological	
investigation. This means that in contrast to previous studies42 the number of tumours 
assessed by the FD technique used in this study was higher than the number of 
tumours determined by clinical diagnosis.  
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Discusion
The occurrence of NMSC is increasing all over the world2 and field	cancerization,	
in which there are multiple (pre)malignant lesions diffusely spread over ultraviolet-
exposed skin in particular, is an increasing problem. Up till now, physicians often need 
to take multiple biopsy specimens of the clinically malignant-suspect lesions, which 
can	be	a	significant	burden	for	the	patient.41 The need for complementary methods for 
detection and accurate demarcation of these skin cancers at an early stage is large 
in order to limit the damage caused by tumours.41 In	fluorescence	diagnosis	 (FD)	
PpIX	exhibits	red	fluorescence	when	excited	with	blue	(405	nm)	light	after	incubation	
of the skin with 5-ALA cream or MAL cream. PpIX accumulates to a higher extent 
in malignant lesions than in nonlesional skin.41  The selective accumulation of Pp IX 
in the tumour tissue after ALA application is dependent on the permeability of ALA 
through the stratum corneum45,46,  the diffusivity and cellular uptake of ALA in the 
epidermis and dermis45-47, the biosynthesis of PpIX48 and the clearance time of ALA 
and PPIX.45,46	In	order	to	obtain	a	good	fluorescent	demarcation	of	tumors	by	FD	it	
is	important	that	the	fluorescence	contrast	between	the	tumor	and	the	normal	skin	is	
as high as possible.31	Liposomes	are	very	efficacious	as	drug	carriers	for	introducing	
both water and fat soluble substances into the skin.38, 49   The	fluorescence	from	skin	
areas treated with 20% ALA cream under occlusion is very uniform, and hence there 
is	only	very	low	discrimination	between	normal	and	diseased	skin.	The	fluorescence	
from skin areas treated with non-occluded liposome-encapsulated 0.5% 5-ALA is 
heterogeneously distributed, allowing for a high discrimination between normal and 
diseased skin.32 Moreover, the lower uptake of 5-ALA-liposomes into the normal 
skin results in a lower risk of post-procedure phototoxicity and the faster clearance 
of 5-ALA from the tissues results in a shorter duration of this phototoxicity compared 
with MAL cream (8 versus 36 hours) (Fig. 4). This means, that patients are less 
restricted from outdoor activities following application of 5-ALA-liposomes compared 
with MAL cream. 
In this study liposomal encapsulated 5-ALA and a specialized version of the Dyaderm® 
fluorescence	detection	system	were	used	to	detect	positive	fluorescence	in	65.6	%	of	
the	patients.	After	histological	examination	the	positive	fluorescence	appeared	to	be	
correlated to benign lesions in 30.2% of the patients and to (pre-) malignant lesions 
35.5%	of	the	patients	(Table	2).	The	benign	lesions	were	histologically	identified	as	
sebaceous	gland	hyperplasia	23.7%	of	the	patients	(figure	5).	This	is	not	surprising,	
because sebaceous hyperplasia is a benign lesion characteristic of ultraviolet 
damaged skin and liposomes penetrate very well into the sebaceous glands.50 
The	benign	 lesions	displaying	positive	 fluorescence,	 could	easily	be	 identified	as	
sebaceous gland hyperplasia on clinical examination because by stretching the 
skin they become clearly visible as yellow-white translucent papules. Other benign 
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lesions	 including	 viral	warts,	 a	 lichenoid	 inflammation	 and	dysplastic	melanocytic	
nevi were found in 6.5% of the patients, indicating, that thickness and pigmentation 
of the epidermis does not considerably interfere with 5-ALA-liposomal FD. This is in 
contrast	with	a	negative	relation	shown	between	the	fluorescence	emitted	from	the	
skin and the thickness of the epidermis using 5-ALA in a cream base.41
The (pre-) malignant lesions were histologically diagnosed as actinic keratosis in 
31.2% of the patients, as BCC in 3.03% and as SCC in 1.01%. Notably in FD, these 
lesions	 usually	 show	 up	 as	 an	 irregularly	 defined	medium	 to	 high	 intensity	 core	
with	a	well	circumscribed	surrounding	medium	intensity	halo	(figures	6	 to	7).	 In	5	
of	the	patients	AKs	not	noted	by	the	patients	and	also	not	by	the	examining	doctors	
were	 identified	by	fluorescence	detection	and	confirmed	by	histological	diagnosis.	
Therefore, the FD technique used in this study appeared to be superior for the 
identification	of	(pre-)	malignant	lesions	than	clinical	examination	in	contrast	to	the	
FD technique used in previous studies.42 Only one patient showed a false negative 
fluorescence.	This	lesion,	situated	on	the	vertex,	was	noted	by	the	patient	because	
of	a	thick	hyperkeratosis	and	clinical	identified	as	actinic	keratosis	by	the	examining	
doctor	and	confirmed	by	histology	(Figure	8).	The	fluorescence	image	of	this	patient	
showed no distinct discrimination between the lesion and the surrounding skin, very 
probably	caused	by	the	abundant	fluorescence	of	the	surrounding	hairs	and	may	be	
also	by	difficult	penetration	of	the	ALA	into	the	highly	keratinized	lesion	(Figure	9).	
This makes it likely, that FD is not an appropriate method to examine skin lesions 
situated on dense hairy sites of the body. Interference may also occur from dermal 
infections,	viral	verrucae	and	inflammatory	diseases,	like	psoriasis.
This new non-invasive technique is time saving for the doctor, because it can be 
performed by auxiliary personnel presenting the physician with images which can be 
assessed at a glance. It is advisable to apply the current system in a professional 
environment.	A	custom	robotic	arm	can	be	used	during	the	fluorescence	detection	
operation and a totally darkened room is needed. In addition, special rooms with 
dimmed light where the patients can apply the 5-ALA spray are required. This makes 
the system less suitable for the daily practice in a general hospital. The creation 
of specialized detection centres would make sense, especially given the large 
population which are at risk of acquiring a NMSC. 
Future	 studies	 may	 optimize	 the	 correlation	 between	 fluorescence	 patterns	 and	
clinical and histological pictures, especially concerning the discrimination of 
penetrating from non-penetrating malignancies.
.
Conclusions
In	the	field	of	fluorescence	detection	5-ALA-liposomes appear to be superior to MAL 
cream for discrimination between normal skin, benign lesions and NMSC lesions. 
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Moreover, 5-ALA-liposomes are safer to use due to lesser- and shorter duration of 
post-procedure photo-toxicity compared with MAL cream. 
A substantial percentage (23.7%) of the patients appeared to have positive 
fluorescence	caused	by	sebaceous	gland	hyperplasia.	Because	sebaceous	gland	
hyperplasia	can	easily	be	identified	on	clinical	examination	they	did	not	interfere	in	
the detection of NMSC. Interference may also occur from dermal infections, viral 
verrucae	and	inflammatory	diseases,	like	psoriasis.
The	FD	technique	used	in	this	study	appeared	to	be	more	sensitive	for	the	identification	
of	(pre-)	malignant	lesions	than	clinical	examination	in	contrast	to	the	fluorescence	
techniques used in previous studies.42 
False	negative	fluorescence	was	found	in	only	one	lesion	(1.01%),	situated	on	the	
hairy scalp of the patient, indicating that FD may not to be an appropriate method for 
examining skin lesions situated on dense hairy sites of the body. 
FD using liposomal encapsulated 5-ALA and a specialized version of the Dyaderm® 
system offers the possibility for detection of NMSC at an early, pre-clinical  stage, 
and	 the	 technique	can	easily	examine	 large	areas	of	skin.	 It	also	 identifies	areas	
of	most	interest	for	performing	confirmatory	skin	biopsies,	as	well	as	pre-operative	
assessment	 of	 boundaries	 of	 skin	malignancies,	 and	 finally	 the	 technique	 is	well	
suited for control of treatment.
References
Marks R. An overview of skin cancers. Incidence and causation. Cancer 1. 
1995; 75: 607-612. 
	English	DR,	Armstrong	BK,	Kricker	A,	Fleming	C.	Sunlight	and	cancer.	2. 
Cancer Causes Control 1997; 8: 271-283.
Salasche SJ. Epidemiology of actinic keratoses and squamous cell 3. 
carcinoma. J Am Acad Dermatol 2000; 42: S4-7. 
Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 4. 
2002; 146, Suppl 61: 1-6.
Trakatelli	M,	Ulrich	C,	del	Marmol	V,	Euvrard	S,	Stockfleth	E,	Abeni	D.	5. 
Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate 
and comparable data are needed for effective public health monitoring and 
interventions. Br J Dermatol 2007; 156, S 3: 1-7. 
Marks R, Rennie G. Malignant transformation of solar keratoses to 6. 
squamous cell carcinoma. Lancet 1988: 795-797.
Jorizzo	JL,	Carney	PS,	Ko	WT,	Robins	P.	Treatment	options	in	the	7. 
management of actinic keratosis. Cutis 2004; 74 (S 6): 9-17.
Epstein E. Quantifying actinic keratosis: assessing the evidence. Am J Clin 8. 
Dermatol 2004; 5: 141-144.
258
Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell 9. 
carcinoma. Brit J Dermatol 2006; 155: 9-22.
Ceilly	RI.	Modalities	and	mechanisms	of	action.	In:	The	field	treatment	of	10. 
actinic keratosis. Skin Aging 2004; October (suppl.): 3-5.
Oppel	T,	Korting	HC.	Actinic	keratosis:	the	key	event	in	the	evolution	from	11. 
photodaged skin to squamous cell carcinoma. Skin Pharmacol Physiol 
2004; 17: 67-76.
Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of 12. 
actinic keratoses and the controversy over treatment: a patient-oriented 
perspective. Arch Dermatol 1991; 127: 1029-1031.
Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol 2007; 46: 895-904.13. 
Housman TS, Feldman SR, Williford PM, Fleisher AB. Skin cancer is 14. 
among the most costly of all cancers to treat for Medicare population. J Am 
Acad Dermatol 2003; 48: 425-429.
Armstrong	BK,	Kricker	A.	The	epidemiology	of	UV	induced	skin	cancer.	J	15. 
Photochem Photobiol B: Biol 2001; 63: 8-18. 
Young AR. Tanning devices-fast track to skin cancer?  Pigment cell Res 16. 
2004; 17: 2-9.
MacKie	RM.	Long-term	health	risk	to	the	skin	of	ultraviolet	radiation.	Prog	17. 
Biophys Mol Biol 2006; 92: 92-96.
The	international	agency	for	research	on	cancer	working	group	on	artificial	18. 
ultraviolet light and skin cancer. The association of use of sunbeds with 
cutaneous malignant melanoma and other skin cancers: a systemic review. 
Int J Cancer 2006; 120: 1116-1122.
Nijsten TEC, Stern RS. The increased risk of skin cancer is persistent after 19. 
discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 
2003; 121: 252-258.
Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of 20. 
non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J. 
Invest Dermatol 2005; 124: 505-513.
Vitasa BC, Taylor HR, Strickland PT, Rosenthal F, West S. Association 21. 
of non-melanoma skin cancer and actinic keratosis with cumulative solar 
ultraviolet exposure in Maryland watermen. Cancer 1990; 65: 2811-2817.
Buja A, Lange JH, Perissinotto E, Rausa G, Grigoletto F, Canova C, 22. 
Mastrangelo G. Cancer incidence among male military and civil pilots and 
flight	attendants:	an	analysis	on	published	data.	Toxicol	Ind	Health	2005;	
21: 273-282. 
Moehrle M. Outdoor sports and skin cancer. Clin Dermatol 2008; 26: 12-15.23. 
Schwartz	RA,	Bridges	TM,	Butani	AK,	Ehrlich	A.	Actinic	keratosis:	an	24. 
259
occupational and environmental disorder. J Eur Ac Dermatol Venereol 
2008: 1-9.
Masini C, Fuchs PG, Gabrielli F, Starks S. Evidence for the association of 25. 
human papillomavirus infection and cutaneous squamous cell carcinoma in 
immunocompetent individuals. Arch Dermatol 2003; 139: 890-894.
Euvrard	S,	Kanitakis	J,	Claudy	A.	Medical	progress:	Skin	cancers	in	organ	26. 
transplant recipients. N Engl J Med 2003; 348: 1681-1691.
De	Hertog	SAE,	Wensveen	CAH,	Bastiaens	MT,	Kielich	CJ,	Leiden	skin	27. 
cancer study. Relation between smoking and skin cancer. J Clin Oncol 
2001; 19: 231-238.
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. Ca Cancer 28. 
J Clin 2002; 52: 23-47.
Venna SS, Lee D, Stadecker MJ, Rogers GS. Clinical recognition of actinic 29. 
keratoses in a high-risk population. Arch Dermatol 2005; 141: 507-509.
Smits	 T,	 Kleinpenning	 MM,	 Blokx	 WAM,	 Kerkhof	 PCM,	 van	 Erp	 PEJ,	30. 
Gerritsen MP. (2007). Fluorescence diagnosis in keratinocytic intraepidermal 
neoplasias. J Am Acad Dermatol 2007; 57: 824-831.
Trakatellis A, Gerochristos I, Trakatelli M. The programme of community 31. 
action	in	the	field	of	health	(2007-2013).	Pharm	Policy	Law	2005,	2006;	8:	
3-11. IOS Press.
Ericson MB, Sandberg C, Gudmundson F, Rosen A, Larkö O. Fluorescence 32. 
contrast and threshold limit: implications for photodynamic diagnosis of 
basal cell carcinoma. J Photochem Photobiol B: Biology 2003; 69: 121-127. 
Svaasand LO, Wyss P, Wyss MT, Tadir Y, Tromberg BJ, Berns MW. 33. 
Dosimetry model for photodynamic therapy with topically administered 
photosensitizers. Lasers Surg Med 1996;  18: 139-149. 
Moan J, Ma LW, Iani V. On the pharmacokinetics of topically applied 34. 
5-aminolevulinic acid and two of its esters. Int J Cancer 2001; 92: 139-143. 
Ackermann G, Abels C, Baumler W, Langer S, Landthaler M, Lang EW, 35. 
Szeimies RM. Simulations on the selectivity of 5-aminolevulinic acid-
induced	fluorescence	in	vivo.	J	Photochem	Photobiol	B:	Biol	1998;	47:	121-
128. 
Hua Z, Gibson SL, Forster TH, Hilf R. Effectiveness of delta-aminolevulinic 36. 
acid-induced protoporphyrin as a photosensitizer for photodynamic therapy 
in vivo. Cancer Res 1995; 55: 1723-1731.
Christiansen,	 K.,	 Bjerring,	 P.,	 &	 Troilius,	 A.	 (2007).	 5-ALA	 Photodynamic	37. 
photorejuvenation-optimization of treatment regume based on normal-skin 
fluorescence	measurements.	Lasers		Surg	Med	2007;	39:	302-310.
Hope	M.J.,	Kitson	C.N.	Liposomes:	A	Perspective	for	Dermatologists.	38. 
260
Dermatol Clin 1993; 11: 143-154.
Lieb	L,	Ramchandran	C,	Egbaria	K,	Weiner	N.	Topical	delivery	39. 
enhancement  with multilamellar liposomes into pilosebaceous units. J. 
Invest Dermat 1992; 99: 108-113.
Artmann C, Roding J, Ghyczy M, Prazel HG. Liposomes from soya 40. 
phospholipids as percutaneous drug carriers. Arzeim Forsch 1990; 40: 
1365-1368.  
Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the 41. 
transepidermal osmotic gradients and hydration force. Biochim Biophys 
Acta 1992; 1104: 226-232.
Plessis	J,	Egbaria	K,	Weiner	N.	Influence	of	formulation	factors	on	the	42. 
deposition of liposomal components into the different strata of the skin. J 
Soc Cosmet Chem 1992; 43: 93-100.
Ostro M. Liposomes. Sci Am 1987; 256: 102-111. 43. 
Verma DD, Verma S, Blume G, Fahr A. Liposomes increase skin penetration 44. 
of entrapped and nonentrapped hydrophilic substances into human skin: a 
skin penetration and confocal laser scanning microscopy study. Eur J Pharm 
Biopharm 2003; 55: 271-277.
Bäumler W, Abels C, Szeimies RM. Fluorescence diagnosis and todynamic 45. 
therapy in dermatology. Med Laser Appl 2003; 18: 47-56.
Fauteck J, Ackermann G, Birkel M, Breuer M, Moor ACE, Ebeling A, Ortland 46. 
C. Fluorescence characteristics and pharmacokinetic properties of a novel 
self-adhesive 5-ALA patch for  photodynamic therapy of actinic keratoses. 
Arch of Dermatol Res 2008; 300: 53-60.
47.  Gambichler	T,	Moussa	G,	Altmeyer	P.	A	pilot	study	of	fluorescence	iagnosis	
of	basal	cell	carcinoma	using	a	digital	flash	light-based	imaging	system.	
Photodermatol Photoimmunol Photomed 2008; 24: 67-71
48. Internet information: http// :www DyaDerm.
Wennberg AM, Gudmundson F, Stenquist B, Ternesten A, Molne L, 49. 
Rosen A, Larkö O. In vivo detection of basal cell carcinoma using imaging 
spectroscopy. Acta Dermatol Venereol 1999; 79: 54-61.
Bernard E, Bubois JL, Wepeirre J. Importance of sebaceous glands in 50. 
cutaneous penetration of an antiandrogen: target effect of liposomes. J 
Pharm Sci 1997; 86: 573-578.
51.  Zaballos P, Ara M, Puig S, Malvehy J. Dermoscopy of sebaceous 
hyperplasia. Arch Dermatol 2005; 141: 808.
52. Stolz W, Braun-Falco O, Bilek P, Landthaler M, Burgdorf WHC, Cognetta 
AB. Color Atlas of Dermatoscopy, second edition. Blackwell Wissenschafts-
Verlag Berlin. Blackwell Plubishing Company 2002: 31-35.
261
Total 93 patients Number  % of Number % of
 of lesions lesions of patients Patients
No	fluorescence	 0	 0	 32	 34,3
Positive	fluorescence	 287	 100%	 61	 65,7
Sebaceous 204 71,1% 22 23,7
gland hyperplasia
Other benign lesions 8 2,8% 6 6,5
Actinic	Keratosis	 71	 24,7%	 29	 31,2
Malignant lesions 4 1,4% 4 4,3 
Table 1.
Table 2.
Differential diagnosis of  actinic keratosis
benign malignant
kerarosis ( seborrheic, stucco, arsenical,  lichenoid ) Bowen’s disease
porokeratosis  basal cell carcinoma
keratoacanthoma squamous cell 
carcinoma
lentigo solaris
discoid lupus erythematodes
psoriasis
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Figure 1.
The sequence of images from the skin of a female patient with a histologically 
confirmed	basal	cell	carcinoma	on	the	upper	back:	
a. Colour image from the upper back b. Fluorescence image showing the skin 
tumor position. 
c. Processed image, where in pseudo-
color the tumor position, known from the 
fluorescence	image,	is	superimposed	
and blended into the original image. 
Irregularly	defined	fluorescence	showing	
medium (yellow) intensity.
Figure2
Fluorescence image right side of the 
forehead, 3 hours after application 
of MAL cream under occlusion: High 
fluorescence	in	most	of	the	studied	
skin area, showing low discrimination 
between normal and diseased skin.
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Figure 3
Fluorescence image left side of the 
forehead 3 hours after application of 
5-ALA 0.5% liposomal spray (every 
5 minutes for 2 ½ hours and ½ hour 
more for optimal absorption of 5-ALA 
into the skin) without occlusion: Low 
fluorescence	from	the	normal	skin	
in the studied skin area and distinct 
fluorescence	from	actinic	keratoses,	
resulting in a high discrimination 
between normal and diseased skin. 
Figure 4
Fluorescence image forehead 36 hours 
after MAL cream right side and 36 hours 
after 5-ALA liposomal spray left side. 
The	fluorescence	of	5-ALA	liposomal	
spray is of lower intensity and of lower 
duration compared to MAL cream.
Figure 5
Fluorescence image from sebaceous 
gland hyperplasia: Circumscribed, 
regularly	defined	fluorescence	showing	
medium (yellow) to high (red) intensity.
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Chapter 14
Summary, general discussion and recommendations for 
further investigations
14.1     Introduction
Topical treatment has been used for centuries in skin diseases because they are 
visible and directly accessible. Since the introduction of arsenic in the 19th century 
as a systemic treatment for psoriasis, an increasing range of systemic drugs are 
available for the treatment of numerous skin diseases. However, none of the topical 
and systemic agents is effective in all patients and adverse effects limit their use. 
Therefore, an ideal drug for most skin diseases still remains to be developed. 
Although on the one hand, systemic drugs have a higher therapeutic potency than 
topically applied drugs, on the other hand, they cause more serious adverse effects.1 
The central subject of this thesis was to promote patient safety, because it should 
be a key focus of every dermatologic practice.2,3  The aims of the investigations that 
were pursued are summarized in chapter 1.
14.2      Phototherapy, fluorescence detection and liposomes
Phototherapy and photo-chemical therapy are positioned between topical therapy 
and systemic therapy because they have topical- and systemic effects. The dilemma 
in the classic light treatment using different ultraviolet (UV) light sources is the risk of 
skin	cancer.	This	has	led	to	a	conflicting	situation	in	which	dermatologists,	on	the	one	
hand, advice the public to limit the exposure of their skin to UV light and on the other 
hand, advice patients suffering from certain skin disorders to undergo treatment 
with	UV	 light.	Long-term	observations	of	psoriasis	patients	who	were	first	 treated	
with UV light and later on with cyclosporine ran a higher risk of Non-melanoma skin 
cancers (NMSCs)  as compared with controls.4  This highlights that the occurrence 
of iatrogenic complications, particularly iatrogenic tumors have to be minimized. In 
the same context, it is the dermatologist’s duty to detect skin cancer at an early stage 
in order to avoid unnecessary damage to the patients from the complications of 
advanced tumors or by the complications of extensive surgery or chemotherapy. 
A new approach is the use of light not of the wavelengths from the UV spectrum 
provided by lasers, intense pulsed light (IPL) systems and light emitting diodes 
(LED). These devices may provide the possibility to banish the risk of carcinogenesis 
from UV light treatment. The basis of the pulsed dye laser (PDL) therapy of vascular 
lesions is the destruction of abnormal vessels by the absorption of laser energy 
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without damaging the surrounding tissues (selective photothemolysis). 
The goal of photodynamic therapy (PDT) is the selective destruction of targeted abnormal 
cells while preserving the normal cells. The key principle is the preferential accumulation 
of 5-aminolaevulinic acid (5-ALA), after application to the skin, in cells with an elevated 
metabolism (such as tumor cells). The higher concentration of 5-ALA, which is not a 
photosensitizer by itself, results in a higher concentration of protoporfyrin IX (PpIX), 
which causes a cascade effect of radical oxygen species after illumination with the 
proper wavelengths. The higher PpIX concentration ratio in tumor cells compared with 
normal	cells	is	used	in	PDT	to	destroy	selectively	the	diseased	tissue	and	in	fluorescence	
detection to visualize the diseased cells. Until recently, clinically approved indications 
were	restricted	to	actinic	keratoses	(AK),	superficial	and	nodular	basal	cell	carcinoma	
(BCC) and Bowen’s disease (intra-epithelial carcinoma). The range of indications has 
been expanding continuously. Nowadays, PDT is also used for treating non-malignant 
disorders such as acne vulgaris, verrucae vulgaris, leishmaniasis and skin ageing. Various 
guidelines on PDT have been published, but complete consensus has not yet been 
reached. Liposomes are microscopic vesicles formed from phospholipids as biological 
membranes and may be used as carriers for hydrophilic as well as lipophilic therapeutic 
agents.	Low	concentrations	of	drugs	in	liposomes	may	be	as	efficacious	as	higher	doses	
in conventional preparations, but with reduced adverse effects from topical as well as 
from systemic absorption. The basic aspects of light absorption, photodynamic therapy, 
fluorescence	detection	and	liposomes	are	reviewed	in	chapter 2.
14.3     Major light-related dermatoses
Psoriasis, vitiligo, acne and NMSCs have a relationship with light and all of them are 
commonly encountered at a general dermatological practice. The epidemiology, the 
clinical aspects and the pathogenesis of these diseases together with the advantages 
and the disadvantages of their treatments are described in chapter 3. 
14.4 PDL treatment of plaque type psoriasis
Although psoriasis is an immune-mediated disease, the prominent increase in 
the dermal microvasculature in the lesional skin indicates that psoriasis is also 
angiogenesis-dependent. Traditional therapies for psoriasis have generally focused 
on	the	inhibition	of	epidermal	proliferation	and	/or	inflammation.	The	abnormities	in	
the capillary vasculature have been therapeutically neglected. Partial- and also total 
clearance of psoriasis after selective photothermolysis of the dermal vasculature by 
the PDL was reported in several studies. This laser was used to treat 74 patients with 
chronic plaque type psoriasis unresponsive to conventional topical therapies. After 
laser treatment, improvement appeared to be good to very good in 73% of patients 
as described in chapter 4.
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14.5      Psoriasis palmoplantaris
Psoriasis	of	 the	hands	and	the	feet	 is	a	distressing	and	disfiguring	disease,	often	
resistant to treatment, especially in case of pustulosis palmoplantaris. A group of 41 
patients with therapy-resistant psoriasis in the hands and in the feet were treated 
once every 4 to 6 weeks with PDL. Concomitant keratolytic treatment with calcipotriol 
ointment or salicylic acid 5% to 10% ointment was used. After an average of 4.2 
treatment sessions, more than 70% clearance was achieved in 76% of the
patients. Transient purpura occurred after each treatment session, crusts were 
noted	 in	 only	 3%	 of	 the	 patients.	 The	mean	 duration	 of	 remission	 after	 the	 final	
treatment	was	10.7	months.	A	 relapse	was	defined	as	 recurrence	of	 psoriasis	 to	
30% or more of the baseline. In many clinical studies, ‘‘remission’’ and ‘‘relapse’’ 
are	not	actively	defined.	Not	all	the	investigators	tend	use	the	same	definitions	even	
when	these	 terms	are	defined.	The	 least	stringent	definition	of	 relapse	 involves	a	
recurrence	of	psoriasis	to	50%	of	the	baseline.	The	strictest	definition	involves	any	
recurrence of psoriasis after clearing.  The results of this open prospective study 
showed that concomitant treatment with PDL and topical calcipotriol or salicylic acid 
was a satisfactory modality for treating psoriasis in the hands and in the feet with 
a subjective improvement in the symptoms and the quality of life in all patients as 
described in chapter 5.
14.6     PDL compared with UVB in the treatment of plaque type psoriasis
Recent breakthroughs in the treatment of psoriasis have led to a better understanding 
of the   pathogenesis of this disease. The traditional systemic psoriasis therapies 
such as Methotrexate (MTX), Cyclosporine (Cs) and mycophenolate mofetil (MMF) 
may be associated with an increased risk of lymphoproliferative disorders during 
treatment.	The	 risk	of	malignancy	with	biologic	 therapy,	 such	as	TNF-α	blockers,	
is still unclear. However, the majority of studies examining this carcinogenic risk 
reported	that	TNF-α	inhibitors	may	cause	a	slightly	increased	risk	of	cancer,	including	
NMSCs and hematological malignancies.5,6	The	status	of	TNF-α	inhibitors	in	relation	
with pan-epidemic threat and multi-resistance of tuberculosis is not yet clear, but 
is a subject of concern. Narrow-band ultraviolet-B light therapy (UVB) is highly 
efficacious	against	psoriasis.	In	contrast	to	UVB	and	psoralen	ultraviolet-A	(PUVA)	
therapy, PDL has no carcinogenic capacity. UVB targets primarily the structures in 
the epidermis, whereas PDL light passes through the epidermis and targets primarily 
the	superficial	vessels	in	the	dermis	indicating	that	UVB	and	PDL	clear	psoriasis	via	
different pathways. The aim of the study described in chapter 6 was to evaluate 
the	efficacy	and	the	safety	of	PDL	treatment	 in	plaque	type	psoriasis,	 to	compare	
the results of PDL treatment with those of the UVB treatment and with those of the 
PDL+UVB treatment, and to look for a synergistic effect of PDL+UVB treatment on 
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psoriasis. PDL and UVB, as well as the combination therapy PDL+UVB, resulted 
in	a	statistically	significant	 improvement.	PDL	was	as	effective	as	UVB	treatment.	
A combination of PDL and UVB treatment had no additional value because of the 
lack	 of	 synergism.	 Surprisingly,	 no	 statistically	 significant	 differences	 were	 noted	
between UVB treatment and PDL treatment on the one hand, and the neighboring 
non-treated (NT) sides, on the other hand. There is no clear explanation for this, but 
an unexpected “carry-over”  effect from the neighboring PDL- and UVB-treated sides 
is supported by the observation of an inverse relationship between improvement 
of NT sides and the distance between the PDL treated sides and the NT sides. 
These	findings	warrant	further	studies,	because	they	indicate	that	overlapping	spot	
sizes	may	not	be	necessary	and	this	implies	multiple	benefits	such	as	a	reduction	in	
the duration of treatment, less discomfort to the patients, and lower costs. Another 
possibility is a systemic effect on the NT sides due to the treatment of the remaining 
plaques. After all, it seems likely that dividing of plaques is not the best approach to 
study	the	efficacy	of	topical	therapies,	but	if	pursued,	the	treatment	must	be	strictly	
restricted to the study plaques without treatment of other remaining plaques. In the 
present study, patients with a complete clearance of the target lesion appeared to 
be divided into either PDL responders or UVB responders indicating that patients 
who do not respond to UVB may respond to PDL and vice versa. Treatment with 
PDL resulted only in mild and transient adverse effects and therefore appeared to be 
safe. PDL treatment should not be used in widespread psoriasis or in patients who 
respond adequately to simple topically applied treatments. PDL treatment should 
be reserved for patients with persistent plaque type psoriasis, not responding to 
usual treatments (particularly on ‘‘non-covered body’’ sites), plaque type psoriasis 
complicated by adverse effects of medication, psoriasis palmoplantaris, psoriasis 
inversa, patients not willing to use topical corticosteroids or systemic treatment, and 
patients at risk for skin cancer caused by actinic damage or immunosuppression. 
Most patients in our study preferred PDL therapy above UVB.    
The results of PDL treatments may be improved by:
Increasing the number of sessions.- 
Reducing the time intervals between treatments.- 
Increasing	the	fluence	and	the	pulse	width	to,	respectively,	10	J/cm- 2 
and 1.5 msec.
Application of optical coupling gel immediately prior to the PDL - 
treatment.
Concomitant treatment with calcipotriol ointment.- 
Further studies may provide additional insights for optimizing the treatment. 
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14.7     Cellular and molecular effects of pulsed dye laser and narrow-band UVB    
 therapy in psoriasis
In a new psoriatic plaque, dilation and proliferation of the dermal papillary 
microvasculature is one of the early changes seen. Increase in the dermal 
microvasculature	facilitates	trafficking	of	immune	cells	into	the	skin,	and	is	therefore	
important	 for	 maintenance	 of	 inflammation	 in	 psoriasis.	 Reduction	 of	 the	 hyper-
proliferation of the papillary microvasculature by selective photothermolysis using 
PDL	may	lead	to	a	reduction	of	immune	cell	trafficking	between	the	vasculature	and	
the interstitium of the skin, resulting in clearance of psoriasis plaqes. From the studies 
described in chapter 7, it appeared that clinical improvement of psoriasis after PDL 
treatment is accompanied by alterations in some classic markers of psoriasis disease 
activity. Clinically high responders to PDL treatment showed decreased expression 
of VEGFR2, VEGFR3 and E-selectin within 24 hours after PDL treatment. After 2 
PDL	 treatments	 IL-23	 and	TNF-α	mRNA	 and	 E-selectin	 protein	 expression	were	
significantly	 decreased,	 whereas	 after	 4	 treatments	 all	 epidermal	 markers	 and	
dermal	T	 cell	 infiltrates	 normalized.	 In	UVB-treated	 plaques,	 epidermal	 activation	
markers	and	E-selectin	expression	were	significantly	decreased	after	13	weeks.	In	
responders to PDL and NB-UVB treatment, the effects observed at the mRNA level 
were	comparable.	The	lower	clinical	efficacy	of	UVB	in	our	study	(52%	improvement	
versus minimally 60% reported for total body irradiation) may be explained by the 
fact that UVB treatment was used focally on selected psoriasis plaques instead 
of total body irradiation. It is assumed that total body UVB irradiation also exerts 
a systemic effect. At the end of the treatment period both PDL and UVB resulted 
in reduced expression of epidermal activation markers and reduced dermal T cell 
infiltrates.	An	interesting	observation	was	the	down	regulation	of	IL-23	during	PDL	
treatment, because it was recently reported that Th17 cells played a major role in the 
pathogenesis of psoriasis. This T helper cell is stimulated by IL-23. A new biological 
blocks IL-23 and seems to be effective in psoriasis, indicating that PDL and this 
biological	share	the	same	target.	The	down-regulation	of	TNF-α	and	IL-23p19	may	
contribute	to	the	efficacy	of	PDL	treatment	in	psoriasis.	
14.8          Liposomes
Liposomes have a high potential for topical therapy in Dermatology. Although the 
skin is an organ, which is directly accessible for topical application of drugs, it does 
not imply that drugs incorporated in conventional transport media such as lotions, 
creams and ointments are delivered at the optimal concentration to the right target 
structure in the skin. Liposomes can be used as carriers for hydrophilic as well as 
lipophilic therapeutic agents. They may improve stabilization of instable drugs by 
encapsulating them and serve as penetration enhancers facilitating the transport 
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of compounds through the epidermis that otherwise cannot penetrate the skin. 
Liposomes will help in reducing skin irritation by sustaining the release of the drugs 
and by hydration of the epidermis. They also have the potential to target drugs into 
the pilosebaceous structures and hence they can be used for treating disorders 
associated with sebaceous glands and hair follicles. Low concentrations of drugs 
in liposomes are as effective as higher doses in conventional preparations, but 
with reduced adverse effects from topical as well as from systemic absorption of 
drugs. Promising results have been obtained with liposomal encapsulated drugs in 
the	treatment	of	acne,	xerosis	cutis,	atopic	dermatitis,	psoriasis,	vitiligo,	superficial	
vein thrombosis and hair removal. ‘Empty’ liposomes (without encapsulated drugs) 
hydrate the skin simply by contributing lipids to the stratum corneum. Moreover, 
the water content of the liposomes promotes further hydration of the skin. Thus, 
liposomes may replace the classic emollients. Liposomes will also help to reduce 
skin irritation to drugs (e.g. tretinoin) by hydration of the epidermis, resulting in better 
acceptance and reliability by the patients.
PDT	is	widely	used	to	treat	AK	and	superficial	BCC.	In	addition,	PDT	is	increasingly	
used to treat acne and for skin-rejuvenation. Side-effects limit patient’s acceptance, 
especially in case of non-malignant skin disorders. Changing the 5-aminolevulinic 
acid (ALA) vehicle from a moisturizing cream to liposome encapsulation lowers its 
concentration	by	a	factor	of	40	still	inducing	the	same	skin	fluorescence	and	at	the	
same time eliminating the need for occlusion. Another advantage is reduction of 
costs. The in and outs of liposomes are dealt with in chapter 8 
The following studies on liposomes may be of value:
 -  5-ALA liposomes and daylight for the treatment of acne.  
	 -	 	5-ALA	liposomes	and	daylight	for	the	prevention	of	skin	aging,	AKs	and		 	
	 superficial	BCCs.
 - 5-ALA liposomes and IPL or PDL for skin rejuvenation.
 - T4-endonuclease-V in liposomes for the treatment and the prevention of   
 NMSC.
 - Cyclosporine in liposomes for the treatment of severe psoriasis and atopic  
 eczema.
 - Methotrexate in liposomes for the treatment of severe psoriasis.
	 -	 “Empty”	liposomes	or	fillagrin	containing	liposomes	for	the	treatment	of	dry		
 skin and atopic dermatitis.
14.9 Treatment of vitiligo with liposomal khellin in combination with UV light 
therapy 
Vitiligo is a non-life threatening dermatosis, which has a serious psychological impact 
and affects of the quality of life of the patient. Vitiligo is histologically characterized by 
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the absence of melanocytes in the epidermis. However, the melanocytes in the hair 
follicles are generally not affected. Therapeutic approaches are aimed at reversing 
the progressive loss of melanocytes and reconstituting normal skin coloration. During 
the process of re-pigmentation, the follicular melanocytes proliferate and migrate into 
the epidermis. Common methods for treatment are topical corticosteroids, tacrolimus, 
systemic	and	 topical	PUVA,	UVB,	and	 topical	khellin	with	UVA	(KUVA).	However,	
none of these is uniformly effective.	 Khellin	 has	 phototherapeutic	 properties	 that	
are similar to those of the psoralens, but with substantially lower phototoxic effects 
and DNA mutation effects. Data on the current status of khellin in the treatment of 
vitiligo were inconclusive. The selection of the vehicle in which khellin is incorporated 
is highly important for the adequate availability of khellin in the skin. Encapsulating 
khellin in phosphatidylcholine liposomes enhances the availability of khellin in the 
hair follicles facilitating the stimulation of the melanocytes. The	 efficacy	 and	 the	
safety of the treatment with khellin encapsulated in L-phenylalanine stabilized 
phosphatidylcholine liposomes in combination with UVA/UVB light therapy was 
evaluated in an open, retrospective study described in chapter 9. A re-pigmentation 
response of 50% to 100% was achieved in 72% of treated locations after a mean 
treatment period of 12 months. The re-pigmentation was not equal for different parts 
of the body. 
14.10     Blister roof transplantation (BRT) for vitiligo 
Surgical techniques are generally reserved for stable and refractory vitiligo. The 
transplantation of epidermal blister grafts on the de-pigmented areas is safe, easy to 
use, has a maximum expansion rate of pigmentaion and is without any scarring as 
described in the study in chapter 10.
14.11 Combination of liposomal khellin and UV light treatment with blister roof 
transplantation for refractory vitiligo
Recent guidelines on the treatment of vitiligo recommended UVB therapy only in 
patients who cannot be adequately managed with conservative treatments, who 
have widespread vitiligo or have localized vitiligo associated with a significant impact 
on the patient’s quality of life (QoL). However, in many patients refractory areas 
may remain. Photo-medical treatment such as PUVA and khellin with ultraviolet light 
(KLUV) may be efficacious where other treatments have failed. It seems rational to 
prefer KLUV because khellin has phototherapeutic properties that are similar to those 
of the psoralens, but substantially lower phototoxic effects and DNA mutation effects. 
Moreover, KLUV results in disease stability in almost all case, which is an important 
requirement for the success of surgical therapy. The procedure and the results of 
patients	who	had	been	treated	for	at	 least	1	year	with	KLUV	followed	by	BRT	for	
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refractory vitiligo lesions are described in Chapter 11. Post-surgery photo-medical 
treatment (KLUV) is necessary to obtain enough peripheral spread of the pigment to 
cover the entire de-pigmented area. Further studies may evaluate the individual role 
of	BRT,	UV	and	Khellin.	Improvements	in	the	blister	roof	transplantation	technique	
may be achieved via:
- Applying a corticosteroid cream or a calcineurin cream to the recipient area 
after the grafts have been taken in order to avoid activation of the vitiligo 
process	 caused	 by	 the	 ablation	 procedure	 (Köebner	 phenomenon)	 or	
spontaneous aggravation of vitiligo.
- A medical intervention for the underlying causes of melanocyte destruction 
(e.g. Efalizumab).
- Suction blister roof ablation of the recipient area instead of the ablation with 
the Erbium laser in order to obtain the same thickness of the removed skin 
and the transplanted skin.
14.12  PDT of acne vulgaris using 5-ALA 0.5% liposomal spray and IPL in 
combination with topical keratolytic agents
The	search	 for	new	efficacious	and	safe	 treatment	modalities	 for	acne	 is	 justified	
because of the increasing antibiotic resistance of Propionibacterium acnes and the 
growing awareness on the adverse effects of conventional topical and systemic 
anti-acne	drugs.	Although,	 the	efficacy	of	PDT	using	20%	5-ALA	cream	has	been	
established, phototoxic adverse effects limit its use. Liposomes have the potential to 
carry lipophilic drugs and hydrophilic drugs such as 5-ALA into the
pilosebaceous structures. It was reported that by changing the vehicle of 5-ALA from 
a moisturizing cream to liposome encapsulation the 5-ALA concentration can be 
lowered	to	0.5%	providing	a	similar	level	of	induced	skin	fluorescence	and	eliminating	
the	need	for	occlusion.	The	low	post-treatment	fluorescence	also	significantly	reduced	
the	risk	of	post-treatment	phototoxicity.	A	study	to	assess	the	efficacy	and	the	safety	
of PDT using 5-ALA 0.5% in liposomal spray and IPL in combination with a peeling 
cream (Li-PDT-PC) in acne vulgaris is described in chapter 12. 
The results of this treatment may be improved by:
-	 Using	double	passes	with	the	IPL	on	inflammatory	lesions.
- Reducing the treatment intervals to 2 or 3 weeks.
14.13  Non-melanoma skin cancer and fluorescence detection  
Non-melanoma skin cancer (NMSC) is the biggest challenge for the next two decades 
in Dermatology. The expected dramatic rise in the prevalence of skin cancer will lead 
to a work-overload at all the dermatological practices if no serious attempts are 
made to educate the general public on prevention to curb the problem. Even with the 
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foreseen increase of the number of dermatologists in the Netherlands, this problem 
is too immense to handle if we continue to carry on in the same way and the settings. 
Screening patients for (pre-) malignant lesions will allow early detection and prompt 
treatment.	Diagnostic	skin	fluorescence	using	liposomal	encapsulated	5-ALA	and	a	
specialized computerized detection and visualization system offers the possibility for 
detection	of	NMSC	at	an	early	(pre-clinical)	stage.	This	fluorescence	detection	(FD)	
technique	is	well-suited	to	examine	large	areas	of	the	skin.	It	also	identifies	areas	
of	most	 interest	 for	obtaining	confirmatory	skin	biopsies,	as	well	as	pre-operative	
assessment of the boundaries of skin malignancies. The technique is also useful in 
the control and the follow-up of skin cancer treatment. The technique and the results 
of FD are described in chapter 13. 
Further	studies	on	fluorescence	detection	are	essential	to	optimize the correlation 
between the fluorescence patterns and the clinical and the histological pictures, 
especially for distinguishing the penetrating from the non-penetrating malignancies. 
Additional studies on	the	efficacy	of	PDT	using	IPL	or	PDL	of	AKs	and	NMSC	directly	
after	 the	 fluorescence	 detection	 in	 the	 same	 session	may	 offer	 a	 highly	 efficient	
treatment modality.
Samenvatting, algemene discussie en aanbevelingen 
voor  verder onderzoek.
14.14    Introductie
Uitwendige geneesmiddelen zijn eeuwenlang gebruikt voor de behandeling van 
huidziekten, omdat de huid zonder hulpmiddelen direct toegankelijk is. Sinds de 
introductie van arsenicum in de 19e eeuw voor de behandeling van psoriasis zijn er 
vele systematisch toepasbare geneesmiddelen ter beschikking gekomen om talrijke 
huidziekten te behandelen. Geen van deze locale en systematische middelen zijn bij 
alle patiënten effectief en bijwerkingen kunnen het gebruik ervan beperken. Voor de 
meeste huidziekten moet daarom een ideaal geneesmiddel nog worden ontwikkeld. 
Systematische geneesmiddelen hebben doorgaans een grotere therapeutische 
potentie dan locale middelen, maar kunnen aan de andere kant ook ernstiger bij 
werkingen hebben.1 Het centrale thema van deze thesis is om de veiligheid van 
de patiënt te bevorderen, omdat dit beschouwd moet worden als de voornaamste 
doelstelling van iedere behandeling en dus ook in de dermatologische praktijk.2,3 De 
doelstellingen van de onderzoekingen die werden uitgevoerd zijn samengevat in 
hoofdstuk 1.
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14.15     Phototherapie, fluorescentie detectie en liposomen
Phototherapie en photochemotherapie hebben locale en systeem effecten en zijn 
daarom gepositioneerd tussen locale therapie en systematische therapie. Het 
dilemma in de klassieke licht therapie, waarbij ultraviolet (UV) lichtbronnen worden 
gebruikt, is het risico op huidkanker. Dit	heeft	geleid	tot	een	conflictueuze	situatie,	
waarin dermatologen aan de ene kant het publiek adviseren om de blootstelling 
van de huid aan UV licht te beperken en aan de andere kant patiënten met 
bepaalde huidziekten juist adviseren om behandelingen met UV licht te ondergaan. 
Observaties op langere termijn van psoriasis patiënten, die eerst zijn behandeld 
met UV licht en later met cyclosporine, hebben aangetoond, dat deze patiënten 
een groter risico lopen op het krijgen van non-melanoma huid kanker (NMSC) 
dan de controle patiënten.4 Deze bevindingen onderstrepen dat het optreden van 
iatrogene complicaties, vooral van iatrogene tumoren geminimaliseerd dienen te 
worden. In dezelfde context is het de taak van de dermatoloog om huidkanker in 
een vroeg stadium op te sporen met het doel om onnodige schade van de patiënt 
door complicaties van uitgebreide tumoren of door de complicaties van uitgebreide 
chirurgie of chemotherapie te vermijden. Een nieuwe benadering is het gebruik van 
licht	zonder	de	UV	golflengten,	dat	geproduceerd	wordt	door	lasers,	intense	pulsed	
light (IPL) systemen en light emitting diodes (LED). Deze apparaten maken het 
mogelijk om het risico op huidkanker door UV licht uit te bannen. De basis van de 
pulsed dye laser (PDL) behandeling van bloedvatafwijkingen is de destructie van 
abnormale bloedvaten door absorptie van laser licht energie zonder schade aan te 
brengen aan de omringende weefsels (selectieve photothermolysis).
Het doel van photodynamische therapie (PDT) is de selectieve destructie van 
abnormale cellen waarbij de normale cellen gespaard blijven. Het basis principe 
hiervan is, dat 5-aminolevulinezuur (5-ALA) na applicatie op de huid in hogere 
concentraties wordt opgenomen door cellen met verhoogde stofwisseling (bv. tumor 
cellen) dan door normale cellen. De hogere concentratie van 5-ALA, dat zelf geen 
photosensitieve eigenschappen bezit, leidt tot hogere concentratie in de abnormale 
cellen	van	protoporfyrine	IX	(PpIX),	dat	na	belichting	met	de	juiste	golflengten	een	
cascade effect teweegbrengt door de vorming van radicale zuurstof species. De 
hogere concentratieratio van PpIX in tumorcellen ten opzichte van normale cellen 
wordt gebruikt in de PDT om selectief het aangetaste weefsel te vernietigen en in 
de	fluorescentie	detectie	(FD)	om	de	aangetaste	cellen	zichtbaar	te	maken.	Tot	voor	
kort waren de geautoriseerde klinische indicaties van PDT beperkt tot actinische 
keratoses	 (AK),	 superficiële	 en	 nodulaire	 basaalcel	 carcinomen	 (BCC)	 en	 M.	
Bowen (intra-epitheliaal carcinoom). De rij van indicaties wordt continue uitgebreid. 
Tegenwoordig wordt PDT ook gebruikt bij de behandeling van niet kwaadaardige 
huidaandoeningen, zoals acne vulgaris, verrucae vulgares, leishmaniasis and 
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huidveroudering. Meerdere richtlijnen op het gebied van de PDT zijn gepubliceerd, 
maar complete concensus is nog niet bereikt. 
Liposomen (microscopische blaasjes, die gemaakt zijn van dezelfde phospholipiden 
als waaruit biologische membranen zijn opgebouwd) kunnen gebruikt worden 
als dragers van zowel in water als van in vet oplosbare geneesmiddelen. Lage 
concentraties van geneesmiddelen in liposomen kunnen even effectief zijn als 
hogere doses in conventionele preparaten, maar met minder kans op bijwerkingen 
van zowel locale als systeem absorptie. De basis aspecten van licht absorptie, PDT, 
FD en liposomen zijn beschreven in hoofdstuk 2.
14.16    Belangrijke aan licht gerelateerde dermatosen
Huidaandoeningen zoals psoriasis, vitiligo, acne en NMSC’s hebben een relatie 
met licht en komen veelvuldig voor in een algemene dermatologische praktijk. 
De epidemiologie, de klinische aspecten en de ontstaanswijze van deze ziekten 
worden, samen met de voordelen en de nadelen van de behandelingen, besproken 
in hoofdstuk 3. 
14.17    PDL behandeling van plaque type psoriasis
Hoewel psoriasis in eerste instantie veroorzaakt wordt door erfelijk bepaalde 
afwijkingen in het afweersysteem wijst de opvallende toename van de kleine 
bloedvaatjes in de bovenste laag van de lederhuid ter plaatse van de psoriasis plekken 
erop dat psoriasis mede veroorzaakt wordt door afwijkingen in deze bloedvaatjes. 
Traditionele behandelingen voor psoriasis zijn gericht op de remming van het 
afweersysteem en de daardoor veroorzaakte ontsteking in de opperhuid en lederhuid 
en de verhoogde celdeling in de opperhuid. De afwijkingen in de bloedvaatjes in 
de lederhuid werden aanvankelijk therapeutisch genegeerd. In meerdere studies 
werd echter gedeeltelijke en ook totale verdwijning van psoriasis plekken vermeld na 
selectieve photothermolyse door de PDL van de verwijde bloedvaten in de lederhuid. 
In hoofdstuk 4 wordt een studie beschreven, waarin de PDL werd toegepast bij de 
behandeling van 74 patiënten met chronische plaque type psoriasis, die niet had 
gereageerd op conventionele locale behandelingen. Na PDL behandeling werd een 
goede tot zeer goede verbetering bereikt bij 73% van de patiënten..
14.18  Psoriasis palmoplantaris
Psoriasis van handen en voeten is een invaliderende en ontsierende aandoening, 
die vaak slecht reageert op behandeling, vooral in het geval van een pustulosis 
palmoplantaris (psoriasis variant, die gepaard gaat met gele en bruine puisten). Een 
groep van 41 patiënten met therapie resistente psoriasis van handen en voeten 
werd iedere 4 tot 6 weken behandeld met PDL in combinatie met calcipotriolzalf 
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of  5% tot 10% salicylzuurzalf. Een verbetering van meer dan 70% werd bereikt in 
76% van de patiënten na een gemiddeld aantal van 4.2 behandelingen. Tijdelijke 
purpura trad, zoals gebruikelijk, op na iedere PDL behandeling, korsten werden 
gezien bij slechts 3% van de patiënten. De gemiddelde remissie duur na de laatste 
behandeling	bedroeg	10.7	maanden.	Een	recidief	van	psoriasis	werd	gedefinieerd	als	
het wederom optreden van psoriasis van 30% of meer ten opzichte van de baseline 
score. In vele klinische studies worden remissie en recidief verschillend of helemaal 
niet	gedefinieerd.	De	minst	strenge	definitie	van	 recidief	 is	het	opnieuw	optreden	
van psoriasis van 50% ten opzichte van de baseline score, terwijl de strengste 
definitie	uitgaat	van	ieder	zichtbaar	recidief	na	een	remissie.	De	resultaten	van	deze	
open prospectieve studie laten zien, dat gecombineerde behandeling met PDL en 
locaal calcipotriol- of salicylzuurzalf een bevredigend resultaat kan opleveren bij de 
behandeling van psoriasis van handen en voeten met een duidelijke verbetering van 
de symptomen en de quality of live, zoals is beschreven in hoofdstuk 5.
14.19  PDL vergeleken met UVB in de behandeling van plaque type psoriasis
Recente doorbraak in de behandeling van psoriasis heeft geleid tot een beter begrip 
van de pathogenese van deze ziekte. Traditionele systemische behandelingen van 
psoriasis, zoals methotrexaat (MTX), cyclosporine (Cs) en mycophenolaat mofetil 
(MMF) kunnen gepaard gaan met een toename van het risico op lymphoproliferatieve 
aandoeningen.	Het	 risico	op	maligniteit	met	de	moderne	biologicals,	zoals	TNF-α	
blokkers is nog niet duidelijk. Het merendeel van de studies naar het carcinogene 
risico van biologicals noemen een gering verhoogd risico op kanker, inclusief 
NMSK’s	en	hematologische	malignitieten.5,6 De	status	van	TNF-α	remmers	in	relatie	
tot pan-epidemische dreiging en multi-resistente tuberculose bacteriën is nog niet 
duidelijk, maar is wel reden tot waakzaamheid. Narrow-band ultraviolet licht (UVB) 
is zeer effectief tegen psoriasis. PDL heeft geen carcinogene eigenschappen 
in tegenstelling tot UVB en psoralen ultraviolet-A (PUVA) therapie. UVB pakt 
primair structuren aan in de epidermis, terwijl PDL de epidermis passeert zonder 
noemenswaardige schade aan te richten en primair de verwijde oppervlakkige 
bloedvaatjes in de dermis uitschakelt. Dit wijst erop, dat UVB en PDL psoriasis via 
verschillende routes kunnen laten verdwijnen. Het doel van de studie beschreven in 
hoofdstuk 6 was om de effectiviteit en de veiligheid van PDL behandeling in plaque 
type psoriasis te evalueren, de resultaten van PDL behandeling te vergelijken met die 
van UVB behandeling en met die van PDL+UVB behandeling en om een eventueel 
synergistisch effect van PDL +UVB behandeling op psoriasis vast te stellen. Zowel 
PDL,	UVB	als	de	combinatie	behandeling	PDL+UVB	resulteerde	in	een	significante	
verbetering. PDL bleek even effectief te zijn als UVB. De combinatie van PDL en 
UVB had geen additioneel effect, tengevolge van het ontbreken van synergie. Een 
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onverwachte	bevinding	was,	dat	er	geen	significante	verschillen	werden	aangetoond	
tussen UVB- en PDL behandelde gedeelten van de psoriasis plaques en de niet 
behandelde (NT) gedeelten. Hiervoor is nog geen duidelijke verklaring gevonden, 
maar een niet verwacht “ carry-over” efect vanuit de UVB- en PDL behandelde 
gedeelten van de psoriasis plaques wordt ondersteund door de bevinding van een 
omgekeerde relatie tussen de verbetering van de NT delen en de afstand tussen de 
PDL behandelde gedeelten en de NT gedeelten van de psoriasis plaques. Met andere 
woorden: de verbetering in de NT gedeelten nam af naarmate de afstand tussen de 
NT gedeelten en de met PDL behandelde gedeelten groter was. Deze bevindingen 
maken verdere studies waardevol, omdat hieruit blijkt, dat het overlappen van laser 
spot sizes waarschijnlijk niet nodig is en dat zou een aantal voordelen opleveren, 
zoals verkorting van de behandeltijd, minder ongemak voor de patiënten en lagere 
kosten. Een andere mogelijkheid is, dat er sprake was van een systemisch effect op 
de NT gedeelten, tengevolge van de behandeling van de overige psoriasis laesies. 
Achteraf lijkt het erop, dat het verschillend behandelen van delen van een individuele 
psoriasis laesie niet de optimale methode is om de effectiviteit van locale therapieën 
te bestuderen. Indien deze methode toch wordt gebruikt is het aan te bevelen om 
de behandeling te beperken tot de voor de studie geselecteerde laesies, zonder 
behandeling van de overige laesies. In de onderhavige studie bleek, dat de patiënten 
met een volledige verdwijning van de psoriasis laesies of goed reageerden op PDL 
of op UVB. Dit wijst erop dat patiënten bij wie UVB faalt wel goed kunnen reageren 
op PDL en vice versa. De behandeling met de  PDL bleek veilig te zijn, omdat er 
alleen milde en tijdelijke bijwerkingen werden waargenomen. De PDL dient niet te 
worden toegepast voor de behandeling van uitgebreide psoriasis of bij patiënten, die 
goed reageren op eenvoudige locale middelen. Behandeling met de PDL kan met 
succes ingezet worden bij patiënten met persisterende plaque type psoriasis (vooral 
op niet met kleding bedekte lichaamsdelen), plaque type psoriasis met bijwerkingen 
van de gebruikelijke middelen, psoriasis palmoplantaris, psoriasis inversa. PDL kan 
ook worden toegepast bij patiënten die bezwaar maken tegen het gebruik van locale 
corticosteroiden of systemische behandeling en bij patiënten met verhoogd risico 
op huidkanker, tengevolge van zonlicht beschadiging of immunosuppressie. De 
meeste patiënten in deze studie gaven de voorkeur aan PDL behandeling boven 
behandeling met UVB. 
De resultaten van PDL behandeling kunnen worden bevorderd door:
Toename van het aantal behandelingen.- 
Vermindering van het tijdsinterval tussen de behandelingen.- 
Verhoging van de energie en de pulsduur tot respectievelijk 10 J/cm- 2 en 
1.5 msec.
Applicatie van optical coupling gel kort voor de laser behandeling.- 
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Combinatie met calcipotriolzalf behandeling.- 
Toekomstige studies kunnen informatie verschaffen om de resultaten te 
optimaliseren. 
14.20 Cellulaire en moleculaire effecten van pulsed dye laser en narrow-band UVB 
behandeling op psoriasis
In een nieuwe psoriasis plaque behoren dilatatie en proliferatie van de dermale, 
papillaire capillairen tot de vroegst zichtbare veranderingen. Toename van de dermale 
microvascularisatie faciliteert het transport van immuun cellen naar de huid en speelt 
daardoor een belangrijke rol bij het in stand houden van de ontsteking in de psoriasis 
huid. Reductie van de hyperproliferatie van de papillaire microvascularisatie via 
selectieve photothermolyse door PDL behandeling kan leiden tot een vermindering 
van het transport van immuun cellen tussen bloedvaten en huid met als beoogd doel 
dat de psoriasis plaques verdwijnen. 
Uit de studies, die beschreven zijn in hoofdstuk 7, is gebleken dat klinische 
verbetering van psoriasis na PDL behandeling vergezeld ging van veranderingen 
van enkele klassieke markers van psoriasis activiteit. Patiënten die goed reageerden 
op PDL behandeling toonden verminderde expressie van VEGFR2, VEGFR3 en 
E-selectine binnen 24 uur na PDL behandeling. Na 2 PDL behandelingen  was de 
expressie van IL-23, TNF-α	mRNA	en	E-selectin	proteine	significant	verlaagt,	terwijl	
na	4	behandelingen	alle	epidermale	markers	en	dermale	infiltraten	genormaliseerd	
waren. In psoriasis plaques, die met UVB werden behandeld  was de expressie van 
de	epidermale	activatie	markers	en	E-selectine	na	13	weken	significant	verlaagd.	
De effecten op de mRNA waarden van patiënten die goed op PDL en UVB therapie 
reageerden bleken vergelijkbaar te zijn. De geringere klinische effectiviteit van UVB in 
deze studie (52% verbetering versus 60% voor totale lichaamsbelichting) kan worden 
verklaard door het feit, dat in de studie UVB alleen werd gebruikt op een beperkt aantal 
geselecteerde psoriasis plaques en niet als totale lichaams behandeling. Uit recent 
onderzoek is namelijk gebleken, dat totale lichaams behandeling een additioneel 
systemisch effect heeft. Aan het einde van de behandel periode toonden zowel PDL 
als UVB een reductie in de expressie van epidermale markers en van de dermale T 
cell	infiltraten.	Een	interessante	observatie	in	deze	studie	was	de	benedenwaartse	
regulatie van IL-23 gedurende PDL behandeling, omdat recent werd gerapporteerd 
dat Th17 cellen een belangrijke rol spelen in the ontstaanswijze van psoriasis. Deze 
T helper cellen worden gestimuleerd door IL-23. Een recent ontwikkelde biological 
blokkeert IL-23 en blijkt effectief te zijn bij de behandeling van psoriasis. Het lijkt 
er dus op, dat PDL en deze nieuwe biological eenzelfde aangrijpingspunt hebben. 
Daarnaast kan de benedenwaartse regulering van TNF-α en IL-23p19 bijdragen tot 
de effectiviteit van de PDL behandeling op psoriasis.
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14.21     Liposomen
Liposomen zijn veelbelovend voor locale behandeling in de dermatologie. 
Hoewel de huid een orgaan is, dat direct toegankelijk is voor locale applicatie 
van geneesmiddelen, wil dat niet zeggen dat de geneesmiddelen verwerkt in 
conventionele bases, zoals lotions, crèmes en zalven in de optimale concentraties 
en op de juiste plaatsen in de huid terecht komen. Liposomen kunnen gebruikt 
worden	als	dragers	van	zowel	hydrofiele	als	lipofiele	geneesmiddelen.	De	stabiliteit	
van instabiele middelen kan worden bevorderd door ze in te bouwen in liposomen. 
Daarnaast versterken liposomen de penetratie in de epidermis van stoffen, die niet 
op een andere manier in de huid kunnen doordringen. Liposomen dragen ertoe bij, 
dat de kans op huidirritatie wordt verminderd door vertraging van het vrijkomen van 
geneesmiddelen en door een vochtinbrengende werking op de epidermis. Ze hebben 
ook het vermogen om geneesmiddelen te concentreren in de haar/talgklier structuren, 
waardoor ze inzetbaar zijn bij aandoeningen van haarfollikels en talgklieren. Lage 
concentraties van  geneesmiddelen in liposomen zijn even effectief als hogere 
doses in conventionele preparaten, maar met minder bijwerkingen zowel locaal als 
door systemische absorptie van het geneesmiddel. Veel belovende resultaten zijn 
bereikt met in liposomen ingekapselde geneesmiddelen bij de behandeling van acne, 
xerosis cutis, atopic dermatitis, psoriasis, vitiligo, oppervlakkig veneuze trombose, 
en verwijdering van overtollige haargroei. “Lege” liposomen (zonder ingekapselde 
geneesmiddelen) hydrateren de huid, eenvoudig weg door de toevoeging van vetten 
en water aan de epidermis en kunnen de plaats innemen van de klassieke emolients 
bij de behandeling van bijvoorbeeld eczeem. Hierdoor wordt ook huidirritatie 
door bepaalde geneesmiddelen (bijvoorbeeld tretinoin) verminderd, waardoor de 
acceptatie en de therapietrouw van de patiënt toeneemt.
PDT	wordt	veelvuldig	gebruikt	om	AK’s	en	oppervlakkige	BCC’s	te	behandelen.	Verder	
wordt PDT in toenemende gebruikt om acne te behandelen en huidveroudering te 
bestrijden. Bijwerkingen beperken echter het gebruik ervan, vooral in geval van 
benigne huidaandoeningen. Door de 5-ALA in een crèmebasis te vervangen door 
5-ALA in liposomen kan de concentratie van 5-ALA verminderd worden met een 
factor	40,	waarbij	het	fluorescerend	vermogen,	dat	een	maat	is	voor	de	potentiële	
effectiviteit, behouden blijft en waardoor tevens de noodzaak tot occlusie overbodig 
wordt. Een bijkomstig voordeel is een kostenverlagend effect. De eigenschappen 
van liposomen worden verder besproken in hoofdstuk 8.
De volgende studies op het gebied van liposomen kunnen waardevol zijn:
5-ALA liposomen en daglicht voor de behandeling van acne.- 
5-ALA liposomen en daglicht voor de preventie van huidveroudering, - 
AK’s	en	oppervlakkige	BCC’s.
5-ALA liposomen en IPL of PDL voor huidverjonging.- 
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T4-endonuclease-V in liposomen voor de behandeling en preventie van - 
NMSC, vooral bij patiënten met immunosuppressie.
Cyclosprine in liposomen voor de behandeling van ernstige vormen van - 
psoriasis en atopisch eczeem.
Methotrexaat in liposomen voor de behandeling van ernstige psoriasis.- 
“Lege	liposomen”	of	fillagrine	bevattende	liposomen	voor	de	behandeling	- 
van xerosis cutis en atopisch eczeem.
- 
14.22    Behandeling van vitiligo met liposomale khelline in combinatie met UV licht  
 therapie
Vitiligo is een niet levensbedreigende huidaandoening, die echter wel een ernstige 
psychologische impact heeft met voor de patiënt een sterk negatieve invloed op de 
kwaliteit van leven. Vitiligo wordt histologisch gekenmerkt door de afwezigheid van 
pigmentcellen (melanocyten) in de epidermis. De melanocyten in de haarfollikels 
worden echter bij vitiligo meestal niet in het proces betrokken. Therapeutische 
maatregelen beogen een ommekeer van het progressieve verlies van melanocyten 
en het terugbrengen van de normale huidskleur. Gedurende het proces van 
repigmentatie prolifereren de folliculaire melanocyten en migreren naar de epidermis. 
Gebruikelijke middelen hiervoor zijn locale corticosteroiden, tacrolimus, systemische 
en	locale	PUVA,	UVB	en	locaal	khelline	met	UVA	(KUVA).	Geen	van	deze	middelen	is	
echter in alle gevallen effectief en bijwerkingen kunnen het gebruik ervan beperken. 
Khelline	heeft	phototherapeutische	eigenschappen,	die	overeenkomen	met	die	van	de	
psoralenen, maar met veel minder kans op phototoxische effecten en DNA mutaties. 
Literatuur gegevens betreffende de huidige status van khelline bij de behandeling 
van vitiligo waren niet overtuigend. De selectie van de basis waarin khelline wordt 
opgelost bleek zeer belangrijk te zijn voor een juiste beschikbaarheid van khelline 
in de huid. Inkapseling van khelline in phophatidylcholine liposomen verhoogt de 
beschikbaarheid van khelline in de haarfollikels, waardoor de stimulatie van de 
melanocyten wordt bevorderd. De effectiviteit en de veiligheid van de behandeling 
met khelline in L-phenylalanine gestabiliseerde phophatidylcholine liposomen 
in combinatie met UVA/UVB licht werd geëvalueerd in een open, retrospectieve 
studie, die beschreven wordt in hoofdstuk 9. Een repigmentatie van 50% tot 100% 
werd verkregen in 72% van de behandelde vitiligo plekken na een gemiddelde 
behandelingsperiode van 12 maanden. De repigmentatie bleek niet gelijk te zijn 
voor verschillende lichaamsdelen.
14.23     Blaardak transplantatie (BRT) voor vitiligo
Chirurgische technieken worden in het algemeen gereserveerd voor stabiele, maar 
therapie resistente vitiligo. De transplantatie van epidermale blaardak grafts op de 
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gedepigmenteerde gebieden is veilig, gemakkelijk uitvoerbaar, geeft een maximale 
expansie van pigment en veroorzaakt geen littekens. Dit wordt beschreven in 
hoofdstuk 10. Deze techniek heeft een aantal voordelen boven de melanocyten 
suspensie transplantatie techniek.
14.24 Combinatie van liposomaal khelline en UV licht behandeling met blaardak 
transplantatie bij therapie resistente vitiligo
In recente richtlijnen betreffende de behandeling van vitiligo wordt UVB behandeling 
alleen aanbevolen bij patiënten, die niet adequaat behandeld kunnen worden met 
conservatieve middelen, patiënten met zeer uitgebreide vitiligo of patiënten met 
gelocaliseerde	 vitiligo	 en	 significante	 impact	 op	 de	 kwaliteit	 van	 het	 leven.	Maar	
bij vele patiënten blijven, ondanks deze maatregelen, hardnekkige vitiligo plekken 
bestaan. Photo-medicamenteuze behandeling zoals PUVA en khelline met ultraviolet 
licht	(KLUV)	kan	effectief	zijn	waar	andere	behandelingen	falen.	Het	 lijkt	rationeel	
om	de	voorkeur	te	geven	aan	KLUV	boven	PUVA,	omdat	khelline	overeenkomstige	
phototherapeutische eigenschappen heeft, met veel minder kans op phototoxische 
effecten	 en	 DNA	 mutaties.	 Daar	 komt	 bij,	 dat	 KLUV	 behandeling	 bij	 vrijwel	 alle	
patiënten leidt tot stabiliteit van de vitiligo en dat is een belangrijke voorwaarde 
voor het succes van chirurgische maatregelen. De procedure en de resultaten 
van	BRT	bij	patiënten,	die	na	minstens	1	 jaar	behandeling	met	KLUV	nog	steeds	
stabiele, hardnekkige vitiligo plekken hadden wordt beschreven in hoofdstuk 11. 
Na	de	transplantatie	is	photo-medicamenteuze	(KLUV)	noodzakelijk	om	voldoende	
uitbreiding van de pigmentatie rond het blaardak transplantaat te bereiken en 
daarmee de repigmentatie van het gehele witte gebied. Verdere studies kunnen de 
individuele rol van BRT, UV en khelline evalueren. 
Verbeteringen in BRT techniek kunnen worden bereikt via:
Applicatie van een corticosteroidcrème of een calcineurinecrème op het - 
getransplanteerde gebied, nadat de transplantaties zijn aangeslagen, 
om te voorkomen dat de vitiligo weer actief (instabiel) wordt door de 
operatie	(Köbner	fenomeen)	of	door	spontane	verergering.
Een medicamenteuze interventie van de onderliggende oorzaken van - 
de melanocyten destructie (b.v. Efalizumab).
Suction blister ablatie van het te behandelen gebied in plaats van ablatie - 
met de Erbium laser om te bereiken dat de verwijderde huid en de 
getransplanteerde huid dezelfde dikte hebben. 
14.25 PDT van acne vulgaris met gebruikmaking van 5-ALA 0.5% liposomale 
spray en IPL in combinatie met locale peeling middelen.
De zoektocht naar nieuwe en veilige therapeutische methoden voor acne wordt 
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gerechtvaardigd door de toename van de resistentie van de Propionibacterium 
(Pr) acnes en het groeiend besef van de bijwerkingen van conventionele locale en 
systemische anti-acne middelen. Hoewel de effectiviteit van PDT waarbij gebruik 
wordt gemaakt van 20% 5-ALA crème onder afsluitend verband is aangetoond, wordt 
het gebruik ervan belemmerd door phototoxische bijwerkingen. Liposomen hebben 
als	eigenschap	om	hydrofiele	geneesmiddelen,	zoals	5-ALA	te	transporteren	naar	
de talgklieren, die bij acne ontstoken zijn. Door 5-ALA in te bouwen in liposomen 
kan de concentratie ervan verlaagd worden tot 0.5% met gelijk blijven van de 
geïnduceerde	huid	fluorescentie	en	waadoor	tevens	een	afsluitend	verband	tijdens	
de	inwerkingfase	niet	meer	nodig	is.	Daarnaast	is	de	huid	fluorescentie	en	daarmee	
de kans op phototoxiciteit na de behandeling veel sneller verdwenen dan na 20% 
5-ALA crème. Een studie, waarin de effectiviteit en de veiligheid worden bepaald 
van PDT met 5-ALA 0.5% in liposomale spray en IPL in combinatie met een peeling 
crème (Li-PDT-PC) wordt beschreven in hoofdstuk 12.
De resultaten van deze behandeling kunnen wellicht verbeterd worden door:
Toepassing van dubbele IPL belichtingen op ontstoken laesies.- 
Vermindering van de intervallen tussen de behandelingen tot 2 of 3 - 
weken.
14.26    Non-melanoma huidkanker en fluorescentie detectie
Non-melanoma huidkanker (NMSC) is de grootste uitdaging voor de komende 2 
decennia in de Dermatologie. De te verwachten stijging van huidkanker zal leiden tot 
een werkoverlast in alle dermatologische praktijken als er geen serieuze pogingen 
worden gedaan tot preventie educatie van het publiek om het probleem te beteugelen. 
Zelfs met de voorziene toename van het aantal dermatologen in Nederland, zal 
dit probleem te groot worden om te behappen als we op dezelfde weg doorgaan 
met dezelfde middelen. Screening van patiënten op (pre-) maligne huidafwijkingen 
maakt vroege detectie en daarmee tijdige behandeling mogelijk. Diagnostische 
huidfluorescentie	met	5-ALA	in	liposomen	en	een	speciaal	gecomputeriseerd	detectie	
en visualisatie systeem biedt de mogelijkheid om NMSC te ontdekken op een vroeg 
(preklinisch)	stadium.	Deze		fluorescentie	detectie	(FD)	techniek		is	goed	geschikt	
om grote huidgebieden te onderzoeken, alsmede om nauwkeurig de plaatsen op 
de	huid	te	identificeren	om	huidbiopsieën	te	verrichten	en	ook	om	pre-operatief	de	
grenzen van maligniteiten van de huid vast te stellen. Daarnaast is deze techniek 
te gebruiken bij de controle en de follow-up na behandeling van huidkanker. De 
techniek en de resultaten van deze FD worden beschreven in hoofdstuk 13.
Verdere	studies	op	het	gebied	van	fluorescentie	detectie	zijn	nodig	om	de	correlatie	
tussen	 de	 fluorescentie	 patronen	 en	 de	 klinische	 en	 histologische	 beelden	 te	
optimaliseren, vooral om penetrerende maligniteiten te kunnen onderscheiden van 
283
niet-penetrerende maligniteiten. Additionele studies betreffende de effectiviteit van 
PDT	met	IPL	of	PDL	van	AK’s	en	NMSC	direct	uitgevoerd	in	dezelfde	sessie	na	FD	
zou	een	zeer	efficiente	methode	tot	behandeling	kunnen	opleveren.
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abbreviations
ADCC antibody-dependent cell- 
 mediated cytotoxicity 
Ag antigen
AK	 actinic	keratosis
ALA aminolaevulinic acid
AP activator protein
APC antigen presenting cell
BBUVB broadband ultraviolet-B 
BCC basal cell carcinoma
Bcl2 B-cell lymphoma/  
 leukemia-2 gene
BSA bovine serum albumin
BPO benzoyl peroxide
BRT blister roof transplantation
CCD camera bharged couple device
CD cluster of differentiation
CHS contact hypersensitivity
Cm centimetre
CLA cutaneous lymphocyte  
 antigen
CO2 carbon dioxide 
CptT critical phase transition  
 temperature
CTLA cytotoxic T-lymphocyte  
 antigen
CW contineous wave
CsA cyclosporin A
DC dendritic cell
DNA deoxyribonucleic acid
E energy (photon)
EM electromagnetic
FD	 fluorescence	detection
H hour  
HBD2	 human	β-defensin-2
HEV high endothelial venule
IFN-γ  interferon-γ 
HLA human leucocyte antigen
ICAM intercellular adhesion  
 molecule
IL interleukin
IPL intense pulsed light
J/cm2 Joule/square centimetre
KLUV	 khellin	liposomal	ultraviolet
KPLUV	 khellin	phenylalanine		
 liposome ultraviolet
KRT	 keratin
KUVA	 khellin	ultraviolet-A
Laser	 light	Amplification	by	the		
 Stimulated Emission of  
 Radiation
LC langerhans cell
LED light emitting diode
LFA lymphocyte function antigen
Li-PDT-PC liposomal 5-ALA PDT in  
 combination with peeling  
 cream
LMV large multi-lamellar vesicle
LMWH low molecular weight heparin
LUV large uni-lamellar vesicle
MAL methyl aminolaevulinate
MED minimal erythema dose
MHC major histocompatibility  
 complex 
Mm millimetre
MMP matrix metalloproteinase
Msec millisecond
MTX methotrexate
MW milliWatt
Nd:YAG neodymium:yttrium 
aluminium  garnet
NF-	κB	 nuclear	factor	kappa	B
NK	cell	 natural	killer	cell
Nm nanometre
NBUVB narrowband ultraviolet-B
NMSC non-melanoma skin cancer 
NT non treated
P propionibacterium
PAMP  pathogen-associated  
 molecular pattern 
PASI psoriasis area and severity  
 index
PBS phosphate buffered saline
PDC plasmacytoid dendritic cell
PDL  pulsed dye laser 
PDT photodynamic therapy
PL pigmented lesions
PGA physician’s global   
 assessment
PPAR peroxisome proliferator- 
 activated receptor
PpIX protoporphyrin IX
PPV ositive predictive value
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PR photorejuvenation
PUVA psoralen ultraviolet A
Qol quality of life
RNA ribonucleic acid
RT-PCR real time-polymerase chain  
 reaction
ROS reactive oxygen species
*S1 singlet excited state
Sec second 
SCC squamous cell carcinoma
SD standard  deviation
Str. bas. stratum basale
Str. corn stratum corneum
Str. gran. stratum granulosum
Str. spinosum stratum spinosum
SUV small uni-lamellar vesicle
T time = week
*T1 triplet state
TCR T cell receptor 
TDS thermal Damage Time
TGF-α	 T	cell	growth	factor-α	
TGK	 transglutaminase
Th1cell T helper 1 cell
Th2 cell T helper 2 cell 
TKS	 thermo-kinetic	selectivity
TLR Toll like receptor
T4N5 T4 endonuclease V
TNF tumor necrosis factor
TRAF tumor necrosis factor- 
 associated factor
TRT thermal relaxation time
UCA uranic acid
UVA ultraviolet A
UVB ultraviolet B
UVC ultraviolet C 
VASI vitiligo area-scoring index
VCAM vascular cell adhesion  
 molecule
VEGF vascular endothelial growth  
 factor
VETF vitiligo European task force
VEGFR vascular endothelial growth  
 factor receptor
VIDAscore vitiligo disease activity score
Vs versus
VWf von Willebrand factor
W Watt
μm micrometre
μsec mcrosecond
h Planck’s constant 
V frequency 
Λ wavelength
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In de periode voor mijn overgang van het Albert Schweitzer Ziekenhuis in Dordrecht 
naar het Erasmus MC in Rotterdam was mijn belangstelling voor de behandeling 
van psoriasis met de Pulsed Dye Laser gewekt door de positieve ervaringen die 
collega Brian Zelickson ervan meldde in de Journal of the American Academy of 
Dermatology van 1996. De klinische resultaten van PDL behandeling in combinatie 
met calcipotriol- of salicylzalf bij 74 psoriasis patiënten leken de ervaringen van Ze-
lickson te bevestigen. Deze studie werd uitgevoerd bij MultiCare in samenwerking 
met Dieter Neugebauer en gepubliceerd in het Nederlands Tijdschrift voor Derma-
tologie en Venereologie. Een vervolg studie van dezelfde behandeling bij psoriasis 
palmoplantaris, werd gestart in MultiCare en afgerond in het Erasmus MC en ook 
dit onderzoek leverde bemoedigende resultaten op. Ik dank Dieter Neugebauer en 
Suzanne	Koetsveld	voor	hun	bijdragen	aan	de	totstandkoming	van	deze	artikelen.
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zoeksresultaten. Dit probleem werd opgelost door Tamar Nijsten, waardoor het arti-
kel alsnog geplaatst kon worden in Dermatologic Surgery. Tamar, ik ben je hiervoor 
zeer erkentelijk.  
In MultiCare hadden we sinds 1996 ervaringen opgedaan met liposomen en in de 
loop van de tijd ben ik steeds meer geïnteresseerd geraakt in de bijzondere moge-
lijkheden, die liposomen kunnen bieden. In eerste instantie heeft dit geleid tot een 
studie die, in goede samenwerking met Dieter Neugebauer, Nick van der Beek en 
Günher Maierhofer, werd uitgevoerd naar de effectiviteit van khelline liposomen met 
ultraviolet	licht	(KLUV)	bij	vitiligo	.	De	resultaten	van	deze	studie	zijn	gepubliceerd	
in de European Journal of Dermatology. Hardnekkige vitiligo lesies reageren echter 
niet altijd op photo-medicamenteuze therapie en daarom werd, in samenwerking met 
Peter Bjerring, een blaardak transplantatie techniek ontwikkeld. Dit heeft geleid tot 
de totstandkoming van een artikel waarin deze techniek beschreven wordt. Daarna 
zijn	de	resultaten	van	de	behandeling	met	KLUV	gecombineerd	met	blaardak	trans-
plantaties gebundeld in een ander artikel. Bij beide artikelen is Yvette Assen nauw 
betrokken geweest. Yvette, ik dank je voor bijdrage. 
Inmiddels had de studie van de PDL bij psoriasis om diverse redenen vertraging 
opgelopen. Dit bood mij de mogelijkheid om dieper in de liposomen te duiken en 
dat heeft geleid tot een review artikel over liposomen in de dermatologie. Ik dank 
Hannah de Vijlder, die in een vorige functie ook al met liposomen in aanraking was 
geweest, voor haar medewerking aan dit artikel, dat geplaatst werd in de Journal of 
the European Academy of Dermatology and Venereology (JEADV). Steeds meer 
werd bij MultiCare duidelijk, dat liposomen multi-inzetbaar zijn. Een studie naar een 
photodynamische behandeling met 5-ALA liposomen bij acne leverde, naast be-
moedigende resultaten, ook een publicatie op, eveneens in de JEADV. Last but not 
least, heeft ons onderzoek met liposomen geleid tot de ontwikkeling van een nieuwe 
methode	van	fluorescentie	detectie	bij	non	melanoma	huid	kanker.	Deze	methode	is	
gepubliceerd in Lasers in Surgery and Mecicine.
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je scherpe verstand en je vrolijke karakter. Ik denk Nick, dat jij een grote toekomst 
tegemoet gaat. 
Uiteindelijk had de PDL studie bij psoriasis toch een vervolg. De resultaten van het 
onderzoek naar de immunologische effecten van PDL bij psoriasis werden vervat in 
een	artikel	in	samenwerking	met	Emöke	Racz,	Ewout	Baerveldt	en	René	Kant	onder	
leiding van prof.dr. Errol Prens. Ik dank jullie allemaal en vooral jou Errol voor de 
goede adviezen, die ik van je heb gekregen en Ewout voor de prettige en humorvolle 
samen werking. 
Peter Bjerring, you are certainly a champion in laser land. I admire you because of 
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your immense knowledge of laser science and Dermatology. I appreciate also your 
cheerful mood and great sense of humor. I thank you very much for all the advices 
you gave to us. Mange tak!!
Mijn copromotor Bob Tank ben ik veel dank verschuldigd. Bob, met jouw 
wetenschappelijke expertise en goede adviezen betreffende inhoud en redactie van 
onze artikelen ben je een grote steun voor mij geweest. Met veel geduld en kennis 
van zaken boog je mijn Nederengels om in echt Engels, waarvoor mijn grote dank.
Johan van der Stek, wij kennen elkaar vanaf het moment dat Dijkzigt gebouwd werd 
tot nu, het moment waarop het weer wordt afgebroken. Veel hebben we meegemaakt, 
we raken daar voorlopig niet over uitgepraat. Johan, ik dank voor je bijdrage aan een 
aantal van de bovenstaande artikelen en voor de prettige samenwerking.  
Hans Moes, Haagse humor is “a joy for ever” en bedankt voor je administratieve 
ondersteuning. 
Peter Lefeber, zonder jou en je fabelachtige geduld was ik zeker ten onder gegaan in 
het IT moeras. Hiervoor mijn oprechte dank. Ik dank jou en ook Erik van der Snoek 
voor	de	leuke	en	interessante	gesprekken,	die	wij	hadden	op	de	flex	kamer.	Ik	denk,	
dat	ik	in	de	toekomst	af	en	toe	langs	kom	om	even	bij	te	flexen.	
De dames op de werkvloer, die mij het meest frequent hebben bijgestaan, zoals 
op het Erasmus Ria, Jeanette, Rita, Jolanda, Helen en alle anderen, die daarbij 
betrokken waren en bij MultiCare, Claire, Suzanne, Nadine en Jeanette wil ik heel 
hartelijk bedanken voor jullie inzet, bekwaamheid en de goede en aangename sfeer, 
die jullie uitstralen.
Klaas	van	der	Beek,	in	de	loop	van	de	tijd	heb	ik	een	grote	bewondering	gekregen	
voor je doorzettingsvermogen en je praktische vindingrijkheid. Ik dank je voor de 
mogelijkheden tot ontplooiing, die je me in MultiCare hebt geboden. Daarnaast is 
onze samenwerking uitgegroeid tot een warme vriendschap.
Martino, onze samenwerking heb ik ervaren als fascinerend, stimulerend, plezierig 
en vriendschappelijk en ik ga ervan uit, dat er een goede basis is gelegd om dit ook 
in de toekomst te continueren. Dank voor al je goede adviezen.
Ik dank alle patiënten, die mee hebben gedaan aan de onderzoekingen.
Andrea en Michiel, mijn paranimfen uit eigen kweek, ik heb het als een groot voorrecht 
ondervonden om jullie vader te mogen zijn. Veel dank voor jullie ondersteuning bij de 
organisatie van mijn promotiedag.
Frits de Leeuw is niet alleen mijn broer, maar hij is ook gedurende mijn gehele leven 
een grote vriend en toeverlaat geweest. Frits bedankt.
Fernanda, de hele poging tot promotie heb ik uiteraard vooral voor jou gedaan. 
Gelukkig heb je mij, zoals altijd, voortreffelijk gesteund met geduld, voortreffelijk 
bereid voedsel en vooral liefde. 
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Ik heb de laatste tijd veel te weinig aandacht gegeven aan mijn vrienden en 
familieleden. Mijn excuus is natuurlijk, dat ik het promotie werk voor een groot deel 
moest doen in de avonduren en in de weekends, omdat ik overdag werd bezig 
gehouden met de patiëntenzorg. Ik beloof jullie, dat ik van nu af aan weer helemaal 
van de partij zal zijn en ik beloof jullie ook, dat ik hierna nooit meer zal promoveren.
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